Introducing PHARMAC 2

June 2015 Volume 22 Number 1

Editor: Kaye Wilson email: enquiry@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section A	
Section B	Aliment
	Blood &

General Rules 6

Alimentary Tract & Metabolism	20
Blood & Blood Forming Organs	40

- Cardiovascular System 49
 - Dermatologicals 62
- Genito Urinary System 73
- Hormone Preparations Systemic 79
- Infections Agents For Systemic Use 91
 - Musculoskeletal System 116
 - Nervous System 125
- Oncology Agents & Immunosuppressants 159
 - Respiratory System & Allergies 195
 - Sensory Organs 202

Various 206

Section C Extemporaneous Compounds (ECPs) 208

Section DSpecial Foods215Section EPractitioner's Supply Orders237Rural Areas241Section FDispensing Period Exemptions242Section GSafety Cap Medicines244

Section I National Immunisation Schedule 247

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A through to G and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that that can be used in DHB hospitals and is a separate publication.


The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg kilogramkg	milligrammg	m ur
international unitiu	millilitre ml	

millimole	mmol
unit	u

Abbreviations Ampoule ...

Ampoule	Amp	Gelatinous	Gel
Capsule	Сар	Granules	Gran
Cream		Infusion	Inf
Device	Dev	Injection	Inj
Dispersible	Disp	Liquid	Liq
Effervescent	Eff		LA
Emulsion	Emul	Ointment	Oint
Enteric Coated	EC	Sachet	Sach

Solution	Soln
Suppository	Supp
Tablet	Tab
Tincture	Tinc
Trans Dermal Delivery	
System	TDDS

BSO Bulk Supply Order.

CBS Cost Brand Source.

ECP Extemporaneously Compounded Preparation.

- Original Pack subsidy is rounded up to a multiple at whole packs. OP
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner or pharmacist.

- Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless the * medicine meets the Dispensing Frequency Rule criteria.
- Safety cap required for oral liquid formulations, including extemporaneously compounded preparations. t
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.
- S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981.
- HP3 Subsidised when dispensed from a pharmacy that has a contract to dispense Special Foods.
- HP4 Subsidised when dispensed from a pharmacy that has a contract to dispense from the Monitored Therapy Variation (for Clozapine Services).

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription for a Community Pharmaceutical is met by the Government through the Combined Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to pharmacies, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to pharmacies does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a V in the product's Schedule listing.

Patient costs

Everyone who is eligible for publicly funded health and disability services should in most circumstances pay only a \$5 co-payment for subsidised medicines, although co-payments can vary from \$0 to \$15. Where the price of a Pharmaceutical is higher than the subsidy, a patient may pay a manufacturer's surcharge in addition to the co-payment. A patient may also pay additional fees for services such as after-hours dispensing and special packaging.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Guide to eligibility on the Ministry of Health's website.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

For more information on patient co-payments or eligibility please visit http://www.moh.govt.nz.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person.

Subsidy

Once approved, the applicant will be provided a Special Authority number which must appear on the prescription.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Combined Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website. For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised.

Making a Special Authority application

Application forms can be found at http://www.pharmac.govt.nz. Except where stated on the application form, applications are processed by the Ministry of Health, and are sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

To register for submission of applications on-line - Contact the Ministry of Health on 0800 505 125 or email at

onlinehelpdesk@moh.govt.nz. For Special Authority approval numbers, applicants can phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666.

Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at

http://www.pharmac.health.nz/link/nppa, or call the Panel Coordinators at 0800 660 050 Option 2.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 June 2015 and is to be referred to as the Pharmaceutical Schedule Volume 22 Number 1, 2015. Distribution will be from 20 June 2015. This Schedule comes into force on 1 June 2015.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"**180 Day Lot**", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria", means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.
- "Act", means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee", means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy", means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation", means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Authority to Substitute", means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order", means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug", means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975. "Community Pharmaceutical", means a Pharmaceutical listed in Sections A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor", means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug", means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply", means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist", means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber", means a nurse who is a Designated Prescriber—Registered Nurses Practising in Diabetes Health as determined by the Nursing Council of New Zealand to practice in diabetes health and has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981.

"Dietitian", means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB", means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital", means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Dispensing Frequency Rule", means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor", means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical", means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements", - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder", means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST", means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator", means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals", means the list of pharmaceuticals set out in Section H part II of the Schedule which includes some National Contract Pharmaceuticals.

"Hospital Pharmacy", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",
 - iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- a) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS", means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination", means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit", means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital", means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot", means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price", means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife", means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month", means a period of 30 consecutive days.

"Monthly Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel", means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical", means a Hospital Pharmaceutical for which PHARMAC has negotiated a

national contract and the Price.

"National DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule", means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

"Not In Combination", means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber", means a person who is a nurse practitioner in terms of the Medicines Act 1981, or a Diabetes Nurse Prescriber

"Optional Pharmaceuticals", means the list of National Contract Pharmaceuticals set out in Section H Part II of the Schedule

"Optometrist", means a person registered with the Optometrists and Dispensing Opticians Board with a scope of practice that includes prescribing medicines (TPA endorsement)

"Outpatient", in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT", means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only", means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution", means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC", means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC). "Pharmaceutical", means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

"Pharmaceutical Benefits", means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget", means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment", means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist Prescriber", means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice.

"Pharmacist", means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner", means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist, a Quitcard Provider, or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order", means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription", means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine", means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations

1984.

"Private Hospital", means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Quitcard Provider", means a person registered with the Ministry of Health as a Quitcard Provider.

"Residential Disability Care Institution", means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home", means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine", means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist", means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol", or
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- a) i) follows a substantive consultation with an appropriate Specialist;
 - ii) the consultation to relate to the Patient for whom the Prescription is written;
 - iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
 - iv) except in emergencies consultation to precede annotation of the Prescription; and
 - v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

"Retail Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Safety Medicine", means a Community Pharmaceutical defined in Section A, Part IV of the Pharmaceutical Schedule.

"Schedule", means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority", means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; or
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of competency; or
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of competency; or
- d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy", means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order", means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication", means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

"Unlisted Pharmaceutical", means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical but is not listed in Section H part II

"Unusual Clinical Circumstances (UCC)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.2.1 and 2.2.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.2.1, 2.2.2 and 2.2.3 are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers', Optometrists and Pharmacist Prescribers' Prescriptions (other than oral contraceptives) The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - A) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - B) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - a) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - b) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, Certain Antibiotics and Unapproved Medicines

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is either:
 - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply, or
 - c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Pharmacist Prescribers' Prescriptions

The following apply to every prescription written by a Pharmacist Prescriber

- 3.4.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or

- b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine.
- 3.4.2 Any Pharmacist Prescribers' prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.5 Dietitians' Prescriptions

- The following provisions apply to every Prescription written by a Dietitian:
- 3.5.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian, providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.5.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.6 Diabetes Nurse Prescribers' Prescriptions

The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:

- 3.6.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.6.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.7 Quitcard Providers' Prescriptions

Prescriptions written by a Quitcard Provider will only be subsidised where they are:

- a) for any of the following Community Pharmaceuticals: nicotine patches, nicotine lozenges or nicotine gum; and
- b) written on a Quitcard.

PART IV DISPENSING FREQUENCY RULE

Rule 3.1.4 of the Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency Rule defines patient groups or medicines eligible for more frequent dispensing periods for Community Pharmaceuticals; and the conditions that must be met to enable any pharmacy to claim for payment of handling fees for the additional dispensings made. This Dispensing Frequency Rule relates to the circumstances in which a subsidy is payable for the Community Pharmaceutical; it does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement or Pharmaceutical Schedule.

For the purposes of this Dispensing Frequency Rule:

"Frequent Dispensing" means:

- i) for a Community Pharmaceutical referred to in Section F Part I, (the Stat exemption) dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
- ii) for any other Community Pharmaceutical dispensing in quantities less than a Monthly Lot "Safety Medicine"
 - i) an antidepressant listed under the "Cyclic and Related Agents" subheading;
 - ii) an antipsychotic;

- iii) a benzodiazepine;
- iv) a Class B Controlled Drug;
- v) codeine (includes combination products);
- vi) buprenorphine with naloxone; or
- vii) zopiclone.

The Dispensing Frequency Rule covers 5 different circumstances where Frequent Dispensing for patients may be clinically or otherwise appropriate. These are:

- 1) Long Term Condition (LTC) patients and Core patients, or
- 2) Persons in residential care, or
- 3) Trial periods, or
- 4) Safety and co-prescribed medicines, or
- 5) Pharmaceutical Supply Management.

4.1 Frequent Dispensing for patients registered as Long Term Condition (LTC) or Core patients

If a Pharmacist considers Frequent Dispensing is required, then:

- 4.1.1 For LTC registered patients, Frequent Dispensing can occur as often as the dispensing Pharmacist deems appropriate to meet that patient's compliance and adherence needs;
- 4.1.2 For Core (non-LTC) patients, Frequent Dispensing should be no more often than a Monthly Lot. Pharmacists may authorise monthly dispensing on a Stat exemption Community Pharmaceutical without prescriber authority. If the Pharmacist considers more frequent (than monthly) dispensing is necessary, prescriber approval is required. Verbal approval from the prescriber is acceptable provided it is annotated by the Pharmacist on the Prescription and dated.

4.2 Frequent Dispensings for persons in residential care

- 4.2.1 Community Pharmaceuticals can be dispensed to:
 - any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
 - a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider via Frequent Dispensing, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than:
 - i) 7 days' supply for a Class B Controlled Drug; or
 - ii) 7 days' supply for clozapine in accordance with a Clozapine Dispensing Protocol; or
 - iii) 28 days' supply for any other Community Pharmaceutical (except under conditions outlined in 4.3 (Trial periods) below; and
- b) the prescribing Practitioner or dispensing Pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.2.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.3 (Trial periods) below.

4.3 Frequent Dispensings for Trial Periods

Frequent Dispensing can occur when a Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only) and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

4.4 Frequent Dispensing for Safety and co-prescribed medicines

- 4.4.1 For a Safety Medicine to be dispensed via Frequent Dispensing, both of the following conditions must be met:
 - a) The patient is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.2 on the previous page; and
 - b) The prescribing Practitioner has:
 - i) Assessed clinical risk and determined the patient requires increased Frequent Dispensing; and
 - ii) Specified the maximum quantity or period of supply to be dispensed for each Safety Medicine at each dispensing.
- 4.4.2 A Community Pharmaceutical that is co-prescribed with a Safety Medicine, which can be dispensed in accordance with rule 4.4.1 above, may be dispensed at the same frequency as the Safety Medicine if the dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing of their co-dispensed medicines; and
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.5 Frequent Dispensing for Pharmaceutical Supply Management

- 4.5.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing under this rule where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders

with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.
- 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner's Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances:
 - a) the RFPP provider name is written on the Practitioner's Supply Order; and
 - b) the total quantity ordered does not exceed a multiple of:
 - ten times the Practitioner's Supply Order current maximum listed in Section E Part I for amoxicillin grans for oral liq 250 mg per 5 ml, amoxicillin cap 250 mg and amoxicillin cap 500 mg; or
 - ii) two times the Practitioner's Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and
 - c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner's Supply Order (e.g. 10 x 300 ml amoxicillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.2;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under

the Medicines Act 1981 or for an Unapproved Indication; or

b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

- a) there is a clinical reason why substitution should not occur; or
- b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Other DHB Funding

A DHB may fund a Community Pharmaceutical outside of the mechanisms established in the Pharmaceutical Schedule, provided that:

- a) specific prior agreement is obtained from PHARMAC for such funding;
- any funding restrictions set out in the Pharmaceutical Schedule for those Community Pharmaceuticals are applied; and
- c) a Contractor (including a DHB Hospital Pharmacy) may not claim a Subsidy for a Community Pharmaceutical dispensed and funded by the DHB via such an alternate mechanism.

5.9 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy		Fully	Brand or
	(Manufacturer's Price \$	e) Per	Subsidised	
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet		30	•	Gaviscon Infant
SIMETHICONE				
 Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml 		500 ml	ſ	Mylanta P
SODIUM ALGINATE				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour		60	(Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml		500 ml		Acidex
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE * Tab 600 mg		100	~	Alu-Tab
CALCIUM CARBONATE				
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for children under 12 years of ag endorsed accordingly. Antidiarrhoeals		500 ml sphate I		Roxane ent and the prescription
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	a PSO			
* Tab 2 mg * Cap 2 mg		400 400		Nodia Diamide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy		90	~ 1	Entocort CIR
SA1155 Special Authority for Subsidy nitial application — (Crohn's disease) from any relevant praction following criteria: Both:		alid for (6 months f	or applications meeting th
 Mild to moderate ileal, ileocaecal or proximal Crohn's dis Any of the following: 	ease; and			

20

continued...

Subsidy	Fu	ully Brand or	
(Manufacturer's Price)	Subsidis	sed Generic	
\$	Per	✓ Manufacture	r

continued...

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)	25.30	21.1 g OP	Colifoam
MESALAZINE			
Tab 400 mg		100	Asacol
Tab EC 500 mg		100	Asamax
Tab long-acting 500 mg		100	Pentasa
Modified release granules, 1 g		120 OP	Pentasa
Enema 1 g per 100 ml		7	Pentasa
Suppos 500 mg		20	Asacol
Suppos 1 g	54.60	30	Pentasa
Pentasa to be Sole Supply on 1 July 2015			
OLSALAZINE			
Tab 500 mg		100	Dipentum
Cap 250 mg		100	Dipentum
SODIUM CROMOGLYCATE			
Cap 100 mg	89.21	100	✓ Nalcrom
		100	
SULPHASALAZINE			
 Tab 500 mg – For sulphasalazine oral liquid formulation i 	refer,		
page 209		100	Salazopyrin
* Tab EC 500 mg		100	Salazopyrin EN

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pr	ice) Su	Fully Brand or bsidised Generic
	\$	Per	Manufacturer
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP 12	 Proctosedyl Proctosedyl
Management of Anal Fissures			
GLYCERYL TRINITRATE – Special Authority see SA1329 below * Oint 0.2%		y 30 g OP	✓ Rectogesic
⇒SA1329 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals val chronic anal fissure that has persisted for longer than three week	lid without further r ks.	enewal unles	ss notified where the patient has
Antispasmodics and Other Agents Altering Gut	t Motility		
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available o a PSO		10	🗸 Max Health
HYOSCINE N-BUTYLBROMIDE	1 / 0	20	✓ Gastrosoothe
 Inj 20 mg, 1 ml – Up to 5 inj available on a PSO 		5	✔ Buscopan
MEBEVERINE HYDROCHLORIDE ★ Tab 135 mg		90	✓ Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
VISOPROSTOL * Tab 200 mcg		120	✓ Cytotec
Helicobacter Pylori Eradication			
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement		14	✓ Apo-Clarithromycin
 a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori era vote: the prescription is considered endorsed if clarithromycin is 			
amoxicillin or metronidazole. H2 Antagonists			
CIMETIDINE - Only on a prescription			
* Tab 200 mg		100	Anna Oliveratistica
₭ Tab 400 mg	(7.50) 10.00 (12.00)	100	Apo-Cimetidine Apo-Cimetidine
RANITIDINE – Only on a prescription	()		P
* Tab 150 mg		500	 ✓ <u>Ranitidine Relief</u> ✓ Ranitidine Relief
1. T 000		500	🖌 Ronitidina Raliaf
 * Tab 300 mg * Oral lig 150 mg per 10 ml 		300 ml	✓ Peptisoothe

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Proton Pump Inhibitors				
LANSOPRAZOLE				
* Cap 15 mg	2.00	28	~	Solox
* Cap 30 mg	2.32	28	~	Solox
OMEPRAZOLE				
For omeprazole suspension refer Standard Formulae, page	212			
* Cap 10 mg	2.23	90	v	Omezol Relief
* Cap 20 mg	2.91	90		Omezol Relief
* Cap 40 mg		90	-	Omezol Relief
* Powder – Only in combination		5 g	~	Midwest
Only in extemporaneously compounded omeprazole sus		_		
* Inj 40 mg		5	~	Dr Reddy's
				Omeprazole
	0.00	100		Dantannaala
* Tab EC 20 mg	2.68	100	v <u></u>	Pantoprazole Actavis 20
* Tab EC 40 mg	3 54	100	~	Pantoprazole
		100	•	Actavis 40
Site Protective Agents				1010110 10
one i locolive Agento				
BISMUTH TRIOXIDE				
Tab 120 mg		112	~	De Nol S29
SUCRALFATE				
Tab 1 g		120		
-	(48.28)		(Carafate
Bile and Liver Therapy	× ,			
Bile and Liver Therapy				
RIFAXIMIN – Special Authority see SA1461 below – Retail pha	rmacy			
Tab 550 mg		56	~	Xifaxan
BACA1461 Special Authority for Subsidy			-	

➡SA1461 Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Hyperglycaemic Agents

DIAZOXIDE - Special Authority see SA1320 on the next page - Retail pharmacy

Cap 25 mg 110.00	100
Cap 100 mg	100
Oral liq 50 mg per ml	30 ml OP

- Proglicem S29
- ✓ Proglicem S29
- Proglycem S29

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
⇒SA1320 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid glycaemia caused by hyperinsulinism. Renewal from any relevant practitioner. Approvals valid without fur priate and the patient is benefiting from treatment.				
GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit – Up to 5 kit available on a PSO		1	🖌 Glu	ucagen Hypokit
Insulin - Short-acting Preparations				
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP	✔ Ac	trapid mulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	🖌 Ac	trapid Penfill mulin R
Insulin - Intermediate-acting Preparations				
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen		5	🗸 No	voMix 30 FlexPen
NSULIN ISOPHANE ▲ Inj human 100 u per ml	17.68	10 ml OP		mulin NPH otaphane
▲ Inj human 100 u per ml, 3 ml	29.86	5	🖌 Hu	mulin NPH otaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL Inj human with neutral insulin 100 u per ml 	25.26	10 ml OP		mulin 30/70 ctard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ Per ✓ Per	mulin 30/70 nMix 30 nMix 40 nMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE ▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml,				
3 ml ▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,		5	🖌 Hu	malog Mix 25
3 ml		5	🖌 Hu	malog Mix 50
Insulin - Long-acting Preparations				
NSULIN GLARGINE ▲ Inj 100 u per ml, 10 ml ▲ Inj 100 u per ml, 3 ml	94.50	1 5	✔ Lai ✔ Lai	ntus
 Inj 100 u per ml, 3 ml disposable pen Insulin - Rapid Acting Preparations 	94.50	5	🖌 La	ntus SoloStar
NSULIN ASPART ▲ Inj 100 u per ml, 3 ml syringe ▲ Inj 100 u per ml, 3 ml	51.19	5 5	🖌 No	voRapid FlexPen voRapid Penfill
Inj 100 u per ml, 10 ml		1	🖌 No	voRapid

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer	
INSULIN GLULISINE					
▲ Inj 100 u per ml, 10 ml	27.03	1	🗸 Aj	pidra	
▲ Inj 100 u per ml, 3 ml	46.07	5	V A	pidra	
▲ Inj 100 u per ml, 3 ml disposable pen	46.07	5	V Aj	pidra SoloStar	
INSULIN LISPRO					
▲ Inj 100 u per ml, 10 ml		10 ml OP	🖌 Hi	umalog	
▲ Inj 100 u per ml, 3 ml	59.52	5	🖌 Hi	umalog	
Alpha Glucosidase Inhibitors					
ACARBOSE					
* Tab 50 mg	9.82	90	🗸 A	ccarb	
* Tab 100 mg	15.83	90	✓ <u>A</u>	<u>ccarb</u>	
Oral Hypoglycaemic Agents					
GLIBENCLAMIDE					
* Tab 5 mg	5.00	100	🖌 Da	aonil	
GLICLAZIDE					
* Tab 80 mg		500	🖌 GI	lizide	
GLIPIZIDE			_		
* Tab 5 mg		100	🖌 M	inidiab	
METFORMIN HYDROCHLORIDE					
* Tab immediate-release 500 mg		1,000	🖌 A1	potex	
* Tab immediate-release 850 mg		500	_	potex	
PIOGLITAZONE			_		
* Tab 15 mg	1.50	28	🖌 Pi	zaccord	
* Tab 30 mg		28		zaccord	
* Tab 45 mg	3.50	28	🖌 Pi	zaccord	

Ketone Testing

Diabetes Management

BLOOD KETONE DIAGNOSTIC TEST METER - Up to 1 meter available on a PSO Meter funded for the purposes of blood ketone diagnostics only. Patient has had one or more episodes of ketoacidosis and is at risk of future episodes or patient is on an insulin pump. Only one meter per patient will be subsidised every 5 years. ✓ Freestyle Optium 1 KETONE BLOOD BETA-KETONE ELECTRODES a) Maximum of 20 strip per prescription b) Up to 10 strip available on a PSO Test strip - Not on a BSO......15.50 10 strip OP ✓ Freestyle Optium Ketone SODIUM NITROPRUSSIDE - Maximum of 50 strip per prescription Accu-Chek 50 strip OP Ketur-Test 14.14 Ketostix

()	Subsidy Manufacturer's Pri \$	ice) Per	Fully Subsidised	
Blood Glucose Testing				
 LOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by ender a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a patien 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperglycaemia 4) has a genetic or an acquired disorder of glucose homeostasinly one CareSens meter per patient. No further prescriptions will b 	ent who: a; or is excluding typ			
or the avoidance of doubt patients who have previously received a f	unded meter, of	ther than	CareSens	, are eligible for a CareSe
eter. The prescription must be endorsed accordingly. Pharmacists record of prior dispensing of insulin or sulphonylureas.	may annotate t	ne presc	npuon as e	endorsed where there exis
Meter with 50 lancets, a lancing device and 10 diagnostic test strips	20.00	1 OP	~	CareSens II
			~	CareSens N
Note: Only 1 meter available per PSO				CareSens N POP
LOOD GLUCOSE DIAGNOSTIC TEST STRIP - Up to 50 test ava	ilable on a PSC)		
LOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test ava The number of test strips available on a prescription is restricted)		
LOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test ava The number of test strips available on a prescription is restricted 1) Prescribed for a patient on insulin or a sulphonylurea and end	to 50 unless:		rmacists m	ay annotate the prescripti
The number of test strips available on a prescription is restricted 1) Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing	d to 50 unless: dorsed accordin of insulin or su	ngly. Phai Ilphonylu	rea; or	
 The number of test strips available on a prescription is restricted Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony 	d to 50 unless: dorsed accordin of insulin or su	ngly. Phai Ilphonylu	rea; or	
 The number of test strips available on a prescription is restricted Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or 	to 50 unless: dorsed accordin of insulin or su rlurea in which c	ngly. Phai Iphonylu case the p	rea; or	
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed 	d to 50 unless: dorsed accordin of insulin or su rlurea in which c ed accordingly;	ngly. Phai Iphonylui case the p or	rea; or prescriptior	n is deemed to be endorse
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord 	t to 50 unless: dorsed accordin of insulin or su rlurea in which c ed accordingly; mia or hypergly	ngly. Phai Iphonylui case the p or caemia a	rea; or prescriptior and endors	n is deemed to be endorse ed accordingly; or
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. 	t to 50 unless: dorsed accordin of insulin or su rlurea in which c ed accordingly; mia or hypergly	ngly. Phai Iphonylui case the p or caemia a	rea; or prescriptior and endors	n is deemed to be endorse ed accordingly; or
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	d to 50 unless: dorsed accordir of insulin or su rlurea in which c ed accordingly; mia or hypergly ler of glucose h	ngly. Phai Ilphonylui case the p or caemia a omeosta	rea; or orescriptior and endors sis excludir	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. 	d to 50 unless: dorsed accordir of insulin or su rlurea in which c ed accordingly; mia or hypergly ler of glucose h	ngly. Phai Iphonylui case the p or caemia a	rea; or prescription and endors sis excludir DP V	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet CareSens
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	d to 50 unless: dorsed accordir of insulin or su rlurea in which c ed accordingly; mia or hypergly ler of glucose h	ngly. Phai Ilphonylui case the p or caemia a omeosta	rea; or prescription and endors sis excludin DP	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	d to 50 unless: dorsed accordir of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56	ngly. Phai Ilphonylui case the p or caemia a omeosta	rea; or prescription and endors sis excludin DP	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet CareSens CareSens N
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	d to 50 unless: dorsed accordir of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56	ngly. Phai Ilphonylui case the p or caemia a omeosta	rea; or prescription and endors sis excludin DP	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet CareSens CareSens N Accu-Chek
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly ler of glucose h 10.56 28.75	ngly. Pha liphonylu ase the p or caemia a omeosta 50 test C	rea; or prescription and endors sis excludin OP () QP () QP () Q) QP () Q () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens</u> <u>CareSens N</u> Accu-Chek Performa
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed Prescribed for a patient on home TPN at risk of hypoglycael Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1291 below 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly ler of glucose h 10.56 28.75 I below – Retail low – Retail pha	ngly. Phai Ilphonylui case the p or caemia a omeosta 50 test C	rea; or prescription and endors sis excludin OP () QP () QP () Q) QP () Q () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens</u> <u>CareSens N</u> Accu-Chek Performa
 The number of test strips available on a prescription is restricted. 1) Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing. 2) Prescribed on the same prescription as insulin or a sulphony or 3) Prescribed for a pregnant woman with diabetes and endorsed. 4) Prescribed for a patient on home TPN at risk of hypoglycael. 5) Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1291 bel c) Note: Accu-Chek Performa and Freestyle Optium are not a 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly ler of glucose h 10.56 28.75 I below – Retail low – Retail pha	ngly. Phai Ilphonylui case the p or caemia a omeosta 50 test C	rea; or prescription and endors sis excludin OP () QP () QP () Q) QP () Q () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens</u> <u>CareSens N</u> Accu-Chek Performa
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing. Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed. Prescribed for a patient on home TPN at risk of hypoglycaet Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56 28.75 4 below – Retail low – Retail pha available on a P	ngly. Phai liphonylui case the p or caemia a omeosta 50 test C b pharmacy SO	rea; or prescription and endors sis excludin OP () () () () () () () () () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens CareSens N</u> Accu-Chek Performa Freestyle Optium
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing. Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed. Prescribed for a patient on home TPN at risk of hypoglycaei. Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 c) Note: Accu-Chek Performa and Freestyle Optium are not at SA1294 Special Authority for Subsidy 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56 28.75 4 below – Retail low – Retail pha available on a P	ngly. Phai liphonylui case the p or caemia a omeosta 50 test C b pharmacy SO	rea; or prescription and endors sis excludin OP () () () () () () () () () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens CareSens N</u> Accu-Chek Performa Freestyle Optium
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing. Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed. Prescribed for a patient on home TPN at risk of hypoglycaet Prescribed for a patient on home TPN at risk of hypoglycaet Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 c) Note: Accu-Chek Performa and Freestyle Optium are not at SA1294 Special Authority for Subsidy otes: Application details may be obtained from PHARMAC's websil PHARMAC 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56 28.75 4 below – Retail low – Retail pha available on a P	ngly. Phai liphonylui case the p or caemia a omeosta 50 test C b pharmacy SO	rea; or prescription and endors sis excludin OP () () () () () () () () () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens CareSens N</u> Accu-Chek Performa Freestyle Optium
 The number of test strips available on a prescription is restricted. Prescribed for a patient on insulin or a sulphonylurea and end as endorsed where there exists a record of prior dispensing. Prescribed on the same prescription as insulin or a sulphony or Prescribed for a pregnant woman with diabetes and endorsed. Prescribed for a patient on home TPN at risk of hypoglycaei. Prescribed for a patient with a genetic or an acquired disord and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below a) Accu-Chek Performa brand: Special Authority see SA1294 b) Freestyle Optium brand: Special Authority see SA1294 c) Note: Accu-Chek Performa and Freestyle Optium are not at SA1294 Special Authority for Subsidy 	d to 50 unless: dorsed accordin of insulin or su vlurea in which c ed accordingly; mia or hypergly der of glucose h 10.56 28.75 4 below – Retail low – Retail pha available on a P	ngly. Phai liphonylui case the p or caemia a omeosta 50 test C b pharmacy SO	rea; or prescription and endors sis excludin OP () () () () () () () () () ()	n is deemed to be endorse ed accordingly; or ng type 1 or type 2 diabet <u>CareSens CareSens N</u> Accu-Chek Performa Freestyle Optium

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to: PHARMAC

PO Box 10 254 Facsimile: (04) 974 4788 Wellington Email: bgstrips@pharmac.govt.nz

	Subsidy (Manufacturer's F \$	Price) Su Per	bsidised Ge	and or neric inufacturer
OOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED) The number of test strips available on a prescription is r 1) Prescribed for a patient on insulin or a sulphonylurea as endorsed where there exists a record of prior dis	and endorsed accord	lingly. Pharma sulphonylurea	; or	
 Prescribed on the same prescription as insulin or a s or Prescribed for a pregnant woman with diabetes and Prescribed for a patient on home TPN at risk of hyp Prescribed for a patient with a genetic or an acquire and metabolic syndrome and endorsed accordingly. 	l endorsed accordingl oglycaemia or hyperg d disorder of glucose	y; or lycaemia and	endorsed ac	cordingly; or
Blood glucose test strips		50 test OP	V Sense	oCard
nsulin Syringes and Needles				
ubsidy is available for disposable insulin syringes, needle r the supply of insulin or when prescribed for an insulin pr notate the prescription as endorsed where there exists a SULIN PEN NEEDLES – Maximum of 100 dev per prescri	atient and the prescri record of prior dispens	ption is endor	sed accordin	
29 g $ imes$ 12.7 mm		30	🖌 B-D N	licro-Fine
	10.50	100	🖌 B-D N	licro-Fine
31 g $ imes$ 5 mm	11.75	100	🖌 B-D N	licro-Fine
$31 \text{ g} \times 6 \text{ mm}$		100	🖌 ABM	
31 g × 8 mm	3.15	30	🖌 B-D N	licro-Fine
-	10.50	100	✔ B-D N ✔ ABM	licro-Fine
$32 \text{ g} \times 4 \text{ mm}$	10.50	100	• • • • • •	licro-Fine
BM 31 g \times 8 mm to be delisted 1 September 2015)				
SULIN SYRINGES, DISPOSABLE WITH ATTACHED NEE		100 day par p	rocarintian	
Syringe 0.3 ml with 29 g × 12.7 mm needle		100 dev per p	rescription	
Synnge 0.5 mil with 29 g × 12.7 min needle	(1.99)	10	BDI	lltra Fine
	13.00	100	✓ B-D U	
Syringe 0.3 ml with 31 g $ imes$ 8 mm needle		100	P D-D 0	
	(1.99)	10	B-D II	Itra Fine II
	13.00	100	-	litra Fine II
Syringe 0.5 ml with 29 g $ imes$ 12.7 mm needle		100	• D-D 0	
	(1.99)	10	B-D I	Iltra Fine
	13.00	100	✓ B-D U	
Syringe 0.5 ml with 31 g $ imes$ 8 mm needle		10	• 550	
	(1.99)	10	B-D I	Iltra Fine II
	13.00	100		lltra Fine II
Syringe 1 ml with 29 g $ imes$ 12.7 mm needle		100	✓ ABM	
	1.30	10		
	(1.99)		B-D II	lltra Fine
		100	✓ B-D U	
			✓ ABM	
Svringe 1 ml with 31 g \times 8 mm needle	13.00 13.00	100		
Syringe 1 ml with 31 g \times 8 mm needle $\hfill \hfill \hf$	13.00	100 10		
Syringe 1 ml with 31 g \times 8 mm needle $\hfill \hfill \hf$	13.00 1.30	100 10		Iltra Fine II
Syringe 1 ml with 31 g \times 8 mm needle $\hfill \hfill \hf$	13.00		B-D U	Iltra Fine II I ltra Fine II

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Insulin Pumps				
INSULIN PUMP – Special Authority see SA1237 below – Retail p a) Maximum of 1 dev per prescription b) Only on a prescription c) Maximum of 1 insulin pump per patient each four year perior Min basal rate 0.025 U/h; black colour Min basal rate 0.025 U/h; blue colour Min basal rate 0.025 U/h; green colour Min basal rate 0.025 U/h; pink colour	pd. 4,500.00 4,500.00 4,500.00 4,500.00	1 1 1		unimas Vibe unimas Vibe unimas Vibe unimas Vibe
Min basal rate 0.025 U/h; silver colour Min basal rate 0.05 U/h; blue colour		1 1	V P	animas Vibe Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; clear colour	4,400.00	1	🖌 P	Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; pink colour		1	🖌 P	Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; purple colour		1	🖌 P	Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; smoke colour	4,400.00	1		Paradigm 522 Paradigm 722

SA1237 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 974 7806
PO Box 10 254	Email: ipp@pharmac.govt.nz
Wellington	

Insulin Pump Consumables

➡SA1240 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990			
PHARMAC	Facsimile: (04) 974 7806			
PO Box 10 254	Email: ipp@pharmac.govt.nz			
Wellington				
INSULIN PUMP ACCESS	ORIES - Special Authority see SA1240) above – Retail pl	harmacy	
a) Maximum of 1 cap	per prescription			
b) Only on a prescrip	tion			
c) Maximum of 1 pres	scription per 180 days.			
Battery cap			1	🖌 Animas Battery Cap

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special a) Maximum of 3 sets per prescription 	Authority see SA1240) on the	e previous	page – Retail pharmacy
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
10 mm steel needle; 29 G; manual insertion; 60 cm tubing \times				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-885
6 mm steel cannula; straight insertion; 60 cm grey line \times 10				
with 10 needles	130.00	1 OP	🖌 C	ontact-D
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	V P	aradigm Sure-T
			• •	MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	19	ure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing \times			• 3	
				anadiana Cuna T
10 with 10 needles	130.00	1 OP	V Pa	aradigm Sure-T MMT-866
				IVIIVI 1-800
6 mm steel needle; 29 G; manual insertion; 80 cm tubing \times	400.00			
10 with 10 needles; luer lock		1 OP	VS	ure-T MMT-865
8 mm steel cannula; straight insertion; 110 cm grey line $ imes$ 10				_
with 10 needles	130.00	1 OP	✔ C	ontact-D
8 mm steel cannula; straight insertion; 60 cm grey line \times 10				
with 10 needles		1 OP	🖌 C	ontact-D
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T
				MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing \times				
10 with 10 needles	130.00	1 OP	V Pa	aradigm Sure-T
			• •	MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles; luer lock		1 OP	~ 9	ure-T MMT-875

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic Manufactu	urer
ISULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN		HINSERTION	DEVICE) - Spec	ial Authority se
A1240 on page 28 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription			opco	
 c) Maximum of 13 infusion sets will be funded per year. 13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line × 10 with 10 needles 		1 OP	✔ Inset 30	
 13 mm teflon cannula; angle insertion; insertion device; 60 cm blue line × 10 with 10 needles 		1 OP	✓ Inset 30	
13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line × 10 with 10 needles		1 OP	✓ Inset 30	
 13 mm teflon cannula; angle insertion; insertion device; 60 cm pink line × 10 with 10 needles 		1 OP	✓ Inset 30	
ISULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN				page 28 – Reta
narmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 13 mm teflon cannula; angel insertion; 60 cm grey line × 5				
with 10 needles	120.00	1 OP	 Comfort Sh 	ort
10 needles		1 OP	Paradigm S MMT-382	ilhouette
13 mm teflon cannula; angle insertion; 45 cm line \times 10 with 10 needles	130.00	1 OP	✓ Paradigm S MMT-368	ilhouette
13 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-381	Silhouette
13 mm teflon cannula; angle insertion; 80 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-383	Silhouette
17 mm teflon cannula; angle insertion; 110 cm grey line × 5 with 10 needles		1 OP	 Comfort 	
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-377	ilhouette
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with 10 needles; luer lock		1 OP	✓ Silhouette	MMT-371
17 mm teflon cannula; angle insertion; 60 cm grey line × 5 with 10 needles		1 OP	✓ Comfort	
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-378	Silhouette
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles; luer lock		1 OP	Silhouette	MMT-373
17 mm teflon cannula; angle insertion; 80 cm line \times 10 with 10 needles		1 OP	 Paradigm S 	
			MMT-384	

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH see SA1240 on page 28 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription	T INSERTION WITH	INSERTIO	ON DE	VICE) – Special Authority
 c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion; insertion device; 110 cm grey line × 10 with 10 needles 	140.00 1	OP	🗸 Ir	nset II
6 mm teflon cannula; straight insertion; insertion device; 45 cm blue tubing \times 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-941
6 mm teflon cannula; straight insertion; insertion device; 45 cm pink tubing \times 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-921
6 mm teflon cannula; straight insertion; insertion device; 60 cm blue tubing × 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-943
6 mm teflon cannula; straight insertion; insertion device; 60 cm pink tubing × 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-923
6 mm teflon cannula; straight insertion; insertion device; 80 cm blue tubing \times 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-945
6 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing \times 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-965
6 mm teflon cannula; straight insertion; insertion device; 80 cm pink tubing × 10 with 10 needles	130.00 1	OP	✔ P	aradigm Mio MMT-925
 6 mm teflon cannula; straight insertionl insertion device; 60 cm blue line × 10 with 10 needles 6 mm teflon cannula; straight insertionl insertion device; 60 	140.00 1	OP	🗸 In	iset II
cm grey line × 10 with 10 needles 6 mm teflon cannula; straight insertionl insertion device; 60		OP		nset II
cm pink line × 10 with 10 needles 9 mm teflon cannula; straight insertion; insertion device; 60 cm blue line × 10 with 10 needles		OP OP		nset II nset II
 9 mm teflon cannula; straight insertion; insertion device; 60 cm grey line × 10 with 10 needles 9 mm teflon cannula; straight insertion; insertion device; 60 	140.00 1	OP	🗸 Ir	nset II
9 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing × 10 with 10 needles		OP OP		nset II
9 mm teflon cannula; straight insertionl insertion device; 110		-		aradigm Mio MMT-975
cm grey line \times 10 with 10 needles	140.00 1	OP	🖌 Ir	nset II

	Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or Ibsidised Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGI	HT INSERTION)	- Special A	uthority see SA1240 on page 28 -
Retail pharmacy a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10			
with 10 needles		1 OP	Paradigm Quick-Set MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10			
with 10 needles; luer lock		1 OP	Quick-Set MMT-391
6 mm teflon cannula; straight insertion; 60 cm tubing \times 10		4.00	
with 10 needles		1 OP	Paradigm Quick-Set MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10)		
with 10 needles; luer lock		1 OP	Quick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing \times 10			
with 10 needles		1 OP	Paradigm Quick-Set MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing $ imes$ 10			
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles; luer lock		1 OP	✔ Quick-Set MMT-390
9 mm teflon cannula; straight insertion; 60 cm tubing \times 10			
with 10 needles		1 OP	Paradigm Quick-Set MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10)		
with 10 needles; luer lock		1 OP	✔ Quick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing $ imes$ 10)		
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-386
INSULIN PUMP RESERVOIR - Special Authority see SA1240 c	on page 28 – Ret	ail pharmacy	
 a) Maximum of 3 sets per prescription b) Only on a prescription 			
c) Maximum of 13 packs of reservoir sets will be funded per y	/oar		
$10 \times \text{luer lock conversion cartridges 1.8 ml for Paradigm}$			
pumps		1 OP	ADR Cartridge 1.8
$10 \times$ luer lock conversion cartridges 3.0 ml for Paradigm			Ū
pumps		1 OP	ADR Cartridge 3.0
Cartridge 200 U, luer lock × 10		1 OP	Animas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml \times 10	50.00	1 OP	 Paradigm 1.8 Reservoir
Cartridge for 7 series pump; 3.0 ml \times 10	50.00	1 OP	 Paradigm 3.0 Reservoir
Syringe and cartridge for 50X pump, 3.0 ml $ imes$ 10		1 OP	✓ 50X 3.0 Reservoir

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease	34 93	100	~ 0	creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease		100		creon 25000
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease	94.40	100	🗸 P	anzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA1383 bell Cap 250 mg – For ursodeoxycholic acid oral liquid formula- tion refer, page 209	•	y 100	 ✓ <u>U</u> 	Irsosan

SA1383 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

continued...

()	Subsidy Manufacturer's Price)	Subs	Fully	Brand or Generic
,	\$	Per	~	Manufacturer

continued...

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

•••				
ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	5.51	500 g OP	✔ Konsyl-D	
MUCILAGINOUS LAXATIVES WITH STIMULANTS		5		
* Dry	2.41	200 g OP		
	(8.72)		Normacol Plus	
	6.02	500 g OP	Normacol Plus	
	(17.32)		Normacor Flus	
Faecal Softeners				
DOCUSATE SODIUM - Only on a prescription				
* Tab 50 mg	2.31	100	✓ <u>Coloxyl</u>	
* Tab 120 mg		100	Coloxyl	
* Enema conc 18%	5.40	100 ml OP	Coloxyl	
DOCUSATE SODIUM WITH SENNOSIDES			<i>.</i> .	
* Tab 50 mg with sennosides 8 mg	4.40	200	Laxsol	
POLOXAMER – Only on a prescription				
Not funded for use in the ear. * Oral drops 10%	3 78	30 ml OP	Coloxyl	
		30 III OF		
Osmotic Laxatives				
GLYCEROL				
* Suppos 3.6 g – Only on a prescription	6.50	20	✓ <u>PSM</u>	
LACTULOSE – Only on a prescription				
* Oral liq 10 g per 15 ml	3.84	500 ml	✓ Laevolac	
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE - Special Authority see				
SA1473 on the next page – Retail pharmacy				
Powder for oral soln 13.125 g with potassium chlori				
46.6 mg, sodium bicarbonate 178.5 mg and sodium ch ride 350.7 mg – Maximum of 90 sach per prescription		30	✓ Lax-Sachets	
nde 656.7 mg Maximum of 50 sach per prescription		00		

			-	
	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
SA1473 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals vali Both:	d for 6 months for app	ications r	neeting t	he following criteria:
1 The patient has problematic constipation despite an a	dequate trial of other	oral nha	rmacothe	eranies including lactulos
 where lactulose is not contraindicated; and 2 The patient would otherwise require a per rectal prepar 		orar pria		
Renewal from any relevant practitioner. Approvals valid for 12 benefit from treatment.		atient is c	compliant	and is continuing to ga
SODIUM ACID PHOSPHATE - Only on a prescription				
Enema 16% with sodium phosphate 8%	2.50	1	🖌 Fl	eet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE		tion		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per m				
5 ml		50	✓ <u>M</u>	icolette
Stimulant Laxatives				
BISACODYL – Only on a prescription				
* Tab 5 mg		200		ax-Tab
* Suppos 5 mg * Suppos 10 mg		6 6		ulcolax ulcolax
		0	VU	uicolax
SENNA – Only on a prescription Tab. standardised 	0.43	20		
	(1.72)	20	S	enokot
	2.17	100	-	
	(6.16)		S	enokot
Metabolic Disorder Agents				
Gaucher's Disease				
MIGLUCERASE – Special Authority see SA0473 below – Reta	il pharmacy			
Inj 40 iu per ml, 200 iu vial	1,072.00	1		erezyme
Inj 40 iu per ml, 400 iu vial	2,144.00	1	V C	erezyme
►SA0473 Special Authority for Subsidy				
Special Authority approved by the Gaucher's Treatment Panel		oot to fur-	dina'	lohilit <i>i</i>
Notes: Subject to a budgetary cap. Applications will be consider Application details may be obtained from PHARMAC's website			ung avai	iadility.
The Co-ordinator, Gaucher's Treatment Panel Phone: (04)	460 4990			

PHARMAC, PO Box 10 254 Wellington Phone: (04) 460 4990 Facsimile: (04) 916 7571 Email: gaucherpanel@pharmac.govt.nz

	Subsidy		Fully Bran	d or
	(Manufacturer's \$	Price) Sub Per	osidised Gene Manu	eric Jacturer
Mouth and Throat				
Agents Used in Mouth Ulceration				
BENZYDAMINE HYDROCHLORIDE				
Soln 0.15% – Higher subsidy of up to \$17.01 per 500 ml wit		000 ml		
Endorsement		200 ml	Difflam	
	9.00	500 ml	Dinam	
	(17.01)		Difflam	
Additional subsidy by endorsement for a patient who has tion is endorsed accordingly.	oral mucositis as	a result of trea	tment for canc	er, and the prescrip-
CHLORHEXIDINE GLUCONATE				
Mouthwash 0.2%	2.68	200 ml OP	✓ healthE	
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE				
* Adhesive gel 8.7% with cetalkonium chloride 0.01%		15 g OP		
	(5.62)		Bonjela	
SODIUM CARBOXYMETHYLCELLULOSE			4 a	
With pectin and gelatin paste	17.20 1.52	56 g OP	 Stomat 	nesive
	(3.60)	5 g OP	Orabas	۵
	4.55	15 g OP	Olabas	0
	(7.90)	- 5 -	Orabas	9
With pectin and gelatin powder	8.48	28 g OP		
	(10.95)		Stomah	esive
TRIAMCINOLONE ACETONIDE				
Paste 0.1%		5 g OP	 Oracor 	-
Kenalog in Orabase to be Sole Supply on 1 July 2015	5.33		 Kenalo 	g in Orabase
(Oracort Paste 0.1% to be delisted 1 July 2015)				
Oropharyngeal Anti-infectives				
AMPHOTERICIN B				
Lozenges 10 mg	5.86	20	🖌 Fungili	n
MICONAZOLE				
Oral gel 20 mg per g	4.95	40 g OP	Decozo	<u>) </u>
NYSTATIN Oral liq 100,000 u per ml	3.35	24 ml OP	🗸 Nilstat	
Other Oral Agents				
For folinic mouthwash, pilocarpine oral liquid or saliva substitute	formula refer Sta	andard Formula	e. page 212	
HYDROGEN PEROXIDE			.,	
* Soln 10 vol – Maximum of 200 ml per prescription	1.28	100 ml	🖌 PSM	
THYMOL GLYCERIN				
* Compound, BPC	9.15	500 ml	🖌 PSM	

ALIMENTARY TRACT AND METABOLISM

(Subsidy Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
Vitamins				
Vitamin A				
ITAMIN A WITH VITAMINS D AND C ∉ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	4 50	10 ml OP	Vi	tadol C
Vitamin B		10 111 01	• •	
YDROXOCOBALAMIN				
 Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO 	5.10	3	✓ <u>A</u> E	<u>3M</u> Hydroxocobalamin
YRIDOXINE HYDROCHLORIDE			-	
a) No more than 100 mg per dose				
 b) Only on a prescription Tab 25 mg – No patient co-payment payable 	2.15	90	🖌 Pv	ridoxADE
				tamin B6 25
Vitamin B6 25 to be Sole Supply on 1 August 2015	11 55	500		o Duridovino
 Tab 50 mg PyridoxADE Tab 25 mg to be delisted 1 August 2015) 	11.55	500		oo-Pyridoxine
HIAMINE HYDROCHLORIDE – Only on a prescription				
 Tab 50 mg 	5.62	100	🖌 Ap	oo-Thiamine
ITAMIN B COMPLEX				
 Tab, strong, BPC 	4.30	500	✓ Br	blex
Vitamin C				
SCORBIC ACID				
a) No more than 100 mg per dose				
b) Only on a prescription ← Tab 100 mg	7 00	500	V C1	vite
Vitamin D			• •	
LFACALCIDOL	00.00	100		Aluba
 € Cap 0.25 mcg € Cap 1 mcg 		100 100		ne-Alpha ne-Alpha
 Cap i mog € Oral drops 2 mcg per ml 		20 ml OP		ne-Alpha
			• •	
≪ Cap 0.25 mcg	3.03	30	🖌 Ai	rflow
	10.10	100		alcitriol-AFT
 Cap 0.5 mcg 		30	🖌 Ai	
	18.73	100	🖌 Ca	alcitriol-AFT
HOLECALCIFEROL				
* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription	7.76	12	🗸 Ca	al-d-Forte
Multivitamin Preparations				
IULTIVITAMINS – Special Authority see SA1036 on the next page	- Retail pharm			
Powder	72.00	200 g OP	🖌 Pa	ediatric Seravit

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Pric \$	e) Sul Per	Fully osidised	Brand or Generic Manufacturer
⇒SA1036 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Approvals valid	id without further r	enewal unle	ess notif	ied where the patient ha
inborn errors of metabolism.				
Renewal from any relevant practitioner. Approvals valid without f approval for multivitamins.	urther renewal unle	ess notified	where p	patient has had a previou
VITAMINS				
* Tab (BPC cap strength)		1,000	✓ M	vite
Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy		60	√ v	itabdeck
 SA1002 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Either: 1 Patient has cystic fibrosis with pancreatic insufficiency; or 	l without further re			
2 Patient is an infant or child with liver disease or short gut				
Minerals				
Calcium				
CALCIUM CARBONATE				
★ Tab eff 1.75 g (1 g elemental)		30		alsource
* Tab 1.25 g (500 mg elemental)	5.38	250	✓ <u>A</u>	rrow-Calcium
CALCIUM GLUCONATE ₭ Inj 10%, 10 ml ampoule		10	🗸 н	ospira
Fluoride				
SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental)	5.00	100	V P	SM
lodine				
POTASSIUM IODATE				
 Tab 253 mcg (150 mcg elemental iodine) 	3.65	90	✓ N	euroTabs
Iron				
FERROUS FUMARATE				
Tab 200 mg (65 mg elemental) Ferro-tab to be Sole Supply on 1 July 2015	2.89	100	🖌 F	erro-tab
FERROUS FUMARATE WITH FOLIC ACID				
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	🖌 F	erro-F-Tabs
ERROUS SULPHATE				
Tab long-acting 325 mg (105 mg elemental)		30 500 ml		errograd
★‡ Oral liq 30 mg (6 mg elemental) per 1 ml	10.28	500 ml	✓ <u>F</u>	erodan
FERROUS SULPHATE WITH FOLIC ACID				
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg		30		
000 mog		00	F	

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
IRON POLYMALTOSE * Inj 50 mg per ml, 2 ml ampoule	15.22	5	✓ <u>F</u>	errum H
Magnesium				
For magnesium hydroxide mixture refer Standard Formulae, page MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule		10	✓ <u>D</u>	<u>BL</u>
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)	11.00	100	✓ <u>z</u>	incaps

Subsidy	Fu	Illy	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	~	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA1469 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin ≤ 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate \leq 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate \leq 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin <100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of <500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

(N	Subsidy /anufacturer's Price) \$	Per	Fully Subsidised	
EPOETIN ALFA [ERYTHROPOIETIN ALFA] – Special Authority see	SA1469 on the p	revious	s page – F	Retail pharmacy
Wastage claimable – see rule 3.3.2 on page 13				
Inj 1,000 iu in 0.5 ml, syringe	48.68	6	~	Eprex
Inj 2,000 iu in 0.5 ml, syringe	120.18	6	~	Eprex
Inj 3,000 iu in 0.3 ml, syringe	166.87	6	~	Eprex
Inj 4,000 iu in 0.4 ml, syringe	193.13	6	/	Eprex
Inj 5,000 iu in 0.5 ml, syringe	243.26	6	/	Eprex
Inj 6,000 iu in 0.6 ml, syringe	291.92	6	~	Eprex
Inj 8,000 iu in 0.8 ml, syringe	352.69	6	-	Eprex
Inj 10,000 iu in 1 ml, syringe	395.18	6		Eprex
Inj 40,000 iu in 1 ml, syringe	263.45	1	~	Eprex
Megaloblastic				
FOLIC ACID				
* Tab 0.8 mg	19.80	1.000	~	Apo-Folic Acid
* Tab 5 mg		500		Apo-Folic Acid
Oral liq 50 mcg per ml		5 ml Ol		Biomed
Antifibrinolytics, Haemostatics and Local Sclerosa				
Antihorniorytics, nacinostatics and Eocal ociciost				
ELTROMBOPAG – Special Authority see SA1418 below – Retail pha Wastage claimable – see rule 3.3.2 on page 13	armacy			
Tab 25 mg	.1.771.00	28	~	Revolade
Tab 50 mg		28	V	Revolade

➡SA1418 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of ≤ 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of \leq 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of >30,000 platelets per microlitre.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - [Xpharm]

For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 1 mg syringe1,163.75	1	NovoSeven RT
Inj 2 mg syringe2,327.50	1	NovoSeven RT
Inj 5 mg syringe5,818.75	1	NovoSeven RT
Inj 8 mg syringe9,310.00	1	NovoSeven RT

	Subsidy (Manufacturer's Price) Si	Fully ubsidised	Brand or Generic
	\$	Per	~	Manufacturer
ACTOR EIGHT INHIBITORS BYPASSING AGENT - [Xpharm				
For patients with haemophilia, whose treatment is managed Haemophilia Management Group.	l by the Haemophilia Tr	reaters Gr	roup in co	njunction with the Nation
Inj 500 U	1,640.00	1	🖌 FE	EIBA
Inj 1,000 U	3,280.00	1	🖌 FE	EIBA
OROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - [Xph	arm]			
For patients with haemophilia, whose treatment is managed Haemophilia Management Group.	l by the Haemophilia Tr	reaters Gr	roup in co	njunction with the Natior
Inj 250 iu vial		1	🖌 Xy	/ntha
Inj 500 iu vial		1	🗸 X	/ntha
Inj 1,000 iu vial	900.00	1	🗸 X	/ntha
Inj 2,000 iu vial	1,800.00	1	🗸 X	/ntha
Inj 3,000 iu vial	2,700.00	1	🖌 X	/ntha
IONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]				
For patients with haemophilia, whose treatment is managed Haemophilia Management Group.	l by the Haemophilia Tr	reaters Gr	roup in co	njunction with the Nation
Inj 250 iu vial		1	V Be	eneFIX
Inj 500 iu vial		1	V B	eneFIX
Inj 1,000 iu vial		1	V B	eneFIX
Inj 2,000 iu vial	<i>'</i>	1		eneFIX
For patients with haemophilia, whose treatment is managed	l by the Haemophilia Tr	reaters Gi	roup in co	njunction with the Natior
For patients with haemophilia, whose treatment is managed Haemophilia Management Group.				
For patients with haemophilia, whose treatment is managed		reaters Gi 1	✓ A	dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial	237.50 250.00		✓ A	dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group.		1	✓ Ac	dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial		1 1	 A K A K 	dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial		1		dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial		1 1		dvate ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial		1 1 1	 A K A K A K K K 	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial		1 1 1 1	 Ac Kc Kc Kc Kc Ac Kc Ac <	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial		1 1 1 1	 Ac Kc Kc Kc Kc Ac Kc Ac <	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial		1 1 1 1 1		dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial		1 1 1 1 1		dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE		1 1 1 1 1		dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE		1 1 1 1 1	 A K A K A K A A K A A K A K K K K K 	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE ≰ Inj 3% 2 ml		1 1 1 1 1	 A K A K A K A A K A A K A K K K K K 	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID	237.50 250.00 475.00 500.00 950.00 1,000.00 1,425.00 1,900.00 2,000.00 2,850.00 3,000.00 28.50 (73.00)	1 1 1 1 1 5	 A A<	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial CODIUM TETRADECYL SULPHATE Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg	237.50 250.00 475.00 500.00 950.00 1,000.00 1,425.00 1,900.00 2,000.00 2,850.00 3,000.00 28.50 (73.00)	1 1 1 1 1	 A A<	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE	237.50 250.00 475.00 500.00 950.00 1,000.00 1,425.00 1,900.00 2,000.00 2,850.00 3,000.00 28.50 (73.00)	1 1 1 1 1 5	 A A<	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K HYTOMENADIONE	237.50 250.00 475.00 500.00 950.00 1,000.00 1,425.00 1,900.00 2,000.00 2,850.00 3,000.00 28.50 (73.00) 23.00	1 1 1 1 1 1 5	 A K A K A K A K A K K K Fi C 	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate obvate ogenate FS dvate ogenate FS dvate bro-vein <u>/klokapron</u>
Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial GODIUM TETRADECYL SULPHATE k Inj 3% 2 ml RANEXAMIC ACID		1 1 1 1 1 5	 A K A K A K A K A K K C 	dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN	10.50	990		thics Aspirin EC
* Tab 100 mg CLOPIDOGREL	10.50	990		
* Tab 75 mg – For clopidogrel oral liquid formulation refer, page 209		84	🖌 A	rrow - Clopid
DIPYRIDAMOLE				<u> </u>
* Tab 25 mg - For dipyridamole oral liquid formulation refer,				
page 209		84	🖌 P	ersantin
 * Tab long-acting 150 mg 	11.52	60	🖌 P	ytazen SR
PRASUGREL - Special Authority see SA1201 below - Retail pha	armacy			
Tab 5 mg		28	🖌 E	ffient
Tab 10 mg		28	🖌 E	ffient
►SA1201 Special Authority for Subsidy Initial application — (coronary angioplasty and bare metal st where the patient has undergone coronary angioplasty in the prev Initial application — (drug eluting stent) from any relevant prac	vious 4 weeks and is	clopid	ogrel-allergi	с*.

a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

TICAGRELOR – Special Authority see SA1382 below – Retail pharmacy

* Tab 90 mg90.00 56 🖌 Brilinta

■SA1382 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Heparin and Antagonist Preparations				
DALTEPARIN SODIUM – Special Authority see SA1270 below –	Retail pharmacy			
Inj 2,500 iu per 0.2 ml prefilled syringe		10	~	Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe		10	~	Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10	~	Fragmin
Inj 10,000 iu per 1 ml graduated syringe	77.55	10	~	Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe		10	~	Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe		10	~	Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe	158.47	10	~	Fragmin

SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM – Special Authority see SA1174 on the next page – Retail pharmacy

Inj 20 mg		10	Clexane
Inj 40 mg		10	Clexane
Inj 60 mg		10	Clexane
Inj 80 mg		10	Clexane
Inj 100 mg	125.06	10	Clexane
Inj 120 mg	155.40	10	Clexane
Inj 150 mg	177.60	10	Clexane

(Mar	Subsidy nufacturer's Price)	F Subsidi	ully	Brand or Generic	
	\$	Per	~	Manufacturer	

➡SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
 - 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
 - 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
 - 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
 - 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml13.36	10	Hospira	
66.80	50	Hospira	
61.04		✓ Pfizer	
Inj 1,000 iu per ml, 35 ml16.00	1	Hospira	
Inj 5,000 iu per ml, 1 ml14.20	5	✓ Hospira	
Inj 5,000 iu per ml, 5 ml236.60	50	✓ Pfizer	
Inj 25,000 iu per ml, 0.2 ml9.50	5	 Hospira 	
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml	50	✓ Pfizer	
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml	10		
(119.23)	10	Artex	
		, it los	
Oral Anticoagulants			
DABIGATRAN			
Cap 75 mg - No more than 2 cap per day148.00	60	Pradaxa	
Cap 110 mg	60	Pradaxa	
Cap 150 mg148.00	60	✓ Pradaxa	
		- I I WWAA	
RIVAROXABAN – Special Authority see SA1066 on the next page – Retail pharmacy			
Tab 10 mg153.00	15	Xarelto	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	50	Coumadin
	6.86	100	Marevan
*	Tab 2 mg4.31	50	Coumadin
*	Tab 3 mg9.70	100	Marevan
*	Tab 5 mg5.93	50	Coumadin
	11.75	100	Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see SA1259 below – Retail pl	harmacy		
Inj 300 mcg per 0.5 ml prefilled syringe		5	Zarzio
Inj 480 mcg per 0.5 ml prefilled syringe		5	 Zarzio

➡SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk $\geq 20\%$ after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM - Special Authority see SA1384 below - Retail pharmacy

Inj 6 mg per 0.6 ml syringe 1,080.00 1 🖌 Veulastim

➡SA1384 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk $\geq 20\%^*$).

Note: *Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	
Fluids and Electrolytes				
Intravenous Administration				
GLUCOSE [DEXTROSE]				
 Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO 		5 1	-	<u>Biomed</u> Biomed
POTASSIUM CHLORIDE		50	-	AstraZeneca
		50	•	Astrazeneca
SODIUM BICARBONATE Inj 8.4%, 50 mla) Up to 5 inj available on a PSO b) Not in combination	19.95	1	~ I	Biomed
a) Up to 5 inj available on a PSO b) Not in combination	20.50	1	✔ I	Biomed
SODIUM CHLORIDE Not funded for use as a nasal drop. Only funded for nebuliser	use when in conjur	nction w	ith an antil	biotic intended for nebulise
use. Inf 0.9% – Up to 2000 ml available on a PSO		500 ml 1.000 m	· · · ·	Baxter Baxter
Only if prescribed on a prescription for renal dialysis, mate for emergency use. (500 ml and 1,000 ml packs)		'		
Inj 23.4%, 20 ml		5	V <u>I</u>	Biomed
For Sodium chloride oral liquid formulation refer Standard Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		2 50		Multichem
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO	15.50 11.50	50	v 1	Pfizer Multichem
Inj 0.9%, 20 ml	15.50	c		Pfizer
inj 0.9%, 20 mi		6 30		Pharmacia Pharmacia
	8.41	20		Multichem
TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Spe Infusion		1 OP	~ 1	FPN
WATER		1 01	•	
 On a prescription or Practitioner's Supply Order only who Schedule requiring a solvent or diluent; or On a bulk supply order; or When used in the extemporaneous compounding of eye 		n as an	injection li	isted in the Pharmaceutica
Purified for inj, 5 ml – Up to 5 inj available on a PSO		50	v 1	Multichem
Purified for inj, 10 ml – Up to 5 inj available on a PSO Purified for inj, 20 ml – Up to 5 inj available on a PSO		50 20	· · · ·	Multichem Multichem
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE	160.05	00 ~ 01		Coloium Descritum
	109.85 3	800 g Ol	- v (Calcium Resonium
COMPOUND ELECTROLYTES Powder for oral soln – Up to 10 sach available on a PSO	1.80	10	✓ <u>I</u>	<u>Enerlyte</u>

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
DEXTROSE WITH ELECTROLYTES				
Soln with electrolytes	6.55	1,000 ml OP		edialyte - Bubblegum
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	🖌 Pl	hosphate-Sandoz
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26	60		
	(11.85)		С	hlorvescent
* Tab long-acting 600 mg	7.42	200	🗸 S	pan-K
SODIUM BICARBONATE				
Cap 840 mg		100	🗸 S	odibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	89.10	450 g OP	V B	esonium-A

	Subsidy (Manufacturer's F	Price) Sub	Fully Brand or osidised Generic
	\$	Per	✓ Manufacturer
Alpha Adrenoceptor Blockers			
DOXAZOSIN			
* Tab 2 mg	6.75	500	✓ Apo-Doxazosin
* Tab 4 mg	9.67	500	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE			
* Cap 10 mg	65.00	30	✓ BNM \$29
PRAZOSIN			
* Tab 1 mg	5.53	100	Apo-Prazosin
* Tab 2 mg		100	Apo-Prazosin
* Tab 5 mg	11.70	100	Apo-Prazosin
TERAZOSIN			
* Tab 1 mg	0.50	28	✓ <u>Arrow</u>
* Tab 2 mg	0.45	28	✓ <u>Arrow</u>
* Tab 5 mg	0.68	28	✓ <u>Arrow</u>
Agents Affecting the Renin-Angiotensin System			
ACE Inhibitors			
CAPTOPRIL			
*‡ Oral liq 5 mg per ml	94.99	95 ml OP	 Capoten
Oral liquid restricted to children under 12 years of age.			
CILAZAPRIL			
* Tab 0.5 mg	2.00	90	✓ Zapril
* Tab 2.5 mg	4.31	90	Zapril
* Tab 5 mg	6.98	90	Zapril
ENALAPRIL MALEATE			
* Tab 5 mg		100	 Ethics Enalapril
* Tab 10 mg		100	 Ethics Enalapril
* Tab 20 mg - For enalapril maleate oral liquid formulation re-			4
fer, page 209	1.91	100	Ethics Enalapril
LISINOPRIL			
* Tab 5 mg		90	Arrow-Lisinopril
* Tab 10 mg		90	Arrow-Lisinopril
* Tab 20 mg	4.88	90	Arrow-Lisinopril
PERINDOPRIL		•-	
* Tab 2 mg		30	✓ <u>Apo-Perindopril</u>
* Tab 4 mg	4.80	30	Apo-Perindopril
QUINAPRIL		• -	. .
* Tab 5 mg		90	Arrow-Quinapril 5
* Tab 10 mg * Tab 20 mg		90 90	Arrow-Quinapril 10
* Tab 20 mg	0.04	50	Arrow-Quinapril 20

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

TRANDOLAPRIL

	Higher subsidy by endorsement is available for patients who were to prior to 1 June 1998. The prescription must be endorsed according are "certified condition" or an appropriate description of the pati cardiac failure" or "CCF". For the purposes of this endorsement infarction with an ejection fraction of less than 40%. Patients who full subsidy by endorsement.	gly. We recommi ient such as "co , congestive hea	end that the ongestive he art failure ind	words used to indicate eligibility eart failure", "CHF", "congestive cludes patients post myocardial
*	Cap 1 mg - Higher subsidy of \$18.67 per 28 cap with En- dorsement	3.06 (18.67)	28	Gopten
*	Cap 2 mg - Higher subsidy of \$27.00 per 28 cap with En- dorsement	4.43 (27.00)	28	Gopten
AC	CE Inhibitors with Diuretics			
	AZAPRIL WITH HYDROCHLOROTHIAZIDE Tab 5 mg with hydrochlorothiazide 12.5 mg	10.72	100	✓ <u>Apo-</u> Cilazapril/Hydrochlorothiazide
	ALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE Tab 20 mg with hydrochlorothiazide 12.5 mg	3.32 (8.70)	30	Co-Renitec
*	NAPRIL WITH HYDROCHLOROTHIAZIDE Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg		30 30	✓ <u>Accuretic 10</u> ✓ <u>Accuretic 20</u>
Ar	ngiotensin II Antagonists			
* * * ■ Initi		4.13 6.10 10.18 17.66 t practitioner. Ap	90 90 90 90 90 pprovals valid	
notif	fied for applications meeting the following criteria:			

- or
- 2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

LOSARTAN POTASSIUM

*	Tab 12.5 mg1.55	84	Losartan Actavis
*	Tab 25 mg	84	Losartan Actavis
*	Tab 50 mg2.25	84	Losartan Actavis
*	Tab 100 mg2.60	84	Losartan Actavis

	Subsidy [Manufacturer's Price] \$) (Per	Fully Subsidised	
Angiotensin II Antagonists with Diuretics				
OSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE				
Tab 50 mg with hydrochlorothiazide 12.5 mg	2.18	30	•	Arrow-Losartan & Hydrochlorothiazid
Antiarrhythmics				
For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesth	etics, Local, page	125		
AMIODARONE HYDROCHLORIDE				
Tab 100 mg – Retail pharmacy-Specialist		30		Aratac
Tab 200 mg Batail pharmacy Specialist	20 52	30		Cordarone-X Aratac
Tab 200 mg – Retail pharmacy-Specialist		30	• •	Cordarone-X
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a				
PSO	22.80	6		Cordarone-X
ATROPINE SULPHATE				
* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a				
PSO	71.00	50	V <u>I</u>	AstraZeneca
DIGOXIN				
* Tab 62.5 mcg – Up to 30 tab available on a PSO		240		Lanoxin PG
* Tab 250 mcg – Up to 30 tab available on a PSO		240		Lanoxin
*‡ Oral liq 50 mcg per ml		60 ml	V	Lanoxin
DISOPYRAMIDE PHOSPHATE				
▲ Cap 100 mg		100		
A Ora 150 mm	(23.87)	100		Rythmodan Buthmodan
▲ Cap 150 mg		100	V	Rythmodan
FLECAINIDE ACETATE – Retail pharmacy-Specialist	00.05			- .
▲ Tab 50 mg		60	V	Tambocor
▲ Tab 100 mg – For flecainide acetate oral liquid formulation	CO 70	~~		Tauchaaau
refer, page 209		60 30		Tambocor Tambocor CR
 ▲ Cap long-acting 100 mg ▲ Cap long-acting 200 mg 		30 30		Tambocor CR
Inj 10 mg per ml, 15 ml ampoule		30 5		Tambocor
		Ũ	•	
MEXILETINE HYDROCHLORIDE ▲ Cap 150 mg	65.00	100	~	Mexiletine
		100	•	Hydrochloride USP \$29
▲ Cap 250 mg	102.00	100	•	Mexiletine Hydrochloride USP §29
PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialisi	t			
▲ Tab 150 mg		50	~	Rytmonorm
Antihypotensives				
MIDODRINE – Special Authority see SA1474 on the next page – F	etail pharmacy			
Tab 2.5 mg		100		Gutron
Tab 5 mg		100		Gutron

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

SA1474 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta Adrenoceptor Blockers

ATENOLOL			
* Tab 50 mg	5.56	500	Mylan Atenolol
* Tab 100 mg	9.12	500	Mylan Atenolol
* Oral liq 25 mg per 5 ml	21.25	300 ml OP	Atenolol AFT
Restricted to children under 12 years of age.			
BISOPROLOL FUMARATE			
Tab 2.5 mg	2.40	30	✓ Bosvate
Tab 5 mg		30	✓ Bosvate
Tab 10 mg	6.40	30	✓ Bosvate
CARVEDILOL			
* Tab 6.25 mg		30	✓ Dilatrend
	3.90	60	✓ Dicarz
Dicarz to be Sole Supply on 1 September 2015			
* Tab 12.5 mg	2.55	30	Dilatrend
Ŭ	5.10	60	Dicarz
Dicarz to be Sole Supply on 1 September 2015			
* Tab 25 mg - For carvedilol oral liquid formulation refer, page			
209	3.15	30	Dilatrend
	6.30	60	Dicarz
Dicarz to be Sole Supply on 1 September 2015			
(Dilatrend Tab 6.25 mg to be delisted 1 September 2015)			
(Dilatrend Tab 12.5 mg to be delisted 1 September 2015)			
(Dilatrend Tab 25 mg to be delisted 1 September 2015)			
CELIPROLOL			
* Tab 200 mg		180	V Celol
LABETALOL			
* Tab 50 mg	8 23	100	✓ Hybloc
 * Tab 50 mg – For labetalol oral liquid formulation refer, page 	0.20	100	• Hybroc
209	10.06	100	✓ Hybloc
* Tab 200 mg		100	✓ Hybloc
 * Inj 5 mg per ml, 20 ml ampoule 		5	• Hybloc
	(88.60)	5	Trandate
	(00.00)		nandate
METOPROLOL SUCCINATE			
* Tab long-acting 23.75 mg		30	Metoprolol - AFT CR
* Tab long-acting 47.5 mg		30	Metoprolol - AFT CR
* Tab long-acting 95 mg		30	Metoprolol - AFT CR
* Tab long-acting 190 mg	4.00	30	Metoprolol - AFT CR

	Subsidy (Manufacturer's F \$	Price) Per	Fully Subsidised	Brand or Generic Manufacturer
IETOPROLOL TARTRATE				
 Tab 50 mg – For metoprolol tartrate oral liquid formu 	lation			
refer, page 209		100	🖌 <u>L</u>	opresor
 Tab 100 mg 	21.00	60	🖌 <u>L</u> a	opresor
 Tab long-acting 200 mg 		28	✓ SI	ow-Lopresor
 Inj 1 mg per ml, 5 ml vial 		5	🖌 <u>Lo</u>	opresor
IADOLOL				
 Tab 40 mg 	15.57	100	🖌 A1	po-Nadolol
← Tab 80 mg		100		po-Nadolol
INDOLOL				
	0.70	100		na Dindalal
Tab 5 mg		100		po-Pindolol
Tab 10 mg		100		po-Pindolol
 Tab 15 mg 	23.40	100		po-Pindolol
ROPRANOLOL				
 Tab 10 mg 	3.65	100	🖌 A	po-
				Propranolol S29
 Tab 40 mg 	165	100	🗸 A	
 Tab 40 mg 	4.00	100		
				Propranolol S29
Cap long-acting 160 mg		100	🖌 Ca	ardinol LA
 Oral lig 4 mg per ml – Special Authority see SA1327 be 				
Retail pharmacy		500 ml	🖌 Re	oxane S29

➡SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL

*	Tab 80 mg - For sotalol oral liquid formulation refer, page 20927.50	500	🖌 Mylan
*	Tab 160 mg 10.50	100	🖌 Mylan
*	Inj 10 mg per ml, 4 ml ampoule65.39	5	 Sotacor
TIN	IOLOL		
*	Tab 10 mg10.55	100	🖌 Apo-Timol

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
alcium Channel Blockers				
hydropyridine Calcium Channel Blockers				
LODIPINE				
Tab 2.5 mg		100	✓ <u>I</u>	Apo-Amlodipine
Tab 5 mg – For amlodipine oral liquid formulation refer, pag 209		250	~ /	Apo-Amlodipine
Apo-Amlodipine to be Sole Supply on 1 August 2015				
Tab 10 mg	7.21	250	V I	Apo-Amlodipine
Apo-Amlodipine to be Sole Supply on 1 August 2015				
ODIPINE		~~		
Tab long-acting 2.5 mg		30 30		<u>Plendil ER</u> Plendil ER
Tab long-acting 5 mg Tab long-acting 10 mg		30 30		Plendil ER
0 0 0	4.00	00	• •	
ADIPINE Cap long-acting 2.5 mg	7.50	30	. .	Dynacirc-SRO
Cap long-acting 2.5 mg		30		Dynacirc-SRO
		00	• -	
EDIPINE Tab long-acting 10 mg	17 79	60		Adalat 10
Tab long-acting 20 mg		100		Vyefax Retard
Tab long-acting 30 mg		30		Adefin XL
Tab long-acting 60 mg		30		Adefin XL
her Calcium Channel Blockers				
TIAZEM HYDROCHLORIDE				
Tab 30 mg	4.60	100	~ [Dilzem
Tab 60 mg - For diltiazem hydrochloride oral liquid formul			-	
tion refer, page 209		100	I = 1	Dilzem
Cap long-acting 120 mg	1.91	30		Cardizem CD
	31.83	500		Apo-Diltiazem CD
Cap long-acting 180 mg		30		Cardizem CD
	47.67	500		Apo-Diltiazem CD
Cap long-acting 240 mg		30 500		Cardizem CD Apo-Diltiazem CD
	03.30	500	• •	Apo-Dimazein CD
	60.00	100		Dovoia
Tab 100 mg		100	•	Pexsig
	7.04			
Tab 40 mg		100		soptin
Tab 80 mg – For verapamil hydrochloride oral liquid formul		400		
tion refer, page 209		100		<u>soptin</u> Iornamil SB
Tab long-acting 120 mg Tab long-acting 240 mg		250 250		/erpamil SR /erpamil SR
Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on		200	•	
$111 z_{0}$ $112 y_{0}$ $111 y_{0}$ $111 z_{0}$ $111 $	a 7.54	5		soptin

	a			
	Subsidy (Manufacturer's Price)	\ \	Full	
	(Inidialidiacidiei 3 1 1106) \$	Per	Subsidiser V	Manufacturer
Centrally-Acting Agents				
CLONIDINE				
* Patch 2.5 mg, 100 mcg per day – Only on a prescription		4	~	Catapres-TTS-1
* Patch 5 mg, 200 mcg per day - Only on a prescription		4		Catapres-TTS-2
* Patch 7.5 mg, 300 mcg per day - Only on a prescription		4		Catapres-TTS-3
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg		112	~	Clonidine BNM
* Tab 150 mcg		100	~	Catapres
* Inj 150 mcg per ml, 1 ml ampoule		5	~	Catapres
METHYLDOPA				
* Tab 125 mg		100	~	Prodopa
* Tab 250 mg		100		Prodopa
* Tab 500 mg		100	~	Prodopa
Diuretics				
Diuretics				
Loop Diuretics				
BUMETANIDE				
* Tab 1 mg	16.36	100	~	Burinex
* Inj 500 mcg per ml, 4 ml vial		5		Burinex
, , , ,		0	•	Burnex
FUROSEMIDE [FRUSEMIDE]	10.05	1 000		Diumin 40
 * Tab 40 mg – Up to 30 tab available on a PSO * Tab 500 mg 		1,000 50		<u>Diurin 40</u> Urex Forte
* 1ab 500 mg *‡ Oral liq 10 mg per ml		0 ml Ol		Lasix
 * Inj 10 mg per ml, 25 ml ampoule 		5		Lasix
 * Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a 		Ū	•	
PSO		5	~	Frusemide-Claris
		Ū	·	
Potassium Sparing Diuretics				
AMILORIDE HYDROCHLORIDE				
* Tab 5 mg		100		Apo-Amiloride
Oral liq 1 mg per ml		5 ml Ol	P 🗸	Biomed
METOLAZONE - Special Authority see SA1349 below - Retail p	harmacy			
Tab 5 mg	CBS	1	~	Metolazone S29
		50	~	Zaroxolyn S29
SA1349 Special Authority for Subsidy				-
Initial application from any relevant practitioner. Approvals valid	without further rene	wal un	less notifi	ed where used for the treat
ment of patients with refractory heart failure who are intolerant or				
nation therapy.	-			
SPIRONOLACTONE				
* Tab 25 mg		100	~	Spiractin
* Tab 100 mg		100		Spiractin
toral liq 5 mg per ml		5 ml Ol	P 🖌	Biomed
Potassium Sparing Combination Diuretics				
rotassium sparing combination Didletics				

AMILORIDE	HYDROCHLORIDE WITH FUROSEMIDE			
* Tab 5 m	ng with furosemide 40 mg	8.63	28	🖌 Frumil

	Subsidy	Duine) Out	Fully Brand or
	(Manufacturer's I \$	Price) Suc Per	vsidised Generic Manufacturer
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIA	ZIDE		
* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	 Moduretic
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
* Tab 2.5 mg – Up to 150 tab available on a PSO		500	Arrow- Bendrofluazide
May be supplied on a PSO for reasons other than emerged		500	
* Tab 5 mg	8.95	500	Arrow- Bendrofluazide
CHLOROTHIAZIDE			
t Oral liq 50 mg per ml		25 ml OP	Biomed
CHLORTALIDONE [CHLORTHALIDONE]			. .
* Tab 25 mg	8.00	50	 Hygroton
NDAPAMIDE * Tab 2.5 mg	2.25	90	✓ Dapa-Tabs
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE			
* Tab 200 mg		90	✓ <u>Bezalip</u>
* Tab long-acting 400 mg	5.70	30	Bezalip Retard
GEMFIBROZIL * Tab 600 mg	17.60	60	🖌 Lipazil
•		00	
Other Lipid-Modifying Agents			
ACIPIMOX	10 75	30	✓ Olbetam
* Cap 250 mg		30	
NICOTINIC ACID * Tab 50 mg		100	Apo-Nicotinic Acid
* Tab 500 mg		100	✓ Apo-Nicotinic Acid
Resins			
CHOLESTYRAMINE			
Powder for oral liq 4 g		50	
	(52.68)		Questran-Lite
	00.00	00	
Grans for oral liq 5 g	22.00	30	✓ Colestid
HMG CoA Reductase Inhibitors (Statins)			

Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

	Subsidy		Fully	Brand or	
	(Manufacturer's Price)		Subsidised	Generic	
	\$	Per	~	Manufacturer	
ATORVASTATIN – See prescribing guideline on the previous page	ne				
* Tab 10 mg		30	V Li	ipitor	
				fizer atorvastatin	
	2.52	90	✓ Z	arator	
* Tab 20 mg		30		ipitor	
				fizer atorvastatin	
	4.17	90	✓ Z	arator	
* Tab 40 mg		30	V L	ipitor	
				fizer atorvastatin	
	7.32	90		arator	
* Tab 80 mg		30	V L	ipitor	
			🖌 P	fizer atorvastatin	
	16.23	90	VZ	arator	
(Lipitor Tab 10 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 10 mg to be delisted 1 November 2015) (Lipitor Tab 20 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 20 mg to be delisted 1 November 2015) (Lipitor Tab 40 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 40 mg to be delisted 1 November 2015) (Lipitor Tab 80 mg to be delisted 1 November 2015) (Lipitor Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015) (Pfizer atorvastatin Tab 80 mg to be delisted 1 November 2015)		30		<u>holvastin</u>	
* Tab 40 mg		30	V C	holvastin	
SIMVASTATIN – See prescribing guideline on the previous page * Tab 10 mg * Tab 20 mg * Tab 40 mg * Tab 80 mg	0.95 	90 90 90 90		rrow-Simva 10mg rrow-Simva 20mg rrow-Simva 40mg rrow-Simva 80mg	
Selective Cholesterol Absorption Inhibitors			_		
Selective cholesteror Absorption inhibitors					
EZETIMIBE – Special Authority see SA1045 below – Retail pha Tab 10 mg		30		zemibe zetrol	

➡SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 \times normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg	5.15	30	Zimybe
	36.68		 Vytorin
Tab 10 mg with simvastatin 20 mg	6.15	30	Zimybe
	38.70		Vytorin
Tab 10 mg with simvastatin 40 mg	7.15	30	 Zimybe
	41.40		🖌 Vytorin
Tab 10 mg with simvastatin 80 mg	8.15	30	 Zimybe
	45.45		 Vytorin

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Nitrates

GLYCERYL TRINITRATE			
* Tab 600 mcg – Up to 100 tab available	le on a PSO8.00	100 OP	 Lycinate
* Oral pump spray, 400 mcg per dose	– Up to 250 dose avail-		
able on a PSO		250 dose OP	 Nitrolingual Pump Spray
* Oral spray, 400 mcg per dose - Up to	250 dose available on		opiay
		250 dose OP	✓ Glytrin
* Patch 25 mg, 5 mg per day		30	Nitroderm TTS
* Patch 50 mg, 10 mg per day		30	Nitroderm TTS
ISOSORBIDE MONONITRATE			
* Tab 20 mg		100	✓ Ismo 20
* Tab long-acting 40 mg	7.50	30	Ismo 40 Retard
* Tab long-acting 60 mg		90	 Duride

	Subsidy (Manufacturer's Price) Si	Fully Brand or ubsidised Generic
	\$	Per	 Manufacturer
Sympathomimetics			
ADRENALINE			
Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO	4.98	5	Aspen Adrenaline
	5.25		✓ Hospira
Inj 1 in 10,000, 10 ml ampoule - Up to 5 inj available on a			
PSO		5	Hospira
	49.00	10	 Aspen Adrenaline
SOPRENALINE	26.00	05	
Inj 200 mcg per ml, 1 ml ampoule	(164.20)	25	Isuprel
N 111 1	(104.20)		ISUPICI
Vasodilators			
MYL NITRITE			
Liq 98% in 0.3 ml cap		12	
	(73.40)		Baxter
IYDRALAZINE HYDROCHLORIDE			
Tab 25 mg – Special Authority see SA1321 below – Retail			
pharmacy	CBS	1	 Hydralazine
h 100		56	✓ Onelink S29
k Inj 20 mg ampoule		5	Apresoline
SA1321 Special Authority for Subsidy			
nitial application from any relevant practitioner. Approvals valic he following criteria:	i without further ren	ewai unie	ess notified for applications meetir
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure in combination with a nit	rate, in patients who	are intole	erant or have not responded to AC
inhibitors and/or angiotensin receptor blockers.			
/INOXIDIL – Special Authority see SA1271 below – Retail pharn	nacy		
Tab 10 mg		100	 Loniten
SA1271 Special Authority for Subsidy			
nitial application only from a relevant specialist. Approvals valid		wal unles	ss notified where patient has seven
efractory hypertension which has failed to respond to extensive n	nultiple therapies.		
licorandil	07.05		4 H H
Tab 10 mg		60	 ✓ Ikorel ✓ Ikorel
Tab 20 mg		60	
APAVERINE HYDROCHLORIDE • Inj 12 mg per ml, 10 ml ampoule	217.00	5	✓ Hospira
	217.90	J	
ENTOXIFYLLINE [OXPENTIFYLLINE]	26.04	50	
Tab 400 mg		50	Trental 400
	(42.20)		iremai 400

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Generic
Endothelin Receptor Antagonists			
► SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertension Notes: Application details may be obtained from PHARMAC's well The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.g	osite http://www.pharr	nac.govt.nz or:	
AMBRISENTAN – Special Authority see SA0967 above – Retail p Tab 5 mg Tab 10 mg	4,585.00	•••••	Volibris Volibris
BOSENTAN – Special Authority see SA0967 above – Retail phar Tab 62.5 mg Tab 125 mg	macy 1,500.00 4,585.00 1,500.00	60 V	oms-Bosentan Iracleer oms-Bosentan Iracleer
Phosphodiesterase Type 5 Inhibitors	4,585.00	V	Induleer

SA1293 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon* - for Pulmonary Arterial Hypertension see note below) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Notes: Sildenafil is also funded for patients with Pulmonary Arterial Hypertension who are approved by the Pulmonary Arterial Hypertension Panel (an application must be made using form <u>SA1293-PAH</u>).

Application details may be obtained from:

The Coordinator, PAH Panel

PHARMAC, PO Box 10 254, Wellington

Phone: (04) 916 7561 Facsimile: (04) 974 4858 Email: PAH@pharmac.govt.nz

Indications marked with * are Unapproved Indications.

harmacy		
	4	🖌 Silagra
1.85	4	 Silagra
ge		
7.45	4	 Silagra
	1.85 1.85 ge	1.85 4 1.85 4 ge

Prostacyclin Analogues

SA0969 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The Coordinator, PAH Panel

60

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer	
ILOPROST – Special Authority see SA0969 on the previous page Nebuliser soln 10 mcg per ml, 2 ml		30	🖌 Ve	entavis	

	Subsidy (Manufacturer's Price)		Fully dised	Brand or Generic
	\$	Per	~	Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, p	age 91			
ADAPALENE				
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Crm 0.1%		0 g OP	🖌 Di	ifferin
Gel 0.1%		0 g OP	🖌 Di	ifferin
ISOTRETINOIN – Special Authority see SA1475 below – Retail ph	armacv			
Cap 10 mg	,	120	v 0	ratane
Cap 20 mg		120	v 0	ratane

SA1475 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 3.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g	 Maximum of 50 g per prescription 	13.90	50 g OP	ReTrieve
------------------	--	-------	---------	----------

	Subsidy (Manufacturer's I \$	Price) Sul Per	Fully Brand or bsidised Generic Manufacturer
Antibacterials Topical			
or systemic antibacterials, refer to INFECTIONS, Antibacterials	s, page 91		
USIDIC ACID			
Crm 2%	2.52	15 g OP	✓ <u>DP Fusidic Acid</u> Cream
a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination			
Oint 2% a) Maximum of 15 g per prescription b) Only on a prescription	3.45	15 g OP	✓ Foban
c) Not in combination			
YDROGEN PEROXIDE € Crm 1%	8.56	15 g OP	✓ Crystaderm
IUPIROCIN Oint 2%	6.60 (9.26)	15 g OP	Bactroban
a) Only on a prescriptionb) Not in combination	()		
ILVER SULPHADIAZINE			4 - 1
Crm 1%a) Up to 250 g available on a PSO b) Not in combination	12.30	50 g OP	Flamazine
Antifungals Topical			
or systemic antifungals, refer to INFECTIONS, Antifungals, pag	1e 97		
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5%		5 ml OP	✓ <u>MycoNail</u>
ICLOPIROX OLAMINE a) Only on a prescription b) Not in combination			
Nail-soln 8%	8.23	7 ml OP	✓ <u>Apo-Ciclopirox</u>
LOTRIMAZOLE ∉ Crm 1%a) Only on a prescription b) Not in combination	0.52	20 g OP	✓ <u>Clomazol</u>
Soln 1%	4.36	20 ml OP	
a) Only on a prescription	(7.55)	_0 01	Canesten
b) Not in combination			

	Subsidy	(i.i) Ou	Fully Brand or
(Manufacturer's P) \$	rice) Su Per	ubsidised Generic Manufacturer
ECONAZOLE NITRATE			
Crm 1%		20 g OP	
••••••	(7.48)	_0 g 0.	Pevaryl
a) Only on a prescription	()		
b) Not in combination			
Foaming soln 1%, 10 ml sachets	9.89	3	
	(17.23)		Pevaryl
a) Only on a prescription			
b) Not in combination			
/ICONAZOLE NITRATE			
₭ Crm 2%	0.55	15 g OP	Multichem
a) Only on a prescription			
b) Not in combination			
₭ Lotn 2%	4.36	30 ml OP	
	(10.03)		Daktarin
a) Only on a prescription			
b) Not in combination			
₭ Tinct 2%		30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription			
b) Not in combination			
VYSTATIN			
Crm 100,000 u per g		15 g OP	
	(7.90)		Mycostatin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription b) Not in combination			
Crm, aqueous, BP	1 77	100 g	Pharmacy Health
Lotn. BP		2.000 ml	✓ PSM
		2,000 m	<u> </u>
CROTAMITON			
a) Only on a prescription			
b) Not in combination Crm 10%	3 / 8	20 g OP	✓ Itch-Soothe
		20 9 01	
IENTHOL – Only in combination			
 Only in combination with a dermatological base or proprie 	etary Iopical C	orticosteriod	- Plain, reter dermatological bas
page 208			
2) With or without other dermatological galenicals.			4
Crystals		25 g	✓ PSM
	6.92	100 -	✓ MidWest
	29.60	100 g	 MidWest

	Subsidy	Price) Deck		Brand or Canoria
	(Manufacturer's F \$	Per Sub		Generic Manufacturer
Corticosteroids Topical				
or systemic corticosteroids, refer to CORTICOSTEROIDS AND F	RELATED AGEN	ITS, page 79		
Corticosteroids - Plain				
ETAMETHASONE DIPROPIONATE				
Crm 0.05%	2.96	15 g OP	•	prosone
	8.97	50 g OP		prosone
Crm 0.05% in propylene glycol base	4.33	30 g OP		prosone OV
Oint 0.05%	2.96	15 g OP		orosone
	8.97	50 g OP	🖌 Dip	orosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	🖌 Dip	prosone OV
ETAMETHASONE VALERATE				
Crm 0.1%		50 g OP	🖌 Bei	ta Cream
Beta Cream to be Sole Supply on 1 July 2015		5 5 5		
Oint 0.1%		50 g OP	🖌 Bei	ta Ointment
Beta Ointment to be Sole Supply on 1 July 2015				
Lotn 0.1%		50 ml OP	🖌 Bet	tnovate
-OBETASOL PROPIONATE Crm 0.05%	2.00	20 ~ OD		betasol BNM
CIII 0.05%	3.20	30 g OP		
Oint 0.05%	2 20	30 g OP	• -•	betasol BNM
Oint 0.05%		30 Y OF		
			V De	rmoi
_OBETASONE BUTYRATE				
Crm 0.05%	5.38	30 g OP		
	(7.09)		Eur	novate
	16.13	100 g OP		
	(22.00)		Eur	novate
FLUCORTOLONE VALERATE				
Crm 0.1%	8.97	50 g OP		
	(15.86)	0	Ne	risone
Fatty oint 0.1%		50 g OP		
-	(15.86)	v	Ne	risone
(DROCORTISONE	. ,			
	3 75	100 g	V Ph	armacy Health
Crm 1% – Only on a prescription		500 g		armacy Health
Powder – Only in combination		25 g		
Up to 5% in a dermatological base (not proprietary Topic galenicals. Refer, page 208		•		
PROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% - Only				
on a prescription		250 ml	🖌 DP	Lotn HC
		200111	+ <u>bi</u>	
YDROCORTISONE BUTYRATE	0.00	00 - 00		
Lipocream 0.1%		30 g OP		coid Lipocream
0:-+ 0.494	6.85	100 g OP		coid Lipocream
Oint 0.1% Milky emul 0.1%		100 g OP 100 ml OP	Loi	<u>coid</u> coid Crelo

	Subsidy		Full	
	(Manufacturer's F \$	Price) Per	Subsidise	d Generic Manufacturer
Crm 0.1%	4.95	15 g Ol	- -	Advantan
Oint 0.1%		15 g Ol		Advantan
MOMETASONE FUROATE				
Crm 0.1%	1 78	15 g Ol	- -	m-Mometasone
	3.42	45 g Ol		m-Mometasone
Oint 0.1%		15 g Ol		m-Mometasone
	3.42	45 g Ol		m-Mometasone
Lotn 0.1%	7.35	30 ml O	Р	
	(11.13)			Elocon
TRIAMCINOLONE ACETONIDE				
Crm 0.02%	6.30	100 g O	P 🖌	Aristocort
Oint 0.02%	6.35	100 g O	P 🖌	Aristocort
Corticosteroids - Combination				
BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a		15 - 0	~	
Crm 0.1% with clioquinol 3%	3.49 (4.90)	15 g Ol		Betnovate-C
	(4.90)			Dell'IOvale-C
BETAMETHASONE VALERATE WITH FUSIDIC ACID	0.40	45 0	_	
Crm 0.1% with fusidic acid 2%		15 g Ol		Fusies
a) Maximum of 15 g per prescription	(10.45)			Fucicort
b) Only on a prescription				
	1			
HYDROCORTISONE WITH MICONAZOLE – Only on a prescrip * Crm 1% with miconazole nitrate 2%		15 g Ol		Micreme H
		•	•	
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - O				-
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g Ol		Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g Ol	~	Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI		N		
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			_	
and gramicidin 250 mcg per g $-$ Only on a prescription .		15 g Ol		
	(6.60)			Viaderm KC
Disinfecting and Cleansing Agents				
CHLORHEXIDINE GLUCONATE – Subsidy by endorsement				
a) No more than 500 ml per month				
b) Only if prescribed for a dialysis patient and the prescription	n is endorsed acc	cordingly.		
* Handrub 1% with ethanol 70%		500 m	· ·	healthE
* Soln 4%	5.90	500 m	 ✓ 	Orion
* JOIN 470				
TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b)				
 TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identified with Methicillin- 		ococcus a	ureus (MF	RSA) prior to elective surger
 TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identified with Methicillin- in hospital and the prescription is endorsed accordingly; 	or			
 TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identified with Methicillininin hospital and the prescription is endorsed accordingly; b) Only if prescribed for a patient with recurrent Staphylocod 	or ccus aureus infec	tion and th	e prescrip	otion is endorsed according
 TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identified with Methicillin- in hospital and the prescription is endorsed accordingly; 	or ccus aureus infec		ie prescrip)P 🖌	

	Subsidy		Fully Brand	or
	(Manufacturer's	Price) Sub	sidised Gener	
	\$	Per		acturer
Reverse Areans and Employee				
Barrier Creams and Emollients				
Barrier Creams				
DIMETHICONE				
* Crm 5% pump bottle	4.73	500 ml OP	✓ <u>healthE</u>	
			Dimet	nicone 5%
ZINC AND CASTOR OIL * Oint BP	2 02	500 g	✓ Multiche	m
		500 g	• Multicite	111
Emollients				
AQUEOUS CREAM				
* Crm	1.96	500 g	🖌 AFT	
CETOMACROGOL				
* Crm BP	3.15	500 g	PSM	
CETOMACROGOL WITH GLYCEROL				
Crm 90% with glycerol 10%	4.50	500 ml OP	Pharmac	
			Glycer	ene with
	6.50	1,000 ml OP	✓ Pharmad	
	0.00	.,		ene with
			Glycer	in
EMULSIFYING OINTMENT				
* Oint BP	2.73	500 g	🖌 AFT	
AFT to be Sole Supply on 1 August 2015				
DIL IN WATER EMULSION * Crm	0.60	500 a	√ health⊑	
	2.03	500 g		Fatty Cream
JREA * Crm 10%	1.65	100 g OP	✔ healthE	Urea Cream
		100 g OI		
NOOL FAT WITH MINERAL OIL − Only on a prescription ★ Lotn hydrous 3% with mineral oil	1 40	250 ml OP		
	(4.53)		DP Lotio	n
	5.60	1,000 ml		
	(11.95)		DP Lotio	-
	(20.53)	250 ml OP	Alpha-Ke	ri Lotion
	1.40 (7.73)	250 ml OP	BK Lotio	n
	5.60	1,000 ml		
	(23.91)	,	BK Lotio	า
Other Dermatological Bases				
PARAFFIN				
White soft – Only in combination		500 g		
	(7.78)	- 3	IPW	
	20.20	2,500 g	🖌 IPW	
	3.58	500 g	5014	
Only in combination with a dermatological galenical or a	(8.69)	· · - ·	PSM	

	Subsidy (Manufacturer's I \$	Price) Sub Per	sidised Gen	nd or eric ufacturer
Minor Skin Infections				
POVIDONE IODINE				
Oint 10%a) Maximum of 100 g per prescription b) Only on a prescription	3.27	25 g OP	 Betadi 	ne
Antiseptic soln 10%	0.19	15 ml		
	(4.45)		Betadir	ne
	1.28	100 ml		
	(8.25)		Betadir	
	6.20	500 ml	🖌 Betadi	ne
	1.28	100 ml		
	(4.20)	500 1	Riodine	
Ohio preservation and ideas is direct 00% with 000% closed	6.20	500 ml	 Riodin 	e
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml	Datadir	ne Skin Prep
	(3.65) 10.00	500 ml		ne Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol		100 ml	• Delaui	ne Skii Fiep
	(6.04)	100 111	Orion	
	8.13	500 ml	•	
	(18.63)		Orion	
Parasiticidal Preparations				
GAMMA BENZENE HEXACHLORIDE				
Crm 1%	3.50	50 g OP	🗸 Benhe	x
 IVERMECTIN - Special Authority see SA1225 below - Retail pl Tab 3 mg - Up to 100 tab available on a PSO 1) PSO for institutional use only. Must be endorsed with th Special Authority for patient of that institution. 		4 stitution for whice	✓ Strome ch the PSO is	
 Ivermectin available on BSO provided the BSO includes For the purposes of subsidy of ivermectin, institution m or penal institutions. 				
► SA1225 Special Authority for Subsidy Initial application — (Scabies) from any relevant practitioner. criteria: Both:	Approvals valid f	or 1 month for	applications I	meeting the following
 Applying clinician has discussed the diagnosis of scat microbiologist; and Fither 	pies with a derma	atologist, infect	tious disease	physician or clinical

2 Either:

2.1 Both:

- 2.1.1 The patient is in the community; and
- 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
- 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
- 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following:

- 1 Filaricides: or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 Filaricides; or
 - 2 Cutaneous larva migrans (creeping eruption); or
 - 3 Strongyloidiasis.

MALATHION

Liq 0.5%		200 ml OP 30 ml OP	
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%11.	15	90 g OP	✓ Para Plus

	Subsidy (Manufacturer's Price)		Fully sidised	Brand or Generic
(s s Fi	Per	siuiseu V	Manufacturer
PERMETHRIN				
Crm 5%	4.20	30 g OP	V Ly	derm
Lotn 5%	3.19	30 ml OP	✓ A-	Scabies
Psoriasis and Eczema Preparations				
CITRETIN – Special Authority see SA1476 below – Retail pharma	асу			
Cap 10 mg		60	🖌 <u>N</u> o	ovatretin
Cap 25 mg	41.36	60	✓ No	ovatretin
➡SA1476 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid fo	r 1 year for appl	lications meeti	ng the f	ollowing criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
- 2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

BETAMETHASONE DIFROFIONATE WITH CALCIFOTRICE			
Oint 500 mcg with calcipotriol 50 mcg	.26.12	30 g OP	Daivobet
Topical gel 500 mcg with calcipotriol 50 mcg	.26.12	30 g OP	 Daivobet
CALCIPOTRIOL			
Crm 50 mcg per g	.16.00	30 g OP	Daivonex
	45.00	100 g OP	Daivonex
Oint 50 mcg per g	.45.00	100 g OP	Daivonex
Soln 50 mcg per ml		30 ml OP	 Daivonex
COAL TAR			
Soln – Only in combination	.12.55	200 ml	✓ Midwest
 Up to 10% only in combination with a dermatological base or probase, page 208 	oprietary To	opical Corticos	teriod – Plain, refer dermatological
With or without other dermatological galenicals.			
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR			
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%	3.43	30 g OP	
	(4.35)	Ū	Egopsoryl TA
	6.59	75 g OP	51 ,
	(8.00)	- 5 -	Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	Coco-Scalp

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
SALICYLIC ACID	ۍ ٦	rei	
Powder – Only in combination	18 88	250 g	✔ PSM
1) Only in combination with a dermatological base or pro		0	
dermatological base, page 208			
2) With or without other dermatological galenicals.			
SULPHUR			4 m · · · ·
Precipitated – Only in combination 1) Only in combination with a dermatological base or prop	6.35 prietary Topical (100 g Corticosteroid –	 Midwest Plain, refer dermatological ba
page 208 2) With or without other dermatological galenicals.			
TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU)nly on a preser	intion
 Soln 2.3% with triethanolamine lauryl sulphate and fluores 		nily on a preser	ipiion
cein sodium		500 ml	Pinetarsol
Pinetarsol to be Sole Supply on 1 October 2015			
Scalp Preparations			
BETAMETHASONE VALERATE			
* Scalp app 0.1%	7.75	100 ml OP	🗸 Beta Scalp
CLOBETASOL PROPIONATE			-
* Scalp app 0.05%	6.96	30 ml OP	 Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml OP	✓ Locoid
KETOCONAZOLE			
Shampoo 2%	2.99	100 ml OP	Sebizole
a) Maximum of 100 ml per prescription			
b) Only on a prescription			
Sunscreens			
SUNSCREENS, PROPRIETARY – Subsidy by endorsement			
Only if prescribed for a patient with severe photosensitivity	secondary to a	defined clinical	I condition and the prescription
endorsed accordingly. Crm	2 20	100 g OP	
		TOU Y OF	Hamilton Sunscreen
Lotn,		100 g OP	✓ Marine Blue Lotion
		0	SPF 50+
	5.10	200 g OP	 Marine Blue Lotion SPF 50+
Lotn	4.13	125 ml OP	
	(6.94)		Aquasun 30+
Wart Preparations			
For salicylic acid preparations refer to PSORIASIS AND ECZEM	A PREPARATIO	NS, page 70	
MIQUIMOD			
Crm 5%, 250 mg sachet	17.98	12	✓ <u>Apo-Imiquimod</u> <u>Cream 5%</u>

	Subsidy (Manufacturer's F \$	rice) Subs Per	Fully sidised	Brand or Generic Manufacturer
PODOPHYLLOTOXIN Soln 0.5% a) Maximum of 3.50 ml per prescription b) Only on a prescription		3.5 ml OP	✔ C	ondyline
Other Skin Preparations Antineoplastics				
FLUOROURACIL SODIUM Crm 5%	25.16	20 g OP	✓ <u>E</u>	fudix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Contraceptives - Non-hormonal				
Condoms				
CONDOMS				
₭ 49 mm – Up to 144 dev available on a PSO	13.36	144		larquisTantiliza hield 49
€ 52 mm – Up to 144 dev available on a PSO	13.36	144	V N	Iarquis Selecta Iarquis Sensolite
				larquis Supalite
52 mm extra strength – Up to 144 dev available on a P		144		larquis Protecta
€ 53 mm – Up to 144 dev available on a PSO		12	🗸 S	iold Knight hield Blue
	13.36	144	V N	hield Blue Iarquis Black Iarquis Titillata
€ 53 mm (chocolate) – Up to 144 dev available on a PSC) 111	12		iold Knight
	13.36	144		iold Knight
53 mm (strawberry) – Up to 144 dev available on a PS		12		iold Knight
	13.36	144		old Knight
54 mm, shaped – Up to 144 dev available on a PSO		12	• •	iona rungin
	(1.24)	12	1	ifestyles Flared
	13.36	144	_	nootyloo i laioa
	(14.84)		1	ifestyles Flared
55 mm – Up to 144 dev available on a PSO		144		larguis Conforma
56 mm – Up to 144 dev available on a PSO		12		old Knight
	13.36	144		old Knight
			VD	ourex Extra Safe ourex Select Flavours
€ 56 mm, shaped – Up to 144 dev available on a PSO	1.11	12	🗸 D	urex Confidence
	13.36	144	🖌 D	urex Confidence
60 mm – Up to 144 dev available on a PSO		144	🖌 S	hield XL
Contraceptive Devices				
DIAPHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO.				
65 mm	10 00	1		ortho All-flex
70 mm		1		ortho All-flex
75 mm		1		ortho All-flex
80 mm		1		ortho All-flex
		•		
ITRA-UTERINE DEVICE a) Up to 40 dev available on a PSO b) Only on a PSO				
 ► IUD 29.1 mm length × 23.2 mm width 		1	v 0	hoice TT380 Short
UD 33.6 mm length × 29.9 mm width		1		choice TT380 Standard

GENITO-URINARY SYSTEM

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

➡SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6.62 (19.80)	84	Mercilon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority	see SA0500 abov	e	
	 b) Up to 84 tab available on a PSO 			
*	Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
		(19.80)		Marvelon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority	see SA0500 abov	e	
	b) Up to 84 tab available on a PSO			
ETI	HINYLOESTRADIOL WITH LEVONORGESTREL			
*	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	2.65	84 🖌	🖊 Ava 20 ED
*	Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	9.45	84 🖌	 Microgynon 50 ED
*	Tab 30 mcg with levonorgestrel 150 mcg	6.62	63	
		(16.50)		Microgynon 30
	a) Higher subsidy of \$15.00 per 63 tab with Special Authority	see SA0500 abov	e	
	b) Up to 63 tab available on a PSO			
*	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	2.30	84 🖌	🖊 Ava 30 ED

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Su Per	Fully ubsidised	Brand or Generic Manufacturer
ETHINYLOESTRADIOL WITH NORETHISTERONE				
* Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO	6.62	63	🗸 В	revinor 1/21
* Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	🗸 В	revinor 1/28
* Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab available on a PSO	6.62	63	🗸 В	revinor 21
 Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO 		84	🗸 N	lorimin

Progestogen-only Contraceptives

➡SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- · have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

* Tab 30 mcg	6.62	84	
	(16.50)		Microlut
 a) Higher subsidy of \$13.80 per 84 tab with Special Au b) Up to 84 tab available on a PSO 	thority see SA0500 ab	ove	
* Subdermal implant (2 × 75 mg rods)		1	✓ Jadelle
MEDROXYPROGESTERONE ACETATE * Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a	a PSO7.00	1	✓ <u>Depo-Provera</u>
NORETHISTERONE * Tab 350 mcg – Up to 84 tab available on a PSO	6.00	84	✓ Noriday 28

	Subsidy (Manufacturer's Pric	a) Sub	Fully Brand or sidised Generic
	(Manulacturer 5 1 110 \$	Per	Manufacturer
Emergency Contraceptives			
LEVONORGESTREL * Tab 1.5 mg a) Up to 5 tab available on a PSO b) Maximum of 2 tab per prescription	3.50	1	✓ Postinor-1
Antiandrogen Oral Contraceptives			
Prescribers may code prescriptions "contraceptive" (code "O") wh prescription charge will be as per other contraceptives, as follows: • \$5.00 prescription charge (patient co-payment) will apply • prescription may be written for up to six months supply. Prescriptions coded in any other way are subject to the non contr of supply. ie. Prescriptions may be written for up to three months = CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL * Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up	: raceptive prescripti supply.	on charges,	and the non-contraceptive period
to 168 tab available on a PSO Gynaecological Anti-infectives	5.36	168	✓ <u>Ginet</u>
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC A Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator		100 g OP	Aci-Jel
CLOTRIMAZOLE * Vaginal crm 1% with applicators * Vaginal crm 2% with applicators		35 g OP 20 g OP	✓ <u>Clomazol</u> ✓ <u>Clomazol</u>
MICONAZOLE NITRATE * Vaginal crm 2% with applicator 	3.95	40 g OP	✓ <u>Micreme</u>
NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations		÷	
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a			
PSO	94.70	5	DBL Ergometrine
OESTRIOL * Crm 1 mg per g with applicator * Pessaries 500 mcg OXYTOCIN – Up to 5 inj available on a PSO		15 g OP 15	✔ Ovestin✔ Ovestin
Inj 5 iu per ml, 1 ml ampoule		5	Oxytocin BNM DNM
Inj 10 iu per ml, 1 ml ampoule Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml		5 5	 ✓ <u>BNM</u> ✓ <u>Syntometrine</u>

		GENITO	-URIN	ARY SYSTEM
	Subsidy (Manufacturer's Pric \$	ce) Subs Per	Fully idised	Brand or Generic Manufacturer
Pregnancy Tests - hCG Urine				
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette		40 test OP	5	novacon hCG One Step Pregnancy Test
Urinary Agents				
For urinary tract Infections refer to INFECTIONS, Antibacterials,	page 112			
5-Alpha Reductase Inhibitors				
FINASTERIDE – Special Authority see SA0928 below – Retail p * Tab 5 mg SA0928 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali the following criteria: Both:	1.95	28 newal unless	✓ <u>Fir</u> notified	·
 Patient has symptomatic benign prostatic hyperplasia; at 2 Either: 2.1 The patient is intolerant of non-selective alpha bl 2.2 Symptoms are not adequately controlled with non Note: Patients with enlarged prostates are the appropriate candid 	ockers or these are n-selective alpha bl	ockers.	ed; or	
Alpha-1A Adrenoreceptor Blockers	17			
TAMSULOSIN HYDROCHLORIDE – Special Authority see SA10 * Cap 400 mcg	13.51	100		msulosin-Rex
1 Patient has symptomatic benign prostatic hyperplasia; a 2 The patient is intolerant of non-selective alpha blockers of		ndicated.		
Other Urinary Agents				
OXYBUTYNIN * Tab 5 mg * Oral liq 5 mg per 5 ml POTASSIUM CITRATE Oral liq 3 mmol per ml – Special Authority see SA1083 or	56.45	500 473 ml		o-Oxybutynin o-Oxybutynin
the next page – Retail pharmacy		200 ml OP	🖌 Bio	omed

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	

➡SA1083 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

SODIUM CITRO-TARTRATE

2.93	28	✓ Ural
– Retail pharm	acy	
37.50	30	Vesicare
37.50	30	 Vesicare
	– Retail pharm 37.50	– Retail pharmacy 37.50 30

SA0998 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

TOLTERODINE – Special Authority see SA1272 below – Retail pharmacy		
Tab 1 mg14.56	56	Arrow-Tolterodine
Tab 2 mg14.56	56	Arrow-Tolterodine

SA1272 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

Detection of Substances in Urine			
ORTHO-TOLIDINE			
* Compound diagnostic sticks	7.50	50 test OP	
	(8.25)		Hemastix
TETRABROMOPHENOL			
* Blue diagnostic strips	7.02	100 test OP	
<u> </u>	(13.92)		Albustix

	Subsidy		Fully Brand or
	(Manufacturer's Pr		osidised Generic
	\$	Per	✓ Manufacturer
Calcium Homeostasis			
CALCITONIN			
* Inj 100 iu per ml, 1 ml ampoule	121.00	5	✓ Miacalcic
ZOLEDRONIC ACID			
Inj 4 mg per 5 ml, vial – Special Authority see SA1512 below	550.00		. / 7
− Retail pharmacy →SA1512 Special Authority for Subsidy		1	Zometa
Initial application only from an oncologist, haematologist or pal unless notified for applications meeting the following criteria: Any of the following:	liative care spec	cialist. Appro	vals valid without further renewal
1 Patient has hypercalcaemia of malignancy; or 2 Both:			
2.1 Patient has bone metastases or involvement; and2.2 Patient has severe bone pain resistant to standard	first-line treatme	ents; or	
3 Both:			
3.1 Patient has bone metastases or involvement; and3.2 Patient is at risk of skeletal-related events patho surgery to bone).	logical fracture,	spinal cord c	compression, radiation to bone or
Corticosteroids and Related Agents for Systemic			
Controsteroids and Related Agents for Systemic	, 056		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	
	(33.60)	5	Celestone Chronodose
DEXAMETHASONE			
* Tab 1 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO	5.87	100	✓ Douglas
 Tab 4 mg – Retail pharmacy-Specialist 	8.16	100	✓ Douglas
Up to 30 tab available on a PSO			
Oral liq 1 mg per ml – Retail pharmacy-Specialist Oral lig prescriptions:	45.00	25 ml OP	Biomed
 Must be written by a Paediatrician or Paediatric Cardiologi 	ist; or		
2) On the recommendation of a Paediatrician or Paediatric C	ardiologist.		
DEXAMETHASONE PHOSPHATE			
Dexamethasone phosphate injection will not be funded for oral Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO		10	Dexamethasone-
		_	hameln
* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	17.98	5	 <u>Dexamethasone-</u> hameln
FLUDROCORTISONE ACETATE			
* Tab 100 mcg	14.32	100	✓ Florinef

	Subsidy (Manufacturer's Pric	e)	Full Subsidise	
	\$	Per	•	
IYDROCORTISONE				
 Tab 5 mg 	8.10	100	~	Douglas
Tab 20 mg - For hydrocortisone oral liquid formulation refer,				
page 209		100	~	Douglas
 Inj 100 mg vial 	4.99	1	~	Solu-Cortef
a) Up to 5 inj available on a PSO b) Only on a PSO				
ETHYLPREDNISOLONE – Retail pharmacy-Specialist				
E Tab 4 mg		100	~	Medrol
Tab 100 mg		20		Medrol
ETHYLPREDNISOLONE ACETATE				
	22 50	-		Dana Madral
Inj 40 mg per ml, 1 ml		5	V	Depo-Medrol
ETHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOC				
Inj 40 mg per ml with lidocaine [lignocaine] 1 ml	7.50	1	~	Depo-Medrol with Lidocaine
ETHYLPREDNISOLONE SODIUM SUCCINATE - Retail pharm	nacy-Specialist			
Inj 40 mg per ml, 1 ml		1	~	Solu-Medrol
Inj 62.5 mg per ml, 2 ml		1		Solu-Medrol
Inj 500 mg		1		Solu-Medrol
lnj 1 g		1		Solu-Medrol
REDNISOLONE				
 Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age. 	7.50	30 ml O	Р 🗸	Redipred
REDNISONE				
• Tab 1 mg	2.13	100	~	Apo-Prednisone S29 S29
	10.68	500	~	Apo-Prednisone
F Tab 2.5 mg		500		Apo-Prednisone
Tab 5 mg – Up to 30 tab available on a PSO		500		Apo-Prednisone
- Tab 20 mg		500		Apo-Prednisone
•	20100		·	
	17 71	4		Currenthen
Inj 250 mcg per ml, 1 ml ampoule		1		Synacthen
hitmanormi tml	177.18	10		Synacthen
Inj 1 mg per ml, 1 ml	29.50	1	V	Synacthen Depot
RIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml ampoule		5		Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule	51.10	5	~	Kenacort-A 40
Sex Hormones Non Contraceptive				
Androgen Agonists and Antagonists				
YPROTERONE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg		50		Siterone
Tab 100 mg		50	~	Siterone
ESTOSTERONE				
	80.00	60	~	Androderm
Transdermal patch, 2.5 mg per day		~~		
Transdermal patch, 2.5 mg per day				
Transdermal patch, 2.5 mg per day ESTOSTERONE CYPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial		1		Depo-Testosterone

✓ fully subsidised [HP4] refer page ??

80

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
TESTOSTERONE ESTERS – Retail pharmacy-Specialist Inj 250 mg per ml, 1 ml	12.98	1	 Sustanon Ampoules
TESTOSTERONE UNDECANOATE - Retail pharmacy-Specialis	st		
Cap 40 mg		60	Andriol Testocaps
Inj 250 mg per ml, 4 ml		1	Reandron 1000
Inj 250 mg per ml, 4 ml vial		1	Reandron 1000
(Reandron 1000 Inj 250 mg per ml, 4 ml to be delisted 1 July 201	5)		

Hormone Replacement Therapy - Systemic

SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

		Subsidy (Manufacturer's P \$	rice) Si Per	Fully Brand or ubsidised Generic ✔ Manufacturer
0	estrogens			
DE	STRADIOL - See prescribing guideline on the previous page			
*	Tab 1 mg	4.12	28 OP	
		(11.10)		Estrofem
*	Tab 2 mg	4.12	28 OP	
		(11.10)		Estrofem
¥	TDDS 25 mcg per day	3.01	8	
		(10.86)		Estradot
	a) Higher subsidy of \$10.86 per 8 patch with Special Auth	ority see SA1018	on the previ	ous page
	b) No more than 2 patch per week			
	c) Only on a prescription			
ŧ	TDDS 3.9 mg (releases 50 mcg of oestradiol per day)		4	0.11
		(13.18)		Climara 50
	a) Higher subsidy of \$13.18 per 4 patch with Special Auth	ority see SA1018	on the previ	ous page
	b) No more than 1 patch per week			
	c) Only on a prescription	4.40	0	
*	TDDS 50 mcg per day		8	Estudiet 50 march
		(13.18)		Estradot 50 mcg
	a) Higher subsidy of \$13.18 per 8 patch with Special Auth	ority see SA1018	on the previ	ous page
	b) No more than 2 patch per week			
	c) Only on a prescription	7.05	4	
*	TDDS 7.8 mg (releases 100 mcg of oestradiol per day)		4	Climara 100
	a) Llinkay subside of \$10.14 year 4 yearsh with Openial Auth	(16.14)		
	a) Higher subsidy of \$16.14 per 4 patch with Special Auth	ority see SA1018	on the previ	ous page
	b) No more than 1 patch per week			
v	c) Only on a prescription	7.05	8	
*	TDDS 100 mcg per day		0	Estradot
	a) Higher subsidy of \$16.14 per 8 patch with Special Auth	· · · ·	on the provi	
	b) No more than 2 patch per week	Unity See SATUTO	on the previ	ous page
	c) Only on a prescription			
ر ۔				
ビー	STRADIOL VALERATE – See prescribing guideline on the pre-		04	
ሾ	Tab 1 mg Progynova to be Sole Supply on 1 July 2015	12.30	84	 Progynova
¥	Tab 2 mg	10 96	84	Progynova
T.	Progynova to be Sole Supply on 1 July 2015	12.00	04	
~~				
	STROGENS – See prescribing guideline on the previous pag		00	
*	Conjugated, equine tab 300 mcg		28	Dromoriz
~	Conjugated equips tob 605 mag	(11.48)	00	Premarin
۴	Conjugated, equine tab 625 mcg		28	Dromorin
		(11.48)		Premarin
P	rogestogens			
/⊨	DROXYPROGESTERONE ACETATE - See prescribing guide	eline on the previo	ous nage	
₩.	Tab 2.5 mg		30	Provera
∽ ¥	Tab 5 mg		100	✓ Provera
•	Tab 10 mg		30	✓ Provera
	····· ·····		50	· <u></u>

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Progestogen and Oestrogen Combined Preparat	ions			
OESTRADIOL WITH NORETHISTERONE – See prescribing guid	deline on page 81			
* Tab 1 mg with 0.5 mg norethisterone acetate		28 OP		
w. Tak O man with 1 man namethiotarana anatata	(18.10)		ł	Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40 (18.10)	28 OP	L	Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	(10.10)		'	liogest
oestradiol tab (12) and 1 mg oestradiol tab (6)	5.40	28 OP		
	(18.10)		٦	Trisequens
OESTROGENS WITH MEDROXYPROGESTERONE - See press	cribing guideline on	page 8	1	
* Tab 625 mcg conjugated equine with 2.5 mg medroxyproges-				
terone acetate tab (28)		28 OP		
	(22.96)		F	Premia 2.5
* Tab 625 mcg conjugated equine with 5 mg medroxyproges-				Continuous
Tab 625 mcg conjugated equine with 5 mg medroxyproges- terone acetate tab (28)	5 40	28 OP		
	(22.96)	20 01	F	Premia 5 Continuous
Other Oestrogen Preparations				
ETHINYLOESTRADIOL				
* Tab 10 mcg		100	~ 1	VZ Medical and
ů –				Scientific
OESTRIOL				
* Tab 2 mg	7.00	30	v (Ovestin
Other Progestogen Preparations				
LEVONORGESTREL				
 Levonorgestrel - releasing intrauterine system 20 mcg/24 hr – 				
Special Authority see SA0782 below - Retail pharmacy		1	~ 1	Airena
SA0782 Special Authority for Subsidy				

Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
 - 3.1 serum ferritin level < 16 mcg/l (within the last 12 months); or
 - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Subsidy		Fully	Brand or	
(Manufacturer's Pri	ce)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
- 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDBOXYPROGESTERONE ACETATE 100 Provera NORETHISTERONE Tab 5 mg - Up to 30 tab available on a PSO......18.29 100 Primolut N Primolut N to be Sole Supply on 1 July 2015 PROGESTERONE Cap 100 mg - Special Authority see SA1392 below - Retail 30 ✓ Utrogestan

►SA1392 Special Authority for Subsidy

Initial application only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

*

1 For the prevention of pre-term labour*; and

2 Fither:

- 2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
- 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Thyroid and Antithyroid Agents

CARBIMAZOLE			
* Tab 5 mg	10.80	100	Neo-Mercazole
LEVOTHYROXINE			
* Tab 25 mcg ‡ Safety cap for extemporaneously compounded oral liqu		90	 Synthroid
* Tab 50 mcg	4.05	90	Synthroid
J. J	64.28	1,000	 Eltroxin
‡ Safety cap for extemporaneously compounded oral liquest	uid preparations.	,	
* Tab 100 mcg		90	Synthroid
	66.78	1.000	 Eltroxin
‡ Safety cap for extemporaneously compounded oral liquest	uid preparations.	,	
LEVOTHYROXINE (MERCURY PHARMA)			
* Tab 50 mcg		28	Mercury Pharma
‡ Safety cap for extemporaneously compounded oral liquidation			
* Tab 100 mcg		28	Mercury Pharma
‡ Safety cap for extemporaneously compounded oral liquid			· · · · · ·
PROPYLTHIOURACIL - Special Authority see SA1199 on the	next page – Retail p	harmacy	
Propylthiouracil is not recommended for patients under the a are contraindicated.	age of 18 years unle	ess the patie	nt is pregnant and other treatments
Tab 50 mg		100	✓ PTU \$29

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones			

Growth Hormones

SO	MATROPIN (OMNITROPE) - Special Authority see SA	1451 below – Retail phar	rmacy	
*	Inj 5 mg cartridge		1	 Omnitrope
*	Inj 10 mg cartridge	219.00	1	 Omnitrope
	Inj 15 mg cartridge		1	 Omnitrope
	SA1451 Special Authority for Subsidy			

SA1451 | Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient seguelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985): and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon followup laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 2 Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred: and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity ≥ 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is \geq 2 cm per year, calculated over six months; and
- 3 A current bone age is \leq 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
 - 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
 - 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is \leq to 14 years (female patients) or \leq to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:

86

- 6.1 The patient has a GFR ≤ 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
- 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

(Man	Subsidy	Fully	Brand or
	ufacturer's Price)	Subsidised	Generic
(\$ Pe		Manufacturer

continued...

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 Either:
 - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or</p>
 - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by \geq 0.5 standard deviations in the preceding 12 months.

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA[®]).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of $\leq 3 \text{ mcg}$ per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of ≤ 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA^(B)) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

GnRH Analogues

GOSERELIN ACETATE

Inj 3.6 mg	1	Zoladex
Inj 10.8 mg443.76	1	Zoladex

	Subsidy		Full	y Brand or
(Manufacturer's Price)		Subsidised	d Generic
	\$	Per	~	Manufacturer
EUPRORELIN				
Inj 3.75 mg prefilled syringe	221.60	1	~	Lucrin Depot PDS
Inj 7.5 mg		1	~	Eligard
Inj 11.25 mg prefilled syringe	591.68	1	~	Lucrin Depot PDS
Inj 22.5 mg		1	~	Eligard
Inj 30 mg	591.68	1	~	Eligard
Inj 30 mg prefilled syringe		1	~	Lucrin Depot PDS
Inj 45 mg	832.05	1	~	Eligard
Vasopressin Agonists				
ESMOPRESSIN ACETATE				
Tab 100 mcg - Special Authority see SA1401 below - Retail				
pharmacy	36.40	30	~	Minirin
Tab 200 mcg – Special Authority see SA1401 below – Retail				
pharmacy	93.60	30	~	Minirin
Nasal drops 100 mcg per ml – Retail pharmacy-Specialist		5 ml O	-	Minirin
Nasal spray 10 mcg per dose – Retail pharmacy-Specialist		ml OF		Desmopressin-
			•	PH&T
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below				<u></u>
– Retail pharmacy	67.18	10	~	Minirin
			5	

SA1401 Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has cranial diabetes insipidus; and
- 2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE

0.5 mg – Maximum of 2 tab per prescription; can be	
waived by Special Authority see SA1370 on the next page6.25 2	Dostinex
25.00 8	Dostinex

Subsidy	Fully	Brand or
(Manufacturer's	Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 pathological hyperprolactinemia; or
- 2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment. Note: Indication marked with * is an Unapproved indication.

CLOMIPHENE CITRATE

Tab 50 mg		10	✓ Serophene
DANAZOL			
Cap 100 mg		100	🖌 Azol
Cap 200 mg		100	🖌 Azol
METYRAPONE			
Cap 250 mg – Retail pharmacy-	Specialist520.00	50	 Metopirone

	Subsidy		Fully Brand or
	(Manufacturer's F	rice) Su	bsidised Generic
	\$	Per	 Manufacturer
Anthelmintics			
ALBENDAZOLE – Special Authority see SA1318 below – Reta	, ,		
Tab 400 mg		60	Eskazole S29
SA1318 Special Authority for Subsidy			
nitial application only from an infectious disease specialist batient has hydatids.	or clinical microbio	logist. Appro	vals valid for 6 months where th
Renewal only from an infectious disease specialist or clinical	microbiologist Ar	nrovals valid	for 6 months where the treatme
remains appropriate and the patient is benefitting from the treat			
MEBENDAZOLE – Only on a prescription			
Tab 100 mg	24.19	24	De-Worm
Oral liq 100 mg per 5 ml	2.18	15 ml	
	(7.17)		Vermox
PRAZIQUANTEL			
Tab 600 mg	68.00	8	 Biltricide
Antibacterials			
 a) For topical antibacterials, refer to DERMATOLOGICALS, paged) b) For anti-infective eye preparations, refer to SENSORY ORG/ 			
	110, page 202		
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE			
Cap 250 mg		100	Ranbaxy-Cefaclor
Grans for oral lig 125 mg per 5 ml – Wastage claimable – s			
rule 3.3.2 on page 13	3.53	100 ml	Ranbaxy-Cefaclor
CEFALEXIN MONOHYDRATE			
Cap 500 mg	5.70	20	Cephalexin ABM
Grans for oral liq 125 mg per 5 ml – Wastage claimable – s			
rule 3.3.2 on page 13		100 ml	Cefalexin Sandoz
Note: Cefalexin grans for oral liq will not be funded in an		4 days treatm	ient per dispensing.
Grans for oral liq 250 mg per 5 ml – Wastage claimable – s rule 3.3.2 on page 13		100 ml	Cefalexin Sandoz
Note: Cefalexin grans for oral liq will not be funded in an			
CEFAZOLIN – Subsidy by endorsement			
Only if prescribed for dialysis or cellulitis in accordance with	n a DHB approved p	protocol and th	ne prescription is endorsed accord
ingly.			
Inj 500 mg vial		5	✓ <u>AFT</u>
Inj 1 g vial	3.38	5	✓ <u>AFT</u>
CEFTRIAXONE – Subsidy by endorsement			
a) Up to 5 inj available on a PSO	vasio notiont or th	a tractment .	of concrubace, or the treatment.
b) Subsidised only if prescribed for a dialysis or cystic fit pelvic inflammatory disease, or the treatment of suspected			
the prescription or PSO is endorsed accordingly.	a meningino in pau	Sind who have	s a known allergy to perilollilli, al
Inj 500 mg vial	1.50	1	Ceftriaxone-AFT
lnj 1 g vial		5	 Ceftriaxone-AFT
CEFUROXIME AXETIL – Subsidy by endorsement			
Only if prescribed for prophylaxis of endocarditis and the p		sed according	
Tab 250 mg	29.40	50	 Zinnat

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	
EFUROXIME SODIUM				
Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement	6.96	5	v 1	n-Cefuroxime
Waiver by endorsement must state that the prescription is f m-Cefuroxime Inj 750 mg to be delisted 1 July 2015)		-		
Macrolides				
ZITHROMYCIN – Maximum of 5 days treatment per prescription For Endorsement, patient has either: 1) Received a lung transplant and requires treatment or prop	phylaxis for bronch	iolitis ob	iterans sy	
 Cystic fibrosis and has chronic infection with Pseudomo isms*. 	nas aeruginosa or	r Pseudo	monas rel	ated gram negative orga
ndications marked with * are Unapproved Indications				
Tab 250 mg Tab 500 mg – Up to 8 tab available on a PSO		30 2		Apo-Azithromycin Apo-Azithromycin
Grans for oral lig 200 mg per 5 ml – Wastage claimable – see	1.20	2	• !	Apo-Azianomycin
rule 3.3.2 on page 13	6.60	15 ml	V 7	Zithromax
CLARITHROMYCIN – Maximum of 500 mg per prescription; can			,	
Tab 250 mg		14	V <u>I</u>	Apo-Clarithromycin
Grane for oral lig 125 mg por 5 ml Wastago glaimable coo				
Grans for oral liq 125 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 13	spiratory specialist	70 ml		Klacid e specialist or paediatricia
rule 3.3.2 on page 13 Special Authority for Waiver of Rule nitial application — (Mycobacterial infections) only from a rest approvals valid for 2 years for applications meeting the following c ither: 1 Atypical mycobacterial infection; or	spiratory specialist riteria:	, infectio	us disease	e specialist or paediatricia
rule 3.3.2 on page 13 SA1131 Special Authority for Waiver of Rule nitial application — (Mycobacterial infections) only from a res pprovals valid for 2 years for applications meeting the following c iither: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug Renewal — (Mycobacterial infections) only from a respiratory s alid for 2 years where the treatment remains appropriate and the	spiratory specialist riteria: -resistance or intol pecialist, infectious	, infectio lerance t	us disease o standard specialist	e specialist or paediatricia pharmaceutical agents.
rule 3.3.2 on page 13 SA1131 Special Authority for Waiver of Rule nitial application — (Mycobacterial infections) only from a res pprovals valid for 2 years for applications meeting the following c iither: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug Renewal — (Mycobacterial infections) only from a respiratory s alid for 2 years where the treatment remains appropriate and the IRYTHROMYCIN ETHYL SUCCINATE Tab 400 mg	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir	, infectio lerance t	us disease o standard specialist eatment.	e specialist or paediatricia pharmaceutical agents.
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from ti 100 7	o standard specialist eatment.	e specialist or paediatricia I pharmaceutical agents. or paediatrician. Approva
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml	o standard specialist eatment.	e specialist or paediatricia pharmaceutical agents. or paediatrician. Approva
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml	o standard specialist eatment.	e specialist or paediatricia I pharmaceutical agents. or paediatrician. Approva
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml	us disease o standard specialist eatment. ✓ I	e specialist or paediatricia I pharmaceutical agents. or paediatrician. Approva
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml 7	us disease o standard specialist eatment. ✓ I	e specialist or paediatricia pharmaceutical agents. or paediatrician. Approva E-Mycin E-Mycin
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml 7	us disease o standard specialist eatment. ✓ I	e specialist or paediatricia pharmaceutical agents. or paediatrician. Approva E-Mycin E-Mycin
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml 7 100 ml	us disease o standard specialist eatment. ✓ I	e specialist or paediatricia l pharmaceutical agents. or paediatrician. Approva E-Mycin E-Mycin
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease ng from tr 100 7 100 ml 7 100 ml	us disease o standard specialist eatment.	e specialist or paediatricia l pharmaceutical agents. or paediatrician. Approva E-Mycin E-Mycin
rule 3.3.2 on page 13	spiratory specialist riteria: -resistance or intol pecialist, infectious patient is benefitir 	, infectio lerance t s disease gg from tr 100 7 100 ml 7 100 ml 1	us disease o standard specialist eatment.	e specialist or paediatricia pharmaceutical agents. or paediatrician. Approva E-Mycin E-Mycin E-Mycin E-Mycin

	Subsidy		Fully	Brand or
			Subsidised	
	(Manufacturer's P \$	Per		Generic Manufacturer
	ą	Fei	~	Manulaciurei
ROXITHROMYCIN				
	7.40			
Tab 150 mg		50	v <u>F</u>	Arrow-
				Roxithromycin
Tab 300 mg	14 40	50		Arrow-
		00	• •	
				Roxithromycin
Penicillins				
AMOXICILLIN				
	10.10	500		
Cap 250 mg		500	v <u>F</u>	Apo-Amoxi
 a) Up to 30 cap available on a PSO 				
b) Up to 10 x the maximum PSO quantity for RFPP - see r	ule 5 2 6 on pag	e 17		
		500		Ana Amavi
Cap 500 mg	20.94	500	•	Apo-Amoxi
 a) Up to 30 cap available on a PSO 				
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on pag	e 17		
Grans for oral lig 125 mg per 5 ml		100 ml		Alphamox
	0.00	100 111		
				Amoxicillin Actavis
			- / F	Ranmoxy
a) Up to 200 ml available on a PSO				-
b) Wastage claimable – see rule 3.3.2 on page 13				
Grans for oral liq 250 mg per 5 ml	0.97	100 ml	v I	Alphamox
			V	Amoxicillin Actavis
			V F	Ranmoxy
a) the telefold and succeeding to the POO			• •	lannoxy
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on pag	e 17		
c) Wastage claimable - see rule 3.3.2 on page 13				
Inj 250 mg vial	10.67	10	1	biamox
Inj 500 mg vial		10		<u>biamox</u>
Inj 1 g vial – Up to 5 inj available on a PSO	17.29	10	✓ 1	<u>biamox</u>
(Ranmoxy Grans for oral liq 125 mg per 5 ml to be delisted 1 Octo	ber 2015)			
(Ranmoxy Grans for oral liq 250 mg per 5 ml to be delisted 1 Octo				
(manificity drans for oral ing 250 mg per 5 millio be delisted i Octo	0012013)			
AMOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab avail-				
able on a PSO	1.95	20	v	Augmentin
	9.75	100	v (Curam Duo
Orono for and lin amoviaillin 105 mm with alayyylania asid				
Grans for oral liq amoxicillin 125 mg with clavulanic acid				
31.25 mg per 5 ml	1.61	100 ml	v <u>i</u>	Augmentin
			v (Curam
a) Up to 200 ml available on a PSO				
 b) Wastage claimable – see rule 3.3.2 on page 13 				
Grans for oral liq amoxicillin 250 mg with clavulanic acid				
62.5 mg per 5 ml	2.19	100 ml	~	Augmentin
				Curam
a) Lin to 000 mil available see a DOO			• (varalli
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 13				
BENZATHINE BENZYLPENICILLIN				
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO	315.00	10	✓ E	Bicillin LA
BENZYLPENICILLIN SODIUM (PENICILLIN G)				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a				
PSO		10	1 9	Sandoz
			• •	

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's P	Price)	Full Subsidise	
	\$	Per	L	
LUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO		250		Staphlex
Cap 500 mg		500		Staphlex
Grans for oral liq 125 mg per 5 ml	2.49	100 ml	~	<u>AFT</u>
 a) Up to 200 ml available on a PSO 				
 b) Wastage claimable – see rule 3.3.2 on page 13 				
Grans for oral liq 250 mg per 5 ml	3.25	100 ml	~	<u>AFT</u>
 a) Up to 200 ml available on a PSO 				
b) Wastage claimable – see rule 3.3.2 on page 13				
Inj 250 mg vial		10		Flucloxin
Inj 500 mg vial		10		Flucloxin
Inj 1 g vial – Up to 10 inj available on a PSO		10	~	Flucloxin
HENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg – Up to 30 cap available on a PSO	2.88	50	~	Cilicaine VK
Cilicaine VK to be Sole Supply on 1 July 2015				
Cap 500 mg	4.73	50	~	Cilicaine VK
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP - see r	ule 5.2.6 on page	17		
c) Cilicaine VK to be Sole Supply on 1 July 2015				
Grans for oral liq 125 mg per 5 ml	1.64	100 ml	~	AFT
 a) Up to 200 ml available on a PSO 				
 b) Wastage claimable – see rule 3.3.2 on page 13 				
Grans for oral liq 250 mg per 5 ml	1.74	100 ml	~	AFT
 a) Up to 300 ml available on a PSO 				
b) Up to 2 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on page	17		
c) Wastage claimable – see rule 3.3.2 on page 13				
ROCAINE PENICILLIN				
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO		5	~	Cilicaine
Tetracyclines				
•				
OXYCYCLINE	0.00	30		
 Tab 50 mg – Up to 30 tab available on a PSO 		30		Doxy-50
Tab 100 mg – Up to 30 tab available on a PSO	(6.00)	250		Doxy-50 Doxine
	0.75	200	•	DOXINE
IINOCYCLINE HYDROCHLORIDE				
 Tab 50 mg – Additional subsidy by Special Authority see 				
SA1355 below – Retail pharmacy	5.79	60		
	(12.05)			Mino-tabs
		100		
€ Cap 100 mg	(EO 04)			Minomycin
Cap 100 mg	(52.04)			
← Cap 100 mg	(52.04)			
	()	r renewal ı	unless no	tified where the patient h
SA1355 Special Authority for Manufacturers Price itial application from any relevant practitioner. Approvals va bsacea.	lid without furthe		unless no	tified where the patient I
SA1355 Special Authority for Manufacturers Price itial application from any relevant practitioner. Approvals va	lid without furthe			tified where the patient I

Subsidy (Manufacturer's Price)	S	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

SA1332 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 63

CIPROFLOXACIN

Recommended for patients with any of the following:

- i) microbiologically confirmed and clinically significant pseudomonas infection; or
- ii) prostatitis; or
- iii) pyelonephritis; or
- iv) gonorrhoea

iv) gonorrnoea.			
Tab 250 mg – Up to 5 tab available on a PSO	1.75	28	 Cipflox
Tab 500 mg – Up to 5 tab available on a PSO		28	✓ Cipflox
Tab 750 mg		28	✓ Cipflox
CLINDAMYCIN			
Cap hydrochloride 150 mg - Maximum of 4 cap per prescrip-			
tion; can be waived by endorsement - Retail pharmacy -			
Specialist	5 80	16	Clindamycin ABM
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-			<u></u>
Specialist	100.00	10	Dalacin C
1	100.00	10	
CO-TRIMOXAZOLE			
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg -			1 - 1 - 1
Up to 30 tab available on a PSO	20.97	500	✓ Trisul
* Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg			
per 5 ml – Up to 200 ml available on a PSO	2.15	100 ml	 Deprim
COLISTIN SULPHOMETHATE - Retail pharmacy-Specialist - Sub	sidy by endors	ement	
Only if prescribed for dialysis or cystic fibrosis patient and the p			rdingly.
Inj 150 mg		1	Colistin-Link
FUSIDIC ACID			
Tab 250 mg – Retail pharmacy-Specialist	34 50	12	🖌 Fucidin
Prescriptions must be written by, or on the recommendation			
		is discuse priy	
GENTAMICIN SULPHATE	0.50	-	
Inj 10 mg per ml, 1 ml – Subsidy by endorsement		5	✓ Hospira
Only if prescribed for a dialysis or cystic fibrosis patient or cor	nplicated urina	iry tract intection	on and the prescription is endorsed
accordingly.	175 10	05	
Inj 10 mg per ml, 2 ml – Subsidy by endorsement	175.10	25	✓ APP
			Pharmaceuticals S29
Only if prescribed for a dialysis or cystic fibrosis patient or cor	nnlicated urina	urv tract infecti	on and the prescription is endorsed
accordingly.	inplicated utilia	iny tract intection	on and the prescription is endorsed
Inj 40 mg per ml, 2 ml – Subsidy by endorsement	6 50	10	✓ Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient or cor			
accordingly.	inpriodicu ullila		and the prescription is chuoised

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
MOXIFLOXACIN - Special Authority see SA1358 below - Retail p	harmacy			
No patient co-payment payable Tab 400 mg		5	🗸 A	velox

SA1358 Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: Fither:

1 Both:

- 1.1 Active tuberculosis*; and
- 1.2 Any of the following:
 - 1.2.1 Documented resistance to one or more first-line medications; or
 - 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium*; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

PAROMOMYCIN - Special Authority see SA1324 below - Retail pharmacy

Cap 250 mg		16	Humatin S29
------------	--	----	-------------

➡SA1324 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

PYRIMETHAMINE – Special Authority see SA1328 below – Retail pharmacy
--

Tab 25 mg	.26.14	30	Daraprim S29
	36.95	50	🖌 Daraprim 😒

SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

	Subsidy (Manufacturer's Pric \$	e) Su Per	Fully Brand or Ibsidised Generic Manufacturer
SULFADIAZINE SODIUM – Special Authority see SA1331 below	v – Retail pharmacy		
Tab 500 mg		56	✓ Wockhardt S29
 SA1331 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali the following criteria: Any of the following: For the treatment of toxoplasmosis in patients with HIV for 2 For pregnant patients for the term of the pregnancy; or 3 For infants with congenital toxoplasmosis until 12 months 	or a period of 3 mor		ss notified for applications me
TOBRAMYCIN	0		
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and	the prescription is e	5 endorsed a	DBL Tobramycin ccordingly.
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by en- dorsement		56 dose	🗸 ТОВІ
a) Wastage claimable – see rule 3.3.2 on page 13	recordination is and are		n al u
b) Only if prescribed for a cystic fibrosis patient and the pr TRIMETHOPRIM	rescription is endors	ed accordi	ngiy.
 Tab 300 mg – Up to 30 tab available on a PSO 	9.28	50	✔ TMP
VANCOMYCIN – Subsidy by endorsement			
Only if prescribed for a dialysis or cystic fibrosis patient or for	r prophylaxis of endo	ocarditis or	for treatment of Clostridium dif
following metronidazole failure and the prescription is endors			
Inj 500 mg	2.64	1	✓ <u>Mylan</u>
Antifungals			
a) For topical antifungals refer to DERMATOLOGICALS, page 63 b) For topical antifungals refer to GENITO URINARY, page 76	ł		
FLUCONAZOLE			
	3.49	28	✓ Ozole
Cap 50 mg – Retail pharmacy-Specialist			
Cap 150 mg - Subsidy by endorsement	0.71	1	✓ <u>Ozole</u>
Cap 150 mg – Subsidy by endorsementa) Maximum of 1 cap per prescription; can be waived by e	0.71 endorsement - Retai	1 il pharmacy	/ - Specialist
Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practitior	0.71 endorsement - Retai ner considers that a	1 il pharmacy topical imi	v - Specialist idazole (used intra-vaginally) is
Cap 150 mg – Subsidy by endorsementa) Maximum of 1 cap per prescription; can be waived by e	0.71 endorsement - Retai ner considers that a gly; can be waived b	1 il pharmacy topical imi	v - Specialist idazole (used intra-vaginally) is
Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practitior recommended and the prescription is endorsed according	0.71 endorsement - Retain ner considers that a gly; can be waived b 9.69	1 il pharmacy topical imi y endorsen	v - Specialist idazole (used intra-vaginally) i nent - Retail pharmacy - Speci
Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practitior recommended and the prescription is endorsed according Cap 200 mg – Retail pharmacy-Specialist	0.71 endorsement - Retai ner considers that a gly; can be waived b 9.69 y 	1 il pharmacy topical imi y endorsen	 r - Specialist idazole (used intra-vaginally) is nent - Retail pharmacy - Speci <u>V Ozole</u> V Diflucan S29 \$29
 Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by et b) Patient has vaginal candida albicans and the practitior recommended and the prescription is endorsed according Cap 200 mg – Retail pharmacy-Specialist Powder for oral suspension 10 mg per ml – Special Authority see SA1359 below – Retail pharmacy 	0.71 endorsement - Retain ner considers that a gly; can be waived b 9.69 y	1 il pharmacy topical imi y endorsen 28	 r - Specialist idazole (used intra-vaginally) is nent - Retail pharmacy - Speci ✓ Ozole
Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practitior recommended and the prescription is endorsed according Cap 200 mg – Retail pharmacy-Specialist Powder for oral suspension 10 mg per ml – Special Authority	0.71 endorsement - Retai ner considers that a gly; can be waived b 9.69 y 	1 il pharmacy topical imi y endorsen 28	 r - Specialist idazole (used intra-vaginally) is nent - Retail pharmacy - Speci <u>V Ozole</u> V Diflucan S29 \$29
 Cap 150 mg – Subsidy by endorsement a) Maximum of 1 cap per prescription; can be waived by et b) Patient has vaginal candida albicans and the practitior recommended and the prescription is endorsed according Cap 200 mg – Retail pharmacy-Specialist Powder for oral suspension 10 mg per ml – Special Authority see SA1359 below – Retail pharmacy 	0.71 endorsement - Retai ner considers that a Jly; can be waived b 9.69 y 34.56 98.50	1 il pharmacy topical imi y endorsen 28 35 ml	y - Specialist idazole (used intra-vaginally) i nent - Retail pharmacy - Speci ✓ <u>Ozole</u> ✓ Diflucan S29 529 ✓ Diflucan

2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

 ntinued Patient is immunocompromised; and Patient is at moderate to high risk of invasive fungal infection Patient is unable to swallow capsules. enewal — (Systemic candidiasis) from any relevant practition lowing criteria: Patient requires prophylaxis for, or treatment of systemic candidiasis Patient is unable to swallow capsules. Patient is unable to swallow capsules. enewal — (Immunocompromised) from any relevant practition 	ner. Approvals v	valid for	6 weeks fo	or applications meeting the
 lowing criteria: a Patient requires prophylaxis for, or treatment of systemic ca b Patient is unable to swallow capsules. cenewal — (Immunocompromised) from any relevant practition 		valid for	6 weeks fo	or applications meeting th
 Patient is unable to swallow capsules. enewal — (Immunocompromised) from any relevant practition 	andidiasis; and			
lowing criteria: I of the following:	ner. Approvals v	alid for (6 months f	or applications meeting the
 Patient remains immunocompromised; and Patient remains at moderate to high risk of invasive fungal Patient is unable to swallow capsules. 	infection; and			
RACONAZOLE				
 Funded for tinea vesicolor where topical treatment has not be or for tinea unguium where terbinafine has not been succes diagnosis has been confirmed by mycology and the prescrip Retail pharmacy - Specialist Specialist must be an infectious or dermatologist. Oral liq 10 mg per ml – Special Authority see SA1322 below – Retail pharmacy 	ssful in eradicatio otion is endorsed s disease physicia	on or the accordi	patient is ngly. Can b al microbic	intolerant to terbinafine and be waived by endorsement
SA1322 Special Authority for Subsidy				operation
itial application only from an infectious disease specialist, clinical the recommendation of a infectious disease physician, clinical onths where the patient has a congenital immune deficiency. enewal from any relevant practitioner. Approvals valid for 6 mont enefitting from the treatment. ETOCONAZOLE	l microbiologist c	or clinica	l immunolo	ogist. Approvals valid for
Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsidy				
by endorsement	CBS	30		Link Healthcare 629 Nizoral 629
Prescriptions must be written by, or on the recommendation	of an oncologist			
YSTATIN				
Tab 500,000 u	14.16	50		
	(17.09)		I	Nilstat
Cap 500,000 u		50		
	(15.47)		l	Nilstat
DSACONAZOLE – Special Authority see SA1285 on the next page	ge – Retail pharn	nacy		
Oral liq 40 mg per ml	761.13	105 ml (DP 🖌 I	Noxafil

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
(Manulaclurer S Frice)	30	Insinisen	Generic	
\$	Per	~	Manufacturer	

SA1285 Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Fither:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy: or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (\geq 1 mg per kilogram of body weight per day for patients with acute GVHD or \geq 0.8 mg per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg – For terbinafine oral liquid formulation refer, page 2091.5	0 14	✓ <u>Dr Reddy's</u> Terbinafine
VORICONAZOLE - Special Authority see SA1273 on the next page - Retai		
Tab 50 mg730.0	0 56	Vfend
Tab 200 mg2,930.0 Powder for oral suspension 40 mg per ml - Wastage	0 56	 Vfend
claimable – see rule 3.3.2 on page 13	0 70 ml	 Vfend

Subsidy (Manufacturer's Price)	g	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Antimalarials

PRIMAQUINE PHOSPHATE – Special Authority see SA1326 below – Retail pharmacy

SA1326 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Antiparasitics

Antiprotozoals

2UININE SULPHATE ★ Tab 300 mg54. ‡ Safety cap for extemporaneously compounded oral liquid preparat		🗸 Q 300
Antitrichomonal Agents		
IETRONIDAZOLE		
Tab 200 mg – Up to 30 tab available on a PSO10.	45 100	Trichozole
Tab 400 mg18.	15 100	Trichozole
Oral lig benzoate 200 mg per 5 ml25.	00 100 ml	FlagyI-S
Suppos 500 mg24.		✓ Flagyl
DRNIDAZOLE		
Tab 500 mg16.	50 10	 Arrow-Ornidazole

	Subsidy (Manufacturer's Price	a) Si	Fully	Brand or Generic
	\$	Per	~	Manufacturer
Antituberculotics and Antileprotics				
Note: There is no co-payment charge for all pharmaceutical	s listed in the Antituber	culotics ar	d Antilep	rotics group regardless of
mmigration status.				
CLOFAZIMINE – Retail pharmacy-Specialist				
a) No patient co-payment payable	indution of an infaction	diagona	nhuaiaian	alinical microbiologist
b) Prescriptions must be written by, or on the recomme dermatologist.		uisease	physician	i, cimical microbiologist (
₭ Cap 50 mg		100	🖌 La	amprene S29
CYCLOSERINE – Retail pharmacy-Specialist				•
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recomme	endation of, an infectious	s disease	physician	, clinical microbiologist o
respiratory physician.	4 00 4 50	100		
Cap 250 mg	1,294.50	100	VK	ing \$29
DAPSONE – Retail pharmacy-Specialist				
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommendation	ndation of an infectious	s disease	nhysician	clinical microbiologist
dermatologist			physiolai	, omnour microbiologist (
Tab 25 mg		100		apsone
Tab 100 mg	110.00	100	✓ <u>D</u>	apsone
THAMBUTOL HYDROCHLORIDE – Retail pharmacy-Spec	cialist			
a) No patient co-payment payable	indution of an infaction	diagona	nhuaiaian	alinical microhiologiat
b) Prescriptions must be written by, or on the recomme respiratory physician		uisease	physician	i, cimical microbiologist (
Tab 100 mg		56	🖌 M	yambutol
Tab 400 mg		56	🖌 М	yambutol
SONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommen-	dation of, an internal me	dicine phy	sician, pa	aediatrician, clinical micro
biologist, dermatologist or public health physician ₭ Tab 100 mg	20.00	100	V P	SM
K Tab 100 mg with rifampicin 150 mg		100		ifinah
Tab 150 mg with rifampicin 300 mg		100	🖌 R	ifinah
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Speciali	st			
a) No patient co-payment payable				
 b) Specialist must be an infectious disease specialist, clin Grans for oral liq 4 g sachet 		spiratory s 30	· .	aser S29
	200.00	30	V Fa	45EI 029
PROTIONAMIDE – Retail pharmacy-Specialist a) No patient co-payment payable				
b) Specialist must be an infectious disease specialist, cli	nical microbiologist or re	spiratory s	pecialist.	
Tab 250 mg		100	· .	eteha S29
PYRAZINAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable 				
b) Prescriptions must be written by, or on the recomme	endation of, an infectious	s disease	physician	, clinical microbiologist o
respiratory physician	rofor			
Tab 500 mg – For pyrazinamide oral liquid formulation r page 209		100	ν Δ	FT-Pyrazinamide
		100	A	

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
RIFABUTIN – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommenda gastroenterologist * Cap 150 mg – For rifabutin oral liquid formulation refer, page		s disease p	hysiciar	n, respiratory physician or
209		30	✓ M	<u>ycobutin</u>
 a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection in based on susceptibilities and the prescription is endorsed a Specialist. Specialist must be an internal medicine physicia health physician. * Tab 600 mg * Cap 150 mg 	accordingly; can be an, clinical microbio 108.70	waived by	endorse natologis <u> <u> <u> </u> <u> Ri</u></u></u>	ment - Retail pharmacy -
* Cap 300 mg		100		ifadin
* Oral liq 100 mg per 5 ml		60 ml	V R	ifadin
Antivirals For eye preparations refer to Eye Preparations, Anti-Infective Pre	parations, page 202			
Hepatitis B Treatment				
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Tab 10 mg		30	✔ H	epsera

SA0829 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and
 - Documented resistance to lamivudine, defined as:
- 2 Patient has raised serum ALT (> 1 $\times\,$ ULN); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient is cirrhotic; and
 - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
 - 5.2 Both:
 - 5.2.1 Patient is not cirrhotic; and
 - 5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT (> 1 $\times\,$ ULN); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and
- iii) Detection of N236T or A181T/V mutation.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
continued Adefovir dipivoxil should be stopped 6 months following HBeAg s adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10 In patients with renal insufficiency adefovir dipivoxil dose should Adefovir dipivoxil should be avoided in pregnant women and chil ENTECAVIR – Special Authority see SA1361 below – Retail ph Tab 0.5 mg	ng daily. be reduced in accordar dren. armacy 400.00	nce with the data	asheet guidelines.
Initial application only from a gastroenterologist or infectious of notified for applications meeting the following criteria: All of the following:	disease specialist. App	provals valid with	out further renewal unless
 Patient has confirmed Hepatitis B infection (HBsAg posi Patient is Hepatitis B nucleoside analogue treatment-na Entecavir dose 0.5 mg/day; and Either: 		onths); and	
4.1 ALT greater than upper limit of normal; or4.2 Bridging fibrosis (Metavir stage 3 or greater or n	noderate fibrosis) or cirr	rhosis on liver hi	stology; and
5 Either:			
5.1 HBeAg positive; or 5.2 patient has \geq 2,000 IU HBV DNA units per ml a	nd fibrosis (Metavir sta	ge 2 or greater)	on liver histology; and
6 No continuing alcohol abuse or intravenous drug use; a	nd	,	0,1
 7 Not co-infected with HCV, HIV or HDV; and 8 Neither ALT nor AST greater than 10 times upper limit c 	f normal: and		
9 No history of hypersensitivity to entecavir; and			
10 No previous documented lamivudine resistance (either Notes:	clinical or genotypic).		
 Entecavir should be continued for 6 months following do of HBeAg plus appearance of anti-HBe plus loss of s commencing this agent. This period of consolidation th fibrosis (Metavir Stage F3 or F4). 	erum HBV DNA) for p	atients who we	re HBeAg positive prior to

• Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA1360 below - Retail pharmacy

Tab 100 mg	6.00	28	✓ Zeffix
Oral liq 5 mg per ml		240 ml	✓ Zeffix

SA1360 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days), or who has received such treatment within the previous two months; or
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,000 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine 2 All of the following:

- 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
- 2.2 Patient is cirrhotic; and
 - Documented resistance to lamivudine, defined as:
- 2.3 Patient has raised serum ALT (> 1 \times ULN); and
- 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
- 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

- 3 All of the following:
 - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as:
 - 3.2 Patient has raised serum ALT (> 1 \times ULN); and
 - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

	Tab dispersible 200 mg1.78	25	 Lovir
*	Tab dispersible 400 mg5.98	56	Lovir
	Tab dispersible 800 mg6.64	35	Lovir
VAL	ACICLOVIR - Special Authority see SA1363 on the next page - Retail pharm	асу	
	Tab 500 mg102.72	30	 Valtrex

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1363 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily. Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains

appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Initial application — (immunocompromised patients) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patients is immunocompromised; and
- 2 Patient has herpes zoster; and
- 3 Valaciclovir is to be given for a maximum of 7 days per course.

VALGANCICLOVIR - Special Authority see SA1404 below - Retail pharmacy

Tab 450 mg	 60	 Valcyte
Valcyte to be Sole Supply on 1 July 2015		

➡SA1404 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 Patient is immunocompromised; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Author	ity "immunocompromised" includes transplant recipie	ents, patients with immunosuppres-
sive diseases (e.g. HIV) or those receiving	immunosuppressive treatment for other conditions.	

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1362 below Endorsement for treatment of HIV: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil furnarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364, page 108

Tab 300 mg	 30	Viread

➡SA1362 Special Authority for Waiver of Rule

Initial application — (Chronic Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has decompensated cirrhosis with a Mayo score >20.

Initial application — (Pregnant, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	~	Manufacturer

continued...

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent pregnancy or Breastfeeding, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant or breastfeeding; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Initial application — (Pregnant, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Renewal — (Subsequent pregnancy, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg
 negative prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Hepatitis C Treatment

BOCEPREVIR - Special Authority see SA1402 on the next page - Retail pharmacy

Cap 200 mg – Wastage claimable – see rule 3.3.2 on page

Victrelis

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1402 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, first-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Initial application — (chronic hepatitis C - genotype 1, second-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any of the following:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Notes:

- Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count < 100 x10⁹ /l or Albumin <35 g/l
- The wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly

Antiretrovirals

SA1364 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts $< 1000 \text{ cells/mm}^3$; or
 - 2.3.2.2 CD4 counts $< 0.25 \times$ total lymphocyte count; or
 - $2.3.2.3 \ \ \mbox{Viral load counts} > 100000 \ \mbox{copies per ml; or}$
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts $< 500 \text{ cells/mm}^3$.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy		Fully	Brand or	_
(Manufacturer's Price)	Subs	idised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic	
\$	Per	<i>v</i>	Manufacturer	

continued...

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA1364 on page 108 – Retail pharmacy		
Tab 50 mg158.33	30	Stocrin S29
Tab 200 mg474.99	90	 Stocrin
Tab 600 mg474.99	30	 Stocrin
Oral liq 30 mg per ml145.79	180 ml OP	✓ Stocrin S29
ETRAVIRINE – Special Authority see SA1364 on page 108 – Retail pharmacy		
Tab 200 mg	60	✓ Intelence
IEVIRAPINE – Special Authority see SA1364 on page 108 – Retail pharmacy		
Tab 200 mg - Brand switch fee payable (Pharmacode		
2433265) - see page 206 for details	60	Nevirapine
		Alphapharm
Oral suspension 10 mg per ml134.55	240 ml	 Viramune
		Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE - Special A	Authority see SA1364 on page 108 – Retail	pharmacy	
Tab 300 mg		60	Ziagen
Oral liq 20 mg per ml		240 ml OP	 Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority Note: abacavir with lamivudine (combination tablets) count: retroviral Special Authority.				
Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa	
DIDANOSINE [DDI] - Special Authority see SA1364 on page 10	8 – Retail pharma	acy		
Cap 125 mg		30	Videx EC	
Cap 200 mg		30	Videx EC	
Cap 250 mg	230.10	30	Videx EC	
Cap 400 mg		30	Videx EC	
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPF – Retail pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil fun of the anti-retroviral Special Authority		·	,	
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxi	I			
fumarate 300 mg	1,313.19	30	 Atripla 	
EMTRICITABINE – Special Authority see SA1364 on page 108 -		, 30	✓ Emtriva	
Cap 200 mg		30		

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	(Manalactarer 3	Per	Manufacturer
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE Note: Emtricitabine with tenofovir disoproxil fumarate coun retroviral Special Authority		•	
Tab 200 mg with tenofovir disoproxil fumarate 300 mg		30	✓ Truvada
AMIVUDINE – Special Authority see SA1364 on page 108 – R			
Tab 150 mg		60	<u>Lamivudine</u> <u>Alphapharm</u>
Oral liq 10 mg per ml		240 ml OP	✓ <u>3TC</u>
STAVUDINE [D4T] – Special Authority see SA1364 on page 108 Cap 40 mg		acy 60	✔ Zerit
Powder for oral soln 1 mg per ml		200 ml OP	V Zerit S29
ZIDOVUDINE [AZT] - Special Authority see SA1364 on page 10			
Cap 100 mg		100 200 ml OP	Retrovir
Oral liq 10 mg per ml			✓ <u>Retrovir</u>
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablets anti-retroviral Special Authority.		•	
Tab 300 mg with lamivudine 150 mg	44.00	60	Alphapharm
Protease Inhibitors			
TAZANAVIR SULPHATE - Special Authority see SA1364 on p	age 108 - Retail	pharmacy	
Cap 150 mg	•	60	✓ Reyataz
Cap 200 mg	757.79	60	✓ Reyataz
DARUNAVIR – Special Authority see SA1364 on page 108 – Re			
Tab 400 mg Tab 600 mg		60 60	 Prezista Prezista
NDINAVIR – Special Authority see SA1364 on page 108 – Reta		00	
Cap 200 mg		360	Crixivan
Cap 400 mg		180	 Crixivan
OPINAVIR WITH RITONAVIR – Special Authority see SA1364		Retail pharmacy	
Tab 100 mg with ritonavir 25 mg		60	✓ Kaletra
Tab 200 mg with ritonavir 50 mg		120 200 ml OB	 ✓ Kaletra ✓ Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml		300 ml OP	
RITONAVIR – Special Authority see SA1364 on page 108 – Rei Tab 100 mg		30	✓ Norvir
Oral liq 80 mg per ml		90 ml OP	✓ Norvir
Strand Transfer Inhibitors			
RALTEGRAVIR POTASSIUM – Special Authority see SA1364 o	n page 108 – Re	etail pharmacy	
Tab 400 mg		60	✓ Isentress
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
ENFUVIRTIDE – Special Authority see SA0845 on the next pag			
Powder for inj 90 mg per ml $ imes$ 60	2,380.00	1	 Fuzeon

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	 ✓ 	Manufacturer	

➡SA0845 Special Authority for Subsidy

Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

- a) Diagnosis
 - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
 - · PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
 - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

- a) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- b) Pregnancy.
- c) Neutropenia (<2.0 \times 10⁹) and/or thrombocytopenia.
- d) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

INTERFERON ALFA-2A - PCT - Retail pharmacy-Specialist

a) See prescribing guideline above

b) Prescriptions must be written by, or on the recomme	endation of, an internal m	nedicine physic	ian or ophthalmologist
Inj 3 m iu prefilled syringe	31.32	1	✓ Roferon-A

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	
INTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist a) See prescribing guideline on the previous page b) Prescriptions must be written by, or on the recommendation		cine phys	sician o	r ophthalmologist
Inj 18 m iu, 1.2 ml multidose pen		1	1	ntron-A
Inj 30 m iu, 1.2 ml multidose pen		1	1	ntron-A
Inj 60 m iu, 1.2 ml multidose pen		1	1	ntron-A
 PEGYLATED INTERFERON ALFA-2A – Special Authority see SA See prescribing guideline on the previous page Inj 135 mcg prefilled syringe Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 	1,448.00 900.00	pharmac 4 4 I OP	· •	Pegasys Pegasys Pegasys RBV Combination Pack
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times 168	1,975.00	OP	✓]	Pegasys RBV Combination Pack
Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112	1,159.84	OP	~ [Pegasys RBV Combination Pack
Inj 180 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times 168	1,290.00	OP	 ✓ I 	Pegasys RBV Combination Pack

►SA1400 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Subsid	dy Fully	Brand or
(Manufacture)	r's Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- · Pegylated Interferon-alfa 2a is not approved for use in children.

Urinary Tract Infections

HE	XAMINE HIPPURATE			
*	Tab 1 g		100	
	•	(38,10)		Hiprex

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
	100	🖌 N	ifuran
37.50	100	🖌 N	ifuran
	100	✓ <u>A</u>	rrow-Norfloxacin
	(Manufacturer's Price) \$; ; 	(Manufacturer's Price) \$ Per 	(Manufacturer's Price) Subsidised \$ Per ✔

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.

MUSCULOSKELETAL SYSTEM

(Manufacturer's Price) Subsidied Generic Per Manufacturer Anticholinesterases Nor-Steroidal Anti-Inflammatory Drugs 50 ✓ AstraZeneca PYRIDOSTIGMINE BROMIDE A tab 60 mg 38.90 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs DIOLOFENAC SODIUM * Apo-Dicio ✓ Voltaren D Tab 60 mg			Subsidy		Ful	
NEOSTIGMINE METILSULFATE Inj 2.5 mg per ml, 1 ml ampoule 98.00 50 ✓ AstraZeneca PYRIDOSTIGMINE BROMIDE 38.90 100 ✓ Mestinon A Tab 60 mg 38.90 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs 00 ✓ Mestinon DICLOFENAC SODIUM 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.00 50 ✓ Voltaren D * Tab EC 55 mg 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.50 50 ✓ Diclax SR * Tab Long-acting 100 mg 32.00 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 100 mg 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren 100 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren 100 ✓ Voltaren			(Manufacturer's Price) \$		Subsidise	
Inj 2.5 mg per ml, 1 ml ampoule 98.00 50 ✓ AstraZeneca PYRIDOSTIGMINE BROMIDE 38.90 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs 100 ✓ Apo-Diclo DICLOFENAC SODIUM 4.00 100 ✓ Apo-Diclo * Tab EC 55 mg 4.00 100 ✓ Apo-Diclo * Tab EC 50 mg 150 20 ✓ Voltaren D * Tab long-acting 75 mg 24.52 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * Tab long-acting 100 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.04 10 ✓ Voltaren * Suppos 20 mg 0 mg 7.00 10 ✓ Voltaren * Suppos 20 mg 9 4.22 10 ✓ Voltaren * Bufor S1 to be Sole Supply on 1 August 2015 1.000 ✓ Hougesic * Tab 200 mg .050 20 .050 20 * Cap 10ng-acting 200 mg .050 20 <td>A</td> <td>nticholinesterases</td> <td></td> <td></td> <td></td> <td></td>	A	nticholinesterases				
PYRIDOSTIGMINE BROMIDE ▲ Tab 60 mg 38.90 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs DICLOFENAC SODIUM 4.00 100 ✓ Apo-Diclo ** Tab EC 25 mg	NE	OSTIGMINE METILSULFATE				
▲ Tab 60 mg				50	V	<u>AstraZeneca</u>
Non-Steroidal Anti-Inflammatory Drugs DICLOFENAC SODIUM * Tab EC 25 mg 4.00 100 ✓ Apo-Diclo * Tab EC 25 mg 1.50 20 ✓ Voltaren D * Tab EC 50 mg 16.00 500 ✓ Apo-Diclo * Tab Iong-acting 75 mg 24.52 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * Tab Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.04 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren * Suppos 100 mg 9.42 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren * Suppos 100 mg 9.45 1,000 ✓ Ibugesic * Tab 200 mg 9.45 1,000 ✓ Ibugesic * Tab 200 mg 0.50 20 ✓ Oruvail SR Bruten SR to be Sole Supply on 1 August 2015 8 Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed KETOPROCEN (5.60) Ponstan	PYF	RIDOSTIGMINE BROMIDE				
DICLOFENAC SODIUM ** Tab EC 25 mg 4.00 100 ✓ Apo-Diclo ** Tab EC 50 mg 1.50 20 ✓ Voltaren D ** Tab EC 50 mg 16.00 500 ✓ Apo-Diclo ** Tab long-acting 75 mg 24.52 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** In J25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren BUPROFEN * Tab 200 mg 9.45 1,000 ✓ Ibugesic * Tab 200 mg		Tab 60 mg		100	V	Mestinon
* Tab EC 25 mg 4.00 100 ✓ Apo-Diclo * Tab 50 mg dispersible 1.50 20 ✓ Voltaren D * Tab long-acting 75 mg 24.52 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Burgersching 800 mg .945 1,000 ✓ Voltaren * Burgersching 800 mg .945 1,000 ✓ Ibugesic * Tab long-acting 200 mg .12.07 28 ✓ Oruvail SR METENANC ACID .125 50 .001 Ponstan .125 50 .001 Ponsta	N	on-Steroidal Anti-Inflammatory Drugs				
* Tab 50 mg dispersible .1.50 20 ✓ Voltaren D * Tab EC 50 mg .1.50 500 ✓ Apo-Dicio * Tab long-acting 75 mg .4.52 500 ✓ Diclax SR * Tab long-acting 100 mg .4.52 500 ✓ Diclax SR * Tab long-acting 100 mg .4.52 500 ✓ Diclax SR * Tab long-acting 100 mg .4.52 500 ✓ Diclax SR * Suppos 12.5 mg .2.04 10 ✓ Voltaren * Suppos 100 mg .2.44 10 ✓ Voltaren * Suppos 100 mg .0 .4.22 10 ✓ Voltaren * Bupos 20 mg .0 .4.22 10 ✓ Voltaren * Bupos 20 mg .9.45 1,000 ✓ Bugesic * * Tab long-acting 200 mg .1.89 200 ml ✓ Fenpaed KETOPROFEN .2.5 .20 .2.5 .2.5 .2.5 .2.5 .2.5 .2.5 </td <td>DIC</td> <td>LOFENAC SODIUM</td> <td></td> <td></td> <td></td> <td></td>	DIC	LOFENAC SODIUM				
* Tab EC 50 mg 16.00 500 ✓ Apo-Diclo * Tab long-acting 75 mg 24.52 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * In 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg	*	Tab EC 25 mg	4.00	100	~	Apo-Diclo
** Tab long-acting 75 mg 24.52 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren ** Suppos 125 mg 2.04 10 ✓ Voltaren ** Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg	*	Tab 50 mg dispersible	1.50	20	~	Voltaren D
** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a 13.20 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.44 10 ✓ Voltaren * Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Tab long-acting 800 mg 7.99 30 ✓ Brufen SR Brufen SR * Tab long-acting 800 mg 7.99 30 ✓ Brufen SR * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR KETOPROFEN * Cap long-acting 750 mg 00 Ponstan * Cap 250 mg 0.50 20 Noffam 250 * </td <td>*</td> <td>Tab EC 50 mg</td> <td></td> <td>500</td> <td></td> <td></td>	*	Tab EC 50 mg		500		
* Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a 5 ✓ Voltaren * Suppos 12.5 mg .2.04 10 ✓ Voltaren * Suppos 25 mg .2.44 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO .4.22 10 ✓ Voltaren * Suppos 100 mg .7.00 10 ✓ Voltaren * Suppos 100 mg .7.00 10 ✓ Voltaren * Tab 200 mg .9.45 1,000 ✓ Ibugesic * Tab 200 mg .9.45 1,000 ✓ Brufen SR Bruten SR to be Sole Supply on 1 August 2015 * Oral liq 20 mg per ml .18.9 200 ml ✓ Fenpaed KETOPROFEN .	*	Tab long-acting 75 mg	24.52	500		
PSO. 13.20 5 ✓ Voltaren ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 0 ✓ Up to 10 supp available on a PSO 2.44 10 ✓ Voltaren ** Suppos 50 mg 0 up to 10 supp available on a PSO 2.44 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Suppos 100 mg 9.45 1,000 ✓ Voltaren ** Tab long-acting 800 mg 9.45 1,000 ✓ Brufen SR Brufen SR to be Sole Supply on 1 August 2015 * Fenpaed ✓ Fenpaed KETOPROFEN 18.9 200 ml ✓ Fenpaed ✓ Poruvail SR MEFENAMIC ACID .50 20 Ponstan 1.25 50 Ponstan 1.25 50 .50 20 ✓ Noflam 250 ✓ Noflam 500 Yotaren Yotaren ** Tab 250 mg .21.25 500 ✓ Noflam 500 ✓ Naprosyn SR 750 Yotaren Yotaren ** Tab 250 mg .22.25 250 ✓ Noflam 500 ✓ Noflam 500 ✓ Naprosyn SR 750 ** Tab 10ng-acting 750 mg .21.00 90	*			500	~	Diclax SR
** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Tab long-acting 800 mg -9.45 1,000 ✓ Voltaren ** Tab long-acting 800 mg -7.99 30 ✓ Brufen SR ** Oral liq 20 mg per ml August 2015 * Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg 0.50 20 0.50 20 * (5.60) Ponstan 1.25 500 ✓ Noftam 250 * NAPROXEN * * Tab long-acting 750 mg 10.01 <	*					
* Suppos 25 mg 2.44 10 ✓ Voltaren * Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren IBUPROFEN * 1,000 ✓ Ibugesic * Tab long-acting 800 mg 9.45 1,000 ✓ Brufen SR Brufen SR to be Sole Supply on 1 August 2015 7.99 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan 1.25 50 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 ✓ Naprosyn SR 750 * Tab 10ng-acting 750 mg 1.800 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 21.00 90 ✓ Napro						
* Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg 7.00 10 ✓ Voltaren IBUPROFEN * Tab long-acting 800 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 200 mg 1.4ugust 2015 ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 Ponstan 1.25 50 (9.16) Ponstan Naprosyn SR 750 Naprosyn SR 750 * Tab 200 mg 22.25 250 ✓ Nofiam 500 ✓ Naprosyn SR 750 * Tab l						
** Suppos 100 mg	•					
IBUPROFEN * Tab 200 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 7.99 30 ✓ Brufen SR Brufen SR to be Sole Supply on 1 August 2015 * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg 0.50 20 Ponstan 1.25 50 90 mstan NAPROXEN * Tab 200 mg 21.25 500 ✓ Noflam 250 * Tab 10ng-acting 750 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 750 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 ng 8.55						
* Tab 200 mg 9.45 1,000 ✓ Ibugesic * Tab long-acting 800 mg 7.99 30 ✓ Brufen SR Brufen SR to be Sole Supply on 1 August 2015 1.89 200 ml ✓ Fenpaed KETOPROFEN 1.89 200 ml ✓ Fenpaed KETOPROFEN 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 0.50 20 0.50 20 * Cap 250 mg 0.50 20 0.50 20 (5.60) Ponstan 1.25 50 90 mstan NAPROXEN 21.25 500 ✓ Noflam 250 ✓ Naprosyn SR 750 * Tab 250 mg 22.25 250 ✓ Noflam 500 ✓ Naprosyn SR 750 * Tab long-acting 750 mg 13.00 90 ✓ Naprosyn SR 750 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC * Tab 100 mg 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin				10	V	voitaren
* Tab long-acting 800 mg 7.99 30 ✓ Brufen SR Brufen SR to be Sole Supply on 1 August 2015 1.89 200 ml ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID	-	-				
Bruten SR to be Sole Supply on 1 August 2015 * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID	•	5		,		
KETOPROFEN ** Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID .0.50 20 .0.50 20 (5.60) Ponstan 1.25 50 .0.50 20 (9.16) Ponstan .0.50 20 .0.50 20 * Tab 250 mg .0.50 20 .0.50 .0.50 20 * Tab 250 mg .0.50 <t< td=""><td></td><td>Brufen SR to be Sole Supply on 1 August 2015</td><td></td><td></td><td></td><td></td></t<>		Brufen SR to be Sole Supply on 1 August 2015				
* Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID .0.50 20 * Cap 250 mg .0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 22.25 250 * Tab 500 mg 22.25 250 * Tab long-acting 750 mg 18.00 90 × Tab long-acting 1 g 21.00 90 × Tab 100 mg 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin * Tab 20 mg 3.05 20 ✓ Reutenox	*	Oral liq 20 mg per ml	1.89	200 ml	~	Fenpaed
MEFENAMIC ACID * Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 ✓ Noflam 250 * Tab 250 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Noflam 500 * Tab long-acting 750 to be Sole Supply on 1 July 2015 21.00 90 ✓ Naprosyn SR 750 SULINDAC * * Tab 100 mg 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin * Aclin * Tab 20 mg 3.05 20 ✓ Reutenox	KE	TOPROFEN				
* Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 22.25 250 * Tab 500 mg 22.25 250 * Tab long-acting 750 mg 18.00 90 * Tab long-acting 150 be Sole Supply on 1 July 2015 * * Tab long-acting 1 g 21.00 90 Naprosyn SR 750 to be Sole Supply on 1 July 2015 * * Tab long-acting 1 g 21.00 90 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 * SULINDAC 8.55 50 * Tab 100 mg 8.55 50 * Tab 200 mg 15.10 50 * Tab 20 mg 3.05 20	*	Cap long-acting 200 mg		28	~	Oruvail SR
* Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 22.25 250 * Tab 500 mg 22.25 250 * Tab long-acting 750 mg 18.00 90 * Tab long-acting 150 be Sole Supply on 1 July 2015 * * Tab long-acting 1 g 21.00 90 Naprosyn SR 750 to be Sole Supply on 1 July 2015 * * Tab long-acting 1 g 21.00 90 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 * SULINDAC 8.55 50 * Tab 100 mg 8.55 50 * Tab 200 mg 15.10 50 * Tab 20 mg 3.05 20	MF	FENAMIC ACID				
(5.60) Ponstan 1.25 50 (9.16) Ponstan * Tab 250 mg 21.25 * Tab 500 mg 22.25 * Tab 500 mg 22.25 * Tab long-acting 750 mg 18.00 * Tab long-acting 150 to be Sole Supply on 1 July 2015 ✓ * Tab long-acting 1 g 21.00 * Tab long mg 8.55 SULINDAC * Tab 200 mg 15.10 50 ✓ Aclin * Tab 20 mg 3.05			0.50	20		
(9.16) Ponstan NAPROXEN 21.25 500 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 21.00 90 ✓ Naprosyn SR 1000 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 21.00 90 ✓ Naprosyn SR 1000 SULINDAC * Tab 200 mg 15.10 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin * * Tab 20 mg 3.05 20 ✓ Reutenox						Ponstan
NAPROXEN ** Tab 250 mg 21.25 500 ✓ Noflam 250 ** Tab 500 mg 22.25 250 ✓ Noflam 500 ** Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 ** Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC * Tab 100 mg 8.55 50 ✓ Aclin ** Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM * 3.05 20 ✓ Reutenox			1.25 [´]	50		
* Tab 250 mg 21.25 500 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM 3.05 20 ✓ Reutenox			(9.16)			Ponstan
* Tab 250 mg 21.25 500 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM 3.05 20 ✓ Reutenox	NA	PROXEN				
* Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 750 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM 3.05 20 ✓ Reutenox				500	~	Noflam 250
* Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750 Naprosyn SR 750 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 * Tab long-acting 1 g 21.00 90 ✓ Naprosyn SR 1000 Naprosyn SR 1000 to be Sole Supply on 1 July 2015 90 ✓ Naprosyn SR 1000 SULINDAC 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM 3.05 20 ✓ Reutenox						
Naprosyn SR 750 to be Sole Supply on 1 July 2015 * Tab long-acting 1 g Naprosyn SR 1000 to be Sole Supply on 1 July 2015 SULINDAC * Tab 100 mg * Tab 200 mg TENOXICAM * Tab 20 mg		5		90		
Naprosyn SR 1000 to be Sole Supply on 1 July 2015 SULINDAC * Tab 100 mg 8.55 50 ✓ Aclin * Tab 200 mg 15.10 50 ✓ Aclin TENOXICAM 3.05 20 ✓ Reutenox						-
SULINDAC * Tab 100 mg * Tab 200 mg	*		21.00	90	~	Naprosyn SR 1000
* Tab 100 mg		Naprosyn SR 1000 to be Sole Supply on 1 July 2015				
* Tab 200 mg	SUI	LINDAC				
TENOXICAM ★ Tab 20 mg	•	•			-	
★ Tab 20 mg	*	Tab 200 mg	15.10	50	~	Aclin
★ Tab 20 mg	TEN					
	*	Tab 20 mg	3.05	20	~	Reutenox
	*			1	~	AFT

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
NSAIDs Other				
MELOXICAM – Special Authority see SA1034 below – Retail pha * Tab 7.5 mg		30	🗸 A	rrow-Meloxicam

SA1034 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
- 2 The patient has haemophilic arthropathy; and
- 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

Topical Products for Joint and Muscular Pain		
CAPSAICIN		
Crm 0.025% – Special Authority see SA1289 below – Retail		
pharmacy	25 g OP	✓ Zostrix
9.95	45 g OP	✓ Zostrix
►>SA1289 Special Authority for Subsidy		
Initial application from any relevant practitioner. Approvals valid without further	er renewal unle	ess notified where the patient has
osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-infl	ammatories ar	e contraindicated.

Antirheumatoid Agents

Tab 3 mg	60	✔ Ridaura s29 S29
HYDROXYCHLOROQUINE * Tab 200 mg18.00	100	✓ Plaquenil
LEFLUNOMIDE Tab 10 mg55.00 Tab 20 mg76.00 Tab 100 mg54.44	30 30 3	✓ Arava ✓ Arava ✓ Arava
PENICILLAMINE Tab 125 mg61.93 Tab 250 mg	100 100	✓ D-Penamine✓ D-Penamine
SODIUM AUROTHIOMALATE Inj 10 mg in 0.5 ml ampoule76.87 Inj 20 mg in 0.5 ml ampoule113.17 Inj 50 mg in 0.5 ml ampoule217.23	10 10 10	 ✓ Myocrisin ✓ Myocrisin ✓ Myocrisin

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

	Subsidy	Ful	y Brand or	
(Man	ufacturer's Price)	Subsidise	d Generic	
	\$ F	Per •	 Manufacturer 	

continued...

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score $\leq~$ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD $\geq~$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq~$ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score $\leq~$ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

MUSCULOSKELETAL SYSTEM

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsid	ised	Generic	
\$	Per	r	Manufacturer	

continued...

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. ALENDRONATE SODIUM - Special Authority see SA1039 on page 117 - Retail pharmacy Fosamax * Tab 70 mg12.90 ALENDRONATE SODIUM WITH CHOLECALCIFEROL - Special Authority see SA1039 on page 117 - Retail pharmacy Fosamax Plus 4 Alendronate for Paget's Disease SA0949 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. ALENDRONATE SODIUM - Special Authority see SA0949 above - Retail pharmacy 30 Fosamax Other Treatments ETIDRONATE DISODIUM - See prescribing guideline below 100 Arrow-Etidronate **Prescribing Guidelines** Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose - 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water. PAMIDRONATE DISODIUM 1 Pamisol 1 Pamisol 1 Pamisol RALOXIFENE HYDROCHLORIDE - Special Authority see SA1138 on the next page - Retail pharmacy Evista Tab 60 mg53.76 28

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg4.00	4	 Risedronate Sandoz
TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy		
Inj 250 mcg per ml, 2.4 ml	1	✓ Forteo

SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable

MUSCULOSKELETAL SYSTEM

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

Inj 0.05 mg per ml, 100 ml, vial – Special Authority see SA1187 below – Retail pharmacy600.00 100 ml OP ✓ Aclasta

➡SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
- 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
- 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 Any of the following:

- 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
- 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
- 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

MUSCULOSKELETAL SYSTEM

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL		
* Tab 100 mg15.11	1,000	Apo-Allopurinol
* Tab 300 mg – For allopurinol oral liquid formulation refer,		
page 20915.91	500	Apo-Allopurinol
BENZBROMARONE - Special Authority see SA1319 below - Retail pharmacy		
Tab 100 mg	100	 Benzbromaron AL
		100 S29

SA1319 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
 - 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
 - 1.3 Both:
 - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note): and
 - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 1.4 All of the following:
 - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 1.4.2 Allopurinol is contraindicated: and
 - 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 2 The patient is receiving monthly liver function tests.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
COLCHICINE * Tab 500 mcg		100	✓ <u>C</u>	olgout
FEBUXOSTAT - Special Authority see SA1431 below - Retail ph	narmacy			
Tab 80 mg		28	🗸 A	denuric
Tab 120 mg		28	🗸 A	denuric

➡SA1431 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following:

- 1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
- 2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
- 3 Both:
 - 3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 3.2 The patient has a rate of creatinine clearance greater than or equal to 30 ml/min.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearanceadjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

* Tab 500 mg		100	Probenecid-AFT
Muscle Relaxants			
BACLOFEN			
Tab 10 mg – For baclofen oral liquid formulation r 209 Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by end Subsidised only for use in a programmable pur caused intolerable side effects and the prescript Inj 2 mg per ml, 5 ml ampoule – Subsidy by endors Subsidised only for use in a programmable pur caused intolerable side effects and the prescript	3.85 lorsement	1 Intispastic ag	 Lioresal Intrathecal
DANTROLENE		•	
* Cap 25 mg	65.00	100	Dantrium
* Cap 50 mg	77.00	100	 Dantrium
ORPHENADRINE CITRATE			
Tab 100 mg		100	✓ Norflex

	Subsidy (Manufacturer's Price)		Fully Brand or Subsidised Generic
	\$	Per	Manufacturer
Agents for Parkinsonism and Related Disorders			
Dopamine Agonists and Related Agents			
MANTADINE HYDROCHLORIDE			
Cap 100 mg		60	Symmetrel
POMORPHINE HYDROCHLORIDE			
Inj 10 mg per ml, 2 ml ampoule	119.00	5	Apomine
BROMOCRIPTINE MESYLATE			
k Tab 2.5 mg		100	Apo-Bromocriptine
NTACAPONE			4 - .
Tab 200 mg	47.92	100	Entapone
EVODOPA WITH BENSERAZIDE	10.05	105	/
Tab dispersible 50 mg with benserazide 12.5 mg		100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg		100 100	 Madopar 62.5 Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	✓ Madopar 250
EVODOPA WITH CARBIDOPA			
 Tab 100 mg with carbidopa 25 mg – For levodopa with car- 			
bidopa oral liquid formulation refer, page 209		100	Kinson
			✓ Sinemet
♦ Tab long-acting 200 mg with carbidopa 50 mg		100	 Sinemet CR
 Tab 250 mg with carbidopa 25 mg 		100	 Sinemet
ISURIDE HYDROGEN MALEATE			
Tab 200 mcg	25.00	30	 Dopergin
RAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg		100	Ramipex
Tab 1 mg	24.39	100	Ramipex
OPINIROLE HYDROCHLORIDE			
Tab 0.25 mg		100	Apo-Ropinirole
Tab 1 mg		100	✓ <u>Apo-Ropinirole</u>
 Tab 2 mg Tab 5 mg 		100 100	 ✓ <u>Apo-Ropinirole</u> ✓ Apo-Ropinirole
ů		100	
ELEGILINE HYDROCHLORIDE • Tab 5 mg	16.06	100	✓ Apo-Selegiline
		100	✓ Apo-Selegiline
			S29 S29
OLCAPONE			
Tab 100 mg		100	✓ Tasmar
Anticholinergics		100	• Roman
ENZTROPINE MESYLATE			
Tab 2 mg		60	 Benztrop
Inj 1 mg per ml, 2 ml		5	Cogentin
a) Up to 5 inj available on a PSO	-		v
b) Only on a PSO			

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 125

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PROCYCLIDINE HYDROCHLORIDE	7.40	100		
Tab 5 mg		100	V K	emadrin
Agents for Essential Tremor, Chorea and Related	Disorders			
RILUZOLE – Special Authority see SA1403 below – Retail pharm Wastage claimable – see rule 3.3.2 on page 13 Tab 50 mg		56	🖌 Ri	lutek
 SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory special following criteria: All of the following: The patient has amyotrophic lateral sclerosis with disease 				applications meeting the
 2 The patient has at least 60 percent of predicted forced vita 3 The patient has not undergone a tracheostomy; and 4 The patient has not experienced respiratory failure; and 5 Any of the following: 5.1 The patient is ambulatory; or 5.2 The patient is able to use upper limbs; or 5.3 The patient is able to swallow. 	al capacity within 2 n	nonths	prior to the	initial application; and
Renewal from any relevant practitioner. Approvals valid for 18 mor All of the following: 1 The patient has not undergone a tracheostomy; and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow.	nths for applications	meetir	ng the follow	ing criteria:
TETRABENAZINE Tab 25 mg	118.00	112	🗸 M	otetis
Anaesthetics				
Local				
LIDOCAINE [LIGNOCAINE] Gel 2%, 10 ml urethral syringe – Subsidy by endorsement a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical adm		10 rescrip	✓ Pf tion is endo	
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE				0,7
Oral (viscous) soln 2%		200 ml		locaine Viscous
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO	17.50	25 50		docaine-Claris
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO	(35.00)	25		/locaine docaine-Claris
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO		1		docaine-Claris
, ,	12.00	5		
	(20.00)			locaine
Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO	2.40	1	✓ Li	docaine-Claris

	Subsidy (Manufacturer's P	rice) Sub	Fully Brand or osidised Generic
	\$	Per	✓ Manufacturer
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes -		10	4 - 4
Subsidy by endorsement		10	✓ Pfizer
a) Up to 5 each available on a PSO	ainistration and th	no proporintior	a is anderead accordingly
b) Subsidised only if prescribed for urethral or cervical adm			•••
IDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Author Crm 2.5% with prilocaine 2.5%		30 g OP	
Crm 2.5% with prilocaine 2.5% (5 g tubes)		5	✓ EMLA
►>SA0906 Special Authority for Subsidy			
nitial application from any relevant practitioner. Approvals valid	d for 2 years whe	ere the patien	t is a child with a chronic medic
ondition requiring frequent injections or venepuncture.			
Renewal from any relevant practitioner. Approvals valid for 2 ye	ears where the tr	eatment rema	ains appropriate and the patient
penefiting from treatment.			
Analgesics			
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page	ge 116		
· · · · · · · · · · · · · · · · · · ·	5		
Non-opioid Analgesics			
or aspirin & chloroform application refer Standard Formulae, pag	ie 212		
SPIRIN	-		
₭ Tab EC 300 mg	2.00	100	
, i i i i i i i i i i i i i i i i i i i	(8.50)		Aspec 300
* Tab dispersible 300 mg – Up to 30 tab available on a PSO	2.55	100	Ethics Aspirin
CAPSAICIN – Subsidy by endorsement			
Subsidised only if prescribed for post-herpetic neuralgia or o	diabetic peripher	al neuropathy	and the prescription is endorse
accordingly.	10 50	45	
Crm 0.075%		45 g OP	Zostrix HP
	00.40		
Tab 30 mg	23.40	90	Acupan
ARACETAMOL			4
Tab 500 mg – Up to 30 tab available on a PSO		1,000	✓ <u>Pharmacare</u>
t Oral liq 120 mg per 5 mla) Up to 200 ml available on a PSO	4.15	1,000 ml	✓ Paracare
b) Not in combination			
kr‡ Oral liq 250 mg per 5 ml	4.35	1,000 ml	Paracare Double
			Strength
a) Up to 100 ml available on a PSO			
b) Not in combination	7.40	00	A Demodel
 ₭ Suppos 125 mg ₭ Suppos 250 mg 		20 20	 Panadol Panadol
		20 50	✓ Paracare
S 20000S 200 mg			•
₭ Suppos 500 mg	20.70		
	20.70		
Opioid Analgesics			
Opioid Analgesics CODEINE PHOSPHATE – Safety medicine; prescriber may deter Tab 15 mg	rmine dispensing 4.75		✓ <u>PSM</u>
Opioid Analgesics CODEINE PHOSPHATE – Safety medicine; prescriber may deter	rmine dispensing 4.75 5.80	frequency	✓ <u>PSM</u> ✓ <u>PSM</u> ✓ PSM

	Subsidy (Manufacturer's Price)		Fully Brand or Subsidised Generic
	\$	Per	✓ Manufacturer
DIHYDROCODEINE TARTRATE			
Tab long-acting 60 mg		60	DHC Continus
FENTANYL			
 a) Only on a controlled drug form 			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequencies		10	A Develop and Muir
Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 10 ml		10 10	 Boucher and Muir Boucher and Muir
Patch 12.5 mcg per hour		5	✓ Fentanyl Sandoz
	8.90	5	✓ Mylan Fentanyl
	0.00		Patch
Fentanyl Sandoz to be Sole Supply on 1 August 2015			
Patch 25 mcg per hour		5	 Fentanyl Sandoz
	9.15		Mylan Fentanyl
			Patch
Fentanyl Sandoz to be Sole Supply on 1 August 2015		_	
Patch 50 mcg per hour		5	Fentanyl Sandoz
	11.50		Mylan Fentanyl Patch
Fentanyl Sandoz to be Sole Supply on 1 August 2015			Falch
Patch 75 mcg per hour	9.18	5	Fentanyl Sandoz
	13.60	Ũ	✓ Mylan Fentanyl
			Patch
Fentanyl Sandoz to be Sole Supply on 1 August 2015			
Patch 100 mcg per hour		5	 Fentanyl Sandoz
	14.50		 Mylan Fentanyl Patch
Fentanyl Sandoz to be Sole Supply on 1 August 2015 Mylan Fentanyl Patch Patch 12.5 mcg per hour to be delisted 1 Au Mylan Fentanyl Patch Patch 25 mcg per hour to be delisted 1 Aug Mylan Fentanyl Patch Patch 50 mcg per hour to be delisted 1 Aug Mylan Fentanyl Patch Patch 75 mcg per hour to be delisted 1 Aug Mylan Fentanyl Patch Patch 75 mcg per hour to be delisted 1 Aug	gust 2015) gust 2015) gust 2015)		
METHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
 c) Safety medicine; prescriber may determine dispensing frequency d) Extemporaneously compounded methadone will only be re 		e of the	e cheapest form available (methado
powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard For	mulaa naga 212		
e) For methadone hydrochloride oral liquid refer Standard For Tab 5 mg		10	Methatabs
Oral liq 2 mg per ml		200 ml	
		200 ml	Biodone Forte
Oral liq 5 mg per ml Oral liq 10 mg per ml		200 ml 200 ml	

NERVOUS	SYSTEM
----------------	--------

	Subsidy		Fully	Brand or
	(Manufacturer's Price		bsidised	Generic
	\$	Per	~	Manufacturer
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fre	allency			
Oral liq 1 mg per ml		200 ml	V R	A-Morph
toral liq 2 mg per ml		200 ml		A-Morph
Oral liq 5 mg per ml		200 ml		A-Morph
formation of the second s		200 ml		A-Morph
1 01		200 111	• <u>n</u>	
MORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fre			4.0	
Tab immediate-release 10 mg		10		evredol
Tab long-acting 10 mg		10		rrow-Morphine LA
Tab immediate-release 20 mg		10		evredol
Tab long-acting 30 mg		10	_	rrow-Morphine LA
Tab long-acting 60 mg		10		rrow-Morphine LA
Tab long-acting 100 mg		10		rrow-Morphine LA
Cap long-acting 10 mg		10		-Eslon
Cap long-acting 30 mg		10		-Eslon
Cap long-acting 60 mg		10	• •	-Eslon
Cap long-acting 100 mg		10		-Eslon
Inj 5 mg per ml, 1 ml ampoule $-$ Up to 5 inj available on a PS	012.48	5		BL Morphine
laide an anna d'airtean aile - thata 5 isteachailtean				Sulphate
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a		-		DI Manulationa
PSO	9.09	5		BL Morphine
laid Case and diasternation. The to Civilate blacks				Sulphate
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a		_		
PSO		5		BL Morphine
lai 00 mar nan milit miliamanula Linita 5 ini available an .				Sulphate
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a		-		DI Maunhina
PSO		5		BL Morphine
				Sulphate
MORPHINE TARTRATE				
a) Only on a controlled drug form				
 b) No patient co-payment payable 				
c) Safety medicine; prescriber may determine dispensing fre				
Inj 80 mg per ml, 1.5 ml		5		ospira
Inj 80 mg per ml, 5 ml	107.67	5	✓ <u>н</u>	ospira

		Subsidy (Manufacturer's Price) \$	Per	Full <u>y</u> Subsidised	
X	YCODONE HYDROCHLORIDE				
	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	c) Safety medicine; prescriber may determine dispensing frequencies	uency			
	Tab controlled-release 5 mg	7.51	20	~	OxyContin
	Tab controlled-release 10 mg	6.75	20	~	Oxycodone
					ControlledRelease
					Tablets(BNM)
	Tab controlled-release 20 mg		20	~	Oxycodone
					ControlledRelease
					Tablets(BNM)
	Tab controlled-release 40 mg		20	~	Oxycodone
					ControlledRelease
					Tablets(BNM)
	Tab controlled-release 80 mg		20	~	Oxycodone
					ControlledRelease
					Tablets(BNM)
	Cap immediate-release 5 mg		20	~	OxyNorm
	Cap immediate-release 10 mg		20	~	OxyNorm
	Cap immediate-release 20 mg	9.77	20	~	OxyNorm
	Oral liq 5 mg per 5 ml		250 m	 ✓ 	OxyNorm
	Inj 10 mg per ml, 1 ml		5	~	Oxycodone Orion
	Inj 10 mg per ml, 2 ml		5	~	Oxycodone Orion
	Inj 50 mg per ml, 1 ml	60.00	5	~	OxyNorm
1	RACETAMOL WITH CODEINE - Safety medicine; prescriber n	nav determine disne	nsina	frequency	
-11	Tab paracetamol 500 mg with codeine phosphate 8 mg		1.000		Paracetamol +
	hab paracetarilor oco mg with obtaine phosphate o mg		1,000	•	Codeine (Relieve)
	THIDINE HYDROCHLORIDE				
-					
	a) Only on a controlled drug form				
	b) No patient co-payment payable	10001			
	c) Safety medicine; prescriber may determine dispensing freq	•	10		DOM
	Tab 50 mg		10		<u>PSM</u> PSM
	Tab 100 mg		10 5		
	Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO	5.51	5	V	DBL Pethidine
	ini E0 ma nav mi .0 mi Lin ta 5 ini avrilatila an a DOO	E 00	F		Hydrochloride
	Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	V	DBL Pethidine
					Hydrochloride
R	AMADOL HYDROCHLORIDE				
	Tab sustained-release 100 mg		20		Tramal SR 100
	Tab sustained-release 150 mg		20	~	Tramal SR 150
	Tab sustained-release 200 mg		20		Tramal SR 200 Arrow-Tramadol

NERVOUS	SYSTEM
---------	--------

	Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
	\$	Per	Vabbilaisea	Manufacturer
Antidepressants				
Annuepressants				
Cyclic and Related Agents				
MITRIPTYLINE - Safety medicine; prescriber may determ				
Tab 10 mg		100	✓ <u>A</u>	rrow Amitriptyline
Tab 25 mg – Brand switch fee payable (Pharma				
2476029) - see page 206 for details		100	VA	rrow-Amitriptyline
Tab 50 mg – Brand switch fee payable (Pharma		400		A
2476029) - see page 206 for details		100		rrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE - Safety medicine; p	,	•	• •	•
Tab 10 mg		100		po-Clomipramine
Tab 25 mg	8.68	100	VA	po-Clomipramine
OOTHIEPIN HYDROCHLORIDE - Safety medicine; prescri				
Tab 75 mg		100		opress
Cap 25 mg	6.17	100	V D	opress
OXEPIN HYDROCHLORIDE - Safety medicine; prescribe	er may determine dispens	ing freq	luency	
Cap 10 mg		100	VA	nten
Cap 25 mg	6.86	100		nten
Cap 50 mg	8.55	100	🗸 A	Inten
MIPRAMINE HYDROCHLORIDE – Safety medicine; presc	riber may determine disp	ensing	frequency	
Tab 10 mg		60		ofranil s29 s29
	5.48	50		ofranil
	10.96	100	🖌 T	ofranil
Tab 25 mg	8.80	50	🖌 T	ofranil
MAPROTILINE HYDROCHLORIDE - Safety medicine; pres	scriber may determine dis	nensin	a frequency	1
Tab 25 mg	,	30		udiomil
···· _•	12.53	50		udiomil
	25.06	100	V L	udiomil
Tab 75 mg	14.01	20	V L	udiomil
Ĵ	21.01	30	V L	udiomil
/IANSERIN HYDROCHLORIDE - Safety medicine; prescr	iber may determine dispe	nsina fi	requency	
Tab 30 mg – Subsidy by endorsement		30		olvon
Subsidised for patients who were taking mianserin hy		2014 ar		
ingly. Pharmacists may annotate the prescription as hydrochloride. Note that supply of mianserin hydroc there will be no stock of mianserin available beyond I	endorsed where there ex hloride is being discontin	ists a r	ecord of pri	or dispensing of mianse
NORTRIPTYLINE HYDROCHLORIDE - Safety medicine; p	prescriber may determine	dispens	sing freque	ncy
Tab 10 mg		100		lorpress
Tab 25 mg	9.00	180	\[\] \[\[\] \[lorpress
Monoamine-Oxidase Inhibitors (MAOIs) - No	on Selective			
PHENELZINE SULPHATE				
* Tab 15 mg		100	V N	lardil
FRANYLCYPROMINE SULPHATE		'		
* Tab 10 mg	22 04	50	~ ¤	Parnate

	Subsidy (Manufacturer's Price \$) S Per	Fully Brand or ubsidised Generic ✔ Manufacturer
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE Note: There is a significant cost differential between moclob expensive). For depressive syndromes it is therefore more co ing prescribing moclobemide.			
₭ Tab 150 mg		500	✓ Apo-Moclobemide
* Tab 300 mg	29.51	100	Apo-Moclobemide
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE K Tab 20 mg	2.34	84	✓ Arrow-Citalopram
SCITALOPRAM			
₭ Tab 10 mg	1.40 2.65	28	 Air Flow Products Loxalate
₭ Tab 20 mg		28	✓ Air Flow Products
	4.20	20	✓ Loxalate
EUOXETINE HYDROCHLORIDE Tab dispersible 20 mg, scored – Subsidy by endorsement	2 50	30	✓ Arrow-Fluoxetine
Subsidised by endorsement	2.00	30	Allow-Fluoxetine
 2) When prescribed in a daily dose that is not a multiple of Note: Tablets should be combined with capsules to facili Cap 20 mg 	itate incremental 10 n		
AROXETINE HYDROCHLORIDE			· · · · · · · · · · · · · · · · · · ·
₭ Tab 20 mg	4.32	90	Loxamine
SERTRALINE			
₭ Tab 50 mg	3.64	90	✓ Arrow-Sertraline
⊱ Tab 100 mg	6.28	90	Arrow-Sertraline
Other Antidepressants			
IIRTAZAPINE – Special Authority see SA0994 below – Retail p	harmacy		
Tab 30 mg	8.78	30	Avanza
Tab 45 mg	13.95	30	Avanza
SA0994 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid	I for 2 years for applic	ations m	eeting the following criteria:
Both:			
 The patient has a severe major depressive episode; and Either: 	1		
2.1 The patient must have had a trial of two differe failed to respond to an adequate dose over an adequate the second se			
2.2 Both:			aadiya aniaaday a a d
2.2.1 The patient is currently a hospital in-patier 2.2.2 The patient must have had a trial of one			

2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
VENLAFAXINE					
Tab 37.5 mg	5.06	28	🗸 A	Arrow-Venlafaxine XR	
Tab 75 mg	6.44	28	🗸 A	Arrow-Venlafaxine	
Tab 150 mg	8.86	28	🗸 A	Arrow-Venlafaxine XR	
Tab 225 mg	14.34	28	🗸 A	Arrow-Venlafaxine XR	
Cap 37.5 mg - Special Authority see SA1061 below - Retail					
pharmacy Cap 75 mg - Special Authority see SA1061 below - Retail	8.68	28	V E	fexor XR	
pharmacy	12.18	28	🖌 E	fexor XR	
Cap 150 mg – Special Authority see SA1061 below – Retail pharmacy	20.16	28	✔ E	fexor XR	

➡SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 1 ml19.00	5	 Rivotril
 DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement11.83 a) Up to 5 inj available on a PSO b) Only on a PSO 	5	✔ Hospira
c) PSO must be endorsed "not for anaesthetic procedures". Rectal tubes 5 mg – Up to 5 tube available on a PSO	5 5	✓ Stesolid✓ Stesolid
PARALDEHYDE * Inj 5 ml1,500.00	5	🖌 AFT
PHENYTOIN SODIUM * Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5 5	✔ Hospira✔ Hospira

ARBAMAZEPINE Tab 200 mg	(Subsidy Manufacturer's Pr \$	ice) S Per	Fully Subsidised	Brand or Generic Manufacturer
Image: Tab 200 mg 14.53 100 Image: Tegretol Image: Tab long-acting 200 mg 16.98 100 Image: Tegretol CR Image: Tab long-acting 400 mg 34.58 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 400 mg 26.37 250 ml Image: Tegretol CR Image: Tab 10 mg 26.37 250 ml Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol LOBAZAM - Safety medicine; prescriber may determine dispensing frequency Image: Tegretol Image: Tegretol LONAZEPAM - Safety medicine; prescriber may determine dispensing frequency Image: Tegretol Image: Tegretol UNAZEPAM - Safety medicine; prescriber may determine dispensing frequency Image: Tegretol Image: Tegretol UNAZEPAM - Safety medicine; prescriber may determine dispensing frequency Image: Tegretol Image: Tegretol Image: Tegretol 250 mg 25 mg per ml 7.38 Image: Tegretol Image: Tegretol<	Control of Epilepsy				
Image: Tab long-acting 200 mg 16.98 100 Image: Tegretol CR Image: Tab 400 mg 34.58 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 400 mg 39.17 100 Image: Tegretol CR Image: Tab long-acting 200 mg per ml 26.37 250 ml Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol CR Image: Tab 10 mg 9.12 50 Image: Tegretol CR Image: Safety cap for extemporaneously compounded oral liquid preparations. Image: Tegretol CR Image: Tegretol CR Image: Cap 250 mg Safety medicine; prescriber may determine dispensing frequency Image: Tegretol CR Image: Tegretol CR Image: Cap 250 mg Safety medicine; prescriber may determine dispensing frequency Image: Tegretol CR Image: Tegretol CR	CARBAMAZEPINE				
 Tab 400 mg	₭ Tab 200 mg	14.53	100		•
 Tab long-acting 400 mg					•
*‡ Oral liq 20 mg per ml 26.37 250 ml ✓ Tegretol LOBAZAM – Safety medicine; prescriber may determine dispensing frequency 9.12 50 ✓ Frisium ‡ Safety cap for extemporaneously compounded oral liquid preparations. 9.12 50 ✓ Frisium LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 0ral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE					•
LOBAZAM - Safety medicine; prescriber may determine dispensing frequency Tab 10 mg 9.12 50 ★ Safety cap for extemporaneously compounded oral liquid preparations. 50 LONAZEPAM - Safety medicine; prescriber may determine dispensing frequency 50 Oral drops 2.5 mg per ml 7.38 10 ml OP THOSUXIMIDE 32.90 200 ✓ Zarontin Cap 250 mg 9 per 5 ml 13.60 200 ml ✓ Zarontin ABAPENTIN - Special Authority see SA1477 below - Retail pharmacy 100 ✓ Arrow-Gabapentin ✓ Nupentin Cap 300 mg - For gabapentin oral liquid formulation refer, page 209 11.00 100 ✓ Arrow-Gabapentin Cap 400 mg - Safety 00 mg - Safety medicine; prescriber may determine dispensing frequency 13.75 100 ✓ Arrow-Gabapentin					•
Tab 10 mg 9.12 50 ✓ Frisium ‡ Safety cap for extemporaneously compounded oral liquid preparations. Frisium LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Oral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE 7.38 10 ml OP ✓ Rivotril Cap 250 mg 32.90 200 ✓ Zarontin ☆ Oral liq 250 mg per 5 ml 13.60 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy ✓ Arrow-Gabapentin ✓ Nupentin Cap 300 mg – For gabapentin oral liquid formulation refer, page 209 11.00 100 ✓ Arrow-Gabapentin Cap 400 mg	¢‡ Oral liq 20 mg per ml	26.37	250 ml	V T	egretol
‡ Safety cap for extemporaneously compounded oral liquid preparations. LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Oral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE 32.90 200 ✓ Zarontin Cap 250 mg 32.90 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy 13.60 200 ml ✓ Zarontin Cap 100 mg For gabapentin oral liquid formulation refer, page 209 11.00 100 ✓ Arrow-Gabapentin Cap 400 mg Cap 400 mg 13.75 100 ✓ Arrow-Gabapentin	CLOBAZAM - Safety medicine; prescriber may determine dispensi	ng frequency			
LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Oral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE 32.90 200 ✓ Zarontin Cap 250 mg 32.90 200 ml ✓ Zarontin * Cral liq 250 mg per 5 ml 13.60 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy 100 ✓ Arrow-Gabapentin Cap 100 mg For gabapentin oral liquid formulation refer, page 209 11.00 100 ✓ Arrow-Gabapentin Cap 400 mg Cap 400 mg 13.75 100 ✓ Arrow-Gabapentin	Tab 10 mg	9.12	50	🖌 F	risium
Oral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE 32.90 200 ✓ Zarontin Cap 250 mg 32.90 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy 200 ml ✓ Zarontin Cap 100 mg For gabapentin oral liquid formulation refer, page 209 100 ✓ Arrow-Gabapentin Cap 400 mg Cap 400 mg 13.75 100 ✓ Arrow-Gabapentin	‡ Safety cap for extemporaneously compounded oral liquid p	reparations.			
Oral drops 2.5 mg per ml 7.38 10 ml OP ✓ Rivotril THOSUXIMIDE 32.90 200 ✓ Zarontin Cap 250 mg 32.90 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy 200 ml ✓ Zarontin Cap 100 mg For gabapentin oral liquid formulation refer, page 209 100 ✓ Arrow-Gabapentin Cap 400 mg Cap 400 mg 13.75 100 ✓ Arrow-Gabapentin	CLONAZEPAM - Safety medicine; prescriber may determine dispe	nsing frequency	/		
 Cap 250 mg				🖌 R	ivotril
 Cap 250 mg					
*‡ Oral liq 250 mg per 5 ml 13.60 200 ml ✓ Zarontin ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy 100 ✓ Arrow-Gabapentin Cap 100 mg		32 90	200	v 7	arontin
ABAPENTIN – Special Authority see SA1477 below – Retail pharmacy Cap 100 mg					
Cap 100 mg			200 111	• -	
 Cap 300 mg – For gabapentin oral liquid formulation refer, page 209			400		0 - h
Cap 300 mg − For gabapentin oral liquid formulation refer, page 209	Cap 100 mg		100		•
page 209 11.00 100 ✓ Arrow-Gabapentin ✓ Cap 400 mg 13.75 100 ✓ Arrow-Gabapentin	Oce 000 mm. For achieventic and limited formed time of the			V N	upenum
✓ Nupentin ✓ Cap 400 mg		11.00	100		waw Cabananti-
Cap 400 mg 13.75 100 🗸 Arrow-Gabapentin	µaye ∠∪9	11.00	100		•
	Cap 400 mg	12 75	100		•
	• Oap 400 mg	13.75	100		•

SA1477 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain or Chronic Kidney Disease associated pruritus) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with neuropathic pain; or
- 2 Both:
 - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
 - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Subsidy (Manufacturer's Pric	2)	Fully Subsidised	Brand or Generic	
(Ivianuiaciulei s Fric	Per	Subsidised V	Manufacturer	

continued...

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain or Chronic Kidney Disease associated pruritus) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Either:
 - 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
 - 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with * are Unapproved Indications (see Interpretations and Definitions). Dosage adjustment of gabapentin is recommended for patients with renal impairment.

▲ Tab 600 mg	 100	Neurontin
▲ Cap 100 mg	100	Neurontin
▲ Cap 300 mg – For gabapentin (neurontin) oral liquid formu-		
lation refer, page 209	100	Neurontin
▲ Cap 400 mg	100	Neurontin

SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

Tab 50 mg	· · · · · · · · · · · · · · · · · · ·	25.04	14	Vimpat
0			14	 Vimpat
5		00.24	56	Vimpat
Tab 150 mg		75.10	14	 Vimpat
0	3	00.40	56	 Vimpat
Tab 200 mg	4	00.55	56	 Vimpat

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
MOTRIGINE				
Tab dispersible 2 mg	6.74	30	~	Lamictal
Tab dispersible 5 mg	9.64	30	~	Lamictal
	15.00	56	~	Arrow-Lamotrigine
Tab dispersible 25 mg	19.38	56	~	Logem
	20.40		~	Arrow-Lamotrigine
			~	Mogine
	29.09		~	Lamictal
Tab dispersible 50 mg		56	~	Logem
· -	34.70		~	Arrow-Lamotrigine
			~	Mogine
	47.89		~	Lamictal
Tab dispersible 100 mg	56.91	56	~	Logem
	59.90		~	Arrow-Lamotrigine
			~	Mogine
	79.16		~	Lamictal
VETIRACETAM				
Tab 250 mg	24.03	60	~	Levetiracetam-Rex
Tab 500 mg – For levetiracetam oral liquid formulation refe		00	•	Level adetain nex
page 209		60	1	Levetiracetam-Rex
Tab 750 mg		60		Levetiracetam-Rex
ů		00	•	Leveliacelaminex
ENOBARBITONE				
For phenobarbitone oral liquid refer Standard Formulae, page				
Tab 15 mg		500		PSM
Tab 30 mg	29.00	500	~	PSM
ENYTOIN SODIUM				
Tab 50 mg		200	~	Dilantin Infatab
Cap 30 mg		200	~	Dilantin
Cap 100 mg		200	~	Dilantin
Oral lig 30 mg per 5 ml		500 ml	~	Dilantin
IMIDONE				
Tab 250 mg	17.05	100		Apo-Primidone
5		100	•	Apo-Fillinuone
DIUM VALPROATE				
Tab 100 mg		100		Epilim Crushable
Tab 200 mg EC		100		Epilim
Tab 500 mg EC		100		Epilim
Oral liq 200 mg per 5 ml		300 ml		Epilim S/F Liquid
				Epilim Syrup
Inj 100 mg per ml, 4 ml	41.50	1	~	Epilim IV
RIPENTOL - Special Authority see SA1330 on the next pag	e – Retail pharmacy			
Cap 250 mg		60	~	Diacomit S29

Subsidy	Fully	Brand or
(Manufacturer's	Price) Subsidised	Generic
\$	Per 🖌	Manufacturer

SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

▲ Tab 25 mg	60	Arrow-Topiramate
		✓ Topiramate Actavis
26.04		Topamax
▲ Tab 50 mg	60	Arrow-Topiramate
Ĵ		Topiramate Actavis
44.26		Topamax
▲ Tab 100 mg31.99	60	Arrow-Topiramate
•		Topiramate Actavis
75.25		Topamax
▲ Tab 200 mg55.19	60	Arrow-Topiramate
-		Topiramate Actavis
129.85		Topamax
Sprinkle cap 15 mg20.84	60	Topamax
▲ Sprinkle cap 25 mg	60	 Topamax
VIGABATRIN – Special Authority see SA1072 below – Retail pharmacy		
▲ Tab 500 mg 119.30	100	Sabril

►SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

 S	Fully ubsidised	Brand or Generic	
\$ Per	~	Manufacturer	

continued...

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 116

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg	31.00	100	✓ Cafergot
RIZATRIPTAN		100	e caloiget
Tab orodispersible 10 mg	8.10	30	Rizamelt
SUMATRIPTAN			·
Tab 50 mg	29.80	100	✓ Arrow-Sumatriptan
Tab 100 mg		100	✓ Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per			
prescription	13.80	2 OP	Arrow-Sumatriptan
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYST	EM, page 52		
PIZOTIFEN			
* Tab 500 mcg	23.21	100	Sandomigran
Antinausea and Vertigo Agents			
For Antispasmodics refer to ALIMENTARY TRACT, page 22			
APREPITANT - Special Authority see SA0987 below - Retail phar	macv		
Cap 2 \times 80 mg and 1 \times 125 mg	,	3 OP	Emend Tri-Pack
►SA0987 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid for			nt is undergoing highly emetogenic
chemotherapy and/or anthracycline-based chemotherapy for the tre		, ,	
Renewal from any relevant practitioner. Approvals valid for 12 month apy and/or anthracycline-based chemotherapy for the treatment of r		tient is underg	going highly emetogenic chemother
BETAHISTINE DIHYDROCHLORIDE			

NERVOUS SYSTEM

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
CYCLIZINE HYDROCHLORIDE				
Tab 50 mg	0.59	10	🖌 <u>N</u>	<u>ausicalm</u>
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml	14.95	5	🗸 N	ausicalm
DOMPERIDONE				
* Tab 10 mg – For domperidone oral liquid formulation refer, page 209	3.25	100	✓ P	rokinex
GRANISETRON				
🖌 Tab 1 mg	5.98	50	✓ <u>G</u>	ranirex
IYOSCINE HYDROBROMIDE				
Inj 400 mcg per ml, 1 ml ampoule	46.50	5	🖌 Н	ospira
	93.00	10	🖌 M	artindale S29
Patch 1.5 mg - Special Authority see SA1387 below - Retail				
pharmacy	11.95	2	✓ <u>S</u>	copoderm TTS

►SA1387 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE

* Tab 10 mg – For metoclopramide hydrochloride oral liquid		
formulation refer, page 2091.82	100	Metamide
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO4.50	10	Pfizer
ONDANSETRON		
* Tab 4 mg5.51	50	Onrex
* Tab disp 4 mg1.00	10	✓ Dr Reddy's
		Ondansetron
* Tab 8 mg6.19	50	✓ Onrex
* Tab disp 8 mg1.50	10	Ondansetron
		ODT-DRLA
PROCHLORPERAZINE		
* Tab 3 mg buccal	50	
(15.00)		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO	500	Antinaus
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	10	✓ Stemetil
* Suppos 25 mg	5	Stemetil
PROMETHAZINE THEOCLATE		
	10	
* Tab 25 mg	10	A
(6.24)		Avomine

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE - Safety medicine; prescriber may determine d	lispensing frequenc	;y	
Tab 100 mg	6.22	30	Solian
Tab 200 mg	21.92	60	Solian
Tab 400 mg		60	Solian
Oral liq 100 mg per ml		60 ml	Solian
ARIPIPRAZOLE – Special Authority see SA0920 below – Reta Safety medicine; prescriber may determine dispensing freq			
Tab 10 mg		30	🖌 Abilify
Tab 15 mg	175.28	30	Abilify
Tab 20 mg	213.42	30	🖌 Abilify
Tab 30 mg		30	Abilify

➡SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CHLORPROMAZINE HYDROCHLORIDE - Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg – Up to 30 tab available on a PSO	 100	Largactil
Tab 25 mg – Up to 30 tab available on a PSO	 100	Largactil
Tab 100 mg – Up to 30 tab available on a PSO	 100	Largactil
Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PSO	 10	Largactil

	Subsidy (Manufacturer's Pric \$	ce) Per	Full Subsidise	Generic
LOZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing frequ	iency			
Tab 25 mg	5.69	50	~	Clozaril
	11.36	100	~	Clozaril
	6.69	50	~	Clopine
	13.37	100	~	Clopine
Tab 50 mg	8.67	50	~	Clopine
	17.33	100	~	Clopine
Tab 100 mg	14.73	50	~	Clozaril
	29.45	100	~	Clozaril
	17.33	50	~	Clopine
	34.65	100	~	Clopine
Tab 200 mg		50	~	Clopine
	69.30	100	~	Clopine
Suspension 50 mg per ml	17.33	100 ml	~	Clopine
LOPERIDOL - Safety medicine; prescriber may determine d		/		
Tab 500 mcg – Up to 30 tab available on a PSO	6.23	100	~	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO	9.43	100	~	<u>Serenace</u>
Tab 5 mg – Up to 30 tab available on a PSO	29.72	100	~	Serenace
Oral liq 2 mg per ml - Up to 200 ml available on a PSO	23.84	100 ml	~	Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	21.55	10	~	Haloperidol -
				MercurvPharma S29
			~	MercuryPharma S29 Serenace
aloperidol - MercuryPharma 🗐 Inj 5 mg per ml, 1 ml to be d	. ,			MercuryPharma 629 Serenace
aloperidol - MercuryPharma see Inj 5 mg per ml, 1 ml to be o	may determine disp	pensing	frequency	<u>Serenace</u>
aloperidol - MercuryPharma 💷 Inj 5 mg per ml, 1 ml to be d	may determine disp	bensing 100	frequency	Serenace Nozinan
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be o VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg	may determine disp 16.93 43.96	bensing t 100 100	frequency	<u>Serenace</u> Nozinan Nozinan
aloperidol - MercuryPharma ^{S29} Inj 5 mg per ml, 1 ml to be o VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml	may determine disp 	bensing 1 100 100 10	frequency	Serenace Nozinan
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be o VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter	may determine disp 	bensing 100 100 100 10 equency	frequency v v	<u>Serenace</u> Nozinan Nozinan Nozinan
Noperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg	may determine disp 	bensing f 100 100 10 equency 500	frequency v v	Serenace Nozinan Nozinan Nozinan Lithicarb FC
aloperidol - MercuryPharma 200 Inj 5 mg per ml, 1 ml to be o VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg	may determine disp 	bensing 1 100 100 10 equency 500 100	frequency v v v	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC
aloperidol - MercuryPharma 229 Inj 5 mg per ml, 1 ml to be o VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg	may determine disp 	bensing 1 100 100 10 equency 500 100 100	frequency v v	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel
Iloperidol - MercuryPharma 229 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg	may determine disp 	bensing 1 100 100 10 equency 500 100	frequency v v	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine disp	may determine disp 	bensing 1 100 100 10 equency 500 100 100 100	frequency	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg	may determine disp 	pensing 1 100 100 10 equency 500 100 100 100 28	frequency V V V V V V V	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine
aloperidol - MercuryPharma 🐲 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 5 mg	may determine disp 	bensing 1 100 100 10 equency 500 100 100 100 28 28	frequency V V V V V V V V V V V V	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml THIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine disg Tab 2.5 mg Tab 5 mg Tab 5 mg	may determine disp 	bensing 1 100 100 10 equency 500 100 100 100 28 28 28 28		Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 5 mg	may determine disp 	bensing 1 100 100 200 100 100 100 100 100 28 28 28 28 28 28	frequency V V V V V V V V V V	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine Zypine
Aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine disp Tab 2.5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg	may determine disp 	bensing 1 100 100 10 equency 500 100 100 100 28 28 28 28	frequency V V V V V V V V V V	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT
Aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine disp Tab 2.5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg	may determine disp 	bensing 1 100 100 200 100 100 100 100 100 28 28 28 28 28 28		Serenace Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine disg Tab 2.5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg Tab 10 mg	may determine disp 	28 28 28 28 28 28 28 28 28 28 28 28 28 2	frequency VV VV VV VV VV VV VV VV	Serenace Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT Zypine ODT
aloperidol - MercuryPharma ³²⁹ Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml 'HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg Tab orodispersible 10 mg RICYAZINE – Safety medicine; prescriber may determine dis	may determine disp 	28 28 28 28 28 28 28 28	frequency VV VV VV VV VV VV VV VV	Serenace Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT
aloperidol - MercuryPharma ³²⁹ Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml 'HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg Tab 2.5 mg Tab 5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg Tab orodispersible 10 mg RICYAZINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 10 mg Tab 10 mg	may determine disp 	28 28 28 28 28 28 28 28 28 28 28 28 28 2	frequency VV VV VV VV VV VV VV VV	Serenace Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT Zypine ODT
aloperidol - MercuryPharma ³²⁹ Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml 'HIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg Tab 2.5 mg Tab 5 mg Tab 5 mg Tab 5 mg Tab orodispersible 5 mg Tab 10 mg Tab orodispersible 10 mg RICYAZINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 10 mg Tab 10 mg	may determine disp 	28 28 28 28 28 28 28 28 28 28 28 28 28 2		Serenace Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT Zypine ODT
aloperidol - MercuryPharma 20 Inj 5 mg per ml, 1 ml to be of VOMEPROMAZINE MALEATE – Safety medicine; prescriber Tab 25 mg Tab 100 mg Inj 25 mg per ml, 1 ml THIUM CARBONATE – Safety medicine; prescriber may deter Tab 250 mg Tab 400 mg Tab long-acting 400 mg Cap 250 mg ANZAPINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 5 mg Tab orodispersible 5 mg Tab orodispersible 5 mg Tab orodispersible 10 mg IRICYAZINE – Safety medicine; prescriber may determine dis Tab 2.5 mg Tab 10 mg	may determine disp 	28 28 28 28 28 28 28 28 28 28 28 28 28 2	frequency VV VV VV VV VV VV VV VV VV	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine Zypine ODT Zypine ODT Neulactil Neulactil
Ialoperidol - MercuryPharma S29 Inj 5 mg per ml, 1 ml to be of the second	may determine disp 	28 28 28 28 28 28 28 28 28 28 28 28 28 2	frequency VV VV VVV VVV VVV VV VV	Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Zypine Zypine Zypine ODT Zypine Zypine ODT Zypine Zypine ODT Neulactil Neulactil Quetapel

	Subsidy (Manufacturer's Price) \$	Per	Full <u>y</u> Subsidised	d Generic
RISPERIDONE – Safety medicine; prescriber may determine disp	pensing frequency			
Tab orodispersible 0.5 mg – Special Authority see SA0927 below – Retail pharmacy	21.42	28	~	Risperdal Quicklet
Tab 0.5 mg – Brand switch fee payable (Pharmacode 2478145) - see page 206 for details	1.90	60	V	Actavis
Tab 1 mg – Brand switch fee payable (Pharmacode 2478145) - see page 206 for details	2.10	60	~	Actavis
Tab orodispersible 1 mg – Special Authority see SA0927 be- low – Retail pharmacy	42.84	28	~	Risperdal Quicklet
Tab 2 mg – Brand switch fee payable (Pharmacode 2478145) - see page 206 for details	2.34	60	~	Actavis
Tab orodispersible 2 mg – Special Authority see SA0927 be- low – Retail pharmacy	85.71	28	V	Risperdal Quicklet
Tab 3 mg – Brand switch fee payable (Pharmacode 2478145) - see page 206 for details	2.55	60	~	Actavis
Tab 4 mg – Brand switch fee payable (Pharmacode 2478145) - see page 206 for details Oral liq 1 mg per ml		60 30 ml	· · · ·	<u>Actavis</u> Risperon

➡SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

TRIFLUOPERAZINE HYDROCHLORIDE - Safety medicine; prescriber may determine dispensing frequency

Tab 1 mg	9.83	100	Stelazine
Tab 2 mg	14.64	100	Stelazine
Tab 5 mg	16.66	100	 Stelazine

	Subsidy (Manufacturer's Price) \$	Per	Full <u>y</u> Subsidised	d Generic
IPRASIDONE – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing free				
b) Ziprasidone is subsidised for patients suffering from schiz				
risperidone or quetiapine that has been discontinued, or is in		discor	ntinued, be	ecause of unacceptable si
effects or inadequate response, and the prescription is endor		~~		Zaldav
Cap 20 mg		60 60	-	Zeldox Zeldox
Cap 40 mg		60 60	-	Zeldox
Cap 60 mg Cap 80 mg		60 60	-	Zeldox
			-	
UCLOPENTHIXOL HYDROCHLORIDE - Safety medicine; pres				
Tab 10 mg		100	~	Clopixol
Depot Injections				
LUPENTHIXOL DECANOATE – Safety medicine; prescriber ma	ay determine dispensi	ng fre	quency	
Inj 20 mg per ml, 1 ml - Up to 5 inj available on a PSO		5	~	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	~	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	40.87	5	~	Fluanxol
LUPHENAZINE DECANOATE – Safety medicine; prescriber ma	av determine dispensi	ng fre	equency	
Inj 12.5 mg per 0.5 ml, 0.5 ml - Up to 5 inj available on a PS	Ó17.60	5	' V	Modecate
Inj 25 mg per ml, 1 ml - Up to 5 inj available on a PSO	27.90	5	~	Modecate
Inj 100 mg per ml, 1 ml - Up to 5 inj available on a PSO	154.50	5	~	Modecate
ALOPERIDOL DECANOATE - Safety medicine; prescriber ma	v determine dispensin	a frec	uencv	
Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO		5		Haldol
Inj 100 mg per ml, 1 ml - Up to 5 inj available on a PSO		5	V	Haldol Concentrate
LANZAPINE – Special Authority see SA1428 below – Retail ph	armacy			
Safety medicine; prescriber may determine dispensing freque				
	,	1	~	Zyprexa Relprevv
Inj 210 mg vial		1		Zyprexa Relprevv

SA1428 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
 - 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE - Special Authority see SA1429 on the next page - Retail pharmacy

Safety medicine; prescriber	may determine dispensing frequency	,	
		1	🗸 Invega Sustenna
Inj 50 mg syringe		1	Invega Sustenna
		1	Invega Sustenna
Inj 100 mg syringe		1	Invega Sustenna
Inj 150 mg syringe		1	Invega Sustenna

Subsidy	Subsid	Fully	Brand or
(Manufacturer's Price)		dised	Generic
\$	Per	~	Manufacturer

➡SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

PIPOTHIAZINE PALMITATE - Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency

b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate.

Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO.		10	Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO.		10	 Piportil
RISPERIDONE - Special Authority see SA1427 below - Re			
Safety medicine; prescriber may determine dispensing f	requency		
Inj 25 mg vial		1	Risperdal Consta
Inj 37.5 mg vial	178.71	1	Risperdal Consta
Inj 50 mg vial	217.56	1	Risperdal Consta

➡SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml $-$ Up to 5	inj available on a PSO.		5	 Clopixol
-------------------------------------	-------------------------	--	---	------------------------------

NERVOUS SYSTEM

LPRAZOLAM - Safety medicine; prescriber may determine dispensing frequency Tab 250 mcg 2.50 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. 3.25 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. 3.25 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.00 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.00 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. USPIRONE HYDROCHLORIDE 28.00 100 ✓ Pacific Buspirone					
LPRAZOLAM - Safety medicine; prescriber may determine dispensing frequency Tab 250 mcg 2.50 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 3.25 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 500 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 500 50 ✓ Xanax USPIRONE HYDROCHLORIDE 500 50 ✓ Pacific Buspirone LONAZEPAM - Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Pacific Buspirone LONAZEPAM - Safety medicine; prescriber may determine dispensing frequency 11.44 500 ✓ Arrow-Diazepam tab 5 mg		(Manufacturer's Price)	Per	Subsidise	d Generic
Tab 250 mcg 2.50 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 50 ✓ Xanax * Safety cap for extemporaneously compounded oral liquid preparations. 50 ✓ Xanax USPIRONE HYDROCHLORIDE 500 50 ✓ Xanax * Tab 5 mg 28.00 100 ✓ Pacific Buspirone IONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 6.68 100 ✓ Paxam Pacific Buspirone IAZEPAM – Safety medicine; prescriber may determine dispensing frequency 7 11.44 500 ✓ Arrow-Diazepam * Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam * Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam * * Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam * * Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam * * Safety cap for extemporaneousl	Anxiolytics				
‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Xanax Tab 500 mcg	ALPRAZOLAM – Safety medicine; prescriber may determine disp	ensing frequency			
Tab 500 mcg 3.25 50 ✓ Xanax x Safety cap for extemporaneously compounded oral liquid preparations. 500 50 ✓ Xanax x Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Xanax v Safety cap for extemporaneously compounded oral liquid preparations. 50 ✓ Xanax vustation of the extemporaneously compounded oral liquid preparations. 50 ✓ Xanax vustation of the extemporaneously compounded oral liquid preparations. 50 ✓ Xanax vustation of the extemporaneously compounded oral liquid preparations. 50 ✓ Yaaam vastation of the extemporaneously compounded oral liquid preparations. 500 ✓ Paxam vastation of the extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam vastation of the extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam vastation of the extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam vastation cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan vastation to be Sole Supply on 1 Ju	6		50	~	Xanax
‡ Safety cap for extemporaneously compounded oral liquid preparations. 50 ✓ Xanax Tab 1 mg 5.00 50 ✓ Xanax USPIRONE HYDROCHLORIDE 28.00 100 ✓ Pacific Buspirone Tab 5 mg 28.00 100 ✓ Pacific Buspirone LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 7.00 100 ✓ Paxam Tab 20 mg 6.68 100 ✓ Paxam IAZEPAM – Safety medicine; prescriber may determine dispensing frequency 7.00 ✓ Paxam Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan 2) b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡			50		V
Tab 1 mg 5.00 50 ✓ Xanax USPIRONE HYDROXE HYDROCHLORIDE 28.00 100 ✓ Pacific Buspirone Tab 5 mg 10 mg 17.00 100 ✓ Pacific Buspirone LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam ✓ Paxam IAZEPAM – Safety medicine; prescriber may determine dispensing frequency 7ab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan tab 10 mg 6.17 100 ✓ Ox-Pam </td <td></td> <td></td> <td>50</td> <td>V</td> <td><u>Xanax</u></td>			50	V	<u>Xanax</u>
USPIRONE HYDROCHLORIDE Tab 5 mg			50	V	Xanax
: Tab 5 mg 28.00 100 ✓ Pacific Buspirone : Tab 10 mg					
i Tab 10 mg 17.00 100 ✓ Pacific Buspirone LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam IAZEPAM – Safety medicine; prescriber may determine dispensing frequency 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 10.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 ✓ Ativan XAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 2.5 mg 6.17 100 ✓ Ox-Pam a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 ✓ Ox-Pam XAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 15 mg<	BUSPIRONE HYDROCHLORIDE				
LONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 500 mcg	6				
Tab 500 mcg 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam IAZEPAM Safety medicine; prescriber may determine dispensing frequency 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam \$ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 10.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 10.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 10.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan 250 XAZEPAM – Safety medicine; prescriber may determine dispensing frequency 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam 200 XAZEPAM – Safety medicine; prescriber may determine dispensing frequency 100	C C		100	V	Pacific Buspirone
Tab 2 mg 12.75 100 ✓ Paxam IAZEPAM - Safety medicine; prescriber may determine dispensing frequency 11.44 500 ✓ Arrow-Diazepam 1 \$ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam 1 \$ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam 1 \$ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) \$ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) \$ Safety cap for extemporaneously compounded oral liquid preparations. 0.079 250 ✓ Ativan a) \$ Safety cap for extemporaneously compounded oral liquid preparations. 0.0 ✓ Ativan 4 a) \$ Safety cap for extemporaneously compounded oral liquid preparations. 0.0 ✓ Ativan 4 a) \$ Safety medicine; prescriber may determine dispensing frequency 13.88 100 ✓ Ativan a) \$ Safety cap for extemporaneously compounded oral liquid preparations. 6.17 100 ✓ Ox-Pam \$ Safety cap for extemporaneously compounded oral liquid preparations. 8.53 100 ✓ Ox-Pam \$ Safety cap for e		• • •	100		Devee
IAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan 4) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan 4) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan 4) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 0 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 10.0 ✓ Ox-Pam ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations.	5				
Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Arrow-Diazepam DRAZEPAM – Safety medicine; prescriber may determine dispensing frequency 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam Tab 10 mg 6.17 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100	0		100	·	
 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 5 mg		• • •	500	~	Arrow-Diazepam
 ‡ Safety cap for extemporaneously compounded oral liquid preparations. DRAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 1 mg					•
DRAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 1 mg	5		500	~	Arrow-Diazepam
Tab 1 mg 10.79 250 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 13.88 100 ✓ Ativan a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 ✓ Ativan XAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg 6.17 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg 8.53 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 8.53 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. MULtiple Sclerosis Treatments INGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13 Multiple Sclerosis Treatments Interventional pharmacy					
a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 Tab 2.5 mg	, , , , , , , , , , , , , , , , , , ,	0 1 7	250	~	Ativan
b) Ativan to be Sole Supply on 1 July 2015 Tab 2.5 mg	6		200	•	Auvan
a) ‡ Safety cap for extemporaneously compounded oral liquid preparations. b) Ativan to be Sole Supply on 1 July 2015 XAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 10 mg					
b) Ativan to be Sole Supply on 1 July 2015 XAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg			100	~	Ativan
XAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 10 mg		uid preparations.			
Tab 10 mg 6.17 100 Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 Ox-Pam Tab 15 mg 8.53 100 Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 Ox-Pam Wultiple Sclerosis Treatments 100 Ox-Pam INGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13	, , , , , , , , , , , , , , , , , , , ,	sing froquonov			
‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg ‡ Safety cap for extemporaneously compounded oral liquid preparations. ‡ Safety cap for extemporaneously compounded oral liquid preparations. Multiple Sclerosis Treatments INGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13		• • •	100	~	Ox-Pam
Tab 15 mg 8.53 100 Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 Ox-Pam Multiple Sclerosis Treatments 100 Streatments INGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13	‡ Safety cap for extemporaneously compounded oral liquid	preparations.			
Multiple Sclerosis Treatments NGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13	Tab 15 mg	8.53	100	~	Ox-Pam
NGOLIMOD – Special Authority see SA1487 below – Retail pharmacy Wastage claimable – see rule 3.3.2 on page 13		preparations.			
Wastage claimable – see rule 3.3.2 on page 13	Multiple Sclerosis Treatments				
Wastage claimable – see rule 3.3.2 on page 13		armacy			
Cap 0.5 mg2,650.00 28 🖌 Gilenya	Wastage claimable – see rule 3.3.2 on page 13				
	Cap 0.5 mg	2,650.00	28	~	Gilenya

SA1487 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to fingolimod; and
- g) patients must have not previously had intolerance to fingolimod; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
 of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to fingolimod; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab and fingolimod is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
- NATALIZUMAB – Special Authority see SA1496 below – Retail ph	armacy			
Inj 20 mg per ml, 15 ml vial	1,750.00	1	🖌 Ty	/sabri

►SA1496 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
- g) patients must have no previous history of lack of response to natalizumab; and
- h) patients must have not previously had intolerance to natalizumab; and
- i) either
 - a) Patient is JC virus negative, or
 - b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
- j) patient will not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

 rice)	Fully Subsidised	Brand or Generic	
\$ Per	~	Manufacturer	

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
 of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to natalizumab; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Switching between natalizumab and fingolimod is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the EDSS stopping criteria are not met.

If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

Other Multiple Sclerosis Treatments

SA1484 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and

Subsidy	Ful	/ Brand or	
(Manufacturer's	Price) Subsidise	d Generic	
\$	Per	 Manufacturer 	

- Evidence of MRI activity on a scan within the past 24 months (either a contrast enhancing lesion or with new T2 lesions(s) compared with a previous scan); and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- g) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- h) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression
 of disability is defined as progress by any of the following EDDSS Points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

Entry Criteria for patients with an EDSS of 4.5-5.5 who have not had an application for funding considered prior to 1 November 2014

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 4.5-5.5 with 2+ relapses:
 - Experienced at least 2 significant relapses of MS in the previous 12 months, and
 - An EDSS score of between 4.5-5.5; and
- d) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- g) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria for patients with an EDSS of 4.5-5.5 who have not had an application for funding considered prior to 1 November 2014

Any of the following:

- a) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression
 of disability is defined as progress by any of the following:
 - a) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - b) an increase in EDSS score to 6.0 or more; or
- b) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) pregnancy and/or lactation; or
- d) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- e) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- f) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	FullyBrand orSubsidisedGeneric✓Manufacturer
GLATIRAMER ACETATE – Special Authority see SA1484 on pa Inj 20 mg prefilled syringe	• • • •	28	Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA1484 Inj 6 million iu prefilled syringe Injection 6 million iu per 0.5 ml pen injector Inj 6 million iu per vial	1,170.00 1,170.00	rm] 4 4 4	✓ Avonex ✓ Avonex Pen ✓ Avonex
INTERFERON BETA-1-BETA – Special Authority see SA1484 o Inj 8 million iu per 1 ml	n page 148 – [Xpharm 1,322.89] 15	✓ Betaferon
Sedatives and Hypnotics			
LORMETAZEPAM – Safety medicine; prescriber may determine Tab 1 mg ‡ Safety cap for extemporaneously compounded oral liqu		30	Noctamid
 MIDAZOLAM – Safety medicine; prescriber may determine disp Inj 1 mg per ml, 5 ml Inj 5 mg per ml, 3 ml 	ensing frequency 10.00 10.75	10 5	 ✓ Pfizer ✓ Hypnovel ✓ Hypnovel
NITRAZEPAM – Safety medicine; prescriber may determine dis Tab 5 mg	pensing frequency	100	 Pfizer <u>Nitrados</u>
‡ Safety cap for extemporaneously compounded oral liqu PHENOBARBITONE SODIUM – Special Authority see SA1386 Inj 200 mg per ml, 1 ml ampoule	below – Retail pharma	acy 10	✔ Martindale 529
 SA1386 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals val the following criteria: Both: 1 For the treatment of terminal agitation that is unrespons 2 The applicant is part of a multidisciplinary team working 	id without further rene ive to other agents; an	wal ur	
TEMAZEPAM – Safety medicine; prescriber may determine disp Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liqu	1.27	25	✓ <u>Normison</u>
TRIAZOLAM – Safety medicine; prescriber may determine dispu- Tab 125 mcg	5.10 (7.25)	100	Hypam
‡ Safety cap for extemporaneously compounded oral liqu Tab 250 mcg ‡ Safety cap for extemporaneously compounded oral liqu	4.10 (8.70)	100	Hypam
ZOPICLONE – Safety medicine; prescriber may determine disp Tab 7.5 mg	ensing frequency	500	✔ Apo-Zopiclone

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Stimulants/ADHD Treatments					
Stimulants/ADHD treatments					
ATOMOXETINE - Special Authority see SA	416 below – Retail pharmacy				
Cap 10 mg		28	/ S	strattera	
Cap 18 mg		28	v s	strattera	
Cap 25 mg		28	v s	strattera	
Con 40 mg	107.03	28	V S	trattera	
Cap 40 mg				liulloiu	
Cap 40 mg Cap 60 mg		28	/ S	strattera	
Cap 40 mg Cap 60 mg Cap 80 mg					

➡SA1416 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexampletamine sulphate tablets.

DEXAMFETAMINE SULFATE - Special Authority see SA1149 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg16.50	100
---------------	-----

SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or

continued...

PSM

Subsic (Manufacture		
(manufacture \$	Per •	Manufacturer

3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1150 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab immediate-release 5 mg	30	Rubifen
Tab immediate-release 10 mg	30	Ritalin
		 Rubifen
Tab immediate-release 20 mg7.85	30	 Rubifen
Tab sustained-release 20 mg10.95	30	Rubifen SR
50.00	100	Ritalin SR

SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Subsic (Manufacture		
(Manuacture \$	Per V	Manufacturer

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1151 on the next page - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Cap modified-release 10 mg Cap modified-release 20 mg Cap modified-release 30 mg	58.96 	30 30 30 30 30 30 30	 Concerta Concerta Concerta Concerta Ritalin LA Ritalin LA Ritalin LA
		30 30	 Ritalin LA Ritalin LA

➡SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:

Subsidy (Manufacturer's Price) Fully Per Brand or Subsidised Generic continued 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within th last 2 years and has recommended treatment for the patient in writing. MODAFINIL – Special Authority see SA1126 below – Retail pharmacy Tab 100 mg			INET	1003 3131 EM
 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing. MODAFINIL - Special Authority see SA1126 below - Retail pharmacy Tab 100 mg		(Manufacturer's Price)	Subsidised	Generic
Tab 100 mg	2.1 Applicant is a paediatrician or psychiatrist;2.2 Applicant is a medical practitioner and con	firms that a paediatrician or	psychiatrist has	been consulted within the
 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting th following: The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurrin almost daily for three months or more; and Either: The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and or more sleep onset rapid eye movement periods; or The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and Either: An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discortinued because of intolerable side effects; or Methylphenidate and dexamphetamine are contraindicated. Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriat and the patient is benefiting from treatment. Treatments for Dementia DONEPEZIL HYDROCHLORIDE Tab 5 mg			30 🖌	Aodavigil
Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriat and the patient is benefiting from treatment. Treatments for Dementia DONEPEZIL HYDROCHLORIDE * Tab 5 mg * Tab 5 mg	Initial application only from a neurologist or respiratory s following criteria: All of the following: 1 The patient has a diagnosis of narcolepsy and ha almost daily for three months or more; and 2 Either: 2.1 The patient has a multiple sleep latency te or more sleep onset rapid eye movement p 2.2 The patient has at least one of: cataplexy, s 3 Either: 3.1 An effective dose of a subsidised formulatio tinued because of intolerable side effects; comparison of the state of the sta	as excessive daytime sleepi st with a mean sleep latenc eriods; or sleep paralysis or hypnagog on of methylphenidate or dex or	ness associated y of less than or ic hallucinations	with narcolepsy occurring equal to 10 minutes and 2 and
DONEPEZIL HYDROCHLORIDE * Tab 5 mg	Renewal only from a neurologist or respiratory specialist.		s where the trea	tment remains appropriate
* Tab 5 mg	Treatments for Dementia			
	* Tab 5 mg			
RIVASTIGMINE - Special Authority see SA1488 below - Retail pharmacy Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour 90.00 30 ✓ Exelon 90.00 30 ✓ Exelon 90.00 30 ✓ Exelon	Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour	90.00	••••	

ecial Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE - Special Authority see SA1203 below - Retail pharmacy

a) No patient	co-payment	payable

) Cofoti m	adiaina, nrac	arihar ma	datarmina diana	aning fragmanau	
)) Salety III	ieuicine, pres	scriber may	/ determine disper	Ising frequency	
, ,	· · ·				
Tala av dalia a	الأسبية معتر كالمنب		0 5	F7 40	

Tab sublingual 2 mg with naloxone 0.5 mg	 Suboxone
Tab sublingual 8 mg with naloxone 2 mg	 Suboxone

NERVOUS SYSTEM

Subsidy (Manufacturer's Price)	S	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health...

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- - 1 Patient received but failed detoxification with buprenorphine with naloxone; and
 - 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
 - 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
 - 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	4.97	30	Zyban
DISULFIRAM			
Tab 200 mg	24.30	100	 Antabuse
NALTREXONE HYDROCHLORIDE - Special Authority see SA14	408 below – Retai	l pharmacy	
Tab 50 mg	76.00	30	✓ Naltraccord

<u> </u>				
Subsidy		Fully	Brand or	
(Manufacturer's Price)	SL	ubsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment.

Patch 7 mg - Up to 28 patch available on a PSO 12.40	28	✓ Habitrol
Patch 14 mg – Up to 28 patch available on a PSO	28	Habitrol
Patch 21 mg – Up to 28 patch available on a PSO14.02	28	Habitrol
Lozenge 1 mg - Up to 216 loz available on a PSO 15.15	216	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO	216	Habitrol
Gum 2 mg (Classic) – Up to 384 piece available on a PSO	384	Habitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO26.13	384	Habitrol
Gum 2 mg (Mint) - Up to 384 piece available on a PSO26.13	384	Habitrol
Gum 4 mg (Classic) – Up to 384 piece available on a PSO	384	Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO	384	Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO30.12	384	Habitrol

VARENICLINE TARTRATE - Special Authority see SA1161 below - Retail pharmacy

a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.
 b) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Tab 1 mg	67.74	28	Champix
-	135.48	56	Champix
Tab 0.5 mg \times 11 and 1 mg \times 14	60.48	25 OP	Champix

➡SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and

continued...

157

Subsidy	-	Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully osidised	Brand or Generic Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	59.50	100	✓ M	lyleran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml		1		arboplatin Ebewe
Inj 10 mg per ml, 15 ml		1		arbaccord
Ini 10 ma normi 15 ml	22.50	4		arboplatin Ebewe arbaccord
Inj 10 mg per ml, 45 ml		1		arbaccord arboplatin Ebewe
	50.00			BL Carboplatin
Inj 10 mg per ml, 100 ml	105.00	1		arboplatin Ebewe
Inj 1 mg for ECP		1 mg		axter
CARMUSTINE – PCT only – Specialist				
Inj 100 mg	532.00	1	✓ B	iCNU
Inj 100 mg for ECP		100 mg OP		axter
		i co nig ci	• •	
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist	00.05	25		eukeran FC
Tab 2 mg	22.30	20	V L	
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	15.00	1		isplatin Ebewe
	01.00			ospira
Inj 1 mg per ml, 100 ml	21.00	1		isplatin Ebewe ospira
Inj 1 mg for ECP	0.27	1 mg		axter
, ,	0.27	Ting	• 0	artei
CYCLOPHOSPHAMIDE			4-	
Tab 50 mg – PCT – Retail pharmacy-Specialist	79.00	50		ndoxan S29
	158.00	100	V P	rocytox S29
Wastage claimable – see rule 3.3.2 on page 13	05.00			
Inj 1 g – PCT – Retail pharmacy-Specialist		1		ndoxan
Ini 9 a DCT only Specialist	127.80	6 1		ytoxan ndoxan
Inj 2 g – PCT only – Specialist Inj 1 mg for ECP – PCT only – Specialist		1 mg	· · ·	axter
	0.04	Ting	• 0	
FOSFAMIDE – PCT only – Specialist	00.00			
lnj 1 g lnj 2 g		1 1		oloxan oloxan
Inj 1 mg for ECP		1 mg	· · ·	axter
, .	0.10	i ing		unio
OMUSTINE – PCT – Retail pharmacy-Specialist	100.50	00		• • • • • •
Cap 10 mg		20 20		eeNU eeNU
Cap 40 mg		20	v 0	CENU
/ELPHALAN		c-	4.	
Tab 2 mg – PCT – Retail pharmacy-Specialist		25		lkeran
Inj 50 mg – PCT only – Specialist		1	V A	lkeran

(Subsidy Manufacturer's Price) \$	Per	Full Subsidise	d Generic
OXALIPLATIN – PCT only – Specialist Inj 50 mg	15.32	1	~	Oxaliplatin Actavis 50
lni 100 mg	55.00 200.00 25.01	1	~	Oxaliplatin Ebewe Eloxatin Oxaliplatin Actavis
Inj 100 mg	110.00 400.00	I	~	100 Oxaliplatin Ebewe Eloxatin
Inj 1 mg for ECP THIOTEPA – PCT only – Specialist		1 mg	· · ·	Baxter
Inj 15 mg	CBS	1	V	Bedford S29 THIO-TEPA S29 Tepadina S29
Antimetabolites				
AZACITIDINE – PCT only – Specialist – Special Authority see SA Inj 100 mg vial		1	~	Vidaza

inj 100 mg viai		1	Vidaza
Inj 1 mg for EC	P6.66	1 mg	 Baxter

SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

(Manufacturer's	Price) Su Per	bsidised V	Generic Manufacturer
00 AE			
00 AE			
	10		3L Leucovorin
	10		Calcium
	5		ospira
			alcium Folinate
10.20	0		Ebewe
7.33	1	-	alcium Folinate
			Ebewe
	1	🖌 Ca	alcium Folinate
			Ebewe
	1	🖌 Ca	alcium Folinate
			Ebewe
0.06	1 ma	🖌 Ba	
20 00	60	V 0.	apecitabine
	60		Winthrop
120.00	120		apecitabine
	120		Winthrop
			<u>wintinop</u>
5 240 72	7	1	uctatin
		• =•	
	To hig Of	• Di	
	-		•
	5		
	4		
	5	V no	ospira
	4	∎ Df	izor
	I		
		• III	ospira
	1	V Df	izor
	I		
	10 ma		•
	0		
122 50	20		udara Oral
			udarabine Ebewe
	5		
,	50 mg OP		
		÷ 50	
06.05	F		uereureeil Eheure
			uorouracil Ebewe
	=		uorouracil Ebewe
	-		uorouracil Ebewe
	•		uorouracil Ebewe
	=		
	17.10 18.25 18.25 18.25 18.25 18.25 18.25 19.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00 18.15 95.36 - 17.65 34.47 0.11 st	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	

Ifacturer's Price 15.89 62.50 149.20 8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	Per 1 1 mg 1 1 mg 25 30 50		d Generic Manufacturer Gemcitabine Ebewe DBL Gemcitabine Gemzar Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan-Rex Irinotecan-Rex Baxter Puri-nethol
62.50 49.20 8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 mg 1 1 mg 25 30 50		DBL Gemcitabine Gemzar Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
62.50 49.20 8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 mg 1 1 mg 25 30 50		DBL Gemcitabine Gemzar Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
62.50 49.20 8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 mg 1 1 mg 25 30 50		DBL Gemcitabine Gemzar Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
49.20 8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 mg 1 1 mg 25 30 50		Gemzar Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
8.36 78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 mg 1 1 mg 25 30 50	222 2 222 222 2 2	Gemcitabine Ebewe Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
78.00 0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 mg 1 1 mg 25 30 50		Gemzar Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
0.02 9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 1 mg 25 30 50	· · · · · · · · · · · · · · · · · · ·	Baxter Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
9.34 41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 1 mg 25 30 50	> >>> >>> >>	Irinotecan Actavis 40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 mg 25 30 50	>>> >>> >>>	40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
41.00 23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 1 mg 25 30 50	>>> >>> >>>	40 Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 mg 25 30 50	55 555 5 5	Camptosar Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
23.34 00.00 0.24 49.41 3.82 26.25 23.65	1 mg 25 30 50	55 555 5 5	Irinotecan-Rex Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
00.00 0.24 49.41 3.82 26.25 23.65	1 mg 25 30 50		Irinotecan Actavis 100 Camptosar Irinotecan-Rex Baxter
00.00 0.24 49.41 3.82 26.25 23.65	1 mg 25 30 50	222 2	100 Camptosar Irinotecan-Rex Baxter
0.24 49.41 3.82 26.25 23.65	25 30 50	<i>v</i> <i>v</i>	Camptosar Irinotecan-Rex Baxter
0.24 49.41 3.82 26.25 23.65	25 30 50	<i>v</i> <i>v</i>	Irinotecan-Rex Baxter
49.41 3.82 26.25 23.65	25 30 50	ר ר	Baxter
49.41 3.82 26.25 23.65	25 30 50	~	
3.82 26.25 23.65	30 50		Puri-nethol
3.82 26.25 23.65	30 50		Puri-nethol
26.25 23.65	50	~	
26.25 23.65	50	~	
26.25 23.65	50	•	Trexate
23.65		~	Trexate
	5		Hospira
17.19	1		Methotrexate
17.13	1	•	Sandoz
17.25	1	~	Methotrexate
17.20		•	Sandoz
17.38	1	~	Methotrexate
17.00	'	•	Sandoz
17.50	1	~	Methotrexate
11.00		•	Sandoz
17.63	1	~	Methotrexate
		•	Sandoz
17.75	1	~	Methotrexate
			Sandoz
20.20	5	~	Hospira
	1		Hospira
	1	~	Methotrexate Ebewe
	1	~	Methotrexate Ebewe
	1 ma		Baxter
			Baxter
	5		
07.16	05		Lanvis
51.10	20	v	
600.00	6	~	Amsidine S29
	27.78 25.00 99.99 0.10	27.78 1 25.00 1 99.99 1 0.10 1 mg 4.73 5 mg OF	27.78 1 25.00 1

	Subsidy (Manufacturer's Pric \$	e) Per	Full Subsidise	d Generic
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Spe	cialist			
Cap 0.5 mg	CBS	100		Agrylin S29 Teva S29
ARSENIC TRIOXIDE – PCT only – Specialist				
Inj 10 mg	4,817.00	10	~	AFT S29
BLEOMYCIN SULPHATE - PCT only - Specialist				
Inj 15,000 iu	136.80	1	~	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP	10.58	1,000 ii	u 🖌	Baxter
BORTEZOMIB - PCT only - Specialist - Special Authority see S	A1127 below			
Inj 1 mg	540.70	1	~	Velcade
Inj 3.5 mg	1,892.50	1	~	Velcade
Inj 1 mg for ECP	594.77	1 mg	~	Baxter

➡SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
 - 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

Inj 10,000 iu	1	Leunase
Inj 10,000 iu for ECP	10,000 iu OP	 Baxter

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
ACARBAZINE – PCT only – Specialist			
Inj 200 mg vial	51.84	1	Hospira
Inj 200 mg for ECP		200 mg OP	✓ Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist		-	
Inj 0.5 mg		1	Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	✓ Baxter
DAUNORUBICIN – PCT only – Specialist		-	
Inj 2 mg per ml, 10 ml	118.72	1	✓ Pfizer
Inj 20 mg for ECP		20 mg OP	✓ Baxter
DOCETAXEL – PCT only – Specialist	10 70	1	DBL Docetaxel
Inj 20 mg		I	✓ Docetaxel Sandoz
Inj 20 mg per ml, 1 ml		1	
		1	 ✓ Taxotere ✓ Taxotere
Inj 20 mg per ml, 4 ml		1	 DBL Docetaxel
Inj 80 mg	29.99 195.00	I	DBL Docetaxel Docetaxel Sandoz
Ini 1 mg for ECD		1 mg	✓ Baxter
Inj 1 mg for ECP	0.01	1 mg	
DOXORUBICIN – PCT only – Specialist			
Inj 10 mg		1	Doxorubicin Ebewe
Inj 50 mg	17.00	1	Arrow-Doxorubicin
	40.00		DBL Doxorubicin
			DBL Doxorubicin S29 S29
			Doxorubicin Ebewe
lnj 100 mg		1	Doxorubicin Ebewe
Inj 200 mg		1	Arrow-Doxorubicin
, 0	150.00		Adriamycin
			Doxorubicin Ebewe
Inj 1 mg for ECP	0.37	1 mg	Baxter
EPIRUBICIN – PCT only – Specialist		5	
Inj 2 mg per ml, 5 ml	25.00	1	Epirubicin Ebewe
, , , , , , , , , , , , , , , , , , , ,		1	 DBL Epirubicin
Inj 2 mg per ml, 25 ml		I	Hydrochloride
	87.50		 Epirubicin Ebewe
Inj 2 mg per ml, 50 ml		1	✓ DBL Epirubicin
ng z mg per mi, so mi		I	Hydrochloride
	125.00		 Epirubicin Ebewe
Inj 2 mg per ml, 100 ml		1	 DBL Epirubicin
III 2 III 9 PEI III, 100 III		I	•
	010.00		Hydrochloride
Ini 1 mg for ECD	210.00	1	Epirubicin Ebewe
Inj 1 mg for ECP	0.82	1 mg	 Baxter
ETOPOSIDE			
Cap 50 mg – PCT – Retail pharmacy-Specialist		20	Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10	Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist .	25.00	1	Hospira
	612.20	10	Vepesid
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	Baxter

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Generic
ETOPOSIDE PHOSPHATE – PCT only – Specialist Inj 100 mg (of etoposide base) Inj 1 mg (of etoposide base) for ECP		1 1 mg		Etopophos Baxter
HYDROXYUREA – PCT – Retail pharmacy-Specialist Cap 500 mg	31.76	100	~	Hydrea
IDARUBICIN HYDROCHLORIDE Inj 5 mg – PCT only – Specialist Inj 10 mg – PCT only – Specialist Inj 1 mg for ECP – PCT only – Specialist	200.00	1 1 1 mg	~	Zavedos Zavedos Baxter
LENALIDOMIDE – Retail pharmacy-Specialist – Special Authorit Wastage claimable – see rule 3.3.2 on page 13	ty see SA1468 belo	w		
Cap 10 mg Cap 25 mg		21 21		Revlimid Revlimid

➡SA1468 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Either:
 - 2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 2.2 Both:
 - 2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 2.2.2 The patient has experienced severe (grade \geq 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

M

Tab 400 mg - PCT - Retail pharmacy-Specialist Tab 600 mg - PCT - Retail pharmacy-Specialist Inj 100 mg per ml, 4 ml ampoule - PCT only – Specialist Inj 100 mg per ml, 10 ml ampoule - PCT only – Specialist Inj 100 mg per ml, 20 mg per ml, 2	339.50 148.05 339.90	50 50 15 15 100 ma	 ✓ Uromitexan ✓ Uromitexan ✓ Uromitexan ✓ Uromitexan ✓ Baxter
Inj 1 mg for ECP – PCT only – Specialist IITOMYCIN C – PCT only – Specialist Inj 5 mg vial Inj 1 mg for ECP	79.75	1 1 mg	✓ <u>Arrow</u> ✓ Baxter

	Subsidy (Manufacturer's Price)	Full	
	\$	Per	v	Manufacturer
IITOZANTRONE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml	110.00	1	~	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml		1	~	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml		1		
	(413.21)			Onkotrone
Inj 1 mg for ECP	5.65	1 mg	~	Baxter
ACLITAXEL – PCT only – Specialist				
Inj 30 mg	45.00	5	~	Paclitaxel Ebewe
Inj 100 mg		1	~	Paclitaxel Ebewe
	91.67		~	Paclitaxel Actavis
Inj 150 mg		1	~	Paclitaxel Ebewe
	137.50		~	Anzatax
			~	Paclitaxel Actavis
Inj 300 mg		1	~	Paclitaxel Ebewe
	275.00		~	Anzatax
			~	Paclitaxel Actavis
Inj 600 mg	73.06	1	~	Paclitaxel Ebewe
Inj 1 mg for ECP	0.17	1 mg	~	Baxter
EGASPARGASE - PCT only - Special Authority see SA1325		•		
Inj 3,750 IU per 5 ml		1	~	Oncaspar S29

SA1325 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has relapsed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specia	list		
Inj 10 mg	CBS	1	Nipent S29
PROCARBAZINE HYDROCHLORIDE - PCT - Retail pharma	acy-Specialist		
Cap 50 mg		50	Natulan S29
TEMOZOLOMIDE - Special Authority see SA1063 on the nex	t page – Retail pharı	macy	
Cap 5 mg	8.00	5	Temaccord
Cap 20 mg		5	Temaccord
Cap 100 mg	175.00	5	Temaccord
Cap 250 mg	410.00	5	Temaccord

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

►SA1063 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE	- PCT only - Specialist - Special Authority see SA1124 below	v	
Cap 50 mg		28	 Thalomid
Cap 100 mg		28	 Thalomid

➡SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

1 The patient has multiple myeloma; or

2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication.

TRETINOIN

Cap 10 mg - PCT - Retail pharmacy-Specialist	100	Vesanoid
VINBLASTINE SULPHATE		
Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist37.29	1	Hospira
186.46	5	 Hospira
Inj 1 mg for ECP – PCT only – Specialist4.14	1 mg	Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist64.80	5	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	 Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	Baxter
VINORELBINE – PCT only – Specialist		
Inj 10 mg per ml, 1 ml12.85	1	Navelbine
42.00		Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml64.25	1	Navelbine
210.00		Vinorelbine Ebewe
Inj 1 mg for ECP1.45	1 mg	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Protein-tyrosine Kinase Inhibitors				
DASATINIB – Special Authority see SA0976 below – [Xpharm]				
Tab 20 mg	3,774.06	60	~	Sprycel
Tab 50 mg	6,214.20	60	~	Sprycel
Tab 70 mg	7.692.58	60	~	Sprycel
	6,214.20	30		Sprvcel

►SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz
Wellington	

Wellington

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - a) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10⁹/L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - b) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10⁹/L, platelets > 20 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - c) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).</p>
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB	- Retail pharmacy-Specialist - Special Authority see SA1519 on the next page
-----------	--

Tab 100 mg	1,000.00	30	Tarceva
Tarceva to be Sole Supply on 1 July 2015			
Tab 150 mg	1,500.00	30	Tarceva
Tarceva to be Sole Supply on 1 July 2015			

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1519 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

- Either:
 - 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Any of the following:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:
 - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
 - 1.3.2.2 Patient has not received prior treatment with gefitinib; or

1.3.3 Both:

- 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
- 1.3.3.2 The cancer did not progress while on gefitinib; and
- 1.4 Erlotinib is to be given for a maximum of 3 months; or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist

Tab 250 mg − Special Authority see SA1520 below......1,700.00 30 🖌 Iressa

➡SA1520 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:

2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and 2.2.2 The cancer did not progress whilst on erlotinib; and

- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

	Tab Too mg - Special Authomy see SA 1400 on the next page		
	- [Xpharm]2,400.00	60	Glivec
*	Cap 100 mg	60	Imatinib-AFT
*	Cap 400 mg	30	Imatinib-AFT

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
(Manulacturer's Trice)	Per		Manufacturer
ψ	1 61		Manulaciurei

SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz

Wellington

Special Authority criteria for GIST - access by application

Funded for patients:

- a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE - Special Authority see SA1191 below - Retail pharmacy

Tab 250 mg 1,899.00 70 V Tykerb

SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
 - 3 Lapatinib not to be given in combination with trastuzumab; and
 - 4 Lapatinib to be discontinued at disease progression.

NILOTINIB – Special Authority see SA1489 on the next page – Retail pharmacy

Wastaye Claimable – see rule 3.3.2 On paye 13			
Cap 150 mg	4,680.00	120	🖌 Tasigna
Cap 200 mg	6,532.00	120	 Tasigna

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

➡SA1489 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with imatinib; or
 - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB - Special Authority see SA1190 below - Retail pharmacy

Tab 200 mg1,334.70	30	Votrient
Tab 400 mg2,669.40	30	Votrient

SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Subsidy	Fu	,	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	~	Manufacturer

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – Special Authority see SA1266 below – Retail pharmacy		
Cap 12.5 mg2,315.38	3 28	Sutent
Cap 25 mg4,630.77	7 28	Sutent
Cap 50 mg9,261.54	4 28	 Sutent

➡SA1266 Special Authority for Subsidy

Initial application - (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 > 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application - (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Fither:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Subsidy		Fully	Brand or	
(Manufacturer's Price		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of $\geq 10\%$ or decrease in tumour density in Hounsfield Units (HU) of $\geq 15\%$ on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

➡SA1515 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
 continued 1 Significant decrease in serum PSA from baseline; and 2 No evidence of clinical disease progression; and 3 No initiation of taxane chemotherapy with abiraterone; an 4 The treatment remains appropriate and the patient is ben 		t.		
BICALUTAMIDE Tab 50 mg	4.90	28	~	Bicalaccord
FLUTAMIDE – Retail pharmacy-Specialist				
Tab 250 mg		30	~	Flutamin S29 S29
	55.00	100	~	Flutamin
MEGESTROL ACETATE – Retail pharmacy-Specialist				
Tab 160 mg	51.55	30	~	Apo-Megestrol
OCTREOTIDE				
Inj 50 mcg per ml, 1 ml vial		5	~	DBL
Inj 100 mcg per ml, 1 ml vial		5		DBL
Inj 500 mcg per ml, 1 ml vial		5	~	DBL
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) - Special Au	uthority see SA1016 b	elow	– Retail p	harmacy
Inj LAR 10 mg prefilled syringe		1		Sandostatin LAR
Inj LAR 20 mg prefilled syringe		1	V	Sandostatin LAR
Inj LAR 30 mg prefilled syringe		1	~	Sandostatin LAR

SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	~	Manufacturer	

continued...

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the followina:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery: or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed: or
- 3 Both:
 - 3.1 Insulinomas: and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal - (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

* Tab 10 mg * Tab 20 mg	2.63	100 30	 Genox 	
Aromatase Inhibitors	8.75	100	 Genox 	

ANASTROZOLE * Tab 1 mg	26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE * Tab 25 mg	14.50	30	✓ <u>Aromasin</u>
LETROZOLE * Tab 2.5 mg	4.85	30	✓ Letraccord

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE – Retail pharmacy-Specialist * Tab 25 mg * Tab 50 mg – For azathioprine oral liquid formulation refer, page 209 * Inj 50 mg MYCOPHENOLATE MOFETIL Tab 500 mg Cap 250 mg Powder for oral liq 1 g per 5 ml – Subsidy by endorsement Mycophenolate powder for oral liquid is subsidised only fo prescription is endorsed accordingly.		60 100 1 50 100 65 ml C swallo		Azamun Azamun muran <u>Cellcept</u> <u>Cellcept</u> Cellcept nd capsules, and when the
Fusion Proteins				
ETANERCEPT – Special Authority see SA1478 below – Retail ph Inj 25 mg Inj 50 mg autoinjector Inj 50 mg prefilled syringe	949.96 1,899.92	4 4 4	V E	Enbrel Enbrel Enbrel

SA1478 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Fither:

unon. 4 D

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, cyclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist: or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
 - 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement: and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Fither:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml2,351.25	5	✔ ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist Subsidised only for bladder cancer.		
Inj $2-8 \times 100$ million CFU	1	OncoTICE
Inj 40 mg per ml, vial149.37	3	SII-Onco-BCG S29
Monoclonal Antibodies		
ADALIMUMAB – Special Authority see SA1479 below – Retail pharmacy		
Inj 20 mg per 0.4 ml prefilled syringe1,799.92	2	Humira
Inj 40 mg per 0.8 ml prefilled pen1,799.92	2	HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe1,799.92	2	Humira

SA1479 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Fither:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis: or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance: and

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm: Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or
- 2 All of the following:

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient diagnosed with JIA; and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease. **Initial application — (pyoderma gangrenosum)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Note: Indications marked with * are Unapproved Indications (refer to (Interpretations and Definitions).

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

Subsidy	Fu	lly Brand or	
(Manufacturer's Price)	Subsidise	ed Generic	
\$	Per	 Manufacturer 	

continued...

- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Fither:
 - 1.1 Applicant is a rheumatologist: or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
 - 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
 - 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.1 Applicant is a named specialist or rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Fither:

- 1.1 Applicant is a gastroenterologist; or
- 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

oun:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

OMALIZUMAB - Special Authority see SA1490 below - Retail pharmacy

Inj 150 mg vial	500.00	1	🖌 Xolair
-----------------	--------	---	----------

SA1490 Special Authority for Subsidy

Initial application only from a respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient is over the age of 6; and
- 2 Patient has a diagnosis of severe, life threatening asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and

 5	Fully Subsidised	Brand or Generic	
\$ Per	~	Manufacturer	

continued...

- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month .

Renewal only from a respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

RITUXIMAB - PCT only - Specialist - Special Authority see SA1152 below

Inj 100 mg per 10 ml vial	2	Mabthera
Inj 500 mg per 50 ml vial2,688.30	1	Mabthera
Inj 1 mg for ECP5.64	1 mg	 Baxter

SA1152 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

	Subsidy (Manufacturer's Price) \$	Per		Brand or Generic Manufacturer	
TRASTUZUMAB – PCT only – Specialist – Speci	al Authority see SA1521 below				
Inj 150 mg vial	1,350.00	1	🖌 Н	lerceptin	
Inj 440 mg vial		1	🖌 Н	lerceptin	
Inj 1 mg for ECP		1 mg	🖌 В	laxter	

SA1521 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CICLOSPORIN

Cap 25 mg Cap 50 mg Cap 100 mg		50 50 50	 ✓ Neoral ✓ Neoral ✓ Neoral
Oral liq 100 mg per ml		50 ml OP	Neoral
EVEROLIMUS – Special Authority see SA1491 below – Ret Wastage claimable – see rule 3.3.2 on page 13	ail pharmacy		
Tab 5 mg	4,555.76	30	 Afinitor
Tab 10 mg	6,512.29	30	 Afinitor

►SA1491 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

SIROLIMUS - Special Authority see SA0866 on the next page - Retail pharmacy

Tab 1 mg	 100	Rapamune
U U		Rapamune
Oral liq 1 mg per ml	 60 ml OP	 Rapamune

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
➡SA0866 Special Authority for Subsidy				
Initial application from any medical practitioner. Approvals valid	I without further rene	wal unle	ess notifie	d where the drug is to be
used for rescue therapy for an organ transplant recipient.				
Notes: Rescue therapy defined as unresponsive to calcineurin inh	ibitor treatment as de	fined by	/ refractor	y rejection; or intolerant to
calcineurin inhibitor treatment due to any of the following:				
 GFR<30 ml/min; or 				
 Rapidly progressive transplant vasculopathy; or 				
 Rapidly progressive obstructive bronchiolitis; or 				
 HUS or TTP; or 				
 Leukoencepthalopathy; or 				
 Significant malignant disease 				
TACROLIMUS – Special Authority see SA0669 below – Retail ph	armacy			
Cap 0.5 mg		100	🖌 Ta	crolimus Sandoz
Cap 1 mg	171.20	100	🖌 <u>T</u> a	acrolimus Sandoz
Cap 5 mg - For tacrolimus oral liquid formulation refer, page				
209		50	🖌 Ta	crolimus Sandoz
►SA0669 Special Authority for Subsidy				

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Subsidy (Manufacturer's Pr	ice) Su	Fully bsidised	Brand or Generic
	(Manulacturer 3 1 1 \$	Per	V	Manufacturer
Antiallergy Preparations				
►SA1367 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals vali	d for 2 years for ap	plications me	eeting the	e following criteria:
Both:				
1 RAST or skin test positive; and				
2 Patient has had severe generalised reaction to the sens	00			
Renewal only from a relevant specialist. Approvals valid for 2 y benefiting from treatment.	years where the tre	eatment rem	ains app	ropriate and the patient is
BEE VENOM ALLERGY TREATMENT - Special Authority see S	SA1367 above – R	etail pharma	су	
Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 dilu				
ent 1.8 ml		1 OP	V A	lbay
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluer		1.00		lh a
9 ml, 3 diluent 1.8 ml		1 OP	🗸 A	ibay
WASP VENOM ALLERGY TREATMENT - Special Authority see		Retail pharm	nacy	
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freez		1 OP	🗸 A	lhov
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freez		TUP	VA	ibay
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	🗸 A	lbav
	200.00		•	
Antihistamines				
CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.59	100	V Ze	
*‡ Oral liq 1 mg per ml	2.99	200 ml	∨ <u>н</u>	istaclear
CHLORPHENIRAMINE MALEATE				
*‡ Oral liq 2 mg per 5 ml	8.06	500 ml	🗸 Н	istafen
DEXTROCHLORPHENIRAMINE MALEATE				
* Tab 2 mg		20	_	
	(5.99) 2.02	40	Po	olaramine
	(8.40)	40	P	plaramine
* Oral lig 2 mg per 5 ml	()	100 ml		
	(10.29)		P	olaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg	4.34	20		
	(11.53)		Te	elfast
* Tab 120 mg		10	-	16
	(11.53) 14.22	30	Te	elfast
	(29.81)	30	Te	elfast
	(20.01)			
LORATADINE * Tab 10 mg	1 30	100	1	orafix
* Oral lig 1 mg per ml		200 ml		oraPaed
				<u> </u>

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
	Ψ	101	• Manuadurer
ROMETHAZINE HYDROCHLORIDE			4 A H H
Tab 10 mg		50	✓ <u>Allersoothe</u>
Tab 25 mg		50	✓ <u>Allersoothe</u>
Cral liq 5 mg per 5 ml	2.79	100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a		_	A
PSO	11.99	5	 Hospira
IMEPRAZINE TARTRATE			
Oral liq 30 mg per 5 ml	2.79	100 ml OP	
	(8.06)		Vallergan Forte
nhaled Corticosteroids			
CLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 50 mcg per dose		200 dose OP	🗸 Qvar
Aerosol inhaler, 50 mcg per dose CFC-free		200 dose OP	 Beclazone 50
Aerosol inhaler, 100 mcg per dose		200 dose OP	✓ Qvar
Aerosol inhaler, 100 mcg per dose CFC-free		200 dose OP	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free		200 dose OP	✓ Beclazone 250
IDESONIDE			
Powder for inhalation, 100 mcg per dose	17 00	200 dose OP	✓ Pulmicort
		200 0036 01	Turbuhaler
Powder for inhalation, 200 mcg per dose	10.00	200 dose OP	✓ Pulmicort
Powder for initialation, 200 mcg per dose		200 005e OF	Turbuhaler
Dourdor for inholation 100 mag nor doop	20.00		✓ Pulmicort
Powder for inhalation, 400 mcg per dose		200 dose OP	Turbuhaler
			Turbunaler
UTICASONE			4 - 1 - 1 - 1
Aerosol inhaler, 50 mcg per dose CFC-free		120 dose OP	✓ Flixotide
Powder for inhalation, 50 mcg per dose		60 dose OP	 Flixotide Accuhale
Powder for inhalation, 100 mcg per dose		60 dose OP	 Flixotide Accuhale
Aerosol inhaler, 125 mcg per dose CFC-free		120 dose OP	 Flixotide
Aerosol inhaler, 250 mcg per dose CFC-free		120 dose OP	✓ Flixotide
Powder for inhalation, 250 mcg per dose		60 dose OP	 Flixotide Accuhale
haled Long-acting Beta-adrenoceptor Agonists	\$		
ORMOTEROL FUMARATE			
Powder for inhalation, 6 mcg per dose, breath activated	10.32	60 dose OP	
	(16.90)		Oxis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de-			
vice		60 dose	
	(35.80)		Foradil
DACATEROL			
Powder for inhalation 150 mcg	61.00	30 dose OP	Onbrez Breezhaler
Powder for inhalation 100 mcg		30 dose OP	 Onbrez Breezhaler
5			
LMETEROL	00.40	100 data 00	. Comment
Aerosol inhaler CFC-free, 25 mcg per dose		120 dose OP	✓ Serevent
Powder for inhalation, 50 mcg per dose, breath activated		60 dose OP	Serevent Accuhale

Turbuhaler 400/12

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
Inhaled Corticosteroids with Long-Acting Beta-A	drenocepto	r Agonists		
BUDESONIDE WITH EFORMOTEROL – Special Authority see SA Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg Powder for inhalation 100 mcg with eformoterol fumarate		•		annair
6 mcg	55.00	120 dose OP		ymbicort Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 200 mcg with eformoterol fumarate	31.25	120 dose OP	🖌 Va	annair
6 mcg	60.00	120 dose OP	✔ S	ymbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg - No more than 2 dose per day	60.00	60 dose OP	✔ S	ymbicort

SA1179 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

FLUTICASONE WITH SALMETEROL

	Aerosol inhaler 50 mcg with salmeterol 25 mcg	120 dose OP	 Seretide
	Aerosol inhaler 125 mcg with salmeterol 25 mcg	120 dose OP	✓ Seretide
	Powder for inhalation 100 mcg with salmeterol 50 mcg - No		
	more than 2 dose per day	60 dose OP	 Seretide Accuhaler
	Powder for inhalation 250 mcg with salmeterol 50 mcg - No		
	more than 2 dose per day49.69	60 dose OP	Seretide Accuhaler
В	eta-Adrenoceptor Agonists		
SA	LBUTAMOL		
‡	Oral liq 400 mcg per ml2.06	150 ml	✓ Ventolin
	Infusion 1 mg per ml, 5 ml	10	
	(130.21)		Ventolin
	Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO12.90	5	 Ventolin

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP	Respigen
	(6.00)		 Salamol Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	3.25	20	✓ <u>Asthalin</u>
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	✓ <u>Asthalin</u>
TERBUTALINE SULPHATE Powder for inhalation, 250 mcg per dose, breath activated	22.00	200 dose OP	🗸 Bricanyl Turbuhaler
Anticholinergic Agents			
PRATROPIUM BROMIDE Aerosol inhaler, 20 mcg per dose CFC-free Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available		200 dose OP	✓ Atrovent
on a PSO Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available	3.26	20	✓ <u>Univent</u>
on a PSO		20	✓ <u>Univent</u>
Inhaled Beta-Adrenoceptor Agonists with Antick	nolinergic A	gents	
SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	12.19	200 dose OP	🗸 Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO		20	✓ <u>Duolin</u>
Long-Acting Muscarinic Antagonists			

Long-Acting Muscarinic Antagonists

SA1485 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium g.i.d for one month; and
- 3 Either:
 - The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
 - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
 - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 All of the following:
 - Applicant must state recent measurement of:
 - 4.1 Actual FEV₁ (litres); and
 - 4.2 Predicted FEV₁ (litres); and
 - 4.3 Actual FEV $_1$ as a % of predicted (must be below 60%); and

5 Either:

		Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
continued					
	Patient is not a smoker (for reporting purp Patient is a smoker and has been offered		ling; an	d	
6 The pati	ent has been offered annual influenza im	nunisation.			
Renewal only fro criteria: All of the followin	om a general practitioner or relevant spec	sialist. Approvals valid for a	2 years	for applicati	ions meeting the following
1 Patient i	s compliant with the medication; and has experienced improved COPD sympton	m control (prescriber deter	nined);	and	
3.1 <i>A</i> 3.2 F	Applicant must state recent measurement Actual FEV ₁ (litres); and Predicted FEV ₁ (litres); and Actual FEV ₁ as a % of predicted.	of:			
Glycopyrroni	IIUM – Special Authority see SA1485 on um treatment will not be subsidised if pat nhalation 50 mcg per dose	ent is also receiving treatm	•	n subsidised	l tiotropium. eebri Breezhaler
Tiotropium tr	ROMIDE - Special Authority see SA1485 eatment will not be subsidised if patient is nhalation, 18 mcg per dose	also receiving treatment v		sidised glyc	opyrronium. piriva
	Receptor Antagonists				
IONTELUKAST Prescribing (Special Authority see SA1421 below – Guideline: Clinical evidence indicates that ment courses. 		elukast i	s strongest	when montelukast is used
0			28		ingulair
0			28		ingulair
iab iu mg		18.48	28	V SI	ingulair

➡SA1421 Special Authority for Subsidy

Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Subsidy (Manufacturer's P		Fully Subsidised	Generic	
\$	Per	· ·	Manufacturer	

continued...

Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a Clinical Immunologist or Allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Mast Cell Stabilisers			
NEDOCROMIL Aerosol inhaler, 2 mg per dose CFC-free		112 dose OP	✔ Tilade
SODIUM CROMOGLYCATE Powder for inhalation, 20 mg per dose Aerosol inhaler, 5 mg per dose CFC-free		50 dose 112 dose OP	✓ Intal Spincaps✓ Intal Forte CFC Free
Methylxanthines			
AMINOPHYLLINE			
* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj av PSO		5	✓ DBL Aminophylline
THEOPHYLLINE * Tab long-acting 250 mg *‡ Oral liq 80 mg per 15 ml	21.51	100 500 ml	✔ Nuelin-SR ✔ Nuelin
Mucolytics			
DORNASE ALFA – Special Authority see SA0611 be Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	✓ Pulmozyme
► SA0611 Special Authority for Subsidy Special Authority approved by the Cystic Fibrosis Adv Notes: Application details may be obtained from PHA		w.pharmac.govt.r	nz or:
The Co-ordinator, Cystic Fibrosis Advisory Panel PHARMAC, PO Box 10 254 Wellington	Phone: (04) 460 4990 Facsimile: (04) 916 7571 Email: CFPanel@pharm	ac govt nz	_
Prescriptions for patients approved for treatment mus and expertise in treating cystic fibrosis.		•	ediatricians who have experience
SODIUM CHLORIDE Not funded for use as a nasal drop.			
Soln 7%		90 ml OP	 Biomed
Nasal Preparations			
Allergy Prophylactics			

BECLOMETHASONE DIPROPIONATE Metered aqueous nasal spray, 50 mcg per dose2.35 200 dose OP (4.85) Alanase Metered aqueous nasal spray, 100 mcg per dose2.46 200 dose OP (5.75)Alanase

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✓ Manufacturer
BUDESONIDE			
Metered aqueous nasal spray, 50 mcg per dose	2.35	200 dose OP	
	(4.85)		Butacort Aqueous
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	D
	(5.75)		Butacort Aqueous
FLUTICASONE PROPIONATE			4
Metered aqueous nasal spray, 50 mcg per dose	2.30	120 dose OP	 Flixonase Hayfever & Allergy
IPRATROPIUM BROMIDE			<u>a Allergy</u>
Aqueous nasal spray, 0.03%	3 95	15 ml OP	✓ Univent
		13 111 01	• <u>onvent</u>
Respiratory Devices			
MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2	2.99	1	✓ EZ-fit Paediatric Mask
PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range		1	wask ✓ Breath-Alert
Normal range		1	✓ Breath-Alert
SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO		,	
230 ml (single patient)	4.72	1	Space Chamber Plus
800 ml		1	✓ Volumatic
SPACER DEVICE AUTOCLAVABLE a) Up to 5 dev available on a PSO b) Only on a PSO 230 ml (autoclavable) – Subsidy by endorsement Available where the prescriber requires a spacer devic endorsed accordingly.		1	✓ Space Chamber
Respiratory Stimulants			
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		25 ml OP	✓ Biomed

	Qubaidu		Fully Deceder
	Subsidy (Manufacturer's	Price) Sub	Fully Brand or osidised Generic
	`\$	Per	 Manufacturer
ar Preparations			
ETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN	ZETHONIUM		
For Vosol ear drops with hydrocortisone powder refer Standa		ge 212	
Ear drops 2% with 1, 2-Propanediol diacetate 3% and		•	
benzethonium chloride 0.02%	6.97	35 ml OP	Vosol
			4 1 1 1 1 1
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform ED's
			✓ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI	Ν ΔΝΟ ΝΥΘΤΔΤ	IN	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate			
2.5 mg and gramicidin 250 mcg per g		7.5 ml OP	 Kenacomb
Ear/Eye Preparations			
EXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN	1		
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml		8 ml OP	
	(9.27)		Sofradex
RAMYCETIN SULPHATE	()		
Ear/Eye drops 0.5%	4.13	8 ml OP	
	(8.65)		Soframycin
Eye Preparations			
ye preparations are only funded for use in the eye, unless explic	itly stated other	Niso	
	iny stated other	MIGC.	
Anti-Infective Preparations			
CICLOVIR			
Eye oint 3%		4.5 g OP	Zovirax
HLORAMPHENICOL			4 a
Eye oint 1%		4 g OP	✓ <u>Chlorsig</u>
Eye drops 0.5% Funded for use in the ear*. Indications marked with * are l		10 ml OP cations	✓ Chlorafast
PROFLOXACIN			
Eye Drops 0.3%		5 ml OP	Ciloxan
For treatment of bacterial keratitis or severe bacterial conju	unctivitis resista	nt to chloramph	enicol.
JSIDIC ACID			4 - - - - - - - - - -
Eye drops 1%	4.50	5 g OP	 Fucithalmic
ANCICLOVIR			4.111
Eye gel 0.15%		5 g OP	Virgan S29
			1 0 ''
Eye drops 0.3%	11.40	5 ml OP	 Genoptic
	0.07	10	
Eye drops 0.1%		10 ml OP	Brolono
	(7.99)		Brolene

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic Manufacture	
TOBRAMYCIN				
Eye oint 0.3%		3.5 g OP	Tobrex	
Eye drops 0.3% Corticosteroids and Other Anti-Inflammatory Pre		5 ml OP	✓ <u>Tobrex</u>	
· · · · ·				
DEXAMETHASONE * Eye oint 0.1%	5.86	3.5 g OP	Maxidex	
* Eye drops 0.1%		5 ml OP	Maxidex	
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYM		ATE		
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin				
b sulphate 6,000 u per g	5.39	3.5 g OP	✓ <u>Maxitrol</u>	
* Eye drops 0.1% with neomycin sulphate 0.35% and polymy-				
xin b sulphate 6,000 u per ml	4.50	5 ml OP	✓ <u>Maxitrol</u>	
DICLOFENAC SODIUM	10.00			
* Eye drops 0.1%	13.80	5 ml OP	Voltaren Opht	ha
FLUOROMETHOLONE			4 -	
* Eye drops 0.1%	3.80	5 ml OP	✓ <u>Flucon</u>	
LEVOCABASTINE	0.74	4 100		
Eye drops 0.5 mg per ml		4 ml OP	Livestin	
	(10.34)		Livostin	
LODOXAMIDE Eye drops 0.1%	8 71	10 ml OP	Lomide	
PREDNISOLONE ACETATE * Eye drops 0.12%	4 50	5 ml OP	Pred Mild	
 ★ Eye drops 0.12 //		5 ml OP	Pred Nind	
SODIUM CROMOGLYCATE				
Eye drops 2%	1.18	5 ml OP	Rexacrom	
Glaucoma Preparations - Beta Blockers				
BETAXOLOL				
* Eye drops 0.25%	11.80	5 ml OP	Betoptic S	
* Eye drops 0.5%	7.50	5 ml OP	 Betoptic 	
LEVOBUNOLOL				
* Eye drops 0.25%		5 ml OP	 Betagan 	
* Eye drops 0.5%	7.00	5 ml OP	 Betagan 	
(Betagan Eye drops 0.25% to be delisted 1 July 2015)				
TIMOLOL	1 15			
		5 ml OP 2.5 ml OP	✓ <u>Arrow-Timolo</u> ✓ Timoptol XE	<u>I</u>
* Eye drops 0.25%, genotrining		5 ml OP	✓ Arrow-Timolo	I
 Eye drops 0.5%, gel forming 		2.5 ml OP	✓ <u>Timoptol XE</u>	-
Glaucoma Preparations - Carbonic Anhydrase In	hibitors			
ACETAZOLAMIDE				
 Tab 250 mg – For acetazolamide oral liquid formulation refer, 				
page 209	17.03	100	✓ Diamox	

SENSORY ORGANS

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
BRINZOLAMIDE * Eye Drops 1%	0.77	5 ml OP	✔ Azopt
DORZOLAMIDE HYDROCHLORIDE		5111101	V Azopi
* Eye drops 2%	9.77 (17.44)	5 ml OP	Trusopt
DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE * Eye drops 2% with timolol maleate 0.5%	15.50	5 ml OP	✔ Cosopt
Glaucoma Preparations - Prostaglandin Analogu	les		
BIMATOPROST			
* Eye drops 0.03%		3 ml OP	🗸 Lumigan
LATANOPROST			A
* Eye drops 50 mcg per ml, 2.5 ml	1.99	2.5 ml OP	✓ <u>Hysite</u>
TRAVOPROST * Eye drops 0.004%	19.50	2.5 ml OP	🖌 Travatan
Glaucoma Preparations - Other		2.0 111 01	• Hutuun
•			
BRIMONIDINE TARTRATE * Eye drops 0.2%	4 32	5 ml OP	✓ Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
* Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	Combigan
PILOCARPINE HYDROCHLORIDE			·
* Eye drops 1%	4.26	15 ml OP	Isopto Carpine
* Eye drops 2%		15 ml OP	Isopto Carpine
* Eye drops 4%		15 ml OP	Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae			
below – Retail pharmacy		20 dose	
	(32.72)		Minims

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	15 ml OP	✓ <u>Atropt</u>
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	15 ml OP	✓ Cyclogyl
TROPICAMIDE * Eye drops 0.5% * Eye drops 1% 8.66	15 ml OP 15 ml OP	 ✓ <u>Mydriacyl</u> ✓ <u>Mydriacyl</u>

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sub Per	osidised Generic ✓ Manufacturer
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer Standard Formulae, page 212			
HYPROMELLOSE			
* Eye drops 0.5%	2.00 (3.92)	15 ml OP	Methopt
HYPROMELLOSE WITH DEXTRAN	(0.02)		Methopt
* Eye drops 0.3% with dextran 0.1%	2.30	15 ml OP	Poly-Tears
POLYVINYL ALCOHOL			
* Eye drops 1.4%		15 ml OP	✓ Vistil
* Eye drops 3%	3./5	15 ml OP	✓ Vistil Forte
Preservative Free Ocular Lubricants			
SA1388 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valic Both:	l for 12 months fo	r applications r	neeting the following criteria:
 Confirmed diagnosis by slit lamp of severe secretory dry Either: 	v eye; and		
2.1 Patient is using eye drops more than four times of2.2 Patient has had a confirmed allergic reaction to patient	• •		
Renewal from any relevant practitioner. Approvals valid for 24 m and has benefited from treatment. CARBOMER – Special Authority see SA1388 above – Retail ph		patient continu	es to require lubricating eye drops
Ophthalmic gel 0.3%, 0.5 g	•	30	✓ Poly-Gel
MACROGOL 400 AND PROPYLENE GLYCOL – Special Author Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml		bove – Retail p 24	oharmacy <u>Systane Unit Dose</u>
SODIUM HYALURONATE - Special Authority see SA1388 abov	•		4 ··· · - ·
Eye drops 1 mg per ml Note: Hylo-Fresh has a 6 month expiry after opening. The not relevant and therefore only the prescribed dosage to t	e Pharmacy Hand		5 1
Other Eye Preparations		lay be claimed.	
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4 15	15 ml OP	Naphcon Forte
Eye drops 0.1%	17.00	5 ml OP	Patanol
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN			
* Eye oint with soft white paraffin	3.63	3.5 g OP	 Refresh Night Time
PARAFFIN LIQUID WITH WOOL FAT	0.00		
* Eye oint 3% with wool fat 3%	3.63	3.5 g OP	Poly-Visc
RETINOL PALMITATE Eye oint 138 mcg per g		5 g OP	✔ VitA-POS
,		- 3	

	Subsidy		Fully	Brand or
	(Manufacturer's Prie \$	ce) Per	Subsidised	Generic Manufacturer
Various				
lay only be claimed once per patient.				
HARMACY SERVICES				
Brand switch fee	4.33	1 fee		BSF Actavis Risperidone BSF Arrow- Amitriptyline
a) The Pharmacode for BSF Arrow-Amitriptyline is 2476029 b) The Pharmacode for BSF Actavis Risperidone is 247814 3SF Actavis Risperidone Brand switch fee to be delisted 1 Augus 3SF Arrow-Amitriptyline Brand switch fee to be delisted 1 July 20	15 - see also page <i>t 2015)</i>			Annuptyme
Agents Used in the Treatment of Poisonings				
Antidotes				
CETYLCYSTEINE – Retail pharmacy-Specialist Inj 200 mg per ml, 10 ml	178.00	10	~ [Martindale Apatulovataina
Inj 200 mg per ml, 30 ml	219.00	4	~	Acetylcysteine Acetadote
IALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO				
 Inj 400 mcg per ml, 1 ml ampoule 		5	~ 1	Hospira
Removal and Elimination				
HARCOAL				
 Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO 	43.50	250 ml (OP 🗸	Carbosorb-X
EFERASIROX – Special Authority see SA1492 below – Retail p Wastage claimable – see rule 3.3.2 on page 13	harmacy			
Tab 125 mg dispersible		28		Exjade
Tab 250 mg dispersible		28		Exjade
Tab 500 mg dispersible	1,105.00	28	~	Exjade

SA1492 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

continued...

3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μL).</p>

Renewal only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Special Authority see SA1480 below – Retail pharmacy

 Ferriprox 	100		Tab 500 mg
 Ferriprox 	250 ml OP	ml266.59	Oral lig 100 m

SA1480 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DESFERRIOXAMINE MESYLATE

* Inj 500 mg vial		10	 Hospira
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml		6	
	(156.71)		Calcium Disodium Versenate

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacyspecialist).
 - c) Menthol crystals only in the following bases:

Aqueous cream

Urea cream 10%

Wool fat with mineral oil lotion

Hydrocortisone 1% with wool fat and mineral oil lotion

Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- · Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Pyrazinamide 100 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Rifabutin 20 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sildenafil 2 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sotalol 5 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Sulphasalazine 100 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Tacrolimus 1 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Terbinafine 25 mg/ml
Diltiazem hydrochloride 12 mg/ml	odopa + 1.25 mg carbidopa)/ml	Ursodeoxycholic acid 50 mg/ml
Dipyridamole 10 mg/ml	Metoclopramide 1 mg/ml	Valganciclovir 60 mg/ml*
Domperidone 1 mg/ml	Metoprolol tartrate 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Enalapril 1 mg/ml	Nitrofurantoin 10 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

qs

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- · Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 208) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



EXTEMPORANEOUSLY COMPOUNDED PRODUCTS AND GALENICALS

to 100 ml

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICAT Aspirin Soluble tabs 300 mg Chloroform	•
CODEINE LINCTUS PAEDIATRIC (3 mg pr Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	⁵ ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pro-	
MAGNESIUM HYDROXIDE 8% MIXTURE Magnesium hydroxide paste 29% Methyl hydroxybenzoate Water	275 g 1.5 g to 1,000 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml o mixture)	10 g to 100 ml
OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP	qs 8.4 g

PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATR LIQUID (10 mg per ml)	IC ORAL
Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml
PILOCARPINE ORAL LIQUID	
Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity sum ore than 5 days.)	ipplied is for
SALIVA SUBSTITUTE FORMULA	
Methylcellulose	5 g
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity su more than 5 days. Maximum 500 ml per p	
SODIUM CHLORIDE ORAL LIQUID	
Sodium chloride inj 23.4%, 20 ml	qs
Water	qs
(Only funded if prescribed for treatment of	hyponatraemia)
VANCOMYCIN ORAL SOLUTION (50 mg	per ml)
Vancomycin 500 mg injection	10 vials
Glycerol BP	40 ml
Water	to 100 ml
(Only funded if prescribed for treatment of difficile following metronidazole failure)	Clostridium
VOSOL EAR DROPS	
WITH HYDROCORTISONE POWDER 1%	
Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

Water

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's F		bsidised Generic
	\$	Per	 Manufacturer
Extemporaneously Compounded Preparations	and Galenica	ls	
BENZOIN			
Tincture compound BP	2.44	50 ml	
	(5.10)		Pharmacy Health
	24.42	500 ml	
	(39.90)	50 ml	Pharmacy Health
	2.44 (5.93)	50 mi	Home Essentials
Home Essentials Tincture compound BP to be delisted 1 Dece	()		
CHLOROFORM – Only in combination	,		
Only in aspirin and chloroform application.			
Chloroform BP	25.50	500 ml	✔ PSM
CODEINE PHOSPHATE – Safety medicine; prescriber may de		frequency	
Powder – Only in combination		5 g	
	(25.46)	- 9	Douglas
	63.09	25 g	Ũ
	(90.09)		Douglas
a) Only in extemporaneously compounded codeine linct			ediatric.
b) \ddagger Safety cap for extemporaneously compounded oral	liquid preparations		
COLLODION FLEXIBLE			4
Collodion flexible	19.30	100 ml	V PSM
COMPOUND HYDROXYBENZOATE - Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln		100 ml	Midwest
	34.18		David Craig
GLYCERIN WITH SODIUM SACCHARIN – Only in combinatio	n		
Only in combination with Ora-Plus.	0E E0	470 ml	A One Sweet SE
Suspension		473 ml	 Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination			
Only in combination with Ora-Plus. Suspension	25 50	473 ml	✓ Ora-Sweet
		4/3 111	V Ora-Sweet
GLYCEROL	0.71	500 ml	
 Liquid – Only in combination Only in extemporaneously compounded oral liquid prepa 		500 ml	healthE Glycerol BP
	aralions.		
Paste 29%	22.61	500 g	🖌 PSM
		500 g	♥ FSM
 a) Only on a controlled drug form b) No patient co-payment payable 			
c) Safety medicine; prescriber may determine dispensing fi	eanency		
d) Extemporaneously compounded methadone will only be		rate of the ch	neapest form available (methadon
powder, not methadone tablets).			,
Powder	7.84	1 g	🖌 AFT
‡ Safety cap for extemporaneously compounded oral liq	uid preparations.		
METHYL HYDROXYBENZOATE			
Powder		25 g	✓ PSM
	8.98		 Midwest

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	d Generic
METHYLCELLULOSE				
Powder Suspension – Only in combination		100 g 473 ml	-	MidWest Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHA Suspension		nbinatior 473 ml		Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only Suspension		473 ml	~	Ora-Blend
PHENOBARBITONE SODIUM Powder – Only in combination		10 g		MidWest
a) Only in children up to 12 years b) ‡ Safety cap for extemporaneously compounded oral liqu	325.00 uid preparations.	100 g	V	MidWest
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzo		500 ml	•	PSM Midwest
SODIUM BICARBONATE				
Powder BP – Only in combination	9.80	500 g		Midwest
Only in extemporaneously compounded omeprazole and la	(29.50)	ncion		David Craig
SYRUP (PHARMACEUTICAL GRADE) – Only in combination Only in extemporaneously compounded oral liquid preparation		131011.		
Liq		2,000 m	nl 🗸	Midwest
Tap – Only in combination	0.00	1 ml	~	Tap water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

 Initial Applications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner.

 Reapplications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioners.

 Very specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE

- ✓ Tab eff 1.75 g (1 g elemental)
- ✓ Tab 1.25 g (500 mg elemental)
- COMPOUND ELECTROLYTES

Powder for oral soln

DEXTROSE WITH ELECTROLYTES Soln with electrolytes

FERROUS FUMARATE ✓ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

✓ Tab 310 mg (100 mg elemental) with folic acid 350 mcg

FERROUS SULPHATE

- ✓ Tab long-acting 325 mg (105 mg elemental)
- ✓ Oral liq 30 mg (6 mg elemental) per 1 ml

FERROUS SULPHATE WITH FOLIC ACID Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

FOLIC ACID Tab 0.8 mg

MULTIVITAMINS

PANCREATIC ENZYME

✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease PHOSPHORUS ✓ Tab eff 500 mg (16 mmol)

POTASSIUM CHLORIDE Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)

✔ Tab long-acting 600 mg

POTASSIUM IODATE

✓ Tab 253 mcg (150 mcg elemental iodine)

PYRIDOXINE HYDROCHLORIDE

- 🖌 Tab 25 mg
- ✔ Tab 50 mg

SODIUM CHLORIDE ✓ Inj 23.4%, 20 ml

SODIUM FLUORIDE

✓ Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE ✓ Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

✓ Tab, strong, BPC

VITAMINS

- ✓ Tab (BPC cap strength)
- ✓ Cap (fat soluble vitamins A, D, E, K)

Subsidy (Manufacturer's Price) \$ Per Brand or Generic Manufacturer

Fully

Subsidised

Nutrient Modules

Carbohydrate

SA1522 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 inborn errors of metabolism; or
- 7 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1522 above – Hospital pharmacy [HP3]

Powder5.29	400 g OP	Polycal
------------	----------	---------

Carbohydrate And Fat

SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

continued...

Subsidy (Manufacturer's Price)	Sub	Fully bsidised	Brand or Generic
\$	Per	~	Manufacturer

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT	- Special Authority see SA1376	on the previous p	age – Hospital pharmacy [HP3]
Powder (neutral)		400 g OP	✓ Duocal Super
		-	Soluble Powder

Fat

➡SA1523 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or
- 10 acites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA1523 on the previous page - Hospital pharmacy [HP3]

Emulsion (neutral)	200 ml OP	✓ Calogen
30.75	500 ml OP	 Calogen
Emulsion (strawberry)12.30	200 ml OP	 Calogen
Oil	500 ml OP	MCT oil (Nutricia)
Oil, 250 ml	4 OP	 Liquigen

Protein

➡SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT - Special Authority see SA1524 above - Hospital pharmacy [HP3]

		~····~~) [···· o]	
Powder		225 g OP	Protifar
	8.95	227 g OP	Resource
			Beneprotein
Powder (vanilla)		275 g OP	Promod

		Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Oral	Supplements/Complete Diet (Nasogastric/	Gastrostomy Tu	be Fe	ed)	
Resp	biratory Products				
Initial a where Renew menda	1094 Special Authority for Subsidy application only from a dietitian, relevant specialist or voo the patient has CORD and hypercapnia, defined as a CO al only from a dietitian, relevant specialist, vocationally registe tion of a dietitian, relevant specialist or vocationally registe g the following criteria:	2 value exceeding 55 egistered general pra	mmHg ctitione	or general	practitioner on the recom-
	The treatment remains appropriate and the patient is be General Practitioners must include the name of the die tioner and date contacted.				registered general practi
	ORAL FEED 1.5KCAL/ML – Special Authority see SA10 uid		pharma 37 ml C		ulmocare
Diab	etic Products				
Initial a where Renew menda	1095 Special Authority for Subsidy application only from a dietitian, relevant specialist or voc the patient is a type I or and II diabetic who is suffering we al only from a dietitian, relevant specialist, vocationally re tion of a dietitian, relevant specialist or vocationally register g the following criteria:	eight loss and malnuing gistered general pra	rition th ctitione	at requires or general	nutritional support. practitioner on the recom-
	The treatment remains appropriate and the patient is be General Practitioners must include the name of the die tioner and date contacted.				registered general practi
DIABE	TIC ENTERAL FEED 1KCAL/ML – Special Authority see	SA1095 above - Ho	spital p	harmacy (H	P3]

Liquid	7.50	1,000 ml OP	 Diason RTH Glucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML - Special Authority see SA	1095 above – Ho	spital pharmacy	[HP3]
Liquid (strawberry)	1.50	200 ml OP	✓ Diasip
Liquid (vanilla)	1.50	200 ml OP	✓ Diasip
	1.88	250 ml OP	 Glucerna Select
	1.78	237 ml OP	
	(2.10)		Resource Diabetic
	(2.10)		Sustagen Diabetic

Fat Modified Products

SA1525 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or

continued...

Subsidy (Manufacturer's Price)	Sub	Fully	Brand or Generic	
\$	Per	~	Manufacturer	

3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED - Special Authority see SA1525 on the previous page - Hospital pharmacy [HP3]

Powder				60.48	400 g OP	Monogen
--------	--	--	--	-------	----------	---------

High Protein Products

➡SA1378 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 decompensating liver disease without encephalopathy; or
- 2 protein losing gastro-enteropathy.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HIGH PROTEIN ORAL FEED 1KCAL/ML – Special Authority see SA1378 above – Hospital pharmacy [HP3]

Liquid1.90 200 ml OP 🖌 Fortimel Regular

(Fortimel Regular Liquid to be delisted 1 September 2015)

Paediatric Products For Children Awaiting Liver Transplant

➡SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Sp	pecial Authority see SA1098 above – I	Hospital pharmacy	' [HP3]
Powder (unflavoured)		400 a OP	Heparon Junior

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

Paediatric Products For Children With Chronic Renal Failure

SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1099 above - Hospital pharmacy [HP3]

Paediatric Products

SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 above Liquid2.68		macy [HP3] V Nutrini RTH Pediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see Liquid6.00		 Hospital pharmacy [HP3] Nutrini Energy Multi Fibre Nutrini Energy RTH
PAEDIATRIC ORAL FEED – Special Authority see SA1379 above – Hospital phan Powder (vanilla)	macy [HP3] 850 g OP	✓ Pediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 above – Liquid (strawberry)	Hospital pharm 200 ml OP 200 ml OP	acy [HP3] ✔ Fortini ✔ Fortini

Specialised And Elemental Products

►SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 malabsorption: or
 - 2 short bowel syndrome; or
 - 3 enterocutaneous fistulas; or
 - 4 eosinophilic oesophagitis: or
 - 5 inflammatory bowel disease; or
 - 6 patients with multiple food allergies requiring enteral feeding.

continued...

SPECIAL FOODS

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML	 Special Authority see SA1377 	on the previous	s page – Hospital pharmacy [HP3]	
Powder	4 40	79 a OP	Vital HN	

7.50	76 g OP	✓ Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see SA1377 on the	previous page -	- Hospital pharmacy [HP3]
Liquid (grapefruit), 250 ml carton171.00	18 OP	 Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton 171.00	18 OP	 Elemental 028 Extra
Liquid (summer fruits), 250 ml carton171.00	18 OP	 Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1377 on the pr Powder (unflavoured)4.50		Hospital pharmacy [HP3]
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA1377 Liquid12.04		s page – Hospital pharmacy [HP3]

Paediatric Products For Children With Low Energy Requirements

➡SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

•			Multi Fibre
Liquid	4.00	500 ml OP	Nutrini Low Energy
PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML - Sp	pecial Authority se	e SA1196 above	e – Hospital pharmacy [HP3]

(Manufacturer's Price)	Fully Subsidised			
\$	Per	~	Manufacturer	

Standard Supplements

SA1228 Special Authority for Subsidy

Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

continued...

Subsidy (Manufacturer's Price		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

Initial application - (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
 - Patient is Malnourished
 - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding: or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant: and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum: or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result: or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant: and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum: or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

continued.

Subsidy		Fully	Brand or	
(Manufacturer's Pric	e)	Subsidised	Generic	
\$	Per	~	Manufacturer	

Initial application - (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria): or
- 2 Cystic Fibrosis; or
- 3 Liver disease: or
- 4 Chronic Renal failure: or
- 5 Inflammatory bowel disease: or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula: or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria): or
- 2 Cystic Fibrosis; or
- 3 Liver disease: or
- 4 Chronic Renal failure: or
- 5 Inflammatory bowel disease: or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome: or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 225 – Liquid		cy [HP3] ✔ Nutrison Energy
ENTERAL FEED 1KCAL/ML - Special Authority see SA1228 on page 225 - Ho	ospital pharmacy	[HP3]
Liquid	250 ml OP	 Isosource Standard Osmolite
5.29	1,000 ml OP	 Isosource Standard RTH
		 Nutrison Standard RTH
2.65	500 ml OP	Osmolite RTH
5.29	1,000 ml OP	 Osmolite RTH
ENTERAL FEED WITH FIBRE 1 KCAL/ML - Special Authority see SA1228 on		
Liquid1.32	237 ml OP	Jevity
2.65	500 ml OP	Jevity RTH
5.29	1,000 ml OP	Jevity RTH
		Nutrison Multi Fibre

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
NTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority s	ee SA1228 on	page 225 – Ho	spital pharmacy [HP3]
Liquid		250 ml OP	Ensure Plus HN
•	7.00	1,000 ml OP	🖌 Ensure Plus RTH
		.,	✓ Jevity HiCal RTH
			✓ Nutrison Energy
			Multi Fibre
RAL FEED (POWDER) – Special Authority see SA1228 on page	e 225 – Hospita	al pharmacy [HI	23]
Note: Higher subsidy for Sustagen Hospital Formula will only	be reimburse	d for patients w	vith both a valid Special Authorit
number and an appropriately endorsed prescription.			
Powder (chocolate) – Higher subsidy of up to \$14.90 per			
900 g with Endorsement	13.00	850 g OP	Ensure
	10.22	900 g OP	
		000 g O	
	(14.90)	000 g 01	Sustagen Hospital
		000 g 01	Sustagen Hospital Formula
Additional subsidy by endorsement is available for patients	(14.90)	Ū	Formula
Additional subsidy by endorsement is available for patients	(14.90)	Ū	Formula
scription must be endorsed accordingly.	(14.90)	Ū	Formula
scription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$14.90 per 900 g	(14.90) with fat mala	bsorption, fat ir	Formula tolerance or chyle leak. The pre
scription must be endorsed accordingly.	(14.90) with fat mala	bsorption, fat ir 350 g OP	Formula tolerance or chyle leak. The pre
scription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$14.90 per 900 g	(14.90) with fat malal 	bsorption, fat ir 350 g OP 850 g OP	Formula tolerance or chyle leak. The pre
scription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$14.90 per 900 g	(14.90) with fat mala 	bsorption, fat ir 350 g OP	Formula tolerance or chyle leak. The pre Fortisip Finsure
scription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$14.90 per 900 g	(14.90) with fat malal 	bsorption, fat ir 350 g OP 850 g OP	Formula tolerance or chyle leak. The pre

scription must be endorsed accordingly.

	Subsidy (Manufacturer's \$		Fully Brand or dised Generic ✔ Manufacturer
ORAL FEED 1.5KCAL/ML - Special Authority see SA1228 on pa	ge 225 – Hospi	ital pharmacy [HP	3]
Additional subsidy by endorsement is available for patients be			
molysis bullosa. The prescription must be endorsed according		0 0	•
Liquid (banana) - Higher subsidy of \$1.26 per 200 ml with			
Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml			
with Endorsement		200 ml OP	
	(1.26)		Ensure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with			
Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip
Liquid (toffee) - Higher subsidy of \$1.26 per 200 ml with			
Endorsement		200 ml OP	–
	(1.26)		Fortisip
Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml	0.70		
with Endorsement		200 ml OP	Fastiain
	(1.26)		Fortisip
Liquid (vanilla) - Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement		200 ml OP	
	(1.26)	007	Ensure Plus
	0.85	237 ml OP	Ensure Plus
	(1.33) 0.72	200 ml OP	Elisule Flus
	(1.26)	200 111 0F	Fortisip
(Fortisip Liquid (toffee) to be delisted 1 September 2015)	(1.20)		Forusip
(Fortisip Liquid (topical fruit) to be delisted 1 September 2013)			
		005 11 11	1
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see			
Additional subsidy by endorsement is available for patients be		irough a feeding t	upe, or who have severe epider-
molysis bullosa. The prescription must be endorsed according			
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with		200 ml OP	
Endorsement	0.72 (1.26)	200 111 0P	Fortisip Multi Fibre
Liquid (strouberry) Llipher subsidy of \$1.00 per 000 pel with	· · ·		
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with			
Endorsement	0./2	200 ml OP	

SPECIAL FOODS

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per ✔ Manufacture	er
---	----

High Calorie Products

►SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML - Special Authority see SA1195 above	e – Hospital	pharmacy [HP3]	
Liquid	5.50	500 ml OP	 Nutrison Concentrated
	11.00	1,000 ml OP	✓ Two Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 above – H Additional subsidy by endorsement is available for patients being molysis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with Endorsement	bolus fed th		tube, or who have severe epider- Two Cal HN

	Subsidy (Manufacturer's Pric \$	e) Sul Per	Fully bsidised	Brand or Generic Manufacturer
Food Thickeners	•			
⇒SA1106 Special Authority for Subsidy itial application only from a dietitian, relevant specialist or voc here the patient has motor neurone disease with swallowing dis enewal only from a dietitian, relevant specialist, vocationally re endation of a dietitian, relevant specialist or vocationally register teeting the following criteria: oth:	sorder. gistered general pra	ctitioner or	general	practitioner on the recon
 The treatment remains appropriate and the patient is be General Practitioners must include the name of the die tioner and date contacted. 	•		ationally	v registered general prac
OOD THICKENER - Special Authority see SA1106 above - H	ospital pharmacy [H	P3]		
Powder	6.53	300 g OP	🖌 N	lutilis
	7.25	380 g OP	🗸 F	eed Thickener Karicare Aptamil

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

SA1107 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

1 Gluten enteropathy has been diagnosed by biopsy; or

2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX – Special Authority see SA1107 at Powder		pharmacy [HP3] 1.000 g OP	
	(5.15)	1,000 y Ol	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA1107 ab	ove – Hospital p	oharmacy [HP3]	
Powder		1,000 g OP	
	(7.32)		NZB Low Gluten Bread Mix
	4.77		
	(8.71)		Bakels Gluten Free Health Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1107 above -			
Powder	5.62 (18.10)	2,000 g OP	Horleys Flour

	Subsidy (Manufacturer's \$		Fully dised	Brand or Generic Manufacturer
GLUTEN FREE PASTA - Special Authority see SA1107 on the p	previous page –	Hospital pharmad	y [HP	3]
Buckwheat Spirals	2.00	250 g OP		
	(3.11)		0	Irgran
Corn and Vegetable Shells		250 g OP		
	(2.92)		0	Irgran
Corn and Vegetable Spirals		250 g OP		
	(2.92)		0	Irgran
Rice and Corn Lasagne Sheets		200 g OP		
	(3.82)		0	Irgran
Rice and Corn Macaroni		250 g OP		
	(2.92)		0	Irgran
Rice and Corn Penne		250 g OP		
	(2.92)		0	Irgran
Rice and Maize Pasta Spirals	2.00	250 g OP		
	(2.92)		0	Irgran
Rice and Millet Spirals	2.00	250 g OP		
	()		0	Irgran
Rice and corn spaghetti noodles	2.00	375 g OP		
	(2.92)		0	Irgran
Vegetable and Rice Spirals		250 g OP		
	(2.92)		0	Irgran
Italian long style spaghetti	2.00	220 g OP		
	(3.11)		0	Irgran
Rice and Millet Spirals Rice and corn spaghetti noodles Vegetable and Rice Spirals		250 g OP 375 g OP 250 g OP		orgran orgran orgran orgran orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Autho Powder)8 above – Hos 500 g OP	pital pharmacy [HP3]
Supplements For MSUD			
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISO pharmacy [HP3]		•	, , , , , , , , , , , , , , , , , , , ,
Powder	300.54 437.22	500 g OP	 MSUD Maxamaid MSUD Maxamum

Subsidy		Fully	Brand or	
(Manufacturer's Pri	ce)	Subsidised	Generic	
\$	Per	~	Manufacturer	

Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]

[IF3]		
Tabs	75 OP	Phlexy 10
Powder (unflavoured) 29 g sachets	30	PKU Anamix Junior
Infant formula	400 g OP	🖌 PKU Anamix Infant
Powder (orange)	500 g OP	🖌 XP Maxamaid
320.00	·	🖌 XP Maxamum
Powder (unflavoured)221.00	500 g OP	🖌 XP Maxamaid
320.00	0	🖌 XP Maxamum
Liquid (berry)13.10	125 ml OP	🖌 PKU Anamix Junior
		LQ
Liquid (citrus)	62.5 ml OP	PKU Lophlex LQ 10
31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (juicy berries)	62.5 ml OP	PKU Lophlex LQ 10
31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (juicy orange)	62.5 ml OP	PKU Lophlex LQ 10
31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (orange)13.10	125 ml OP	✓ PKU Anamix Junior
		LQ
Liquid (unflavoured)13.10	125 ml OP	🖌 PKU Anamix Junior
		LQ
Liquid (forest berries), 250 ml carton540.00	18 OP	Easiphen Liquid
Liquid (juicy berries) 62.5 ml	60 OP	PKU Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml	60 OP	PKU Lophlex LQ 10
Liquid (juicy orange) 62.5 ml	60 OP	PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml	30 OP	PKU Lophlex LQ 20
Liquid (juicy citrus) 125 ml	30 OP	PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml	30 OP	PKU Lophlex LQ 20
(PKU Lophlex LQ 10 Liquid (citrus) to be delisted 1 August 2015)		· · · · · · · · · · · · · · · · · · ·
(PKU Lophlex LQ 20 Liquid (citrus) to be delisted 1 August 2015)		
(PKU Lophlex LQ 10 Liquid (juicy berries) to be delisted 1 August 2015)		
(PKU Lophlex LQ 20 Liquid (juicy berries) to be delisted 1 August 2015)		
(PKU Lophlex LQ 10 Liquid (juicy orange) to be delisted 1 August 2015)		
(PKUL set les 10 Eiguid (juicy orange) to be delisted 1 August 2015)		

Foods

LOW PROTEIN BAKING MIX – Special Authority see SA1108 on the property Powder			harmacy [HP3] ✓ Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the previous	page – He	ospital pharma	cy [HP3]
Animal shapes	11.91	500 g OP	 Loprofin
Lasagne	.5.95	250 g OP	 Loprofin
Low protein rice pasta	11.91	500 g OP	 Loprofin
Macaroni	.5.95	250 g OP	 Loprofin
Penne	11.91	500 g OP	 Loprofin
Spaghetti	11.91	500 g OP	 Loprofin
Spirals	11.91	500 g OP	 Loprofin

(PKU Lophlex LQ 20 Liquid (juicy orange) to be delisted 1 August 2015)

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Infant Formulae				
For Premature Infants				
PRETERM POST-DISCHARGE INFANT FORMULA – Special / Powder		3 below 400 g O		harmacy [HP3] -26 Gold Premgro
SA1198 Special Authority for Subsidy nitial application only from a dietitian, relevant specialist or nonths for applications meeting the following criteria: Both:	vocationally registere	ed gene	ral practitio	ner. Approvals valid for 6
1 The infant was born before 33 weeks gestation or weigh 2 Either:	ned less than 1.5 kg a	at birth;	and	
2.1 The infant has faltering growth (downward cross2.2 The infant is not maintaining, or is considered up	U 1 /·		growth on a	standard infant formula.
For Williams Syndrome				
►>SA1110 Special Authority for Subsidy nitial application only from a dietitian, relevant specialist or voo where the patient is an infant suffering from Williams Syndrome Renewal only from a dietitian, relevant specialist, vocationally registen nendation of a dietitian, relevant specialist or vocationally registen neeting the following criteria: Both:	and associated hype gistered general pra	rcalcaer	nia. r or general	practitioner on the recom-
 The treatment remains appropriate and the patient is be General Practitioners must include the name of the die tioner and date contacted. 				registered general practi-
OW CALCIUM INFANT FORMULA – Special Authority see SA Powder		tal pharı 400 g O		ocasol
Gastrointestinal and Other Malabsorptive Prob	lems	-		

AMINO ACID FORMULA - Special Authority see SA1219 below -	Hospital phar	macy [HP3]	
Powder	6.00	48.5 g OP	Vivonex Pediatric
	53.00	400 g OP	Neocate LCP
Powder (unflavoured)	53.00	400 g OP	Elecare
		Ū	Elecare LCP
			Neocate Advance
			Neocate Gold
Powder (vanilla)	53.00	400 g OP	Elecare
· · · ·		0	Neocate Advance

SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

continued...

Subsic	dy Full	/ Brand or	
(Manufacture	er's Price) Subsidise	d Generic	
\$	Per 🖌	 Manufacturer 	

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

EXTENSIVELY HYDROLYSED FORMULA - Special Authority see SA1380 below - Hospital pharmacy [HP3]

Powder	 450 g OP	Pepti Junior Gold
		Karicare Aptamil

SA1380 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following:

1 Both:

- 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
- 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 The infant is currently receiving funded amino acid formula; and

2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Ketogenic Diet

SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA	 Special Authority see SA1197 a 	above – Retail p	harmacy
Powder (unflavoured)		300 g OP	KetoCal 4:1
		-	Ketocal 3:1
Powder (vanilla)		300 g OP	KetoCal 4:1

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml ampoule5 ✓ Inj 1 in 10,000, 10 ml ampoule5
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml ampoule5
AMIODARONE HYDROCHLORIDE ✓ Inj 50 mg per ml, 3 ml ampoule6
AMOXICILLIN ✓ Cap 250 mg
AMOXICILLIN WITH CLAVULANIC ACID ✓ Tab 500 mg with clavulanic acid 125 mg
ASPIRIN ✔ Tab dispersible 300 mg
ATROPINE SULPHATE Inj 600 mcg per ml, 1 ml ampoule5
AZITHROMYCIN V Tab 500 mg – See note on page 928
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] Tab 2.5 mg – See note on page 56
BENZATHINE BENZYLPENICILLIN V Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE V Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✓ Inj 600 mg (1 million units) vial
BLOOD GLUCOSE DIAGNOSTIC TEST METER ✓ Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Subsidy by endorsement – See note on page 261
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP ✓ Blood glucose test strips – See note on page 26
BLOOD KETONE DIAGNOSTIC TEST METER Meter – See note on page 251

CEFTRIAXONE	
✓ Inj 500 mg vial – Subsidy by endorsemen See note on page 91	ıt – 5
Inj 1 g vial – Subsidy by endorsement – S note on page 91	See
CHARCOAL	
✓ Oral liq 50 g per 250 ml	250 ml
CHLORPROMAZINE HYDROCHLORIDE	30
✓ Tab 25 mg	
✓ Tab 100 mg	
✓ Inj 25 mg per ml, 2 ml	5
CIPROFLOXACIN	
✓ Tab 250 mg – See note on page 95	5
✓ Tab 500 mg – See note on page 95	5
CO-TRIMOXAZOLE	
✓ Tab trimethoprim 80 mg and	
sulphamethoxazole 400 mg	
✓ Oral lig trimethoprim 40 mg and	
sulphamethoxazole 200 mg per	
5 ml	200 ml
COMPOUND ELECTROLYTES	
✓ Powder for oral soln	
CONDOMS	
✓ 49 mm	144
✓ 52 mm	
✓ 52 mm extra strength	
✓ 53 mm	
✓ 53 mm (chocolate)	
✓ 53 mm (strawberry)	144
54 mm, shaped	
✓ 55 mm	
 ✓ 56 mm ✓ 56 mm, shaped 	
✓ 60 mm	
CYPROTERONE ACETATE	WITH
ETHINYLOESTRADIOL	VVII⊓
✓ Tab 2 mg with ethinyloestradiol 35 mcg ai	nd
7 inert tabs	
DEXAMETHASONE	
Tab 1 mg – Retail pharmacy-Specialist	20
 Tab 4 mg – Retail pharmacy-specialist 	
DEXAMETHASONE PHOSPHATE	
Inj 4 mg per ml, 1 ml ampoule – See note	
page 79	
	continued

(continued)

Inj 4 mg per ml, 2 ml ampoule – See note on page 79	5
DIAPHRAGM	
✓ 65 mm – See note on page 73	1
✓ 70 mm – See note on page 73	1
✓ 75 mm – See note on page 73	1
✓ 80 mm – See note on page 73	1

DIAZEPAM

✓ Inj 5 mg per ml, 2 ml ampoule – Subsidy by	
endorsement - See note on page 133	5
✓ Rectal tubes 5 mg	5
✓ Rectal tubes 10 mg	

DICLOFENAC SODIUM

✓ Inj 25 mg per ml, 3 ml ampoule	5
✓ Suppos 50 mg	10

DIGOXIN

✓ Tab 62.5 mcg	
✓ Tab 250 mcg	

DOXYCYCLINE Tab 50 mg

Tab	50 mg	30
🗸 Tab	100 mg	30

ERGOMETRINE MALEATE

/	nj 500	mcg p	per ml,	1 m	I ampoule5
----------	--------	-------	---------	-----	------------

ERYTHROMYCIN ETHYL SUCCINATE

✓ Tab 400 mg	20
✓ Grans for oral liq 200 mg per 5 ml	
✓ Grans for oral liq 400 mg per 5 ml	200 ml

ERYTHROMYCIN STEARATE

Tab 250 mg

ETHINYLOESTRADIOL WITH DESOGESTREL

Tab 20 mcg with desogestrel 150 mcg and 7	
inert tab	84
Tab 30 mcg with desogestrel 150 mcg and 7	
inert tab	84

ETHINYLOESTRADIOL WITH LEVONORGESTREL

Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab	84
Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab	84
Tab 30 mcg with levonorgestrel 150 mcg ✓ Tab 30 mcg with levonorgestrel 150 mcg and	
7 inert tab	84
ETHINYLOESTRADIOL WITH NORETHISTERONE	

	r	Tab 35	mcg with	norethisterone	1	mg63
--	---	--------	----------	----------------	---	------

✓ Tab 35 mcg with norethisterone 1 mg and 7	
 Inert tab ✓ Tab 35 mcg with norethisterone 500 mcg ✓ Tab 35 mcg with norethisterone 500 mcg and 7 inert tab 	63
FLUCLOXACILLIN ✓ Cap 250 mg ✓ Grans for oral liq 125 mg per 5 ml ✓ Grans for oral liq 250 mg per 5 ml	
FLUPENTHIXOL DECANOATE ✔ Inj 20 mg per ml, 1 ml ✔ Inj 20 mg per ml, 2 ml ✔ Inj 100 mg per ml, 1 ml	5
FLUPHENAZINE DECANOATE ✔ Inj 12.5 mg per 0.5 ml, 0.5 ml ✔ Inj 25 mg per ml, 1 ml ✔ Inj 100 mg per ml, 1 ml	5
FUROSEMIDE [FRUSEMIDE] ✔ Tab 40 mg ✔ Inj 10 mg per ml, 2 ml ampoule	
GLUCAGON HYDROCHLORIDE ✓ Inj 1 mg syringe kit	5
GLUCOSE [DEXTROSE] ✔ Inj 50%, 10 ml ampoule ✔ Inj 50%, 90 ml bottle	5 5
GLYCERYL TRINITRATE ✔ Tab 600 mcg ✔ Oral pump spray, 400 mcg per dose	250 dose
GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule	10
HALOPERIDOL Tab 500 mcg Tab 1.5 mg Tab 5 mg Oral liq 2 mg per ml Inj 5 mg per ml, 1 ml	
HALOPERIDOL DECANOATE ✓ Inj 50 mg per ml, 1 ml ✓ Inj 100 mg per ml, 1 ml	5
HYDROCORTISONE ✔ Inj 100 mg vial	
HYDROXOCOBALAMIN ✔ Inj 1 mg per ml, 1 ml	6
con	tinued

PRACTITIONER'S SUPPLY ORDERS

(continued)	✓ Inj 15 m
HYOSCINE N-BUTYLBROMIDE	contro
✔ Inj 20 mg, 1 ml	✓ Inj 30 m
INTRA-UTERINE DEVICE	contro
✓ IUD 29.1 mm length × 23.2 mm width40	NALOXON
✓ IUD 33.6 mm length × 29.9 mm width40	✔ Inj 400 r
IPRATROPIUM BROMIDE	NICOTINE
✓ Nebuliser soln, 250 mcg per ml, 1 ml40	Patch 7
✓ Nebuliser soln, 250 mcg per ml, 2 ml40	Patch 14
IVERMECTIN ✓ Tab 3 mg – See note on page 68	 Patch 21 Lozenge Lozenge
KETONE BLOOD BETA-KETONE ELECTRODES	✔ Gum 2 r
✔ Test strip	✔ Gum 2 r
LEVONORGESTREL Tab 30 mcg	 ✓ Gum 2 r ✓ Gum 4 r ✓ Gum 4 r ✓ Gum 4 r
LIDOCAINE [LIGNOCAINE]	NORETHIS
✓ Gel 2%, 10 ml urethral syringe – Subsidy by	Tab 350
endorsement – See note on page 1265	Tab 5 m
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✓ Inj 1%, 5 ml ampoule ✓ Inj 2%, 5 ml ampoule ✓ Inj 1%, 20 ml ampoule 5 ✓ Inj 2%, 20 ml ampoule	OXYTOCIN ✓ Inj 5 iu p ✓ Inj 10 iu ✓ Inj 5 iu v per m
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE ✓ Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 1275	PARACETA Tab 500 Oral liq Oral liq
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg	PEAK FLO ✓ Low ran ✓ Normal
MASK FOR SPACER DEVICE	PETHIDINI
✓ Size 2 – See note on page 20120	🖌 lnj 50 m
MEDROXYPROGESTERONE ACETATE	drug t
✓ Inj 150 mg per ml, 1 ml syringe5	✔ Inj 50 m
METOCLOPRAMIDE HYDROCHLORIDE	drug f
✓ Inj 5 mg per ml, 2 ml ampoule5	PHENOXY
METRONIDAZOLE ✓ Tab 200 mg	 Cap 250 Cap 500 Grans for
 MORPHINE SULPHATE ✓ Inj 5 mg per ml, 1 ml ampoule – Only on a controlled drug form	 ✓ Grans for PHENYTO ✓ Inj 50 m ✓ Inj 50 m

 Inj 15 mg per ml, 1 ml ampoule – Only on a controlled drug form
ALOXONE HYDROCHLORIDE [•] Inj 400 mcg per ml, 1 ml ampoule5
ICOTINE ? Patch 7 mg – See note on page 157
ORETHISTERONE 7 Tab 350 mcg
XYTOCIN Inj 5 iu per ml, 1 ml ampoule
ARACETAMOL 7 Tab 500 mg
EAK FLOW METER ' Low range
ETHIDINE HYDROCHLORIDE ' Inj 50 mg per ml, 1 ml – Only on a controlled drug form
HENOXYMETHYLPENICILLIN (PENICILLIN V) Cap 250 mg
HENYTOIN SODIUM [•] Inj 50 mg per ml, 2 ml5 [•] Inj 50 mg per ml, 5 ml5 continued

(continued)

 PHYTOMENADIONE ✓ Inj 2 mg per 0.2 ml ✓ Inj 10 mg per ml, 1 ml
 PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 1 ml – Subsidy by endorsement – See note on page 1445 ✓ Inj 50 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1445
PREDNISOLONE ✓ Oral liq 5 mg per ml – See note on page 80
PREDNISONE ✔ Tab 5 mg
PREGNANCY TESTS - HCG URINE Cassette
PROCAINE PENICILLIN V Inj 1.5 g in 3.4 ml syringe
PROCHLORPERAZINE ✓ Tab 5 mg
PROMETHAZINE HYDROCHLORIDE V Inj 25 mg per ml, 2 ml ampoule
SALBUTAMOL ✓ Inj 500 mcg per ml, 1 ml
 ✓ Nebuliser soln, 1 mg per ml, 2.5 ml

SALBUTAMOL WITH IPRATROPIUM BROMIDE ✓ Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml20 SILVER SULPHADIAZINE SODIUM BICARBONATE ✓ Inj 8.4%, 50 ml......5 ✓ Inj 8.4%, 100 ml......5 SODIUM CHLORIDE ✓ Inf 0.9% – See note on page 47 2000 ml ✓ Inj 0.9%, 5 ml – See note on page 47......5 ✓ Inj 0.9%, 10 ml – See note on page 47......5 SPACER DEVICE SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement - See note on page 2015 TRIMETHOPRIM VERAPAMIL HYDROCHLORIDE ✓ Inj 2.5 mg per ml, 2 ml ampoule5 WATER ✓ Purified for inj, 5 ml – See note on page 47......5 ✓ Purified for inj, 10 ml – See note on page 47......5 ✓ Purified for inj, 20 ml – See note on page 47......5 ZUCI OPENTHIXOL DECANOATE

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB Tuakau

Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB

Mangakino Turangi

Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls Marton Ohakune Raetihi Taihape Waiouru

MidCentral DHB

Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Greytown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburah Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a ***** within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II
- Note the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN ACETATE Nasal drops 100 mcg Minirin per ml Nasal spray 10 mcg per Desmopressin-PH&T

MUSCULOSKELETAL SYSTEM

PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

dose

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

CARDIOVASCULAR SYSTEM

AMIODARONE HYDH	IOCHLORIDE
Tab 100 mg	Cordarone-X
Tab 200 mg	Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

lab 50 mg	lambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG
	. 52. 4

ALIMENTARY TRACT AND METABOLISM

FERROUS SULPHATE Oral lig 30 mg (6 mg el- Ferodan emental) per 1 ml

CARDIOVASCULAR SYSTEM

AMILORIDE HYDROCHLORIDE Oral liq 1 mg per ml Biomed

CAPTOPRIL Oral lig 5 mg per ml Capoten

CHI OROTHIAZIDE Oral lig 50 mg per ml Biomed

DIGOXIN Oral liq 50 mcg per ml Lanoxin

FUROSEMIDE [FRUSEMIDE] Oral lig 10 mg per ml Lasix

SPIBONOI ACTONE Oral liq 5 mg per ml Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

LEVOTHYROXINE

Tab 25 mcg	Synthroid
Tab 50 mcg	Eltroxin
-	Synthroid
Tab 100 mcg	Eltroxin
-	Synthroid

(Extemporaneously compounded oral liquid preparations)

LEVOTHYROXINE (MERCURY PHARMA)

Tab 50 mcg Mercury Pharma Tab 100 mcg Mercurv Pharma (Extemporaneously compounded oral liquid preparations)

INFECTIONS - AGENTS FOR SYSTEMIC USE

QUININE SULPHATE Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM

ALPRAZOLAM Tab 250 mcg Xanax Xanax Tab 500 mcg Tab 1 mg Xanax (Extemporaneously compounded oral liquid preparations)

Tegretol

CARBAMAZEPINE

Oral lig 20 mg per ml

CLOBAZAM Frisium Tab 10 mg (Extemporaneously compounded oral liquid preparations)

CLONAZEPAM Oral drops 2.5 mg per Rivotril ml

DIAZEPAM

Tab 2 mg Arrow-Diazepam Arrow-Diazepam Tab 5 mg (Extemporaneously compounded oral liquid preparations)

ETHOSUXIMIDE Oral lig 250 mg per 5 ml Zarontin

LORAZEPAM Tab 1 mg Ativan Ativan Tab 2.5 mg (Extemporaneously compounded oral liquid preparations)

I ORMETAZEPAM

Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Oral liq 2 mg per ml Biodone **Biodone Forte** Oral lig 5 mg per ml **Biodone Extra Forte** Oral lig 10 mg per ml

MORPHINE HYDROCHLORIDE

Oral lig 1 mg per ml Oral lig 2 mg per ml Oral lig 5 mg per ml Oral lig 10 mg per ml

RA-Morph **RA-Morph RA-Morph RA-Morph**

NITRA7FPAM

Nitrados Tab 5 mg (Extemporaneously compounded oral liquid preparations)

OXA7FPAM

Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations)

OXYCODONE HYDROCHLORIDE Oral lig 5 mg per 5 ml OxvNorm

PARACETAMOL Oral lig 120 mg per 5 ml Paracare Oral lig 250 mg per 5 ml Paracare Double Strength

PHENYTOIN SODIUM Oral lig 30 mg per 5 ml

Dilantin

SAFETY CAP MEDICINES

SODIUM VALPROATE Oral liq 200 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM Tab 125 mcg Hypam Tab 250 mcg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Histaclear

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Allersoothe SALBUTAMOL Oral liq 400 mcg per ml Ventolin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

	Subsidy (Manufacturer's Price) \$	F Subsid Per	Fully lised	Brand or Generic Manufacturer
Vaccinations				
ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm] Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml Any of the following:	0.00			DT Booster DT Booster
 For vaccination of patients aged 45 and 65 years old; ou For vaccination of previously unimmunised or partially in For revaccination following immunosuppression; or For boosting of patients with tetanus-prone wounds; or For use in testing for primary immunodeficiency disear paediatrician. 	mmunised patients; or ses, on the recommend			nal medicine physician or
Note: Please refer to the Immunisation Handbook for appropriat	e schedule for catch up	programme	₽S.	
 BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm] For infants at increased risk of tuberculosis. Increased risk i 1) living in a house or family with a person with current or 2) having one or more household members or carers who to 40 per 100,000 for 6 months or longer; or 	past history of TB; or	ved in a cou	ntry w	vith a rate of TB > or equal
 during their first 5 years will be living 3 months or longe Note a list of countries with high rates of TB are available at www. Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin 	health.govt.nz/tuberculo			
Danish strain 1331, live attenuated, vial with diluent	/ ·			CG Vaccine CG Vaccine
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE - [Xpha	rm]			
Funded for any of the following criteria:A single vaccine for pregnant woman between gestationA course of up to four vaccines is funded for children fror				
or 3) A course of up to four vaccines is funded for children from suppression.	m age 7 to 17 years incl	lusive for rei	mmur	nisation following immuno-
Notes: Tdap is not registered for patients aged less than 10 y schedule for catch up programmes. Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pe tussis toxoid, 8 mcg pertussis filamentous haemagluttini	r-	ne Immunisa	ation I	Handbook for appropriate
and 2.5 mcg pertactin in 0.5 ml syringe		1	🖌 Bo	oostrix

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
 DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Funded for any of the following: A single dose for children up to the age of 7 who have co A course of four vaccines is funded for catch up program immunisation; or An additional four doses (as appropriate) are funded for or post splenectomy; pre- or post solid organ transplant, or Five doses will be funded for children requiring solid orga Note: Please refer to the Immunisation Handbook for appropriate Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagluttinin, 8 mcg pertactin and 80 D-antigen units 	mpleted primary immu mes for children (to th (re-)immunisation for p renal dialysis and oth n transplantation. schedule for catch up	ne age of patients p ner sever	10 year bost HS ely imm	CT, or chemotherapy; pre-
poliomyelitis virus in 0.5ml syringe		1 10	-	fanrix IPV fanrix IPV
 DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AN Funded for patients meeting any of the following criteria: 1) Up to four doses for children up to the age of 10 for prima 2) Up to four doses (as appropriate) for children are funder pre- or post splenectomy; renal dialysis and other severe 3) Up to five doses for children up to the age of 10 receiving Note: A course of up-to four vaccines is funded for catch up pr primary immunisation. Please refer to the Immunisation Handboo Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg per- tussistoxoid, 25mcg pertussisfilamentoushaemagluttinin, 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitisB- surfaceantigen in 0.5ml syringe 	ary immunisation; or d for (re)immunisation ly immunosuppressive solid organ transplan ogrammes for childrei k for the appropriate s	for patie regimer tation. n (to the	ents posities; or age of for catch	HSCT, or chemotherapy; 10 years) to complete full
 HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm] Inj 10 mcg vial with diluent syringe	n; or es, on the recommend ease; or	1 dation of	_	ct-HIB nal medicine physician or
Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 0.5 ml syringe	0.00	1 1		<u>avrix</u> avrix Junior

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm] Inj 5 mcg per 0.5 ml vial Funded for any of the following criteria:		1	✓ <u>H</u>	BvaxPRO
 for household or sexual contacts of known hepatitis B car for children born to mothers who are hepatitis B surface a for children up to the age of 18 years inclusive who are or additional vaccination; or for HIV positive patients; or for hepatitis C positive patients; or for patients following immunosuppression; or for transplant patients. 	ntigen (HBsAg) positi		d a pos	itive serology and require
 Inj 10 mcg per 1 ml vial	riers; or ntigen (HBsAg) positi			BvaxPRO sitive serology and require
 Inj 40 mcg per 1 ml vial	– [Xpharm] ng criteria:	1	✓ <u>H</u>	<u>BvaxPRO</u>
Inj 120 mcg in 0.5 ml syringe		1 10		ardasil ardasil

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

INFLUENZA VACCINE - [Xpharm]

- A) is available each year for patients who meet the following criteria, as set by PHARMAC:
 - a) all people 65 years of age and over;
 - b) people under 65 years of age who:
 - i) have any of the following cardiovascular disease:
 - a) ischaemic heart disease,
 - b) congestive heart disease,
 - c) rheumatic heart disease,
 - d) congenital heart disease, or
 - e) cerebo-vascular disease;
 - ii) have either of the following chronic respiratory disease:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function;
 - iii) have diabetes;
 - iv) have chronic renal disease;
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive;
 - vi) have any of the following other conditions:
 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - vii) are pregnant
 - children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

Inj 45 mcg in 0.5 ml syringe	 10	Fluarix
		Influvac

MEASLES, MUMPS AND RUBELLA VACCINE - [Xpharm]

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000

TCID50 rubella vial with diluent 0.5 ml vial	0.00	1	🖌 <u>М-М-R II</u>
		10	🖌 M-M-R II

	Subsidy (Manufacturer's Price) \$	Sub: Per	Fully sidised	Brand or Generic Manufacturer
MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONGUGA	TE VACCINE – [Xpha	rm]		
Any of the following:		·		
 Up to three doses for patients pre- and post splenectom; One dose every five years for patients with HIV, comp asplenia or pre or post solid organ transplant; or One dose for close contacts of meningococcal cases; or A maximum of two doses for bone marrow transplant pa 	lement deficiency (acq			
5) A maximum of two doses for patients following immunos				
Note: children under seven years of age require a second dose the		and the	n five ye	early.
Immunosuppression due to steroid or other immunosuppressive Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid	t, t	period of	greater	than 28 days.
carrier per 0.5 ml vial		1	✓ <u>M</u>	enactra
MENINGOCOCCAL C CONGUGATED VACCINE – [Xpharm]				
Any of the following:				
 Up to three doses for patients pre- and post splenectom One dose every five years for patients with HIV, comp 				
asplenia or pre or post solid organ transplant; or				
 One dose for close contacts of meningococcal cases; or A maximum of two doses for bone marrow transplant pa 				
5) A maximum of two doses for patients following immunos				
Note: children under seven years of age require a second dose the		and the	n five ye	early.
Immunosuppression due to steroid or other immunosuppressive		•		
Inj 10 mcg in 0.5 ml syringe	0.00	1 10		<u>eisvac-C</u> eisvac-C
		10	• 1	eisvac-C
PNEUMOCOCCAL (PCV13) VACCINE – [Xpharm]				
Any of the following: 1) A primary course of four doses for previously unvaccinat	ed individuals up to the	e age of 5	9 mont	hs inclusive: or
 Up to three doses as appropriate to complete the primary who have received one to three doses of PCV10; or 				
3) One dose is funded for high risk children who have previ				
 Up to an additional four doses (as appropriate) are fur HSCT, or chemotherapy; pre- or post splenectomy; func and other severely immunosuppressive regimens up to t 	tional asplenia, pre- or			
5) For use in testing for primary immunodeficiency diseas paediatrician.		dation of a	an inter	nal medicine physician
Note: please refer to the Immunisation Handbook for the appropr	iate schedule for catch	up progr	ammes	
Inj 30.8 mcg in 0.5 ml syringe	0.00	1		revenar 13
		10	v <u>P</u>	revenar 13
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [> Either of the following:				
 Up to three doses for patients pre- or post-splenectomy Up to two doses are funded for high risk children to the a 	age of 18.	enia; or		
Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococca serotype)		1	🖌 Pi	neumovax 23
Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23		•		
pneumococcal serotype)	0.00	1		neumovax 23
Pneumovax 23 Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pn				D

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 POLIOMYELITIS VACCINE – [Xpharm] Up to three doses for patients meeting either of the following 1) For partially vaccinated or previously unvaccinated indivi 2) For revaccination following immunosuppression. Note: Please refer to the Immunisation Handbook for appropriate Inj 80D antigen units in 0.5 ml syringe ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – [Xpharm] Maximum of three doses for patients meeting the following: 1) first dose to be administered in infants aged under 15 we 2) no vaccination being administered to children aged 8 mc 	duals; or schedule for catch-up 0.00 eeks of age; and onths or over.) prog 1	rammes. ✔ <u>IF</u>	2 <u>0L</u>
Oral susp G1, G2, G3, G4, P1(8)11.5 million CCID50 units per 2 ml, tube VARICELLA VACCINE [CHICKEN POX VACCINE] – [Xpharm]		10	✓ <u>R</u>	otaTeq
 Maximum of two doses for any of the following: For non-immune patients: with chronic liver disease who may in future be c with deteriorating renal function before transplan prior to solid organ transplant; or prior to any elective immunosuppression*. For patients at least 2 years after bone marrow transplar For patients at least 6 months after completion of chemic For patients with inborn errors of metabolism at risk of ma For household contacts of paediatric patients who are immic compromise where the household contact has no clinica For household contacts of adult patients who have no comised, or undergoing a procedure leading to immune covaricella. 	tation; or ntation, on advice of th therapy, on advice of derate immunosuppre ajor metabolic decomp munocompromised, ou I history of varicella. clinical history of varic	eir sp their s ssion ensati unde ella a	ecialist. pecialist. on advice o ion, with no rgoing a pro	clinical history of varicella. ocedure leading to immune severely immunocompro-

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days Inj 2000 PFU vial with diluent0.00 1 Varilrix

- Symbols -

3TC	111
50X 3.0 Reservoir	32
-A-	
A-Lices	60
A-Scabies	
Abacavir sulphate	70 110
Abacavir sulphate with	110
lamivudine	110
Abilify	
Abiraterone acetate	
ABM Hydroxocobalamin	
Acarbose	
Accarb Accu-Chek Ketur-Test	25
Accu-Chek Performa	
Accuretic 10	
Accuretic 20	
Acetadote	
Acetazolamide	203
Acetic acid with 1, 2- propanediol	
diacetate and	
benzethonium	202
Acetic acid with hydroxyquinoline	
and ricinoleic acid	. 76
Acetylcysteine	206
Aci-Jel	76
Aciclovir	
Infection	104
Infection Sensory	104 202
Infection	104 202
Infection Sensory Acidex Acipimox	104 202 20 56
Infection Sensory Acidex	104 202 20 56
Infection	104 202 20 56 70 121
Infection	104 202 20 56 70 121 116
Infection	104 202 20 56 70 121 116 248
Infection	104 202 20 56 70 121 116 248 142
Infection	104 202 20 56 70 121 116 248 142 164
Infection	104 202 20 56 70 121 116 248 142 164 24
Infection	104 202 20 56 70 121 116 248 142 164 24 24
Infection	104 202 20 56 70 121 116 248 142 164 24 24
Infection	104 202 20 56 70 121 116 248 142 164 24 24 127
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182 62
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182 62 54
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182 62 54 102
Infection	104 202 20 56 70 121 116 248 142 164 24 24 124 124 154 154 1.02 1.24
Infection	104 202 20 56 248 142 164 24 54 182 54 182 54 102 124 32
Infection	104 202 20 56 70 121 116 248 142 164 24 127 54 182 54 102 124 32
Infection	104 202 20 56 70 121 116 248 142 164 24 1127 54 102 124 32 59

Adult diphtheria and tetanus	
vaccine	247
Advantan	66
Advate	
Afinitor	193
AFT-Pyrazinamide	101
Agents Affecting the	
Renin-Angiotensin System Agents for Parkinsonism and	49
Agents for Parkinsonism and	
Related Disorders	125
Agents Used in the Treatment of	
Poisonings	206
Agrylin	163
Air Flow Products	132
Alanase	200
Albay	195
Albendazole	91
Albustix	78
Alendronate sodium	119
Alendronate sodium with	
cholecalciferol	119
Alfacalcidol	37
Alginic acid	20
Alitraq	224
Alkeran	159
Allersoothe	
Allopurinol	123
Alpha Adrenoceptor Blockers	49
Alpha-Keri Lotion	67
Alphamox	93
Alprazolam	145
Alu-Tab	20
Aluminium hydroxide	20
Amantadine hydrochloride	125
Ambrisentan	60
Amiloride hydrochloride	55
Amiloride hydrochloride with	
furosemide	55
Amiloride hydrochloride with	
hydrochlorothiazide	56
Aminophylline	200
Amiodarone hydrochloride	51
Amisulpride	
Amitriptyline	
Amlodipine	
Amorolfine	
Amoxicillin	93
Amoxicillin Actavis	93
Amoxicillin with clavulanic	
acid	93
Amphotericin B	36
Amsacrine	

AmsaLyo16	32
Amsidine10	
Amyl nitrite	
Anaesthetics12	26
Anagrelide hydrochloride16	
Analgesics12	27
Anastrozole1	
Andriol Testocaps	31
Androderm	
Animas Battery Cap	28
Animas Cartridge	32
Animas Vibe	28
Antabuse1	56
Antacids and Antiflatulants	20
Anten13	31
Anthelmintics	
Antiacne Preparations	ô2
Antiallergy Preparations19	95
Antianaemics	
Antiandrogen Oral	
Contraceptives	76
Antiarrhythmics	
Antibacterials	
Antibacterials Topical	63
Anticholinergic Agents	98
Anticholinesterases1	
Antidepressants	
Antidiarrhoeals	
Antiepilepsy Drugs13	33
Antifibrinolytics, Haemostatics	
and Local Sclerosants	41
Antifungals	
Antifungals Topical	
Antihistamines	
Antihypotensives	
Antimalarials10	51
Antimigraine Preparations	28
Antinaus1	
Antinausea and Vertigo	50
Agents13	20
Antiparasitics	
Antipruritic Preparations	
Antipsychotics	
Antiretrovirals10	
Antiretrovirals - Additional	70
Therapies1	4.4
Antirheumatoid Agents1	17
Antispasmodics and Other	17
Agents Altering Gut	
	20
Motility Antithrombotic Agents	22 40
Antitumonito Agents	+3
Antithymocyte globulin	

(equine)182
Antitrichomonal Agents100
Antituberculotics and
Antileprotics 101
Antiulcerants22
Antivirals102
Anxiolytics145
Anzatax
Apidra
Apidra SoloStar25
Apo-Allopurinol
Apo-Amiloride
Apo-Amlodipine
Apo-Amoxi
Apo-Azithromycin92
Apo-Bromocriptine125
Apo-Ciclopirox63
Аро-
Cilazapril/Hydrochlorothiazide50
Apo-Cimetidine22
Apo-Clarithromycin
Alimentary22
Infection
Apo-Clomipramine131
Apo-Diclo116
Apo-Diltiazem CD54
Apo-Doxazosin
Apo-Folic Acid41
Apo-Imiquimod Cream 5%71
Apo-Megestrol
Apo-Moclobemide
Apo-Nadolol53 Apo-Nicotinic Acid
Apo-Nicolinic Aciu
Apo-Oxybutynin
Apo-Perindopril49
Apo-Pindolol53
Apo-Prazosin49
Apo-Prednisone80
Apo-Prednisone S2980
Apo-Primidone136
Apo-Propranolol53
Apo-Pyridoxine
Apo-Ropinirole125
Apo-Selegiline125
Apo-Selegiline S29125
Apo-Thiamine
Apo-Timol53
Apo-Zopiclone151
Apomine125
Apomorphine hydrochloride
Aprepitant
Apresoline
Aquasun 30+71
/ \quuuuu l 00+/ I

Aqueous cream	67
Aratac	
Arava	
Aremed	1/5
Arimidex	
Aripiprazole	140
Aristocort	66
Aromasin	175
Arrow - Clopid	43
Arrow Amitriptyline	131
Arrow-Amitriptyline	131
Arrow-Bendrofluazide	
Arrow-Brimonidine	204
Arrow-Calcium	
Arrow-Citalopram	132
Arrow-Diazepam	145
Arrow-Doxorubicin	164
Arrow-Etidronate	
Arrow-Fluoxetine	
Arrow-Gabapentin	
Arrow-Lamotrigine	136
Arrow-Lisinopril	
Arrow-Lisinophi	49
Hydrochlorothiazide	F 4
Arrow-Meloxicam	
Arrow-Morphine LA	129
Arrow-Norfloxacin	
Arrow-Ornidazole	100
Arrow-Quinapril 10	49
Arrow-Quinapril 20	49
Arrow-Quinapril 5	49
Arrow-Roxithromycin	93
Arrow-Sertraline	132
Arrow-Simva 10mg	57
Arrow-Simva 20mg	57
Arrow-Simva 40mg	57
Arrow-Simva 80mg	57
Arrow-Sumatriptan	138
Arrow-Timolol	
Arrow-Tolterodine	
Arrow-Topiramate	
Arrow-Tramadol	130
Arrow-Venlafaxine XR	133
Arsenic trioxide	
Asacol	
Asamax	
Ascorbic acid	3/
Aspec 300	12/
Aspen Adrenaline	59
Aspirin Blood	
Nervous	
Asthalin	198

Atazanavir sulphate	111
Atenolol	52
Atenolol AFT	52
ATGAM	
Ativan	
Atomoxetine	
Atorvastatin	
Atripla	
Atropine sulphate	
Cardiovascular	51
Sensory	
Atropt	
Atrovent	
Augmentin	
Auranofin	
Ava 20 ED	74
Ava 30 ED	
Avanza	
Avelox	
Avomine	
Avonex	
Avonex Pen	
Azacitidine	
Azamun	
Azathioprine	
Azithromycin	
Azol	
Azopt	
Azopt AZT	204
•	204
AZT	204 111
AZT - B - B-D Micro-Fine	204 111
AZT	204 111 27 27
AZT	204 111 27 27
AZT	204 111 27 27 27
AZT	204 1111 27 27 27 182
AZT	204 1111 27 27 27 182
AZT	204 1111 27 27 27 182 247
AZT	204 111 27 27 27 182 247 .124
AZT - B - B-D Micro-Fine B-D Ultra Fine B-D Ultra Fine II Bacillus Calmette-Guerin (BCG) vaccine Bacillus Calmette-Guerin vaccine Baclofen	204 111 27 27 27 182 247 .124
AZT	204 111 27 27 182 247 124 63
AZT	204 111 27 27 182 247 124 63 231 103
AZT	204 111 27 27 182 247 124 63 231 103
AZT - B - B-D Micro-Fine B-D Ultra Fine B-D Ultra Fine II Bacillus Calmette-Guerin (BCG) vaccine Bacillus Calmette-Guerin vaccine Baclofen Baclofen Bactroban Bakels Gluten Free Health Bread Mix	204 111 27 27 182 247 124 63 231 103
AZT	204 111 27 27 182 247 124 63 231 103 67 247
AZT - B - B-D Micro-Fine B-D Ultra Fine B-D Ultra Fine II Bacillus Calmette-Guerin (BCG) vaccine Baclofen Baclofen Baclofen Baclofen Bakels Gluten Free Health Bread Mix Barrier Creams and Emollients BCG Vaccine Beclazone 100	204 111 27 27 182 247 124 63 231 103 67 247 196
AZT	204 111 27 27 182 247 124 63 231 103 67 247 196 196
AZT - B - B-D Micro-Fine B-D Ultra Fine B-D Ultra Fine II Bacillus Calmette-Guerin (BCG) vaccine Bacillus Calmette-Guerin vaccine Baclofen Baclofen Bactofen Bactofen Bactofen Bactofen Bactofen Bactorban Barier Creams and Emollients BCG Vaccine Beclazone 100 Beclazone 50 Beclazone 50	204 111 27 27 182 247 124 63 231 103 67 247 196 196
AZT	204 111 27 27 182 247 124 63 231 103 67 247 196 196 196
AZT	204 111 27 27 182 247 124 63 231 103 67 247 196 196 196
AZT	204 111 27 27 27 182 247 124 63 231 103 67 247 196 196 196 200
AZT	204 111 27 27 182 247 124 63 231 103 67 247 196 196 196 200 195

Bendroflumethiazide	
[Bendrofluazide]	. 56
BeneFIX	42
Benhex	68
Benzathine benzylpenicillin	93
Benzbromaron AL 100	123
Benzbromarone	123
Benzoin	213
Benztrop	125
Benztropine mesylate	125
Benzydamine hydrochloride	36
Benzylpenicillin sodium (penicillin	
G)	. 93
Beta Adrenoceptor Blockers	52
Beta Cream	
Beta Ointment	
Beta Scalp	
Beta-Adrenoceptor Agonists	197
Betadine	
Betadine Skin Prep	80
Betaferon	
Betagan	
Betahistine dihydrochloride	120
Betamethasone dipropionate	100
Betamethasone dipropionate	05
with calcipotriol	70
Betamethasone sodium	. 70
phosphate with	70
betamethasone acetate	. 79
Betamethasone valerate65	, 71
Betamethasone valerate with	
clioquinol	. 66
Betamethasone valerate with	
fusidic acid	
Betaxolol	
Betnovate	
Betnovate-C	
Betoptic	203
Betoptic S	
Bezafibrate	56
Bezalip	56
Bezalip Retard	
Bicalaccord	174
Bicalutamide	174
Bicillin LA	
BiCNU	159
Bile and Liver Therapy	23
Biltricide	91
Bimatoprost	204
Biodone	128
Biodone Extra Forte	128
Biodone Forte	400
	128

Bismuth trioxide23
Bisoprolol fumarate52
BK Lotion67
Bleomycin sulphate163
Blood Colony-stimulating
Factors
Blood glucose diagnostic test
meter
Blood glucose diagnostic test
strip
Blood glucose test strips (visually
impaired)27
Blood ketone diagnostic test
meter
BNM
Cardiovascular49
Genito-Urinary76
Boceprevir107
Bonjela
Boostrix247
Bortezomib163
Bosentan60
Bosvate52
Bplex
Breath-Alert201
Brevinor 1/2175
Brevinor 1/2875
Brevinor 2175
Bricanyl Turbuhaler198
Brilinta43
Brimonidine tartrate204
Brimonidine tartrate with timolol
maleate 204
Brinzolamide204
Brolene202
Bromocriptine mesylate125
Brufen SR116
BSF Actavis Risperidone206
BSF Arrow-Amitriptyline206
Buccastem139
Budesonide
Alimentary20
Respiratory196, 201
Budesonide with
eformoterol 197
Bumetanide55
Buprenorphine with
naloxone
Bupropion hydrochloride156
Burinex55
Buscopan22
Buspirone hydrochloride145
Busulphan159

Butacort Aqueous	201
Bulabort / iquobub	

- C -	
Cabergoline	89
Cafergot	138
Caffeine citrate	201
Cal-d-Forte	
Calamine	
Calcipotriol	70
Calcitonin	
Calcitriol	
Calcitriol-AFT	37
Calcium carbonate	
Calcium Channel Blockers	
Calcium Disodium	
Versenate	207
Calcium folinate	
Calcium Folinate Ebewe	161
Calcium gluconate	
Calcium Homeostasis	00
Calcium polystyrene	19
sulphonate	47
Calcium Resonium	47
Calogen	
5	
Calsource	
Camptosar Candesartan cilexetil	162
Candestar	
Canesten	
Capecitabine	161
Capecitabine Winthrop	
Capoten	49
Capsaicin	
Musculoskeletal System	
Nervous	
Captopril	
Carafate	
Carbaccord	
Carbamazepine	
Carbimazole	
Carbomer	205
Carboplatin	159
Carboplatin Ebewe	159
Carbosorb-X	
Cardinol LA	
Cardizem CD	54
CareSens	
CareSens II	26
CareSens N	26
CareSens N CareSens N POP	26
Carmustine	
Carvedilol	
Catapres	55

Catapres-TTS-155
Catapres-TTS-255
Catapres-TTS-355
CeeNU159
Cefaclor monohydrate91
Cefalexin monohydrate91
Cefalexin Sandoz91
Cefazolin
Ceftriaxone91
Ceftriaxone-AFT 91
Ceftriaxone-AFT91 Cefuroxime axetil91
Cefuroxime sodium92
Celestone Chronodose
Celiprolol
Cellcept176
Celol
Centrally-Acting Agents55
Cephalexin ABM91
Cerezyme35
Cetirizine hydrochloride195
Cetomacrogol67
Cetomacrogol with glycerol67
Champix157
Charcoal206
Chemotherapeutic Agents159
Chicken pox vaccine252
Chlorafast
Chlorambucil159
Chloramphenicol202
Chlorhexidine gluconate
Alimentary
Dermatological66
Chloroform
Chlorothiazide
Chlorpheniramine maleate
Chlorpromazine
hydrochloride
Chlorsig202
Chlortalidone
[Chlorthalidone]
Chlorthalidone
Chlorvescent
Choice TT380 Short73
Choice TT380 Standard73
Cholecalciferol
Cholestyramine56
Choline salicylate with
cetalkonium chloride
Cholvastin57
Ciclopirox olamine63
Ciclosporin193
Cilazapril49
Cilazapril with

hydrochlorothiazide50
Cilicaine94
Cilicaine VK94
Ciloxan202
Cimetidine22
Cipflox95
Ciprofloxacin
Infection95
Sensory202
Cisplatin159
Cisplatin Ebewe159
Citalopram hydrobromide132
Cladribine161
Clarithromycin
Alimentary
Intection
Clexane44 Climara 10082
Climara 10082 Climara 50
Clindamycin95
Clindamycin ABM95
Clobazam134
Clobetasol BNM65
Clobetasol propionate65, 71
Clobetasone butyrate
Clofazimine101
Clomazol
Clomazol
Clomazol Dermatological63
Clomazol Dermatological63 Genito-Urinary76
Clomazol Dermatological63 Genito-Urinary76 Clomiphene citrate90 Clomipramine hydrochloride131
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55
Clomazol Dermatological
Clomazol Dermatological
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clonipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clopidogrel 43 Clopine 141
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clonidine MM 43 Clopine 141 Clopixol 143, 144
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clonidine hydrochloride 43 Clopidogrel 43 Clopicol 143, 144 Clotrimazole 143, 144
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clonidine NM 55 Clopidogrel 43 Clopidogrel 141 Clopixol 143, 144 Clotrimazole Dermatological
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clonidine hydrochloride 43 Clopidogrel 43 Clopixol 143, 144 Clopixol 143, 144 Clotrimazole Dermatological Dermatological 63 Genito-Urinary 76
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clonidine hydrochloride 55 Clonidine hydrochloride 55 Clopidogrel 43 Clopixol 1441 Clopixol 143, 144 Clotrimazole Dermatological Dermatological 63 Genito-Urinary 76 Clozapine 141
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozapine 141
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopino 141 Clopixol 143, 144 Clotrimazole Dermatological Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141
Clomazol 63 Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozarie 141 Co-Renitec 50 Co-trimoxazole 55
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopidogrel 143, 144 Clopidogrel 143 Clopixol 143, 144 Clopixol 143, 144 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141 Co-Renitec 50 Co-trimoxazole 95 Coal tar 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozapine 141 Co-Renitec 50 Co-trimoxazole 95 Coal tar 70 Coal tar with allantoin, menthol, 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141 Clozaril 141 Co-Renitec 50 Co-trimoxazole 95 Coal tar 70 Coal tar with allantoin, menthol, phenol and sulbhur 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomiphene citrate 91 Clomiphene citrate 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidgrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 63 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozapine 141 Clozapine 141 Co-Renitec 50 Coaltar 70 Coal tar with allantoin, menthol, phenol and sulphur 70 Coal tar with salicylic acid and 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 0 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141 Clozaril 141 Co-Renitec 50 Coal tar 70 Coal tar with allantoin, menthol, phenol and sulphur 70 Coal tar with salicylic acid and sulphur 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole Dermatological Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141 Co-trimoxazole 95 Coal tar 70 Coal tar with allantoin, menthol, 70 Coal tar with salicylic acid and sulphur 70 Coco-Scalp 70 70
Clomazol Dermatological 63 Genito-Urinary 76 Clomiphene citrate 90 Clomipramine hydrochloride 131 Clonazepam 133–134, 145 Clonidine 55 Clonidine BNM 55 Clopidogrel 43 Clopine 141 Clopixol 143, 144 Clotrimazole 0 Dermatological 63 Genito-Urinary 76 Clozapine 141 Clozaril 141 Clozaril 141 Co-Renitec 50 Coal tar 70 Coal tar with allantoin, menthol, phenol and sulphur 70 Coal tar with salicylic acid and sulphur 70

Nervous	
Cogentin	125
Colaspase [L-asparaginase]	163
Colchicine	124
Colestid	
Colestipol hydrochloride	56
Colgout	12/
Colifoam	
Colistin sulphomethate	95
Colistin-Link	95
Collodion flexible	
Colofac	
Coloxyl	
Combigan	204
Comfort	30
Comfort Short	30
Compound electrolytes	47
Compound	
hydroxybenzoate	212
Concerta	
Condoms	
Condyline	
Contact-D	29
Contraceptives - Hormonal	74
Contraceptives -	
Non-hormonal	73
Copaxone	151
Cordarone-X	51
Corticosteroids and Related	
Agents for Systemic Use	79
Corticosteroids Topical	65
Cosmegen	
0	
Cosopt	
Coumadin	
Creon 10000	
Creon 25000	
Crixivan	111
Crotamiton	
Crystaderm	63
Curam	
Curam Duo	93
Cvite	
Cyclizine hydrochloride	
Cyclizine lactate	
Cyclogyl	
	204
Cyclopentolate hydrochloride	~~ 4
nyarochioride	204
Cyclophosphamide	159
Cycloserine	101
Cyklokapron	
Cyproterone acetate	80
Cyproterone acetate with	
ethinyloestradiol	. 76

Cytarabine161
Cytotec22
Cytoxan
•
- D -
D-Penamine117
d4T111
Dabigatran45
0
Dacarbazine164
Dactinomycin [Actinomycin
D] 164
Daivobet70
Daivonex70
Daktarin
Dalacin C95
Dalteparin sodium44
Danazol90
Dantrium124
Dantrolene124
Daonil25
Dapa-Tabs56
Dapsone101
Daraprim
Darunavir111
Dasatinib
Daunorubicin
DBL Aminophylline
DBL Bleomycin Sulfate163
DBL Carboplatin159
DBL Docetaxel164
DBL Doxorubicin164
DBL Doxorubicin S29164
DBL Epirubicin
Hydrochloride
DBL Ergometrine
DBL Gemcitabine
DBL Leucovorin Calcium161
DBL Morphine Sulphate129
DBL Pethidine
Hydrochloride130
DBL Tobramycin97
DDI110
De Nol23
De-Worm91
Decozol
Deferasirox206
Deferiprone
Deoxycoformycin
Depo-Medrol
Depo-Medrol with Lidocaine80
Depo-Provera75
Depo-Testosterone80
Deprim95

Dermol65,	
Desferrioxamine mesylate2	
Desmopressin acetate	89
Desmopressin-PH&T	89
Detection of Substances in	
Urine	78
Dexamethasone	
Hormone	79
Sensory2	
Dexamethasone phosphate	
Dexamethasone with framycetin	
and gramicidin2	02
and gramicidin2	
sulphate and polymyxin B	
sulphate2	03
Dexamethasone-hameln	
Dexamfetamine sulfate1	
Dextrochlorpheniramine	
maleate1	92
Dextrose	47
Dextrose with electrolytes	
DHC Continus1	
Diabetes	
Diabetes Management	20
Diacomit1	20
Diaconni	00
Diamox2	
Dianiox2 Diaphragm	
Diaphraghi2	
Diasip2 Diason RTH2	20
Diazepam	
Diazoxide	
Diazoxide	
Diclax SR1	10
Diclofenac sodium	10
Musculoskeletal System1	16
Sensory2	01
Didanosine [DDI]1	10
Didariosine [DDi]i Differin	10
Difflam	02 06
Diflucan	00
Diflucan S29	
Diflucortolone valerate	
Diagotivos Includina	
Enzymes	<u></u>
Enzymes	33
Digoxin Dihydrocodeine tartrate1	51
Dilantin1	30
Dilantin Infatab1	30
Dilatrend Diltiazem hydrochloride	52
Dilzem	04 67
Dimethicone	0/

Dipentum21
Diphtheria, tetanus and pertussis
vaccine
and polio vaccine
Diphtheria, tetanus, pertussis,
polio, hepatitis B and
haemophilus influenzae type B
vaccine
Diprosone65
Diprosone OV65
Dipyridamole43
Disinfecting and Cleansing
Agents 66
Disopyramide phosphate51
Disulfiram156
Diuretics55
Diurin 4055
Docetaxel164
Docetaxel Sandoz164
Docusate sodium34
Docusate sodium with
sennosides34
Domperidone139
Donepezil hydrochloride155
Donepezil-Rex155
Dopergin125
Dopress131
Dornase alfa200
Dorzolamide hydrochloride204
Dorzolamide hydrochloride with
timolol maleate204
Dostinex89
Dothiepin hydrochloride131
Doxazosin49
Doxepin hydrochloride131
Doxine94
Doxorubicin164
Doxorubicin Ebewe164
Doxy-5094
Doxycycline94
DP Fusidic Acid Cream63
DP Lotion
DP Lotn HC65
DP-Anastrozole175
Dr Reddy's Omeprazole23
Dr Reddy's Ondansetron
Dr Reddy's Terbinafine
Drugs Affecting Bone
Metabolism 117
Dulcolax
Duocal Super Soluble Powder
Powder

Duolin198
Duolin HFA
Durex Confidence
Durex Extra Safe73
Durex Select Flavours73
Duride
Dynacirc-SRO54
- E -
E-Mycin
Ear Preparations
Ear/Eye Preparations202
Easiphen Liquid233
Econazole nitrate64
Efavirenz110
Efavirenz with emtricitabine and
tenofovir disoproxil
fumarate
Efexor XR133
Effient
Eformoterol fumarate
Efudix
Egopsoryl TA70
Elecare
Elecare LCP234
Elemental 028 Extra224
Eligard89
Elocon
Eloxatin
Eltrombopag41
Eltroxin
Emend Tri-Pack
EMLA
Emtricitabine110
Emtricitabine with tenofovir
disoproxil fumarate 111
Emtriva110
Emulsifying ointment67
Enalapril maleate
Enalapril maleate with
Enalapril maleate with hydrochlorothiazide50
Enbrel
Endocrine Therapy173
Endoxan
Enerlyte
Enfuvirtide111
Enoxaparin sodium44
Ensure228
Ensure Plus229
Ensure Plus HN228
Ensure Plus RTH228
Entacapone125
Entapone
Entecavir 103

Entocort CIR	
Epilim	.136
Epilim Crushable	.136
Épilim IV	.136
Epilim S/F Liquid	136
Epilim Syrup	136
Epirubicin	164
Epirubicin Ebewe	16/
Epoetin alfa [Erythropoietin	.104
alfa]	44
Eprex	
	41
Eptacog alfa [Recombinant factor	
VIIa]	
ERA	
Ergometrine maleate	/6
Ergotamine tartrate with	
caffeine	
Erlotinib	
Erythrocin IV	92
Erythromycin ethyl succinate	
Erythromycin lactobionate	92
Erythromycin stearate	92
Erythropoietin alfa	40
Escitalopram	.132
Eskazole	
Estradot	
Estrofem	
Etanercept	
Ethambutol hydrochloride	101
Ethics Aspirin	127
Ethics Aspirin EC	127
Ethics Enalapril	40
Ethinyloestradiol	49
Ethinyloestradiol with	83
Ethinyloestradiol with	74
desogestrel	74
Ethinyloestradiol with	
levonorgestrel	74
Ethinyloestradiol with	
norethisterone	
Ethosuximide	
Etidronate disodium	
Etopophos	.165
Etoposide	.164
Etoposide phosphate	
Etravirine	.110
Eumovate	65
Everolimus	
Evista	
Exelon	
Exemestane	
Exjade	
Extemporaneously Compounded	
Preparations and	
i ieparatione dilu	

Galenicals	213
Eye Preparations	202
EZ-fit Paediatric Mask	201
Ezemibe	57
Ezetimibe	
Ezetimibe with simvastatin	58
Ezetrol	57
- F -	
Factor eight inhibitors bypassing	
agent	42
Febuxostat	124
Feed Thickener Karicare	
Aptamil	231
FEIBA	42
Felodipine	
Fenpaed	116
Fentanyl	128
Fentanyl Sandoz	128
Ferodan	38
Ferriprox	207
Ferro-F-Tabs	
Ferro-tab	38
Ferrograd	38
Ferrograd F	38
Ferrous fumarate	38
Ferrous fumarate with folic	
acid	38
Ferrous sulphate	38
Ferrous sulphate with folic	
acid	
Ferrum H	
Fexofenadine hydrochloride	
Fibro-vein	
Filgrastim	
Finasteride	
Fingolimod	
Finpro	
Flagyl	
Flagyl-S	
Flamazine	
Flecainide acetate	
Fleet Phosphate Enema	35
Flixonase Hayfever & Allergy	004
Flixotide	100
Flixotide Accuhaler	190
Florinef	
Fluanxol Fluarix	
Flucloxacillin	
Flucioxaciiiin	94 იл
Flucioxin	
Fluconazole	
I 10001102010	

Fludara161
Fludara Oral161
Fludarabine Ebewe161
Fludarabine phosphate161
Fludrocortisone acetate79
Fluide and Fleetrakites
Fluids and Electrolytes47
Flumetasone pivalate202
Fluocortolone caproate with
fluocortolone pivalate and
cinchocaine21
Fluorometholone203
Fluorouracil Ebewe161
Fluorouracil sodium
Dermatological72
Oncology161
Fluoxetine hydrochloride132
Flupenthixol decanoate143
Fluphenazine decanoate143
Flutamide174
Flutamin174
Flutamin S29174
Fluticasone196
Fluticasone propionate201
Fluticasone with salmeterol
Foban63
Folic acid41
Food Thickeners231
Foods And Supplements For
Foods And Supplements For
Inborn Errors Of
Foods And Supplements For Inborn Errors Of Metabolism
Inborn Errors Of Metabolism232
Inborn Errors Of Metabolism
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortimel Regular 222 Fortini 222 Fortini Multi Fibre 223 Fortisip 228, 229 Fortisip Multi Fibre 229 Fosamax 119 Fosamax Plus 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Fresetyle Optium Ketone 25 Frisium 134 Frumil 55 Frusemide 55 Frusemide 55 Frusemide 55
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 223 Fortisip 228, 229 Fosamax 119 Fosamax 119 Fosamax 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Freestyle Optium Ketone 25 Frisum 134 Frusemide 55 Frusemide 55 Fucort 66 Fucidin 95
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 223 Fortisip 228, 229 Fortisip Multi Fibre 229 Fosamax 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Freestyle Optium Ketone 25 Frisum 134 Frumil 55 Frusemide 55 Frusemide 55 Frusemide 55 Fuciort 66 Fucidin 95 Fucithalmic 202
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 223 Fortisip Multi Fibre 228 Fortisip Multi Fibre 229 Fosamax 119 Fosamax Plus 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Freestyle Optium Ketone 25 Frisium 134 Frumil 55 Frusemide-Claris 55 Fucithalmic 202 Fuestyle Optium Ketone 25 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 202 Fusemide 202
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 223 Fortisip 228, 229 Fortisip Multi Fibre 229 Fosamax 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Freestyle Optium Ketone 25 Frisum 134 Frumil 55 Frusemide 55 Frusemide 55 Frusemide 55 Fuciort 66 Fucitin 95 Fucithalmic 202
Inborn Errors Of Metabolism 232 Foradil 196 Forteo 120 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 223 Fortisip Multi Fibre 228 Fortisip Multi Fibre 229 Fosamax 119 Fosamax Plus 119 Fragmin 44 Framycetin sulphate 202 Freestyle Optium 25, 26 Freestyle Optium Ketone 25 Frisium 134 Frumil 55 Frusemide-Claris 55 Fucithalmic 202 Fuestyle Optium Ketone 25 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 202 Fusemide 55 Fusemide 55 Fusemide 55 Fusemide 202 Fusemide 202

	-
Dermatological	63
Infection	
Sensory	
Fuzeon	
- G -	
Gabapentin	13/
Gabapentin (Neurontin)	125
Gamma benzene	100
	~~
hexachloride	
Ganciclovir	
Gardasil	
Gastrosoothe	
Gaviscon Double Strength	20
Gaviscon Infant	
Gefitinib	169
Gemcitabine Ebewe	
Gemcitabine hydrochloride	
Gemfibrozil	56
Gemzar	
Genoptic	202
Genox	175
Gentamicin sulphate	
Infection	95
Sensory	
Gilenya	
Ginet	
Glatiramer acetate	
Glibenclamide	
Gliclazide	
Glipizide	
Glivec	
Glizide	
Glucagen Hypokit	
Glucagon hydrochloride	24 04
Glucerna Select	<u>24</u> 000
Glucerna Select RTH	220
Glucose [Dextrose]	4/
Gluten Free Foods	231
Glycerin with sodium	~ ~ ~
saccharin	
Glycerin with sucrose	213
Glycerol	
Alimentary	
Extemporaneous	213
Glyceryl trinitrate	
Alimentary	22
Cardiovascular	58
Glycopyrronium	
Glycopyrronium bromide	22
Glytrin	
Gold Knight	
Gopten	
Goserelin acetate	

Granirex	.139
Granisetron	.139
Gutron	51
Gynaecological	
Anti-infectives	76
- H -	
Habitrol	.157
Haemophilus influenzae type B	
vaccine	. 248
Haldol	
Haldol Concentrate	.143
Haloperidol	
Haloperidol -	
MercuryPharma	. 141
Haloperidol decanoate	
Hamilton Sunscreen	71
Havrix	.248
Havrix Junior	.248
HBvaxPRO	.249
healthE Dimethicone 5%	67
healthE Fatty Cream	
healthE Glycerol BP	.213
healthE Urea Cream	67
Healtheries Simple Baking	
Mix	. 231
Hemastix	
Heparin sodium	
Heparinised saline	45
Heparon Junior	.221
Hepatitis A vaccine	.248
Hepatitis B recombinant	
vaccine	. 249
Hepsera	.102
Herceptin	.192
Hexamine hippurate	
Hiprex	
Histaclear	
Histafen	
Holoxan	.159
Horleys Bread Mix	.231
Horleys Flour	.231
Hormone Replacement Therapy -	
Systemic	
HPV	
Humalog	
Humalog Mix 25	
Humalog Mix 50	24
Human papillomavirus (6, 11, 16	
and 18) vaccine [HPV]	
Humatin	
Humira	
HumiraPen	
Humulin 30/70	24

Humulin NPH	
Humulin R	
Hybloc	52
Hydralazine	59
Hydralazine hydrochloride	59
Hydrea	165
Hydrocortisone	
Dermatological	65
Hormone	00
Hydrocortisone acetate	00
	21
Hydrocortisone and paraffin	
liquid and lanolin	65
Hydrocortisone butyrate6	5, 71
Hydrocortisone with cinchocaine	
cinchocaine	22
Hydrocortisone with	
miconazole	66
Hydrocortisone with natamycin	
and neomycin	66
Hydrogen peroxide	
Alimentary	36
Dermatological	63
Hydroxocobalamin	
Hydroxychloroquine	117
Hydroxyurea	165
Hygroton	56
Hylo-Fresh	205
Hyoscine hydrobromide	1200
Hyoscine N-butylbromide	139
Hypam	151
Hyperuricaemia and Antigout	400
Antigout	123
Hypnovel	151
Hypromellose	205
Hypromellose with Dextran	
Hysite	204
-1-	
Ibiamox	93
Ibugesic	
Ibuprofen	
Idarubicin hydrochloride	165
Ifosfamide	
lkorel	
lloprost	
Imatinib mesilate	10
Imatinib-AFT	
Imiglucerase	
Imipramine hydrochloride	131
Imiquimod	71
Immune Modulators	
Immunosuppressants	176

Imuran176

Indacaterol196

Indapamide56
Indinavir111
Infanrix IPV248
Infanrix-hexa248
Infant Formulae234
Influenza vaccine250
Influvac250
Inhaled Corticosteroids196
Inhaled Long-acting
Beta-adrenoceptor
Agonists 196
Innovacon hCG One Step
Pregnancy Test77
Inset 30
Inset II
Insulin aspart24
Insulin aspart with insulin aspart
protamine
Insulin glargine
Insulin glulisine
Insulin isophane24
Insulin isophane with insulin
neutral
Insulin lispro25
Insulin lispro with insulin lispro
protamine
Insulin neutral24
Insulin pen needles27
Insulin pump
Insulin pump accessories
Insulin pump infusion set (steel
cannula)
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, angle insertion)
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir
Insulin syringes, disposable with
attached needle
Intal Forte CFC Free200
Intal Spincaps
Intelence110
Interferon alfa-2a112 Interferon alfa-2b113
Interferon beta-1-alpha151
Interferon beta-1-alpha151
Interferon beta-1-beta
inita-uterine device

Intron-A	113
Invega Sustenna	143
IPOĽ	252
Ipratropium bromide198,	201
Iressa	169
Irinotecan	162
Irinotecan Actavis 100	162
Irinotecan Actavis 40	162
Irinotecan-Rex	162
Iron polymaltose	39
Isentress	111
Ismo 20	58
Ismo 40 Retard	58
Isoniazid	101
Isoprenaline	59
Isoptin	54
Isopto Carpine	204
Isosorbide mononitrate	58
Isosource Standard	227
Isosource Standard RTH	
Isotretinoin	
Ispaghula (psyllium) husk	
Isradipine	54
Isuprel	59
Itch-Soothe	64
Itraconazole	98
Itrazole	98
lvermectin	68
- J -	
Jadelle	
Jevity	227
Jevity HiCal RTH	
Jevity RTH	227
- K -	
Kaletra	111
Kemadrin	126
Kenacomb	202
Kenacort-A 10	80
Kenacort-A 40	80
Kenalog in Orabase	36
Ketocal 3:1	236
KetoCal 4:1	236
Ketoconazole	
Dermatological	71
Infection	98
Ketogenic Diet	236
Ketone blood beta-ketone	
electrodes	25
Ketoprofen	116
Ketostix	25
Kindergen	იიი
Kinson	222

Kivexa110
Klacid92
Kliogest83
Kliovance
Kogenate FS42
Konakion MM42
Konsyl-D34
-L-
L-asparaginase163
Labetalol52
Lacosamide135
Lactulose34
Laevolac
Lamictal136
Lamivudine103, 111
Lamivudine Alphapharm111
Lamotrigine136
Lamprene101
Lanoxin51
Lanoxin PG51
Lansoprazole23
Lantus24
Lantus SoloStar24
Lanvis
Lapatinib ditosylate170
Largactil140
Lasix
Latanoprost204
Lax-Sachets34
Lax-Tab35
Laxatives34
Laxsol
Leflunomide117
Lenalidomide165
Letraccord175
Letrozole175
Leukeran FC159
Leukotriene Receptor
Antagonists
Leunase
Leuprorelin
Leustatin
Levetiracetam
Levetiracetam-Rex
Levelinacetam-nex
Levocabastine
Levodopa with benserazide
Levodopa with carbidopa125
Levomepromazine maleate141
Levonorgestrel
Genito-Urinary75-76
Hormone83

Levothyroxine	84
Levothyroxine (mercury pharma)	
pharma)	84
Lidocaine [Lignocaine]	126
Lidocaine [Lignocaine]	
hydrochloride	126
Lidocaine [Lignocaine] with	
chlorhexidine	127
Lidocaine [Lignocaine] with	
prilocaine	127
Lidocaine-Claris	
Lifestyles Flared	
Lignocaine80, 126	
Hormone	
Nervous126	·
Link Healthcare	98
Lioresal Intrathecal	
Lipazil	
Lipid-Modifying Agents	
Lipitor	
Liquigen	
Lisinopril	49
Lisuride hydrogen maleate	125
Lithicarb FC	141
Lithium carbonate	
	000
Livostin	203
Locacorten-Viaform ED's	203
Locacorten-Viaform ED's	202
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders	202 21
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55, 71
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5, 71 65
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 65
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 65 202
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 65 202 203
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 65 202 203 136
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5,71 65 202 203 136 203
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5,71 65 65 202 203 136 203 159
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol Locoid Crelo Locoid Cipocream Locorten-Vioform Lodoxamide Logem Lomustine Loniten	202 21 234 65 65 202 203 136 203 159 59
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 202 203 136 203 136 203 159 59 20
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5,71 65 202 203 136 203 159 59 20 111
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 5,71 65 202 203 136 203 136 203 159 59 20 111 53
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 55,71 65 202 203 159 203 159 203 159 203 159 203 111 53 233
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 65 65 202 203 136 203 159 20 111 53 233 233
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 5,71 65 202 203 136 203 159 20 111 53 233 233 233 195
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5,71 65 202 203 136 203 159 203 159 203 159 203 111 53 233 233 195 195
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5,71 65 202 203 136 203 159 203 159 203 159 233 233 233 195 195
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5, 71 65 202 203 136 203 136 203 159 203 159 203 151 233 233 195 195 195 195 195 195
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 i5, 71 65 202 203 136 203 139 203 139 233 233 195 195 195 195 195
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 .5,71 65 202 203 136 203 136 203 159 20 111 53 233 195 195 195 195 145 151 151
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 .5,71 65 202 203 136 203 136 203 159 20 111 53 233 195 195 195 195 145 151 151
Locacorten-Viaform ED's Local preparations for Anal and Rectal Disorders Locasol	202 21 234 .5,71 65 202 203 136 203 136 59 59 59 59 53 53 195 195 195 195 195 151 50

Lovir	104
Lovir	104
Loxalate	132
Loxamine	132
Lucrin Depot PDS	89
Ludiomil	131
Lumigan	204
Lycinate	58
Lyderm	70

- M -

- 141 -	
m-Cefuroxime	
m-Eslon	
M-M-R II	250
m-Mometasone	
Mabthera	190
Macrogol 3350 with potassium	
chloride, sodium bicarbonate	
and sodium chloride	34
Macrogol 400 and propylene	
glycol	
Madopar 125	
Madopar 250 Madopar 62.5	125
Madopar 62.5	125
Madopar HBS	
Madopar Rapid	
Magnesium hydroxide	213
Magnesium sulphate	39
Malathion	69
Malathion with permethrin and	
piperonyl butoxide	
Maprotiline hydrochloride	131
Marevan	46
Marine Blue Lotion SPF 50+	
Marquis Black	73
Marquis Conforma	
Marquis Protecta	
Marquis Selecta	
Marquis Sensolite	
Marquis Supalite	
Marquis Titillata	
MarquisTantiliza	73
Martindale Acetylcysteine	
Marvelon 28	
Mask for spacer device	201
Mast Cell Stabilisers	200
Max Health	
Maxidex	203
Maxitrol	
MCT oil (Nutricia)	219
Measles, mumps and rubella	
vaccine	250
Mebendazole	
Mebeverine hydrochloride	22
Medrol	80

Medroxyprogesterone acetate
Genito-Urinary75
Hormone
Mefenamic acid116
Megestrol acetate174
Meloxicam117
Melphalan159
Menactra251
Meningococcal (groups A, C, Y
and W-135) congugate
vaccine
Meningococcal c congugated
vaccine
Menthol64
Mercaptopurine162
Mercilon 2874
Mesalazine21
Mesna
Mestinon116
Metabolic Disorder Agents35
Metamide
Metformin hydrochloride25
Methadone hydrochloride
Extemporaneous213
Nervous128
Methatabs
Methopt
Methotrexate
Methotrexate Ebewe
Methotrexate Sandoz
Methyl hydroxybenzoate213
Methylcellulose
Methylcellulose with glycerin and
sodium saccharin
Methylcellulose with glycerin and
sucrose
Methyldopa55
Methylphenidate
hydrochloride 153
Methylphenidate hydrochloride
extended-release
Methylprednisolone
Methylprednisolone
aceponate
Methylprednisolone acetate80
Methylprednisolone acetate with
lidocaine [Lignocaine]
Methylprednisolone sodium
succinate
Methylxanthines
Metoclopramide
hydrochloride 139
Metolazone55

Metopirone Metoprolol - AFT CR	90
Metoprolol - AFT CR	52
Metoprolol succinate	52
Metoprolol tartrate	
Metronidazole	.100
Metyrapone	
Mexiletine hydrochloride	51
Mexiletine Hydrochloride	
USP	51
Miacalcic	
Mianserin hydrochloride	
Micolette	25
Miconazole	
Miconazole nitrate	
Dermatological	~
Genito-Urinary	/6
Micreme	
Micreme H	
Microgynon 30	74
Microgynon 50 ED	
Microlut	
Midazolam	
Midodrine	
Minerals	
Minidiab	25
Minirin	89
Mino-tabs	94
Minocycline hydrochloride	94
Minomycin	94
Minor Skin Infections	68
Minoxidil	
Mirena	
Mirtazapine	.132
Misoprostol	
Mitomycin C	165
Mitozantrone	
Mitozantrone Ebewe	166
Mixtard 30	
Moclobemide	
Modafinil	155
Modavigil	
Modecate	
Moduretic	
Mogine	
Mometasone furoate	.130
Monetasone luroate	00
Monogen	.221
Montelukast	.199
Moroctocog alfa [Recombinant	40
factor VIII]	42
Morphine hydrochloride	.129
Morphine sulphate	.129
Morphine tartrate	.129
Motetis	.126

Mouth and Throat	36
Moxifloxacin	96
MSUD Maxamaid	232
MSUD Maxamum	
Mucilaginous laxatives with	
stimulants	34
Mucolytics	
Multiple Sclerosis	200
Treatments	145
Multivitamins	
Mupirocin	
Muscle Relaxants	124
Mvite	
Myambutol	
Mycobutin	
MycoNail	
Mycophenolate mofetil	
Mycostatin	
Mydriacyl	
Mylan Atenolol	
Mylan Fentanyl Patch	
Mylanta P	20
Myleran	150
Myocrisin	
Myometrial and Vaginal Hormone	117
Preparations	70
	70
- N -	
Nadolol	
Nalcrom	
Naloxone hydrochloride	
Naltraccord	156
Naltrexone hydrochloride	156
Naphazoline hydrochloride	205
Naphcon Forte	205
Naprosyn SR 1000	
Naprosyn SR 750	
Naproxen	
Nardil	131
Nasal Preparations	
Natalizumab	
Natulan	
Nausicalm	
Navelbine	
Nedocromil	200

Nepro HP (strawberry)	223
Nepro HP (vanilla)	223
Nepro HP RTH	223
Nerisone	
Neulactil	
Neulastim	
Neurontin	
NeuroTabs	
Nevirapine	110
Nevirapine Alphapharm	110
Nicorandil	
Nicotine	
Nicotinic acid	
Nifedipine	
Nifuran	115
Nilotinib	170
Nilstat	
Alimentary	36
Genito-Urinary	
Infection	98
Nipent	166
Nitrados	151
Nitrates	58
Nitrazepam	
Nitroderm TTS	
Nitrofurantoin	
Nitrolingual Pump Spray	
Nizoral	
Noctamid	151
Nodia	
Noflam 250	116
Noflam 500	
Non-Steroidal Anti-Inflammatory	
Drugs	116
Nonacog alfa [Recombinant	
factor IX]	10
Norethisterone	42
Genito-Urinary	75
Hormone	
Norflex	
Norfloxacin	115
Noriday 28	75
Norimin	75
Normacol Plus	34
Normison	151
Norpress	
Nortriptyline hydrochloride	121
Norvir	
NovaSource Renal	
Novatretin	70
NovoMix 30 FlexPen	
NovoRapid	24
NovoRapid FlexPen	24

NovoRapid Penfill24	1
NovoSeven RT41	
Noxafil98	3
Nozinan141	
Nuelin200	
Nuelin-SR200)
Nupentin134	1
Nutilis231	1
Nutrient Modules217	7
Nutrini Energy Multi Fibre222	2
Nutrini Energy RTH222	2
Nutrini I ow Eneray Multi	
Fibre	1
Nutrini RTH222	
Nutrison Concentrated230)
Nutrison Energy227	7
Nutrison Energy Multi Fibre	2
Nutrison Multi Fibre227	7
Nutrison Standard RTH227	7
Nyefax Retard	
Nystatin	T
Alimentary	2
Dermatological64	1
Genito-Urinary	
Infection	
NZB Low Gluten Bread Mix231	
- 0 -	
Octocog alfa [Recombinant factor	
Octocog alfa [Recombinant factor	5
VIII]	2
VIII]42 Octreotide	2
VIII]42 Octreotide174 Octreotide LAR (somatostatin	1
VIII]42 Octreotide	1 1
VIII]42 Octreotide	1 1 2
VIII]	1 1 2
VIII]42 Octreotide	1
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83	1
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestroil 83	4 4 2 2
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 83 Oestriol 83	4 4 22 33
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 83 Oestriol 84 Hormone 83	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 83 Gestriol 84 Genito-Urinary 76 Hormone 83 Oestrogens 84	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 85 Oestriol 85 Gestriol 85 Oestroil 86 Oestroil 86 Oestroil 86 Oestroil 86 Oestroil 86 Oestrogens 82 Oestrogens 82 Oestrogens with 82	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 64 Genito-Urinary 76 Hormone 83 Oestrogens 82	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 64 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens 83 Oestrogens 83 Oestrogens 83 Oil in water emulsion 67	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 66 Genito-Urinary 76 Hormone 82 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oistrogens with medroxyprogesterone 85 Oil in water emulsion 67 Olanzapine 141, 143	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 66 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oli in water emulsion 67 Olanzapine 141, 143	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 66 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oil in water emulsion 67 Olanzapine 141, 143 Olopatadine 205	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 82 Oestroil 66 Genito-Urinary 76 Hormone 82 Oestrogens 82 Oestrogens with medroxyprogesterone 83 Oil in water emulsion 67 Olanzapine 141, 142 Olbetam 56 Olopatadine 205 Olsalazine 21	4 4 2 2 3 3 3 3 2 3 3 3 5 3 2 3 3 5 3 5 1
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol with norethisterone 83 Oestriol 66 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens 82 Oli in water emulsion 67 Olanzapine 141, 143 Olpatadine 205 Olsalazine 21 Omalizumab 185	
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol valerate 82 Oestradiol valerate 83 Oestradiol valerate 83 Oestroil Genito-Urinary Gentro-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens with 67 Oli in water emulsion 67 Olazapine 241 Olopatadine 20 Olsalazine 21 Omalizumab 185 Omeprazole 22	4 4 2 2 3 3 3 2 2 3 3 5 5 1 9 3
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol valerate 82 Oestradiol valerate 83 Oestradiol valerate 83 Oestroil 6 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oli in water emulsion 67 Olanzapine 141, 143 Olopatadine 20 Olaalzine 21 Omalizumab 188 Omeprazole 22 Omezol Relief 25	4 4 2 2 3 3 3 2 2 3 3 5 5 1 9 3 3 3
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol valerate 82 Oestradiol valerate 83 Oestradiol valerate 83 Oestradiol valerate 83 Oestroil 6 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens with 83 medroxyprogesterone 83 Oil in water emulsion 67 Olanzapine 141, 143 Olopatadine 205 Olagalazine 21 Omalizumab 186 Omeprazole 22 Omezol Relief 22 Omnitrope 85	4 4 4 2 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 7 3 6 7 3 6 7 3 6 7 3 3 5 1 9 3 5 1 1 1 1 1 1 1 1 1 1 1 1 1 <td< td=""></td<>
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol valerate 82 Oestradiol valerate 83 Oestradiol valerate 83 Oestradiol valerate 83 Oestroil 6 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oestrogens 82 Oli in water emulsion 67 Olanzapine 141, 143 Olopatadine 20 Olaalzine 21 Omalizumab 188 Omeprazole 22 Omezol Relief 25 Omitrope 85 Onbrez Breezhaler 196	1 1 1 2 3 <td< td=""></td<>
VIII] 42 Octreotide 174 Octreotide LAR (somatostatin analogue) 174 Oestradiol 82 Oestradiol valerate 82 Oestradiol valerate 82 Oestradiol valerate 83 Oestradiol valerate 83 Oestradiol valerate 83 Oestroil 6 Genito-Urinary 76 Hormone 83 Oestrogens 82 Oestrogens with 83 medroxyprogesterone 83 Oil in water emulsion 67 Olanzapine 141, 143 Olopatadine 205 Olagalazine 21 Omalizumab 186 Omeprazole 22 Omezol Relief 22 Omnitrope 85	1 1 1 2 3 <td< td=""></td<>

OncoTICE	.182
Ondansetron	
Ondansetron ODT-DRLA	.139
One-Alpha	
Onelink	
Onkotrone	
Onrex	
Ora-Blend	
Ora-Blend SF	
Ora-Plus	
Ora-Sweet	213
Ora-Sweet SF	
Orabase	
Oracort	36
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)	220
Oratane	62
Orgran	.232
Ornidazole	
Orphenadrine citrate	.124
Ortho All-flex	
Ortho-tolidine	
Oruvail SR	
Osmolite	
Osmolite RTH	207
Other Endocrine Agents	221
Other Oestrogen	09
Preparations	00
	83
Other Progestogen Preparations	00
Preparations	83
Other Skin Preparations	72
Ovestin	
Genito-Urinary	
Hormone	
Ox-Pam	
Oxaliplatin	
Oxaliplatin Actavis 100	
Oxaliplatin Actavis 50	.160
Oxaliplatin Ebewe	.160
Oxazepam	.145
Oxis Turbuhaler	.196
Oxpentifylline	
Oxybutynin	
Oxycodone ControlledRelease	
Tablets(BNM)	130
Oxycodone hydrochloride	130
Oxycodone Orion	
OxyContin	
OxyNorm	
Oxytocin	70
Oxytocin BNM	/0
Ozole	97

- P -	
Pacifen1	24
Pacific Buspirone1	45
Paclitaxel1	66
Paclitaxel Actavis1	
Paclitaxel Ebewe1	66
Paediatric Seravit	37
Paliperidone1	43
Pamidronate disodium1	19
Pamisol1	
Panadol1	27
Pancreatic enzyme	33
Pantoprazole	
Pantoprazole Actavis 20	
Pantoprazole Actavis 40	23
Panzytrat	
Papaverine hydrochloride	59
Para Plus	
Para-amino salicylic acid1	
Paracare1	
Paracare Double Strength1	27
Paracetamol1	
Paracetamol + Codeine	
(Relieve)1	30
Paracetamol with codeine1	
Paradigm 1.8 Reservoir	
Paradigm 3.0 Reservoir	32
Paradigm 522	
Paradigm 722	28
Paradigm Mio MMT-921	31
Paradigm Mio MMT-923	
Paradigm Mio MMT-925	
Paradigm Mio MMT-941	31
Paradigm Mio MMT-943	
Paradigm Mio MMT-945	
Paradigm Mio MMT-965	
Paradigm Mio MMT-975	31
Paradiam Quick Sat	
MMT-386	32
Paradium Quick-Set	
MMT-387	32
Paradigm Quick-Set	
MMT-396	32
Paradigm Quick-Set	
MMT-397	32
Paradigm Quick-Set	
MMT-398	32
Paradigm Quick-Set	
MMT-399	32
Paradigm Silhouette	
Paradigm Silhouette MMT-368	30
Paradiam Silhouette	

MMT-377 30
Paradigm Silhouette
MMT-378 30
Paradigm Silhouette
MMT-381
Paradigm Silhouette
MMT-382
Paradigm Silhouette
ММТ-383 30
Paradigm Silhouette
MMT-384
Paradigm Sure-T MMT-86429
Paradigm Sure-T MMT-86629
Paradigm Sure-T MMT-87429
Paradigm Sure-T MMT-876
Paradigm Sure-T MMT-88429
Paradigm Sure-T MMT-88629
Paraffin67
Paraffin liquid with soft white
paraffin
Paraffin liquid with wool fat
Paraldehyde133
Parasiticidal Preparations
Parnate131
Paromomycin96
Paroxetine hydrochloride132
Paser101
Patanol205
Paxam145
Pazopanib171
Pazoparilo
Pedialyte - Bubblegum48
Pediasure
Pediasure RTH222
Pegaspargase166
Pegasys113
Pegasys RBV Combination
Pack
Pegfilgrastim
Pegylated interferon alfa-2a113 Penicillamine117
PenMix 3024
PenMix 4024
PenMix 50
Pentasa21
Pentostatin
[Deoxycoformycin] 166
Pentoxifylline [Oxpentifylline]59
Pepti Junior Gold Karicare
Aptamil
Peptisoothe22
Peptisorb224
Perhexiline maleate54

Pericyazine	141
Perindopril	49
Permethrin	70
Persantin	43
Peteha	101
Pethidine hydrochloride	130
Pevaryl	64
Pexsig	
Pharmacare	
Pharmacy Services	206
Phenelzine sulphate	121
Phenobarbitone	126
Phenobarbitone sodium	100
Extemporaneous	014
Nervous	
Phenoxybenzamine hydrochloride	
hydrochloride	49
Phenoxymethylpenicillin	
(Penicillin V)	
Phenytoin sodium13	
Phlexy 10	233
Phosphate-Sandoz	48
Phosphorus	48
Phytomenadione	42
Pilocarpine hydrochloride	204
Pimafucort	
Pindolol	
Pinetarsol	
Pioglitazone	
Piportil	144
Pipothiazine palmitate	144
Pizaccord	25
Pizotifen	
PKU Anamix Infant	
PKU Anamix Junior	233
PKU Anamix Junior LQ	233
PKU Lophlex LQ 10	233
PKU Lophlex LQ 20	233
Plaquenil	
Plendil ER	
pms-Bosentan	60
Pneumococcal (PCV13)	
vaccine	251
Pneumococcal (PPV23)	
polysaccharide vaccine	251
Pneumovax 23	251
Podophyllotoxin	72
Polaramine	
Poliomyelitis vaccine	252
Poloxamer	
Poly-Gel	205
Poly-Tears	
Poly-Visc	
· / ····	

Polycal	
	217
Polyvinyl alcohol	205
Ponstan	
Posaconazole	98
Postinor-1	76
Potassium chloride	
Potassium citrate	
Potassium iodate	
Povidone iodine	68
Pradaxa	45
Pramipexole hydrochloride	
Prasugrel	
Pravastatin	
Praziquantel	91
Prazosin	
Pred Forte	
Pred Mild	
Prednisolone	80
Prednisolone acetate	
Prednisone	
	00
Pregnancy Tests - hCG Urine	//
Premarin	
Premia 2.5 Continuous	83
Premia 5 Continuous	83
Prevenar 13	
Prezista	
Priadel	141
Primacin	100
Primaquine phosphate	100
Primidone	
Primolut N	
Probenecid	124
Probenecid-AFT	124
Procaine penicillin	94
Procarbazine hydrochloride	166
Prochlorperazine	139
Prochlorperazine Proctosedyl	139 22
Prochlorperazine Proctosedyl	139 22
Prochlorperazine Proctosedyl Procyclidine hydrochloride	139 22 126
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox	139 22 126 159
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox Prodopa	139 22 126 159 55
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox Prodopa Progesterone	139 22 126 159 55 84
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox Prodopa Progesterone Proglicem	139 126 159 55 84 23
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox Prodopa Progesterone Proglicem	139 126 159 55 84 23
Prochlorperazine Proctosedyl Procyclidine hydrochloride Procytox Prodopa Progesterone Proglicem Proglycem	139 22 126 159 55 84 23 23
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Progynova	139 126 159 55 84 23 23 23
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Progynova Prokinex	139 22 126 55 84 23 23 82 82 82
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Prodopa Proglicem Proglicem Proglycem Progynova Prokinex Promethazine hydrochloride	139 22 126 55 84 23 23 82 82 139 196
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Proglopa Proglicem Proglycem Proglycem Proglycem Prognova Prokinex Promethazine hydrochloride Promethazine theoclate	139 22 126 159 55 84 23 23 23 82 139 196 139
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Proglopa Proglicem Proglycem Proglycem Proglycem Prognova Prokinex Promethazine hydrochloride Promethazine theoclate	139 22 126 159 55 84 23 23 23 82 139 196 139
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Proglycem Proglycem Prosynova Promethazine hydrochloride Promethazine theoclate Promod	139 22 126 159 55 84 23 23 23 82 139 196 139 219
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Proglycem Proglycem Prokinex Promethazine hydrochloride Promethazine theoclate Promethazine hydrochloride Propafenone hydrochloride	139 22 126 55 84 23 23 23 82 139 139 196 139 219 51
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Proglycem Proglycem Promethazine hydrochloride Promethazine hydrochloride Promethazine hydrochloride Propafenone hydrochloride Propamidine isethionate	139 22 126 55 84 23 23 23 23 23 139 196 139 196 51 51 51
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Proglycem Proglycem Proghyova Promethazine hydrochloride Promethazine hydrochloride Promethazine hydrochloride Propafenone hydrochloride Propamidine isethionate Propranolol	139 22 126 159 55 84 23 25 55
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Progesterone Proglicem Proglycem Proglycem Progynova Promethazine hydrochloride Promethazine hydrochloride Promethazine hydrochloride Propafenone hydrochloride Propamidine isethionate Propanolol Propylene glycol	139 22 126 159 55 84 23 23 23 82 139 196 139 196 139 51 51 51 53 51
Prochlorperazine Proctosedyl Procyclidine hydrochloride Prodopa Proglesterone Proglicem Proglycem Proglycem Proglycem Proghyova Promethazine hydrochloride Promethazine hydrochloride Promethazine hydrochloride Propafenone hydrochloride Propamidine isethionate Propranolol	139 22 126 159 55 84 23 23 23 82 139 196 139 196 139 51 51 51 53 51

Protamine sulphate	45
Protaphane	24
Protaphane Penfill	24
Protifar	
Protionamide	101
Provera	82, 84
PSO	
Psoriasis and Eczema	
Preparations	70
PTU	84
Pulmicort Turbuhaler	
Pulmocare	220
Pulmozyme	200
Puri-nethol	
Pyrazinamide	101
Pyridostigmine bromide	116
PyridoxADE	
Pyridoxine hydrochloride	
Pyrimethamine	
Pytazen SR	
,	

- Q -

Q 300	100
Questran-Lite	56
Quetapel	141
Quetiapine	141
Quick-Set MMT-390	32
Quick-Set MMT-391	32
Quick-Set MMT-392	32
Quick-Set MMT-393	32
Quinapril	49
Quinapril with	
hydrochlorothiazide	50
Quinine sulphate	100
Qvar	196

- R -

RA-Morph Raloxifene hydrochloride Raltegravir potassium Ramipex Ranbaxy-Cefaclor Ranitidine Relief Ranitidine Relief Ranmoxy Rapamune Reandron 1000 Recombinant factor IX Recombinant factor VIIa Recombinant factor VIII	119 111 125 91 22 93 193 81 42 41 42
Rectogesic	22
Redipred	80
Refresh Night Time	
Renilon 7.5	

Resonium-A48	
	3
Resource Beneprotein219	9
Resource Diabetic220)
Respigen198	3
Respiratory Devices201	1
Respiratory Stimulants201	1
Retinol palmitate	5
ReTrieve	5
Retrovir111	
Reutenox116	
Revlimid165	
Revolade41	
Rexacrom203	
	2
Reyataz111	
Ridaura s29117	
Rifabutin102	
Rifadin102	
Rifampicin102	
Rifaximin23	3
Rifinah101	
Rilutek126	
Riluzole126	
Riodine68	
Risedronate Sandoz120)
Risedronate sodium120)
Risperdal Consta144	1
Risperdal Quicklet142	2
Risperidone142, 144	
	ŧ.
Risperon142	+ 2
Risperon142 Ritalin	2
Ritalin153	2
Ritalin153 Ritalin LA154	2 3 4
Ritalin	2343
Ritalin 150 Ritalin LA 154 Ritalin SR 156 Ritonavir 111	2 3 4 3
Ritalin 150 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190	2 3 4 3 1 2
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 45	2343105
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivastigmine 155	23431055
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivastigmine 155 Rivotril 133, 134	234310554
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 48 Rivastigmine 155 Rivotril 133, 134 Rizamelt 136	2343105543
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivastigmine 155 Rivotril 133, 134 Rizamelt 138 Rizatriptan 138	23431055488
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivaroxaban 45 Rivotril 133, 134 Rizamelt 138 Rizatriptan 132	2 3 4 3 1 0 5 5 4 8 8 2
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivaroxaban 45 Rivaroxaban 133 Rivaroxaban 133 Rizarroxaban 133 Rizarroxaban 133 Rizarroxaban 133 Rizatriptan 138 Roferon-A 112 Ropinirole hydrochloride 125	2343105548825
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 45 Rivaroxaban 45 Rivaroxaban 45 Rivaroxaban 133 Rizarroxaban 133 Rizarroxaban 133 Rizarroyaban 133 Rizatriptan 138 Roferon-A 112 Ropinirole hydrochloride 122 RotaTeq 252	2343105548825
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 44 Rivastigmine 155 Ritonavir 133, 134 Rizamelt 136 Roferon-A 111 Ropinirole hydrochloride 122 RotaTeq 252 Rotavirus live reassortant oral 252	23431055433252
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 44 Rivaroxaban 45 Rivotril 133, 134 Rizamelt 138 Roferon-A 111 Ropinirole hydrochloride 122 RotaTreq 252 Rotavirus live reassortant oral vaccine	23431055488252 2
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 44 Rivastigmine 155 Rivotril 133, 134 Rizatriptan 136 Roferon-A 112 Ropinirole hydrochloride 125 Rotavirus live reassortant oral 252 Rotavirus live reassortant oral 252 Roxane 55	23431055433252 23
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 44 Rivastigmine 155 Rivotril 133, 134 Rizamelt 138 Roferon-A 112 Ropinirole hydrochloride 125 RotaTeq 252 Rotavirus live reassortant oral vaccine Vacane 55 Alimentary 20	
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 46 Rivastigmine 155 Rivotril 133, 134 Rizatriptan 138 Roferon-A 112 Rotarreq 252 Rotavirus live reassortant oral 252 Roxane 55 Alimentary 202 Cardiovascular 55	
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 46 Rivastigmine 155 Rivotril 133, 134 Rizamelt 138 Ropinirole hydrochloride 125 RotaTeq 252 Rotavirus live reassortant oral 262 Vaccine 252 Roxane 53 Alimentary 22 Cardiovascular 53 Roxithromycin 93	
Ritalin 153 Ritalin LA 154 Ritalin SR 155 Ritonavir 111 Rituximab 190 Rivaroxaban 46 Rivastigmine 155 Rivotril 133, 134 Rizatriptan 138 Roferon-A 112 Rotarrophysical Revenues 252 Rotarrophysical Revenues 252 Rotavirus live reassortant oral 252 Roxane 53 Alimentary 20 Cardiovascular 53 Roxithromycin 93 Rubifen 153	
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 48 Rivastigmine 153 Rivornil 133, 134 Rizarriptan 138 Roferon-A 112 RotaTeq 252 Rotavirus live reassortant oral vaccine Vaccine 252 Roxane 53 Alimentary 20 Cardiovascular 53 Roxithromycin 93 Rubifen 155 Rubifen SR 155	
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 48 Rivastigmine 153 Rivornil 133, 134 Rizarriptan 138 Roferon-A 112 RotaTeq 252 Rotavirus live reassortant oral vaccine Vaccine 252 Roxane 53 Alimentary 20 Cardiovascular 53 Roubifen 155 Rubifen SR 155 Rythmodan 51	
Ritalin 153 Ritalin LA 154 Ritalin SR 153 Ritonavir 111 Rituximab 190 Rivaroxaban 48 Rivaroxaban 48 Rivastigmine 153 Rivornil 133, 134 Rizarriptan 138 Roferon-A 112 Ropinirole hydrochloride 125 RotaTeq 252 Rotavirus live reassortant oral vaccine Vaccine 252 Roxane 53 Alimentary 20 Cardiovascular 53 Roxithromycin 93 Rubifen 155 Rubifen SR 155	

- S -	
S-26 Gold Premgro234	
Sabril	
Salamol198	
Salazopyrin21	
Salazopyrin EN21	
Salbutamol197-198	
Salbutamol with ipratropium	
bromide 198	
Salicylic acid71	
Salmeterol196	
Sandomigran138	
Sandostatin LAR	
Scalp Preparations71	
Scopoderm TTS	
Sebizole71	
Sedatives and Hypnotics	
Seebri Breezhaler	
Selegiline hydrochloride125	
Senna	
Senokot	
SensoCard27	
Serenace	
Seretide	
Seretide Accuhaler197	
Serevent196	
Serevent Accuhaler196	
Serophene90	
Sertraline132	
Sevredol129 Sex Hormones Non	
Contraceptive	
Shield 49	
Shield Blue73 Shield XL73	
SII-Onco-BCG	
Silagra	
Sildenafil60 Silhouette MMT-37130	
Silhouette MMT-373	
Silver sulphadiazine	
Simethicone20	
Simvastatin57	
Sinemet	
Sinemet CR125	
Singulair	
Sirolimus193	
Siterone80	
Slow-Lopresor53	
Sodibic48	
Sodium acid phosphate35	
Sodium alginate20	

Sodium aurothiomalate117
Sodium bicarbonate
Blood47–48
Extemporaneous214
Sodium calcium edetate207
Sodium
carboxymethylcellulose
Sodium chloride
Blood47
Respiratory
Sodium citrate with sodium lauryl
sulphoacetate35
Sodium citro-tartrate78
Sodium cromoglycate
Alimentary21
Respiratory200
Sensory203
Sodium fluoride
Sodium hyaluronate205
Sodium nitroprusside25
Sodium polystyrene
sulphonate
Sodium tetradecyl sulphate42
Sodium valproate
Sofradex
Soframycin
Solian
Solifenacin succinate
Solox
Solu-Cortef80
Solu-Medrol
Somatropin (Omnitrope)85
Sotacor53
Sotalol53
Space Chamber201
Space Chamber Plus201
Spacer device201
Spacer device autoclavable201
Span-K48
Spiractin55
Spiriva199
Spironolactone55
Sporanox
Sprycel168
Staphlex
Stavudine [d4T]111
Stelazine
Stemetil
Stesolid133
Stimulants/ADHD
Treatments 152
Stiripentol
Stocrin110

Stomahesive
Strattera152
Stromectol68
Suboxone155
Sucralfate23
Sulfadiazine sodium
Sulindac116
Sulphasalazine21
Sulphur71
Sumatriptan138
Sunitinib172
Sunscreens71
Sunscreens, proprietary71
Sure-T MMT-863
Sure-T MMT-86529
Sure-T MMT-87329
Sure-T MMT-87529
Sure-T MMT-88329
Sure-T MMT-88529
Sustagen Diabetic220
Sustagen Hospital Formula
Sustanon Ampoules
Sustantin Ampoules
Sutent
Symbicort Turbuhaler 100/6197
Symbicort Turbuhaler 200/6
Symbicort Turbuhaler
400/12
Symmetrel125
Sympathomimetics
Synacthen80
Synactinen Denet
Synacthen Depot80
Synthroid84
Syntometrine76
Syrup (pharmaceutical grade)
grade)214
Systane Unit Dose205
-Т-
Tacrolimus194
Tacrolimus Sandoz194
Tambocor51
Tambocor CR51
Tamoxifen citrate175
Tamsulosin hydrochloride77
Tamsulosin-Rex
Tap water
Tap water
Tar with triethanolamine lauryl
sulphate and fluorescein
Tarceva168
Tasigna170
Tasmar125
Taxotere164
Tegretol134

Tegretol CR134
Telfast195
Temaccord166
Temazepam151
Temozolomide166
Tenofovir disoproxil
fumarate106
Tenoxicam116
Tepadina160
Terazosin49
Terbinafine
Terbutaline sulphate198
Teriparatide120
Testosterone80
Testosterone cypionate80
Testosterone esters
Testosterone undecanoate81
Tetrabenazine126
Tetrabromophenol78
Tetracosactrin80
Tetracyclin Wolff94
Tetracycline94
Teva163
Thalidomide167
Thalomid167
Theophylline200
Thiamine hydrochloride
THIO-TEPA160
Thioguanine162
Thiotepa160
Thymol glycerin
Thursid and Antithursid
Thyroid and Antithyroid
Agents
Agents
Agents 84 Ticagrelor 43 Tilade 200
Ticagrelor43 Tilade200
Ticagrelor43 Tilade200 Timolol
Ticagrelor43 Tilade200 Timolol Cardiovascular53
Ticagrelor43 Tilade200 Timolol Cardiovascular53 Sensory203
Ticagrelor
Ticagrelor43 Tilade200 Timolol Cardiovascular53 Sensory203
Ticagrelor

Muscular Pain 117	
Topiramate137	
Topiramate Actavis137	
Total parenteral nutrition	
(TPN)	
TPN	
Tracleer60	
Tramadol hydrochloride130	
Tramal SR 100130	
Tramal SR 150130	
Tramal SR 200130	
Trandate	
Trandolapril50	
Tranexamic acid42	
Tranylcypromine sulphate	
Trastuzumab192	
Travatan	
Travoprost	
Treatments for Dementia155	
Treatments for Substance	
Dependence 155	
Trental 40059	
Tretinoin	
Dermatological62	
Oncology167	
Trexate162	
Triamcinolone acetonide	
Alimentary36	
Dermatological66	
Hormone	
Triamcinolone acetonide with	
gramicidin, neomycin and nystatin	
Dermatological66	
Sensory	
Triazolam151	
Trichozole100	
Triclosan	
Trifluoperazine	
hydrochloride142	
Trimonrozino tortroto	
Trimeprazine tartrate	
Trimethoprim97	
Trisequens83	
Trisul	
Trophic Hormones85	
Tropicamide204	
Trusopt204	
Truvada111	
Two Cal HN230	
Two Cal HN RTH230	
Tykerb170	
Tysabri147	

- U -

Ultraproct	21
Univent	.198, 201
Ural	78
Urea	67
Urex Forte	55
Urinary Agents	77
Urinary Tract Infections	114
Uromitexan	
Ursodeoxycholic acid	33
Ursosan	33
Utrogestan	84

- V -		
Vaccinations	247	
Valaciclovir	104	
Valcyte		
Valganciclovir		
Vallergan Forte		
Valtrex		
Vancomycin	97	
Vannair		
Varenicline tartrate	157	
Varicella vaccine [Chicken pox		
vaccine]		
Varilrix	252	
Various		
Vasodilators	59	
Vasopressin Agonists		
Velcade		
Venlafaxine		
Ventavis		
Ventolin197	·	
Vepesid	164	
Verapamil hydrochloride		
Vergo 16		
Vermox		
Verpamil SR		
Vesanoid		
Vesicare		
Vfend		
Viaderm KC		
Victrelis		
Vidaza		
Videx EC		
Vigabatrin		
Vimpat		
Vinblastine sulphate	167	
Vincristine sulphate		
Vinorelbine		
Vinorelbine Ebewe		
Viramune Suspension		
Viread	106	

Virgan	202	
Vistil	205	
Vistil Forte	205	
VitA-POS	205	
Vitabdeck		
Vitadol C		
Vital HN		
Vitamin A with vitamins D and		
С	37	
Vitamin B complex	37	
Vitamin B6 25		
Vitamins		
Vivonex Pediatric	234	
Vivonex TEN	224	
Volibris	60	
Voltaren	116	
Voltaren D	116	
Voltaren Ophtha	203	
Volumatic		
Voriconazole		
Vosol	202	
Votrient	171	
Vytorin		
- W -		
Warfarin sodium	46	
Wart Preparations		
Wasp venom allergy		
treatment	105	
	195	

Water	
Blood	47
Extemporaneous	.214
Wool fat with mineral oil	67

- X -

Xanax	145
Xarelto	45
Xifaxan	23
XMET Maxamum	232
Xolair	189
XP Maxamaid	233
XP Maxamum	233
Xylocaine	126
Xylocaine Viscous	126
Xyntha	42

- Z -

-	
Zantac	22
Zapril	49
Zarator	57
Zarontin	134
Zaroxolyn	55
Zarzio	46
Zavedos	165
Zeffix	103
Zeldox	143
Zerit	111
Zetop	195
Ziagen	110

Zidovudine [AZT]	111
Zidovudine [AZT] with	
lamivudine	
Zimybe	
Zinc and castor oil	
Zinc sulphate	
Zincaps	
Zinnat	
Ziprasidone	143
Zithromax	92
Zoladex	88
Zoledronic acid	
Hormone	79
Musculoskeletal System	121
Zometa	
Zopiclone	151
Zostrix	
Zostrix HP	127
Zovirax	
Zuclopenthixol decanoate	144
Zuclopenthixol	
hydrochloride	143
Zyban	
Zypine	
Zypine ODT	
Zyprexa Relprevv	
Zytiga	
∠yuyu	